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ABSTRACT 
 
The apicoplast within Plasmodium falciparum has been thought of as an attractive 
source of potential drug targets since its discovery. While the apicoplast is essential 
throughout the parasite lifecycle it has been demonstrated that the organelle is dispensable in 
the asexual blood-stage of the parasite as long as the isoprenoid precursor isopentenyl 
pyrophosphate (IPP) is supplemented. IPP supplementation thus provides a bypass system 
which allows for the investigation and deletion of essential apicoplast specific proteins that 
would otherwise be impossible. Building on this work, we were successful in optimizing this 
system though the creation of a parasite line containing a genetically encoded alternative 
bypass we are calling PfMev. We have validated the functionality of the PfMev line and have 
established it as a new user-friendly platform that more easily allows for the investigation of 
essential apicoplast processes.  
Using PfMev line we elucidated the essentiality of numerous proteins and pathways 
within the apicoplast including multiple components of the SUF iron-sulfur cluster 
biosynthetic pathway and the proteins within the organelle that are reliant on these cofactors, 
the various proteins involved in carbon metabolism and the production of energy and 
reducing power within the organelle, in addition to the proteins involved in the generation 
and utilization of CoA within the apicoplast, among others. Not only were we able to 
determine which components of these pathways are essential for blood stage parasite 
survival, we also were able to determine which are required for the maintenance of the 
apicoplast organelle. Additionally, we made considerable progress in uncovering the 
functions of these proteins, and determining the ultimate roles that these various proteins 
play in the maintenance of the organelle. 
Advisor: Dr. Sean T. Prigge 
Thesis readers: Dr. Michael Matunis, Anna Durbin, MD, and David Sullivan, MD.   
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Plasmodium falciparum Malaria 
Malaria is a disease caused by a parasitic infection from Plasmodium spp. and 
represents a significant public health burden throughout the world. In 2017 alone there were 
an estimated 219 million cases, and 435,000 deaths (1). Of the five species of Plasmodium that 
infect humans, P. falciparum causes the largest majority of malaria-related deaths, responsible 
for 99.7% of malaria cases in the African region, with 93% of all malaria deaths occurring 
within that region (1). While individuals infected with P. falciparum can be non-symptomatic, 
those with mild or uncomplicated malaria can present clinically with fever, sweating, chills, 
diarrhea, and swelling of the spleen (2). However, infection can also result in severe or 
complicated malaria, in which individuals can present clinically with severe anemia, 
metabolic acidosis, coma, convulsions, pulmonary edema, or hemoglobinuria, with infection 
also potentially resulting in death (2). 
P. falciparum parasites have a complex lifecycle that requires a human host in addition 
to requiring a female Anopheles mosquito vector as well (Figure 1-1) (3). Within the human 
host, during the disease causing asexual stage of the lifecycle, parasites invade and replicate 
within red blood cells (RBCs) in a cycle that takes ~48 hours (4). This asexual cycle begins 
when parasites in the merozoite stage invade RBCs, and develop into ring-stage parasites, 
progressing further into the trophozoite stage of the parasite, before forming the schizont 
stage of the parasite, in which parasites have undergone division and formed ~16-32 
daughter merozoites, which are released and invade other RBCs (5). A subpopulation of 
blood-stage parasites (~0.8-1%) can undergo differentiation into the sexual forms of the 
parasite, forming male and female gametocytes (6, 7). These sexual forms of the parasite are 
then taken up by a female Anopheles mosquito during a blood meal (8). Once the gametocytes 





female macrogametes (9). The gametes then egress out of the RBCs and the microgamete 
and macrogamete can fuse, forming a zygote (9). The zygote then develops into the motile 
ookinete form and traverses through the midgut of the mosquito (10). On the opposite side 
of the midgut wall, the parasites form a cyst-like structure called an oocyst in which serves as 
a protective structure for the formation of thousands of sporozoites. The sporozoites are a 
motile form of the parasite and, after release from the oocyst, they migrate to the salivary 
gland of the mosquito (11). The now infectious mosquito then takes another bloodmeal, and 
is capable of transmitting the sporozoites into the dermis of the human (12). The 
sporozoites then enter into the bloodstream, eventually reaching the liver where they invade 
and replicate inside of liver hepatocyte cells (13, 14). Within the liver, infectious merozoites 
are ultimately formed and released into the bloodstream; these parasites specifically infect 
RBCs within the human host, beginning the lifecycle anew (12).  
 The current recommendation for the treatment of uncomplicated infection with P. 
falciparum are artemisinin-based combination therapies (ACTs) (15). Prior treatments relied 
on drugs such as chloroquine, sulfadoxine–pyrimethamine, mefloquine, quinine and 
lumefantrine (16, 17). Due to treatment failures and resistance to these previously used 
therapies, ACTs are now the frontline therapy (18–22). The introduction and widespread 
utilization of ACTs is believed to have significantly attributed to the 18% reduction in 
malaria cases between 2010 and 2016 (23). However, parasite recrudescence, delayed parasite 
clearance, and treatment failures are now being seen with ACTs in certain regions of the 
world (24–26). Treatment failures observed after standard artemisinin treatment regimens 
have been attributed to mutations within the Kelch-13 protein of the parasite (27, 28). 
Selection of this mutation is believed to have arisen in Southeast Asia, and appears to be 





elimination (29, 30).  
 Due to resistance being seen to current frontline antimalarial treatments, there is a 
critical need to develop new antimalarial drugs with novel mechanisms of action. In order to 
develop new drugs to treat infection, the apicoplast organelle within the parasite has been 
thought of as a source of additional drug targets since its initial discovery and 
characterization (31, 32). This is largely due to the unique evolutionary lineage of the 
organelle, which contains biochemical pathways that are highly dissimilar from that of the 
human host (33). 
 
The Apicoplast Organelle  
Plasmodium falciparum parasites are a member of the Apicomplexa phylum, with many 
of the species within this phylum, including P. falciparum, possessing a non-photosynthetic 
plastid organelle, called an apicoplast (34). The apicoplast is an organelle surrounded by four 
membranes, a result of its evolutionary origin resulting from a secondary endosymbiotic 
process. In the first endosymbiotic event, the chloroplast of an algal cell was formed from an 
engulfed cyanobacterium. The algal cell was then phagocytosed, and lost all of its cellular 
contents except for its chloroplast organelle (35). The two inner membranes of the 
apicoplast are believed to correspond to the algal chloroplast membranes, while the third 
membrane corresponds to the algal plasma membrane, and the fourth membrane derives 
from the phagocytic membrane that originally engulfed the endosymbiont (36).  
Over the course of endosymbiosis, the apicoplast has become extremely reduced in 
terms of the biochemical processes and genetic material that it possesses. The genetic 
material that continues to be retained within the apicoplast exists as a small circular 35kb 





polymerase subunits, a translation elongation factor, small and large subunit ribosomal 
RNAs, ribosomal proteins, a caseinolytic protease C (ClpC), and SufB of the iron-sulfur 
cluster biosynthetic pathway (37, 38). The remainder, and vast majority of apicoplast-specific 
proteins are now encoded by the nuclear genome, likely due to multiple gene transfer events 
that occurred over time (39–41). The trafficking of these apicoplast-specific proteins is 
mediated by an N-terminal signal and transit peptide (42), with these proteins being 
packaged into vesicles and then trafficked to the organelle via the secretory system (43–45). 
There are an estimated ~400 proteins trafficked to the organelle, representing ~7% of the 
parasite genome [36]–[39].  
 Each parasite cell contains only one apicoplast organelle, but it is essential for the 
survival of blood-stage P. falciparum parasites. This essentiality has been demonstrated 
through the administration of antibiotics such as chloramphenicol, clindamycin, or 
doxycycline. These antibiotics are effective in inhibiting translation within prokaryotic 
organisms, and due to the prokaryotic origin of the apicoplast, are also effective at 
specifically inhibiting translation within the apicoplast (51, 52). The requirement for the 
apicoplast is driven by the metabolism that takes place inside the organelle, with the 
apicoplast being home to biochemical pathways involved in the biosynthesis of heme, fatty 
acids, isoprenoid precursors, and iron-sulfur cluster cofactors (46). While the FasII fatty acid 
biosynthetic pathway was initially thought to be an attractive drug target, it was ultimately 
proven to be dispensable for blood-stage P. falciparum parasites (53, 54). It has also been 
demonstrated that the heme biosynthetic pathway that is shared between the apicoplast and 
mitochondrion is dispensable for P. falciparum blood-stage survival as well (55, 56). The 
methylerythritol phosphate (MEP) pathway, which generates the isoprenoid precursors 





for generating the seemingly only essential product of the apicoplast required for the survival 
of blood-stage P. falciparum parasites (57). This was demonstrated through the treatment of 
blood-stage parasites with the above-mentioned antibiotics, which typically results in parasite 
death (58, 59). However, the lethality of these drugs can be bypassed if the parasites are 
supplemented with a sufficient concentration of IPP (57). But due to the action of the 
antibiotic, inhibiting protein expression within the organelle, the apicoplast becomes 
disrupted and lost (57). However, these ‘apicoplast-negative’ parasites can continue to 
survive and replicate, seemingly in perpetuity, as long as IPP is provided, demonstrating that 
the entire organelle is dispensable as long the isoprenoid precursor production functionality 
of the organelle is compensated through the direct supplementation of IPP (57). The 
resulting apicoplast disruption phenotype has been analyzed and results in the loss of the 
35kb apicoplast organelle genome, in addition to loss of the typically intact structure of the 
apicoplast, replaced by the accumulation of multiple vesicles throughout the cell, presumably 
containing proteins destined for the apicoplast (57, 60). 
 
Apicoplast Metabolic Bypass 
 The above-mentioned work demonstrating that the apicoplast is dispensable in 
blood-stage P. falciparum parasites under IPP supplementation helped to establish a powerful 
tool in the form of a chemical bypass system, useful for the investigation of essential 
apicoplast-specific proteins and pathways (57). This chemical bypass system allows for the 
interrogation of the apicoplast in ways that would have previously been impossible, including 
investigating the essentiality of genes encoding apicoplast-specific proteins (61–65), in 
addition to having the ability to determine if drugs are apicoplast-specific by looking for 





 While the establishment of the IPP chemical bypass system has been invaluable, 
there are certain drawbacks to the system that make longer-term and larger-scale 
experimentation untenable, potentially explaining why there have been no published genetic 
knockouts of essential apicoplast-specific genes since its establishment in 2011 (57). 
Drawbacks include the incomplete rescue of apicoplast-negative parasites to wild-type 
growth levels, the inability of IPP-dependent parasites to survive cryopreservation, and the 
expense of the chemical at ~$22,500/g (Sigma-Aldrich) with the large amounts (200µM) 
required to rescue parasite growth, in addition to the chemical being labile and requiring 
frequent media exchange (60).  
 As detailed in chapter 2 of this thesis, in order to overcome these issues we have 
developed an alternative genetically-encoded bypass system by engineering parasites to 
express enzymes from the mevalonate (MVA) isoprenoid precursor pathway, creating a 
separate controllable pathway reliant on supplementation with the biomolecule mevalonate 
(67). The mevalonate pathway is an alternative pathway used to generate isoprenoid 
precursors that is common to most other eukaryotes and uses an entirely different set of 
enzymes than the endogenous MEP isoprenoid precursor pathway found within the 
apicoplast organelle of the parasite (67, 68). This line, that we are calling PfMev, converts 
exogenously supplied mevalonate into IPP and DMAPP (Figure 1-2). This alternative 
bypass system addresses many of the problems seen in the chemical bypass, namely, 
mevalonate supplementation in parasites lacking an apicoplast restores growth to wild-type 
levels and only requires 10µM mevalonate. Mevalonate-dependent parasites can be 
successfully cryopreserved, the compound is stable reducing the need for frequent media 
exchanges, and the compound is affordable at $142/g (Sigma Aldrich). These aspects make 





larger-scale and longer-term experimentation, which would be not be feasible without it. The 
PfMev line also contains a fluorescently labeled apicoplast, easily allowing for the 
determination of the resulting phenotype of the organelle from any potential perturbations 
(69). Using this system, we have been able to elucidate the essentiality of numerous proteins 
and pathways within the apicoplast including the SUF iron-sulfur cluster biosynthetic 
pathway, carbon metabolism, and the generation of CoA among others. Investigations into 
these pathways form three of the data chapters of this thesis. 
 
Iron-Sulfur Cluster Biosynthesis in the Apicoplast Organelle 
Within the apicoplast, iron-sulfur clusters are believed to be generated by the SUF 
iron-sulfur cluster biosynthetic pathway and utilized as cofactors in multiple pathways 
throughout the organelle (64, 70, 71). The generation of iron-sulfur clusters by the SUF 
pathway begins with sulfur acquisition, in which the cysteine desulfurase SufS liberates sulfur 
from L-cysteine (72, 73). A non-enzymatic effector protein, SufE, transfers the sulfur to the 
SufBCD iron-sulfur cluster assembly complex (74), which joins the sulfur with iron to form 
the iron-sulfur cluster (Figure 1-3) (75, 76). The iron-sulfur clusters are then handed off to 
the iron-sulfur cluster transfer proteins SufA and NifU (SufU) (77, 78), which deliver the 
iron-sulfur cluster cofactors to the terminal acceptors within the apicoplast (79–81). These 
iron-sulfur cluster dependent proteins are predicted to include lipoic acid synthase (LipA) 
involved the lipoylation of pyruvate dehydrogenase (PDH) (82), MiaB believed to be 
involved in tRNA modification (46, 83), ferredoxin (Fd) which delivers reducing power 
throughout the organelle (46, 84–86), and IspG and IspH of the MEP pathway, which are 
involved in isoprenoid precursor generation (46, 87). Previous work has suggested that the 





pathway are refractory to deletion (78). Additional experimentation involving the generation 
of a SufC (K140A) dominant-negative mutant resulted in the disruption of the organelle 
(64), suggesting that iron-sulfur cluster formation is essential for parasite survival, as well as 
maintenance of the apicoplast. However, the ultimate mechanism by which iron-sulfur 
cluster generation is potentially responsible for organelle maintenance has remained unclear. 
Although, it is hypothesized to potentially occur due to the dysfunction of one of the 
downstream proteins that are reliant on these cofactors for their activity (64). In chapter 3 of 
this thesis we investigate which iron-sulfur cluster dependent proteins and components of 
the SUF pathway are required for blood-stage parasite survival and apicoplast maintenance.  
 
Carbon Metabolism in the Apicoplast Organelle  
 In order to fuel any anabolic pathway within the apicoplast there needs to be a 
source of energy, reducing power, and carbon backbones. These requirements are believed 
to be met from the import and utilization of glycolytic products from the parasite in the 
form of the triose phosphate compounds phosphoenolpyruvate (PEP) and 
dihydroxyacetone phosphate (DHAP), which are imported by the triose phosphate 
transporters on the inner (iTPT) and outer (oTPT) membranes (Figure 1-4) (46, 88). Within 
the apicoplast, DHAP is believed to be utilized as a substrate by triose phosphate isomerase 
(TPI), generating glyceraldehyde-3-phosphate (GA3P) (46), which is fed into the MEP 
pathway, to generate IPP and DMAPP (89). DHAP is also believed to be utilized for 
phospholipid biosynthesis (46, 90), and to potentially be an important source of reducing 
power within the apicoplast (89, 91). Once PEP is imported it is believed to be used as a 
substrate, along with ADP, by pyruvate kinase II (PyrKII) to generate pyruvate and ATP 





the apicoplast (94). The ATP generated presumably powers all energy requiring reactions 
within the organelle (46). The pyruvate generated is fed into the MEP pathway along with 
DHAP for the generation of isoprenoid precursors (89), in addition to being utilized by the 
pyruvate dehydrogenase (PDH) complex, to generate NADH and acetyl-CoA (95). The 
acetyl-CoA is then presumably fed into the FasII pathway for fatty acid biosynthesis, and the 
NADH generated is believed to provide an important source of reducing power in the 
apicoplast, if not providing the only source (46, 96, 97). Additionally, while PyrKII is 
purportedly the only source of ATP and pyruvate within the apicoplast, it may also be 
required for the generation of all NTPs and dNTPs within the apicoplast, as there is no 
other known source for the generation or import of these biomolecules (46). Pyruvate kinase 
enzymes can be active against different NDPs and often don’t exclusively use ADP as a 
substrate (98–101). In other systems pyruvate kinase enzymes are believed to play an import 
role in the generation of nucleoside triphosphates, and may function as a competent 
substitute for nucleoside diphosphate kinase (99). In chapter 4 of this thesis we investigate 
carbon metabolism within the apicoplast, and attempt to determine the importance and role 
that the proteins within this pathway play in blood-stage parasite survival and apicoplast 
maintenance.  
 
CoA Generation in P. falciparum  
 In addition to the pathways and proteins previously mentioned, the last step of 
Coenzyme A (CoA) generation within the parasite is believed to occur within the apicoplast 
(46), being mediated by dephospho-CoA kinase (DPCK) (Figure 1-5). P. falciparum parasites 
are reliant on an exogenous source of pantothenate (vitamin B5) (102, 103), which is used 





parasites (105) and is required for several key processes including fatty acid biosynthesis and 
modification, cellular oxidation and metabolism, and gene expression (106). The CoA 
biosynthetic pathway is essential for parasite survival, with pantothenate analogs inhibiting 
this pathway, and are effective against the asexual blood-stage of the parasite (107–109). 
However, while DPCK is predicted to be localized to the apicoplast and be essential for 
parasite survival, previous work has demonstrated that the entire apicoplast organelle is 
dispensable in blood-stage P. falciparum parasites if supplemented with a sufficient 
concentration of IPP (57). This has been interpreted as IPP being the only essential product 
of the apicoplast, but due to the proposed essential activity and putative localization of 
DPCK, the requirement for this enzyme should not be bypassable with IPP supplementation 
(46, 110). The phenotype of parasites containing a disrupted organelle has been 
characterized, with the typically intact structure of the organelle being lost, replaced by the 
accumulation of vesicles throughout the cell, in addition to the ~35kb apicoplast genome 
being lost as well (57, 64). However, these vesicles are predicted to contain proteins that 
would typically be trafficked to the apicoplast organelle (43). Thus, it is possible these 
vesicles potentially containing apicoplast-specific proteins are still biochemically active, with 
DPCK possibly being present and active within these vesicles, fulfilling its essential function 
required for parasite survival. In chapter 5 of this thesis we investigate DPCK, and the 
importance of this protein for parasite survival, and the localization and function of DPCK 
activity when the apicoplast is intact or disrupted.    
 
Thesis Rationale  
 The impetus for this work began with research conducted previously in our lab 





disruption of the apicoplast organelle when expressed in the presence of IPP 
supplementation (64). While the ultimate mechanism was not elucidated in that work, it was 
speculated that the loss of the organelle was likely due to the loss of function of one of the 
downstream iron-sulfur cluster dependent proteins being deprived of its essential iron-sulfur 
cluster cofactor. We wanted to follow up on this, and determine which of these iron-sulfur 
cluster dependent proteins may replicate the previously observed phenotype. However, 
further exploration of essential apicoplast-specific proteins would likely require the 
generation of genetic knockouts, and since its establishment in 2011 (57), there have been no 
published deletions of genes encoding essential apicoplast-specific proteins, likely due to the 
cost and inherent difficulty associated with the IPP chemical bypass system. Thus, in order 
to follow up on this work, and potentially identify other apicoplast-specific proteins in other 
pathways that are essential for parasite survival and apicoplast maintenance, our lab 
produced the PfMev apicoplast metabolic bypass line.  
 As outlined in this thesis, our lab was successful in generating a genetic-based 
apicoplast bypass system, reliant on the supplementation of mevalonate, which is converted 
into IPP by the parasite through the expression of four exogenous enzymes from the 
alternative mevalonate pathway. We were able to characterize this line and validate it as a 
useful platform that could be used to interrogate essential apicoplast proteins and pathways. 
Perhaps most importantly, we were able to demonstrate the facile deletion of a gene 
encoding an essential apicoplast-specific protein using the PfMev line through CRISPR-Cas9 
mediated genome editing. This set the stage for the rest of the work outlined in this thesis. 
Having this tool allowed us to follow up on which, if any iron-sulfur cluster dependent 
proteins were essential for parasite survival and organelle maintenance through their deletion 





proteins and pathways within the apicoplast may also be required for parasite survival and 
apicoplast maintenance as well.  
In an attempt to uncover the ultimate mechanism by which iron-sulfur cluster 
generation is required for organelle maintenance and parasite survival we made use of the 
PfMev line by generating a series of genetic knockouts. Through this work we were able to 
determine which iron-sulfur cluster dependent proteins, in addition to which proteins 
involved in the apicoplast SUF iron-sulfur cluster biosynthetic pathway are essential for 
parasite survival and apicoplast maintenance. The results obtained were surprising and 
unexpected, and demonstrated that while iron-sulfur cluster generation is not required for 
the maintenance of the organelle, the generation and utilization of sulfur by a tRNA 
modifying enzyme likely is.  
We went on to use this tool to explore, and potentially solve additional unanswered 
questions in the field relating to P. falciparum apicoplast metabolism. For example, it is not 
entirely clear how the apicoplast generates energy and reducing equivalents needed to supply 
the various metabolic pathways within the organelle (46), and which if any of the anabolic 
pathways within the apicoplast are required for the maintenance of the organelle. Thus, we 
attempted to determine this through a series of genetic knockouts in the pathways involved 
in apicoplast carbon metabolism, using our PfMev line under mevalonate supplementation, 
in addition to using other techniques as well.  
 It has also been shown that the apicoplast can be disrupted as long as IPP is 
provided (57). However, it appears as if apicoplast-specific proteins are still being 
transcribed, translated, packaged, and sent out into the cell within vesicles (43). It is not clear 
if all apicoplast-specific proteins are functionally null due to the loss of the intact organelle, 





dephospho-CoA kinase (DPCK), which is predicted to be apicoplast localized, but whose 
activity should be essential for parasite survival, and not be able to be bypassed through IPP 
supplementation (106, 110). Additionally, it is not clear why DPCK would be localized to the 
extremely reduced apicoplast, and if its activity is required within the apicoplast organelle. 
Thus, we also utilized the PfMev line in an attempt to answer these questions through a 












































Figure 1-1 The lifecycle of Plasmodium falciparum parasites 
P. falciparum parasites complete their lifecycle by replicating within the human host in 
addition to an Anopheles mosquito vector. The asexual stage of the parasite within the human 
host cyclically infects RBCs, progressing through the ring, trophozoite and schizont stages 
before releasing merozoites, which invade RBCs. A subpopulation of these parasites 
undergo sexual differentiation, forming male and female gametocytes. These gametocytes are 
taken up by an Anopheles mosquito, eventually fusing and forming a zygote, before forming 
infectious sporozoites that localize to the salivary gland of the mosquito and are later 
released into a human host. These parasites then invade hepatocyte liver cells, and undergo 







Figure 1-2 The endogenous (MEP) and engineered (MVA) isoprenoid pathways 
Plasmodium parasites contain the endogenous MEP isoprenoid precursor pathway within the 
apicoplast organelle of the parasite. PfMev parasites were engineered to convert exogenously 
supplied mevalonate into IPP and DMAPP through the expression of four enzymes from 




















Figure 1-3 Iron-sulfur cluster assembly and transfer in the apicoplast 
Iron-sulfur cluster assembly takes place in three steps: sulfur acquisition – mediated by the 
cysteine desulfurase SufS along with SufE. Sulfur is transferred by SufE to the SufBCD 
cluster assembly complex. Fe-S clusters are handed off to SufA or NifU, which deliver the 























Figure 1-4 Carbon metabolism in the apicoplast 
Carbon backbones are imported into the apicoplast organelle in the form of 3-carbon 
phosphates by the apicoplast membrane outer triose phosphate transporter (oTPT) and 
inner triose phosphate transporter (iTPT). Phosphoenolpyruvate (PEP) along with 
adenosine diphosphate (ADP) are converted into pyruvate as well as adenosine triphosphate 
(ATP). Pyruvate is utilized by the FasII fatty acid pathway as well as the isoprenoid precursor 
pathway. Dihydroxyacetone phosphate (DHAP) is also imported and converted to 
glyceraldehyde-3-phosphate (GA3P) by triose phosphate isomerase (TPI), which is also 


















Figure 1-5 Generation of CoA and utilization in the apicoplast 
Parasites are reliant on scavenged pantothenate, which is used to generate CoA through a 
series of enzymes within the cytosol. The final step involving the conversion of dephospho-
CoA to CoA by DPCK is believed to occur within the apicoplast. CoA is presumably 























1.  Health Organization W. WORLD MALARIA REPORT 2018 ISBN 978 92 4 156565 
3. 
2.   2000. Severe falciparum malaria. World Health Organization, Communicable Diseases 
Cluster. Trans R Soc Trop Med Hyg 94 Suppl 1:S1-90. 
3.  Cowman AF, Healer J, Marapana D, Marsh K. 2016. Malaria: Biology and Disease. 
Cell 167:610–624. 
4.  Hawking F, Worms MJ, Gammage K. 1968. 24- and 48-hour cycles of malaria 
parasites in the blood; their purpose, production and control. Trans R Soc Trop Med 
Hyg 62:731–65. 
5.  Bannister LH, Hopkins JM, Fowler RE, Krishna S, Mitchell GH. 2000. A brief 
illustrated guide to the ultrastructure of Plasmodium falciparum asexual blood stages. 
Parasitol Today 16:427–33. 
6.  Bruce MC, Alano P, Duthie S, Carter R. 1990. Commitment of the malaria parasite 
Plasmodium falciparum to sexual and asexual development. Parasitology 100 Pt 2:191–
200. 
7.  Sinden RE. 1983. Sexual Development of Malarial Parasites. Adv Parasitol 22:153–
216. 
8.  Molina-Cruz A, Zilversmit MM, Neafsey DE, Hartl DL, Barillas-Mury C. 2016. 
Mosquito Vectors and the Globalization of Plasmodium falciparum Malaria. Annu Rev 
Genet 50:447–465. 
9.  Bennink S, Kiesow MJ, Pradel G. 2016. The development of malaria parasites in the 
mosquito midgut. Cell Microbiol 18:905–18. 
10.  Aly ASI, Vaughan AM, Kappe SHI. 2009. Malaria Parasite Development in the 
Mosquito and Infection of the Mammalian Host. Annu Rev Microbiol 63:195–221. 
11.  Ghosh AK, Jacobs-Lorena M. 2009. Plasmodium sporozoite invasion of the mosquito 
salivary gland. Curr Opin Microbiol 12:394–400. 
12.  Ménard R, Tavares J, Cockburn I, Markus M, Zavala F, Amino R. 2013. Looking 
under the skin: the first steps in malarial infection and immunity. Nat Rev Microbiol 
11:701–712. 
13.  Vaughan AM, Aly ASI, Kappe SHI. 2008. Malaria parasite pre-erythrocytic stage 
infection: gliding and hiding. Cell Host Microbe 4:209–18. 
14.  Yuda M, Ishino T. 2004. Liver invasion by malarial parasites - how do malarial 





15.   2018. WHO | Responding to antimalarial drug resistance. WHO. 
16.  Jong EC, Nothdurft HD. 2001. Current drugs for antimalarial chemoprophylaxis: a 
review of efficacy and safety. J Travel Med 8:S48-56. 
17.  Jensen M, Mehlhorn H. 2009. Seventy-five years of Resochin® in the fight against 
malaria. Parasitol Res 105:609–627. 
18.  Gatton ML, Martin LB, Cheng Q. 2004. Evolution of resistance to sulfadoxine-
pyrimethamine in Plasmodium falciparum. Antimicrob Agents Chemother 48:2116–23. 
19.  Price RN, Uhlemann A-C, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, 
Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S. 2004. Mefloquine 
resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 
(London, England) 364:438–447. 
20.  Jelinek T, Schelbert P, Löscher T, Eichenlaub D. 1995. Quinine resistant falciparum 
malaria acquired in east Africa. Trop Med Parasitol 46:38–40. 
21.  Cui L, Mharakurwa S, Ndiaye D, Rathod PK, Rosenthal PJ. 2015. Antimalarial Drug 
Resistance: Literature Review and Activities and Findings of the ICEMR Network. 
Am J Trop Med Hyg 93:57–68. 
22.  Ljolje D, Dimbu PR, Kelley J, Goldman I, Nace D, Macaia A, Halsey ES, Ringwald P, 
Fortes F, Udhayakumar V, Talundzic E, Lucchi NW, Plucinski MM. 2018. Prevalence 
of molecular markers of artemisinin and lumefantrine resistance among patients with 
uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015. Malar 
J 17:84. 
23.  Ouji M, Augereau J-M, Paloque L, Benoit-Vical F. 2018. Plasmodium falciparum 
resistance to artemisinin-based combination therapies: A sword of Damocles in the 
path toward malaria elimination. Parasite 25:24. 
24.  Health Organization W. Artemisinin resistance and artemisinin-based combination 
therapy efficacy (Status report -- August 2018). 
25.  Huang F, Takala-Harrison S, Jacob CG, Liu H, Sun X, Yang H, Nyunt MM, Adams 
M, Zhou S, Xia Z, Ringwald P, Bustos MD, Tang L, Plowe C V. 2015. A Single 
Mutation in K13 Predominates in Southern China and Is Associated With Delayed 
Clearance of Plasmodium falciparum Following Artemisinin Treatment. J Infect Dis 
212:1629–1635. 
26.  Cheng Q, Kyle DE, Gatton ML. 2012. Artemisinin resistance in Plasmodium falciparum: 
A process linked to dormancy? Int J Parasitol Drugs drug Resist 2:249–255. 
27.  Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. 2016. Artemisinin Action and 
Resistance in Plasmodium falciparum. Trends Parasitol 32:682–696. 





falciparum malaria. Curr Opin Pharmacol 42:46–54. 
29.  Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, 
Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, 
Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, 
Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han K-T, 
Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong 
M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra 
N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, 
Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam 
A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, 
Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, 
Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, 
Flegg JA, Das D, Smith J, Venkatesan M, Plowe C V., Stepniewska K, Guerin PJ, 
Dondorp AM, Day NP, White NJ, Tracking Resistance to Artemisinin Collaboration 
(TRAC). 2014. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. N 
Engl J Med 371:411–423. 
30.  Hemming-Schroeder E, Lo E. 2017. Evidence of a hard selective sweep for 
artemisinin resistant Plasmodium falciparum. Lancet Infect Dis 17:462–463. 
31.  McFadden GI, Reith ME, Munholland J, Lang-Unnasch N. 1996. Plastid in human 
parasites. Nature 381:482–482. 
32.  Köhler S, Delwiche CF, Denny PW, Tilney LG, Webster P, Wilson RJ, Palmer JD, 
Roos DS. 1997. A plastid of probable green algal origin in Apicomplexan parasites. 
Science 275:1485–9. 
33.  Mukherjee A, Sadhukhan CG. 2016. Anti-malarial Drug Design by Targeting 
Apicoplasts: New Perspectives. J pharmacopuncture 19:7–15. 
34.  Janouskovec J, Horák A, Oborník M, Lukes J, Keeling PJ. 2010. A common red algal 
origin of the apicomplexan, dinoflagellate, and heterokont plastids. Proc Natl Acad 
Sci U S A 107:10949–54. 
35.  Gould SB, Waller RF, McFadden GI. 2008. Plastid Evolution. Annu Rev Plant Biol 
59:491–517. 
36.  Gould SB, Maier U-G, Martin WF. 2015. Protein Import and the Origin of Red 
Complex Plastids. Curr Biol 25:R515–R521. 
37.  Arisue N, Hashimoto T, Mitsui H, Palacpac QNM, Kaneko A, Kawai S, Hasegawa M, 
Tanabe K, Horii T. 2012. The Plasmodium apicoplast genome: conserved structure and 
close relationship of P. ovale to rodent malaria parasites. Mol Biol Evol 29:2095–
2099. 
38.  Wilson RJ, Denny PW, Preiser PR, Rangachari K, Roberts K, Roy A, Whyte A, Strath 





like DNA of the malaria parasite Plasmodium falciparum. J Mol Biol 261:155–72. 
39.  McFadden GI. 2000. Mergers and acquisitions: malaria and the great chloroplast heist. 
Genome Biol 1:reviews1026.1. 
40.  Lim L, McFadden GI. 2010. The evolution, metabolism and functions of the 
apicoplast. Philos Trans R Soc Lond B Biol Sci 365:749–63. 
41.  Martin W. 2003. Gene transfer from organelles to the nucleus: Frequent and in big 
chunks. Proc Natl Acad Sci 100:8612–8614. 
42.  Gallagher JR, Matthews KA, Prigge ST. 2011. Plasmodium falciparum apicoplast transit 
peptides are unstructured in vitro and during apicoplast import. Traffic 12:1124–38. 
43.  Bouchut A, Geiger JA, DeRocher AE, Parsons M. 2014. Vesicles Bearing Toxoplasma 
Apicoplast Membrane Proteins Persist Following Loss of the Relict Plastid or Golgi 
Body Disruption. PLoS One 9:e112096. 
44.  Parsons M, Karnataki A, Feagin JE, DeRocher A. 2007. Protein trafficking to the 
apicoplast: deciphering the apicomplexan solution to secondary endosymbiosis. 
Eukaryot Cell 6:1081–8. 
45.  Chaudhari R, Dey V, Narayan A, Sharma S, Patankar S. 2017. Membrane and luminal 
proteins reach the apicoplast by different trafficking pathways in the malaria parasite 
Plasmodium falciparum. PeerJ 5:e3128. 
46.  Ralph SA, van Dooren GG, Waller RF, Crawford MJ, Fraunholz MJ, Foth BJ, 
Tonkin CJ, Roos DS, McFadden GI. 2004. Tropical infectious diseases: metabolic 
maps and functions of the Plasmodium falciparum apicoplast. Nat Rev Microbiol 2:203–
16. 
47.  Foth JB, Ralph AS, Tonkin JC, Struck SN, Fraunholz M, Roos SD, Cowman FA, 
McFadden IG. 2003. Dissecting apicoplast targeting in the malaria parasite Plasmodium 
falciparum. Science 299:705–708. 
48.  Zuegge J, Ralph S, Schmuker M, McFadden GI, Schneider G. 2001. Deciphering 
apicoplast targeting signals – feature extraction from nuclear-encoded precursors of 
Plasmodium falciparum apicoplast proteins. Gene 280:19–26. 
49.  Cilingir G, Lau AOT, Broschat SL. 2013. ApicoAMP: The first computational model 
for identifying apicoplast-targeted transmembrane proteins in Apicomplexa. J 
Microbiol Methods 95:313–319. 
50.  Cilingir G, Broschat SL, Lau AOT. 2012. ApicoAP: The First Computational Model 
for Identifying Apicoplast-Targeted Proteins in Multiple Species of Apicomplexa. 
PLoS One 7:e36598. 
51.  Fichera ME, Roos DS. 1997. A plastid organelle as a drug target in apicomplexan 





52.  Ramya TNC, Mishra S, Karmodiya K, Surolia N, Surolia A. 2007. Inhibitors of 
nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium 
falciparum. Antimicrob Agents Chemother 51:307–16. 
53.  Yu M, Kumar STR, Nkrumah JL, Coppi A, Retzlaff S, Li DC, Kelly JB, Moura AP, 
Lakshmanan V, Freundlich SJ, Valderramos J-C, Vilcheze C, Siedner M, Tsai H-CJ, 
Falkard B, Sidhu SAB, Purcell AL, Gratraud P, Kremer L, Waters PA, Schiehser G, 
Jacobus PD, Janse JC, Ager A, Jacobs RW, Sacchettini CJ, Heussler V, Sinnis P, 
Fidock AD. 2008. The fatty acid biosynthesis enzyme FabI plays a key role in the 
development of liver-stage malarial parasites. Cell Host Microbe 4:567–578. 
54.  Vaughan MA, O’Neill TM, Tarun SA, Camargo N, Phuong MT, Aly IAS, Cowman 
FA, Kappe ISH. 2009. Type II fatty acid synthesis is essential only for malaria parasite 
late liver stage development. Cell Microbiol 11:506–520. 
55.  Nagaraj VA, Sundaram B, Varadarajan NM, Subramani PA, Kalappa DM, Ghosh SK, 
Padmanaban G. 2013. Malaria Parasite-Synthesized Heme Is Essential in the 
Mosquito and Liver Stages and Complements Host Heme in the Blood stages of 
Infection. PLoS Pathog 9:e1003522. 
56.  Ke H, Sigala PA, Miura K, Morrisey JM, Mather MW, Crowley JR, Henderson JP, 
Goldberg DE, Long CA, Vaidya AB. 2014. The Heme Biosynthesis Pathway Is 
Essential for Plasmodium falciparum Development in Mosquito Stage but Not in Blood 
stages. J Biol Chem 289:34827–34837. 
57.  Yeh E, DeRisi LJ. 2011. Chemical rescue of malaria parasites lacking an apicoplast 
defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol 9. 
58.  Dahl LE, Shock LJ, Shenai RB, Gut J, DeRisi LJ, Rosenthal JP. 2006. Tetracyclines 
specifically target the apicoplast of the malaria parasite Plasmodium falciparum. 
Antimicrob Agents Chemother 50:3124–3131. 
59.  Dahl LE, Rosenthal JP. 2007. Multiple antibiotics exert delayed effects against the 
Plasmodium falciparum apicoplast. Antimicrob Agents Chemother 51:3485–3490. 
60.  Gisselberg JE, Dellibovi-Ragheb T a., Matthews K a., Bosch G, Prigge ST. 2013. The 
Suf Iron-Sulfur Cluster Synthesis Pathway Is Required for Apicoplast Maintenance in 
Malaria Parasites. PLoS Pathog 9. 
61.  Amberg-Johnson K, Hari BS, Ganesan MS, Lorenzi AH, Sauer TR, Niles CJ, Yeh E. 
2017. Small molecule inhibition of apicomplexan FtsH1 disrupts plastid biogenesis in 
human pathogens. Elife 6. 
62.  Pasaje ACF, Cheung V, Kennedy K, Lim EE, Baell BJ, Griffin WMD, Ralph AS. 
2016. Selective inhibition of apicoplast tryptophanyl-tRNA synthetase causes delayed 
death in Plasmodium falciparum. Sci Rep 6. 





2017. PfClpC Is an Essential Clp Chaperone Required for Plastid Integrity and Clp 
Protease Stability in Plasmodium falciparum. Cell Rep 21. 
64.  Gisselberg EJ, Dellibovi-Ragheb AT, Matthews AK, Bosch G, Prigge TS. 2013. The 
suf iron-sulfur cluster synthesis pathway is required for apicoplast maintenance in 
malaria parasites. PLoS Pathog 9. 
65.  Walczak M, Ganesan SM, Niles JC, Yeh E. 2018. ATG8 Is Essential Specifically for 
an Autophagy-Independent Function in Apicoplast Biogenesis in Blood-Stage Malaria 
Parasites. MBio 9:e02021-17. 
66.  Wu W, Herrera Z, Ebert D, Baska K, Cho HS, DeRisi LJ, Yeh E. 2015. A chemical 
rescue screen identifies a Plasmodium falciparum apicoplast inhibitor targeting MEP 
isoprenoid precursor biosynthesis. Antimicrob Agents Chemother 59:356–364. 
67.  Kuzuyama T, Seto H. 2012. Two distinct pathways for essential metabolic precursors 
for isoprenoid biosynthesis. Proc Jpn Acad Ser B Phys Biol Sci 88:41–52. 
68.  Guggisberg MA, Amthor ER, Odom RA. 2014. Isoprenoid biosynthesis in Plasmodium 
falciparum. Eukaryot Cell 13:1348–1359. 
69.  Stanway RR, Witt T, Zobiak B, Aepfelbacher M, Heussler VT. 2009. GFP-targeting 
allows visualization of the apicoplast throughout the life cycle of live malaria parasites. 
Biol Cell 101:415–435. 
70.  Ellis EK, Clough B, Saldanha WJ, Wilson JR. 2001. Nifs and Sufs in malaria. Mol 
Microbiol 41:973–981. 
71.  Charan M, Singh N, Kumar B, Srivastava K, Siddiqi IM, Habib S. 2014. Sulfur 
mobilization for Fe-S cluster assembly by the essential SUF pathway in the Plasmodium 
falciparum apicoplast and its inhibition. Antimicrob Agents Chemother 58:3389–3398. 
72.  Loiseau L, Ollagnier-de-Choudens S, Nachin L, Fontecave M, Barras F. 2003. 
Biogenesis of Fe-S cluster by the bacterial Suf system: SufS and SufE form a new type 
of cysteine desulfurase. J Biol Chem 278:38352–38359. 
73.  Outten FW, Wood MJ, Munoz FM, Storz G. 2003. The SufE protein and the 
SufBCD complex enhance SufS cysteine desulfurase activity as part of a sulfur 
transfer pathway for Fe-S cluster assembly in Escherichia coli. J Biol Chem 278:45713–
9. 
74.  Layer G, Gaddam AS, Ayala-Castro NC, Ollagnier-de Choudens S, Lascoux D, 
Fontecave M, Outten WF. 2007. SufE transfers sulfur from SufS to SufB for iron-
sulfur cluster assembly. J Biol Chem 282:13342–13350. 
75.  Saini A, Mapolelo TD, Chahal KH, Johnson KM, Outten WF. 2010. SufD and SufC 
ATPase activity are required for iron acquisition during in vivo Fe-S cluster formation 





76.  Hirabayashi K, Yuda E, Tanaka N, Katayama S, Iwasaki K, Matsumoto T, Kurisu G, 
Outten FW, Fukuyama K, Takahashi Y, Wada K. 2015. Functional Dynamics 
Revealed by the Structure of the SufBCD Complex, a Novel ATP-binding Cassette 
(ABC) Protein That Serves as a Scaffold for Iron-Sulfur Cluster Biogenesis. J Biol 
Chem 290:29717–31. 
77.  Haussig MJ, Matuschewski K, Kooij ATW. 2013. Experimental Genetics of 
Plasmodium berghei NFU in the Apicoplast Iron-Sulfur Cluster Biogenesis Pathway. 
PLoS One 8. 
78.  Haussig MJ, Matuschewski K, Kooij ATW. 2014. Identification of vital and 
dispensable sulfur utilization factors in the Plasmodium apicoplast. PLoS One 9. 
79.  Gupta V, Sendra M, Naik GS, Chahal KH, Huynh HB, Outten WF, Fontecave M, de 
Choudens S. 2009. Native Escherichia coli SufA, coexpressed with SufBCDSE, purifies 
as a [2Fe-2S] protein and acts as an Fe-S transporter to Fe-S target enzymes. J Am 
Chem Soc 131:6149–6153. 
80.  Py B, Gerez C, Angelini S, Planel R, Vinella D, Loiseau L, Talla E, Brochier-Armanet 
C, Garcia Serres R, Latour J-M, Ollagnier-de Choudens S, Fontecave M, Barras F. 
2012. Molecular organization, biochemical function, cellular role and evolution of 
NfuA, an atypical Fe-S carrier. Mol Microbiol 86:155–171. 
81.  Chahal KH, Dai Y, Saini A, Ayala-Castro C, Outten WF. 2009. The SufBCD Fe-S 
scaffold complex interacts with SufA for Fe-S cluster transfer. Biochemistry 
48:10644–10653. 
82.  Wrenger C, Müller S. 2004. The human malaria parasite Plasmodium falciparum has 
distinct organelle-specific lipoylation pathways. Mol Microbiol 53:103–113. 
83.  Esberg B, Leung HC, Tsui HC, Björk GR, Winkler ME. 1999. Identification of the 
miaB gene, involved in methylthiolation of isopentenylated A37 derivatives in the 
tRNA of Salmonella typhimurium and Escherichia coli. J Bacteriol 181:7256–65. 
84.  Seeber F, Soldati-Favre D. 2010. Metabolic Pathways in the Apicoplast of 
Apicomplexa. Int Rev Cell Mol Biol 281:161–228. 
85.  Seeber F, Aliverti A, Zanetti G. 2005. The plant-type ferredoxin-NADP+ 
reductase/ferredoxin redox system as a possible drug target against apicomplexan 
human parasites. Curr Pharm Des 11:3159–72. 
86.  Röhrich CR, Englert N, Troschke K, Reichenberg A, Hintz M, Seeber F, Balconi E, 
Aliverti A, Zanetti G, Köhler U, Pfeiffer M, Beck E, Jomaa H, Wiesner J. 2005. 
Reconstitution of an apicoplast-localised electron transfer pathway involved in the 
isoprenoid biosynthesis of Plasmodium falciparum. FEBS Lett 579:6433–6438. 
87.  Saggu SG, Garg S, Pala RZ, Yadav KS, Kochar KS, Kochar KD, Saxena V. 2017. 





from Plasmodium vivax and it’s potential as an antimalarial drug target. Int J Biol 
Macromol 96:466–473. 
88.  Lim L, Linka M, Mullin KA, Weber APM, McFadden GI. 2010. The carbon and 
energy sources of the non-photosynthetic plastid in the malaria parasite. FEBS Lett 
584:549–554. 
89.  Lim L, McFadden GI. 2010. The evolution, metabolism and functions of the 
apicoplast. Philos Trans R Soc Lond B Biol Sci 365:749–63. 
90.  Lindner SE, Sartain MJ, Hayes K, Harupa A, Moritz RL, Kappe SHI, Vaughan AM. 
2014. Enzymes involved in plastid-targeted phosphatidic acid synthesis are essential 
for P lasmodium yoelii liver-stage development. Mol Microbiol 91:679–693. 
91.  Fleige T, Fischer K, Ferguson DJP, Gross U, Bohne W. 2007. Carbohydrate 
metabolism in the Toxoplasma gondii apicoplast: localization of three glycolytic 
isoenzymes, the single pyruvate dehydrogenase complex, and a plastid phosphate 
translocator. Eukaryot Cell 6:984–96. 
92.  Saito T, Nishi M, Lim IM, Wu B, Maeda T, Hashimoto H, Takeuchi T, Roos SD, 
Asai T. 2008. A novel GDP-dependent pyruvate kinase isozyme from Toxoplasma 
gondii localizes to both the apicoplast and the mitochondrion. J Biol Chem 283:14041–
14052. 
93.  Israelsen JW, Vander Heiden GM. 2015. Pyruvate kinase: function, regulation and 
role in cancer. Semin Cell Dev Biol 43:43–51. 
94.  Lim L, Linka M, Mullin KA, Weber APM, McFadden GI. 2010. The carbon and 
energy sources of the non-photosynthetic plastid in the malaria parasite. FEBS Lett 
584:549–554. 
95.  Foth JB, Stimmler ML, Handman E, Crabb SB, Hodder NA, McFadden IG. 2005. 
The malaria parasite Plasmodium falciparum has only one pyruvate dehydrogenase 
complex, which is located in the apicoplast. Mol Microbiol 55:39–53. 
96.  Foth JB, Stimmler ML, Handman E, Crabb SB, Hodder NA, McFadden IG. 2004. 
The malaria parasite Plasmodium falciparum has only one pyruvate dehydrogenase 
complex, which is located in the apicoplast: The single, plastidic PDH of Plasmodium 
falciparum. Mol Microbiol 55. 
97.  Laine LM, Biddau M, Byron O, Müller S. 2015. Biochemical and structural 
characterization of the apicoplast dihydrolipoamide dehydrogenase of Plasmodium 
falciparum. Biosci Rep 35. 
98.  Boehme C, Bieber F, Linnemann J, Breitling R, Lorkowski S, Reissmann S. 2013. 
Chemical and enzymatic characterization of recombinant rabbit muscle pyruvate 





99.  Saeki T, Hori M, Umezawa H. 1974. Pyruvate kinase of Escherichia coli. Its role in 
supplying nucleoside triphosphates in cells under anaerobic conditions. J Biochem 
76:631–7. 
100.  Knowles VL, Smith CS, Smith CR, Plaxton WC. 2001. Structural and Regulatory 
Properties of Pyruvate Kinase from the Cyanobacterium Synechococcus PCC 6301 . J 
Biol Chem 276:20966–20972. 
101.  Abbe K, Yamada T. 1982. Purification and properties of pyruvate kinase from 
Streptococcus mutans. J Bacteriol 149:299–305. 
102.  Geary GT, Divo AA, Bonanni CL, Jensen BJ. 1985. Nutritional requirements of 
Plasmodium falciparum in culture. III. Further observations on essential nutrients and 
antimetabolites. J Protozool 32:608–613. 
103.  Saliba KJ, Ferru I, Kirk K. 2005. Provitamin B5 (pantothenol) inhibits growth of the 
intraerythrocytic malaria parasite. Antimicrob Agents Chemother 49:632–7. 
104.  Spry C, Saliba JK. 2009. The human malaria parasite Plasmodium falciparum is not 
dependent on host coenzyme A biosynthesis. J Biol Chem 284:24904–24913. 
105.  Spry C, Kirk K, Saliba JK. 2008. Coenzyme A biosynthesis: an antimicrobial drug 
target. FEMS Microbiol Rev 32:56–106. 
106.  Spry C, van Schalkwyk DA, Strauss E, Saliba KJ. 2010. Pantothenate utilization by 
Plasmodium as a target for antimalarial chemotherapy. Infect Disord Drug Targets 
10:200–16. 
107.  Spry C, Chai LCL, Kirk K, Saliba JK. 2005. A class of pantothenic acid analogs 
inhibits Plasmodium falciparum pantothenate kinase and represses the proliferation of 
malaria parasites. Antimicrob Agents Chemother 49:4649–4657. 
108.  Spry C, Macuamule C, Lin Z, Virga KG, Lee RE, Strauss E, Saliba KJ. 2013. 
Pantothenamides Are Potent, On-Target Inhibitors of Plasmodium falciparum Growth 
When Serum Pantetheinase Is Inactivated. PLoS One 8:e54974. 
109.  Macuamule CJ, Tjhin ET, Jana CE, Barnard L, Koekemoer L, de Villiers M, Saliba 
KJ, Strauss E. 2015. A Pantetheinase-Resistant Pantothenamide with Potent, On-
Target, and Selective Antiplasmodial Activity. Antimicrob Agents Chemother 
59:3666–3668. 
110.  Hart JR, Abraham A, Aly IAS. 2017. Genetic Characterization of Coenzyme A 
Biosynthesis Reveals Essential Distinctive Functions during Malaria Parasite 











































- The generation of the pMPC-aSFG plasmid was a collaborative effort between Dr. 
Sean Prigge, Dr. Hugo Jhun, Dr. Aleah Roberts, and Dr. Krista Matthews. 
- The Figure 2-4 IFA was generated by Dr. Aleah Roberts 
- The Figure 2-5 IFA was generated by Dr. Krithika Rajaram 








The apicoplast plays an essential role in the survival of Plasmodium falciparum parasites. 
However, the entire organelle is dispensable in blood-stage parasites as long as the 
isoprenoid precursor isopentenyl pyrophosphate (IPP) is added to the culture medium. 
Previous research established a chemical bypass system, allowing for the rescue of parasites 
missing the apicoplast organelle through the direct supplementation of IPP. While this tool 
has been invaluable to the field, the system has drawbacks that make larger-scale and longer-
term experiments unfeasible. In order to overcome these issues, we have developed an 
alternative genetically-encoded bypass system by engineering parasites to express enzymes 
from an exogenous mevalonate isoprenoid precursor pathway. This parasite line, that we are 
calling PfMev, contains an IPP production pathway that is controllable through the 




 Work to eliminate or control the spread of the malarial infections span a century or 
more but have been hindered by the rise and spread of resistance to the antimalarial drugs 
(1–7). In order to continue the progress that has been made in reducing malarial infections 
and deaths attributed to the disease there is a critical need for new drugs with novel 
mechanisms of action (8). In efforts to identify new drug targets, the apicoplast organelle 
within the parasite has often been considered due to the organelle possessing evolutionarily 
distinct biochemical pathways that are not present in the human host (9), in addition to the 
organelle being essential for parasite survival, features which make it an attractive source of 





The apicoplast is home to a number of biochemical pathways including the FasII 
fatty acid biosynthetic pathway, the methylerythritol phosphate (MEP) pathway responsible 
for the generation of the isoprenoid precursors isopentenyl pyrophosphate (IPP) and 
dimethylallyl pyrophosphate (DMAPP), the heme biosynthetic pathway shared with the 
mitochondrion, and the SUF pathway that generates iron-sulfur cluster cofactors for usage 
within the organelle (12). Additionally, there are an estimated ~400 proteins trafficked to the 
apicoplast, representing ~7% of the parasite genome [36]–[39]. However, of all the proteins 
and processes present within this organelle it has appeared that the isoprenoid precursors 
generated by the MEP pathway are the only essential products produced by the apicoplast 
that are required in other compartments of the cell during the asexual blood-stage of the 
parasite (17). Previous work by Yeh et al. in 2011 established a chemical bypass system, 
demonstrating that parasites can continue to survive and replicate without an intact 
apicoplast organelle as long as IPP is supplemented in sufficient quantities (17).  
This chemical bypass system established by Yeh et al. has proven to be invaluable to 
the study of the apicoplast in malaria parasites, with previous research utilizing this bypass to 
interrogate the essentiality of apicoplast-specific genes (18–22), and test differential drug 
sensitivity to better determine the specificity and mechanism of action of certain drugs (18, 
23). However, this system has some drawbacks that make certain longer-term and larger-
scale experiments difficult to accomplish, including the expense of the chemical at 
~$25,800/g (Sigma-Aldrich) with the large amounts (200µM) required to rescue parasite 
growth (17), in addition to the chemical being labile and requiring frequent media exchange. 
In our hands, we have also experienced incomplete rescue of apicoplast-negative parasites to 
wild-type growth levels under IPP supplementation, and have found IPP-dependent 





after 30-days of culturing. For these reasons, the chemical bypass system is not easily 
amenable to longer-term experimentation, such as the generation of nuclear-encoded 
apicoplast-specific genetic knockouts, which is likely why none have been published since 
the discovery of the IPP chemical bypass in 2011. However, it should be noted that there 
have been multiple published reports of transcripts encoding essential apicoplast-specific 
proteins being knocked-down using conditional systems and rescued through IPP 
supplementation (18–20, 22), in addition to IPP rescuing the expression of a dominant-
negative mutant (21).  
In order to address these issues we have developed an alternative method of IPP 
supplementation through the cytosolic expression of four enzymes from the mevalonate-
dependent (MVA) isoprenoid precursor pathway (24), encoded by a single plasmid that has 
been integrated into the parasite genome (Figure 2-1). The MVA pathway is an alternative 
pathway used to generate isoprenoid precursors that is common to gram-positive bacteria 
and most eukaryotes (25). This pathway uses an entirely different set of enzymes and 
intermediates than the endogenous MEP isoprenoid precursor pathway within the apicoplast 
organelle of the parasite (25, 26). This newly established line, that we are calling PfMev, 
converts exogenously supplied mevalonate into IPP and DMAPP. We have found that this 
alternative bypass system addresses many of the problems seen in the chemical bypass, 
namely, mevalonate supplementation in PfMev parasites lacking an apicoplast restores 
growth to wild-type levels and requires as little as 10µM mevalonate. Additionally, 
mevalonate-dependent PfMev parasites can be easily cryopreserved and thawed, mevalonate 
is stable, abrogating the need of frequent media exchange, and the compound is affordable 





alternative to the chemical bypass system, and should allow for larger-scale and longer-term 
experimentation that would be unfeasible without it.  
We also engineered the PfMev parasite line to express a stable green fluorescent 
protein called super-folder green (SFG) in the apicoplast organelle. SFG has improved 
folding kinetics and is less likely to misfold when expressed with other proteins (27), 
particularly in higher redox potential environments like the secretory system (28). Since 
proteins traffic through the secretory pathway en route to the apicoplast, this final property 
is highly desirable. We appended the first 55 amino acids of the P. falciparum acyl-carrier 
protein to the N-terminus of SFG (api-SFG), resulting in its trafficking to the apicoplast, 
fluorescently labeling the organelle (29). Fluorescent labeling makes it easy to assess the 
morphology of the apicoplast after drug treatments or genetic perturbations that can result 
in disruption of the organelle (17, 30). Another useful feature of the PfMev line is that the 
cassette encoding the enzymes from the MVA pathway serves as its own genetic selection 
marker, and can be selected for with the drug fosmidomycin in the presence of mevalonate. 
This leaves any previously established drug resistance markers available for future genetic 
manipulations. 
Through the work outlined here we have validated and characterized the PfMev line, 
showing that mevalonate supplementation provides an effective, and arguably superior 
apicoplast bypass system. We demonstrated that mevalonate can bypass the toxic effect of 
drugs that target proteins within the organelle, in addition to enabling the survival of 
parasites containing a disrupted apicoplast with as little as 10µM mevalonate. We also 
demonstrate the utility of this line in determining apicoplast morphology using live 
epifluorescent microscopy, by examining parasites with intact and disrupted organelles. We 





demonstrating the functionality of the mevalonate pathway. Additionally, we were able to 
establish that genetic deletions of essential apicoplast-specific genes can be generated in 




Mevalonate Rescue of Fosmidomycin Treated PfMev Parasites 
 Previous work attempting to circumvent the necessity of essential apicoplast-specific 
genes or bypass the toxicity of apicoplast-specific drugs have relied on direct 
supplementation of IPP (17–22, 31). However, the IPP chemical bypass system has some 
inherent downsides as outlined above. To overcome these issues, we engineered an 
alternative genetically encoded bypass in P. falciparum that can generate the isoprenoid 
precursors IPP and DMAPP using enzymes from the mevalonate (MVA) pathway, which 
are distinct from the enzymes that comprise the endogenous MEP pathway (Figure 2-2a). 
This parasite line that we are calling PfMev contains three enzymes from the MVA pathway 
capable of forming IPP from mevalonate (24) and a fourth enzyme (IPP Isomerase) that 
catalyzes the interconversion of IPP and its regioisomer DMAPP (32). All four enzymes 
were integrated into parasite genome and are expressed within the cytosol (Figure 2-2b).  
In order to validate the PfMev line, we wanted to test whether the parasites could 
rely on the introduced MVA pathway for isoprenoid production. Therefore, we treated 
PfMev parasites with 25µM fosmidomycin (50x IC50), which inhibits the activity of the 
DOXP-reductoisomerase (DXPR) enzyme of the endogenous MEP pathway within the 
apicoplast organelle (33), and supplemented the parasites with mevalonate at concentrations 





supplemented with mevalonate served as controls. Parasitemia was quantified daily using 
SYBR green staining and flow-cytometry. As shown in Figure 2-3, mevalonate 
concentrations of 10µM or more successfully bypassed the lethal effect of fosmidomycin 
(30). These data also show that the ability to bypass the toxicity of the drug is reliant on 
mevalonate, consistent with reliance on the engineered mevalonate pathway for the 
generation of essential isoprenoid precursors.  
 
Apicoplast Labeling for Determination of Organelle Phenotype 
 In addition to the MVA pathway enzymes, the PfMev parasite line also expresses the 
super-folder green protein (34) with the signal and transit peptide of the P. falciparum acyl-
carrier protein (ACP) appended to the N-terminus of the protein. This results in SFG being 
trafficked to the apicoplast and fluorescently labeling the organelle (api-SFG) (29). Previous 
work demonstrated that under IPP supplementation, certain drug treatments or genetic 
perturbations can result in disruption of the apicoplast, and the fluorescent labeling of the 
organelle allows for a phenotypic readout (17, 30). Using live epifluorescent microscopy we 
were able to confirm that SFG is trafficked to a subcellular compartment consistent with the 
elongated morphology of the apicoplast organelle (Figure 2-4a). Trafficking of api-SFG to 
the apicoplast was confirmed using immunofluorescence (IFA) by co-localizing api-SFG 
with the Acyl Carrier Protein (ACP), a known apicoplast marker (29) (Figure 2-4b).  
 
Titration of Mevalonate in Apicoplast Negative PfMev Parasites 
Having established that the PfMev parasites can use the alternate bypass system, we 
wanted to determine how much mevalonate is required for the rescue of parasites lacking the 





treating PfMev parasites with 100nM azithromycin (1x 96 hr IC50) supplemented with 50µM 
mevalonate for one week. These parasites were permanently dependent on mevalonate for 
survival, indicating that azithromycin disrupted the apicoplast organelle, as previously 
described (30). Consistent with this result, we were unable to PCR amplify a gene from the 
apicoplast organellar genome while being able to amplify other genes from the nuclear and 
mitochondrial genomes (21) (Figure 2-5a). We were able to confirm loss of the apicoplast 
through live epifluorescent microscopy, and were unable to locate parasites with intact 
organelles, but instead observed the presence of multiple discrete vesicles, indicative of 
organelle loss (17) (Figure 2-5b). IFA co-localization experiments showed that ACP is also 
found in these api-SFG vesicles providing further evidence that the apicoplast organelle is 
disrupted (Figure 2-5c). Once parasites lacking an apicoplast were obtained, apicoplast 
negative parasites were grown in the presence of 0µM, 2.5µM, 10µM, 50µM, or 100µM 
mevalonate and compared with the growth of apicoplast intact PfMev parasites grown in the 
presence of 0µM or 50µM mevalonate. Parasitemia was counted via SYBR green staining 
and flow-cytometry. We found that supplementation with as little as 10µM mevalonate 
restored the growth of apicoplast-negative parasites to near wild-type levels (Figure 2-6). 
  
Metabolic Labeling of PfMev Parasites with [2-13C]-mevalonate 
 We also conducted metabolic labeling of PfMev parasites to demonstrate that 
exogenously supplemented mevalonate was being used by the MVA enzymes introduced 
into the parasite to form IPP and downstream isoprenoids. To show this, we generated 
parallel PfMev parasite cultures, both treated with 25µM fosmidomycin (50x IC50) and 
supplemented with either 50µM [12C]-mevalonate or [2-13C]-mevalonate. After 48 hours of 





spectrometry mass spectrometry (LC-MS/MS) using selected reaction monitoring (SRM) 
(35). Using this method, we were able to detect the isoprenoid precursor IPP (and/or the 
isobaric isomer DMAPP) (Figure 2-7a) in addition to the downstream isoprenoid product 
farnesyl pyrophosphate (FPP) (Figure 2-7b). We observed clear mass shifts of these 
metabolites between unlabeled and labeled parasite samples (36, 37), demonstrating 
incorporation of [13C] carbon in the labeled samples. Furthermore, we were able to show 
that we were successful in inhibiting the endogenous MEP pathway, with an increased level 
of labeled metabolite to unlabeled metabolite in the labeled sample. These data clearly 
indicate usage of mevalonate by the MVA pathway enzymes to generate IPP/DMAPP and 
the downstream isoprenoid FPP. 
 
Deletion of an Apicoplast Essential Gene using Cas9-mediated Genome Editing 
Supplementation of PfMev parasites with mevalonate allows us to disrupt the 
apicoplast organelle, and thus should also allow for the deletion of essential apicoplast-
specific genes. In order to test this, we chose to delete the target of fosmidomycin, DXPR 
(PF3D7_1467300; 1-deoxy-D-xylulose 5-phosphate reductoisomerase) (33). Genetic 
deletions were obtained utilizing Cas9-mediated editing, as previously described (38), but 
under continuous supplementation with 50µM mevalonate. The DXPR deletion was 
confirmed via PCR, showing the expected 5’ and 3’ integration of the hDHFR selection 
cassette. Parasites were also screened for the original locus to detect if there were any 
residual wild-type parasites (Figure 2-8a). The phenotype of the apicoplast was then 
ascertained in order to determine if DXPR deletion had any effect on the organelle. Previous 
experiments showed that drug treatment or genetic disruptions can result in the loss of the 





resulting phenotype (17, 21). Namely, the 35kb organellar genome of the apicoplast is lost, 
and the organelle itself is no longer intact, with proteins normally sent to the apicoplast 
instead accumulating in multiple discrete vesicles throughout the cell (17, 21). However, the 
parasites containing the disrupted DXPR locus retained the apicoplast organelle as evidenced 
by PCR amplification of SufB, a gene encoded by the apicoplast organellar genome (Figure 
2-8b), in addition to live epifluorescent microscopy showing the presence of a single intact 
organelle (Figure 2-8c). We were also able to determine the essentiality of this gene through 
the removal of mevalonate. ΔDXPR parasites are reliant on mevalonate supplementation for 
growth indicating that this gene is essential for the blood-stage survival of the parasite 
(Figure 2-8d). These results confirm that the activity of DXPR is essential for parasite 
survival, but also show that the activity of DXPR is not needed for maintaining the 
apicoplast organelle. These results are similar to what has been seen with fosmidomycin 
treatment. Even at doses of 25µM fosmidomycin (50x IC50), supplementation with IPP 
allowed parasites to survive and retain an intact apicoplast organelle (21). This differed from 
treatment with 100nM azithromycin (1x IC50) and IPP supplementation, which resulted in 
disruption of the organelle (21), likely due to the target of azithromycin (protein translation 
within the organelle) playing a key role in the maintenance and replication of the organelle 
(39). 
 
CONCLUSIONS AND DISCUSSION 
 
Through the generation of our PfMev line we have been able to overcome many of 
the issues associated with the apicoplast chemical bypass system reliant on the direct 





can grow at wild-type levels, even when lacking the apicoplast, if supplemented with 
mevalonate, and can quickly resume growth post-cryopreservation. The ability to easily 
cryopreserve parasite lines makes longer-term experimental approaches that may take place 
over many months or years, or larger-scale experiments that generate tens or hundreds of 
parasite lines reliant on mevalonate more feasible by allowing for the storage and future 
analysis of the lines. Additionally, the system is vastly more affordable due to the drastically 
lower cost of mevalonate in comparison to IPP. There are also the added benefits that 20-
fold lower concentrations of mevalonate are needed to support parasite growth, and that the 
chemical is more stable than IPP which has a half-life of ~4.5 hours at 37°C (40). PfMev 
parasites also contain a fluorescent reporter that is trafficked to and labels the apicoplast. 
This allows for the observation of the organellar phenotype via live epifluorescent 
microscopy and the ability to determine if a given treatment or manipulation has resulted in 
the disruption of the organelle.  
We were able to successfully generate the PfMev line by selecting for transfectants 
with 25µM fosmidomycin supplemented with 50µM mevalonate. By doing so we were able 
to select for these parasites using a novel method, not reliant on any previously validated 
drug selectable markers. Selection of the line using this method is beneficial, as it allows for 
further genetic manipulation of this line by sparing the commonly used drug selectable 
markers in P. falciparum, such as human dihydrofolate reductase (hDHFR) (41), blasticidin S 
deaminase (BSD), neomycin phosphotransferase (NEO) (42), and yeast dihydroorotate 
dehydrogenase (yDHOD) (43). This should facilitate straightforward selection in the PfMev 
line using previously established genetic tools and plasmids. Additionally, this should allow 
for selection of multiple drug resistance markers, enabling the generation of double 





Furthermore, we have been able to provide in-depth metabolic characterization of 
the PfMev line by tracking the utilization of the MVA pathway and detecting the breakdown 
of mevalonate into IPP/DMAPP and FPP through isotopic-labeling and LC-MS/MS. 
Seeing as how the generation of isoprenoid precursors for the production of downstream 
isoprenoids is the only presumed essential function of the intact apicoplast during the 
asexual blood-stage of the parasite (17), the importance of further investigation into this 
metabolic pathway is clear. While our motivation was to prove the activity of the introduced 
mevalonate-pathway enzymes, we believe that similar metabolic labeling techniques using the 
PfMev line may be useful in the identification of previously unknown isoprenoid products. 
Investigation and discovery of novel isoprenoid products is an active area of research, with 
the recent discovery of parasite produced volatile isoprenoid products that act as mosquito 
attractants (44). 
Using CRISPR-Cas9 in PfMev parasites we were able to successfully delete DXPR, 
an essential apicoplast-specific protein, and maintain the knockout line in culture through 
mevalonate supplementation. This work represents the first published result of this kind, 
clearly demonstrating the utility of this system as a platform that can be used to investigate 
additional essential apicoplast-specific proteins and their roles in parasite survival. While the 
production of isoprenoid precursors has been proposed to be the only essential function of 
the apicoplast during the asexual blood-stage of the parasite, additional proteins with 
functions supporting the MEP pathway also represent an important area of potential 
research. Furthermore, it has previously been shown that certain genes are essential for the 
maintenance or replication of the apicoplast, with their disruption causing the loss of the 
organelle under IPP supplementation (21). There are likely to be numerous proteins required 





genome replication, trafficking of proteins to the organelle, import of substrates, export of 
products, and replication and division of the organelle, among others. Although the proteins 
involved in these processes probably number in the 100s, most of them have not been 
identified or studied. As mentioned above, there are a predicted ~400 proteins that are 
trafficked to the apicoplast, representing ~7% of the genes in the parasite genome [36]–[39]. 
However, approximately half of the proteins predicted to be apicoplast localized in 
PlasmoDB are annotated as having an unknown function (45), representing a significant gap 
in our basic understanding of apicoplast biology. The PfMev line provides a viable method 
to interrogate genes essential to apicoplast maintenance and replication by utilizing the 
engineered metabolic bypass, in addition to allowing for phenotypic characterization of the 
organelle through the visualization of the SFG-labeled apicoplast, in order to determine 
whether a given genetic manipulation resulted in the loss of the organelle. Investigation of 
these genes may be especially attractive because drugs that inhibit proteins that result in 
apicoplast loss may help to prevent recrudesce and the subsequent development of drug 
resistance. 
In order to uncover the importance of unannotated apicoplast-trafficked proteins, 
PfMev parasites could be used for forward genetic screens in order to determine which are 
essential for parasite survival, and which are required for the maintenance and replication of 
the organelle. Initial hits using this approach could help to prioritize which genes to follow 
up on to characterize the role and function of the gene product. Forward genetic screens 
using the PfMev line could take advantage of current chemical mutagenesis (46) or PiggyBac 
transposon insertional mutagenesis techniques used in P. falciparum (47). Furthermore, the 
PfMev line could be used for drug discovery efforts by screening compound libraries against 





sensitivity indicative of compounds that are apicoplast-specific. Finding drugs with such 
differential activity would be useful in helping to narrow down the list of potential targets, 
and help to inform the potential mechanism of action. Previous efforts using the IPP 
chemical bypass system have accomplished this for certain compound libraries (23). 
However, the reduced cost of mevalonate would make screening much larger compound 
libraries more feasible.  
Ultimately, we hope that the work done using the PfMev line to identify and validate 
proteins that are essential for apicoplast maintenance and parasite survival will be translated 
to practical applications such as drug discovery efforts. The PfMev line is likely to be a useful 
tool in drug target identification as well as validation. Previous work on putative drug targets 
such as those within the FasII pathway led to vast amounts of wasted time, effort, resources, 
and millions of dollars, because the enzymes were not properly validated and were 
erroneously assumed to be essential (48, 49). This misspent effort could have been avoided 
by validating the essentiality of a given gene by deleting it in a bypass system such as the 
PfMev parasite line.  
Overall, we believe that the generation of the PfMev line will be a valuable tool for 
the investigation of the apicoplast organelle and represents a significant improvement to the 
existing IPP chemical bypass system. To our knowledge, this is also the first time a metabolic 
pathway has been reconstituted in malaria parasites. The benefits of the PfMev line include 
the decreased expense of supplementation, the restoration of growth of apicoplast defective 
parasites to wild-type levels, and the relative ease of cryopreservation. The PfMev line should 
make longer-term experimentation such as the deletion of apicoplast-essential genes more 
feasible. We also envision this line being useful for larger-scale experimentation, such as 





or without mevalonate supplementation to test for the differential drug sensitivity of 
compounds that may be apicoplast-specific. Additionally, discoveries pertaining to basic 
apicoplast biology or the identification of essential apicoplast proteins that are potential drug 
targets in P. falciparum using the PfMev line may have a broader impact and assist in 
understanding basic plastid biology that may be applicable to other Apicomplexan species 




P. falciparum culture and maintenance 
 Unless otherwise noted, blood-stage P. falciparum parasites were cultured in human 
erythrocytes collected under IRB protocol NA_00019050 at 1% hematocrit in a 10mL total 
volume of CMA (complete medium with Albumax) medium containing RPMI 1640 media 
with L-glutamine (USBiological Life Sciences), supplemented with 25mM HEPES, 0.2% 
sodium bicarbonate, 12.5µg/mL hypoxanthine, 5g/L Albumax II (Life Technologies) and 
25µg/mL gentamicin. Cultures were maintained in gassed flasks (94% N2, 3% O2, 3% CO2) 
and incubated in sealed 25cm2 flasks at 37°C. 
 
Construction of the pMPc-aSFG (PfMev) mevalonate bypass plasmid 
Generation of the mevalonate bypass plasmid utilized a modified pACYC replicon, 
with a p15a origin and chloramphenicol resistance cassette. The sequence encoding the 
MVA pathway itself was developed through the generation of synthetic genes encoding 
Streptococcus pneumoniae mevalonate kinase (MevK), Homo sapiens phosphomevalonate kinase 





coli isopentenyl diphosphate isomerase (Idi) gene. All genes were codon optimized for 
expression in E. coli and manually modified to avoid rare codons for expression in P. 
falciparum. The four genes are connected by nucleotides encoding seven amino acid flexible 
linkers. 
To visualize apicoplast morphology another cassette was added to the plasmid 
expressing the first 55 amino acids of the P. falciparum Acyl Carrier Protein (ACP) fused to a 
N-terminus of a codon-optimized variant of GFP called Super Folder Green (SFG). The 
ACP leader peptide is known to traffic proteins to the apicoplast (50) and SFG is a fast 
folding version of GFP that minimizes the kinetic trap of disulfide formation in the 
oxidizing environment of the endoplasmic reticulum (28, 34). To drive expression of the 
apicoplast SFG (api-SFG) and MVA bypass pathway cassettes a strong bidirectional 
promoter (Pcam/Psti) was used (51, 52).  
  
Generation of the PfMev bypass line 
For generation of the PfMev line we transfected P. falciparum NF54attB parasites, 
generously provided by Dr. David Fidock (Columbia University), using methods previously 
described (53, 54). Briefly, 400µL of red blood cells were washed with 5mL of CytoMix and 
resuspended in 340µL of CytoMix and electroporated with 75µg each of the pmpc-asfg 
(expressing the MVA pathway enzymes and api-SFG) and pINT (encoding the 
mycobacteriophage Bxb1 integrase) plasmids (53). The electroporated RBCs were then 
mixed with ~2.5mL of a 10mL culture of NF54attB parasites synchronized as schizonts at 1% 
hematocrit and ~10% parasitemia, with an additional 10mL of CMA media added. After 48 
hours, transfectants were selected for integration of the pMPc-aSFG plasmid into the attB 





mevalonate until parasites were observed. Infected red blood cells (iRBC) were first 
observed approximately 20-25 days after beginning drug selection. Once parasites were 
observed the culture was maintained on CMA medium.  
 
Mevalonate rescue of fosmidomycin treated parasites growth curve  
 PfMev parasites were seeded in a 96-well flat bottom cell culture plate (Corning) at a 
starting parasitemia of 0.5% at 2% hematocrit, at a total volume of 250µL in quadruplicate. 
There was one parental control condition of PfMev parasites grown in CMA (positive 
control). For the rest of the conditions, parasites were grown in the presence of 25µM 
fosmidomycin (50x IC50), and supplemented with mevalonate at concentrations of either 
0µM (negative control), 2.5µM, 10µM, 50µM, or 100µM. Parasites were collected every 24 
hours for four days, and the parasitemia was counted via SYBR green staining and flow-
cytometry as outlined below. 
 
Mevalonate titration of apicoplast negative parasites growth curve 
Apicoplast negative parasites were generated by treating PfMev parasites with 100nM 
azithromycin (1x IC50) supplemented with 50µM mevalonate for one week. Loss of the 
organelle was confirmed via PCR as outlined below, and additionally verified via live 
epifluorescent microscopy using methods described below. Parasites were seeded in a 96-
well flat bottom cell culture plate (Corning) at a starting parasitemia of 0.5% at 2% 
hematocrit, at a total volume of 250µL in quadruplicate. To serve as a control, PfMev 
parasites with an intact apicoplast were cultured in either 0µM or 50µM mevalonate. The 
apicoplast negative PfMev parasites were grown with mevalonate at concentrations of either 





hours for four days, and the parasitemia was counted via SYBR green staining and flow-
cytometry as described below. 
 
Testing mevalonate dependence in PfMev deletion mutants via growth curve 
For each of the PfMev deletion lines, the parasitemia was determined via Gimesa 
stain, with the appropriate amount of the parental culture removed to seed quadruplicate 
samples with or without mevalonate. This volume was resuspended in a total of 10mL CMA 
and centrifuged at 1,600rcf at room temperature (~25°C) for 5 minutes, washed a second 
time with an additional 10mL CMA, and then resuspended in the appropriate volume of 
CMA, and then split equally into two tubes. To one of the tubes, the appropriate volume of 
a 10mM stock of mevalonate was added to bring to final concentration to 50µM mevalonate. 
Parasites were seeded in a 96-well plate at 0.5% starting parasitemia, 2% hematocrit, and at a 
total volume of 250µL per well in quadruplicate. Additionally, 150µL of the appropriate 
media was replaced in each well on days 1, 2, and 3. Parasite samples were collected every 24 
hours for four days, and the parasitemia was counted via SYBR green staining and flow-
cytometry as outlined below. 
 
Flow cytometry for parasite growth curve determination  
Growth curves were generated by staining parasites with SYBR Green and counting 
parasitemia via flow cytometry. In order to setup the growth curve, the parasitemia of the 
starting culture was determined via Giemsa stain. Based on the determined parasitemia the 
culture was used to seed a 96-well flat bottom cell culture plate (Corning) at a 0.5% starting 
parasitemia and 2% hematocrit, at a total volume of 250µL in quadruplicate. In order to 





1mM EDTA. Plates were incubated in chambers gassed with 94% N2, 3% O2, 3% CO2 for 1 
minute and 15 seconds, and incubated at 37°C.  
Parasite samples were collected immediately after seeding and analyzed via flow 
cytometry to verify the starting parasitemia and then collected every 24 hours thereafter. 
Samples collected on days 1-3 were diluted 1:10 in phosphate-buffered saline (PBS) and 
stored in a 96-well plate (Corning) at 4°C. We have previously verified that storage under 
these conditions and subsequent staining with SYBR Green reflects accurate parasitemia 
values.  
 On day 4 parasites were stained with SYBR Green by transferring 1µL of parasite 
culture, or 10µL of the 1:10 dilutions (the day 1-3 samples), to a 96-well plate containing 
100µL of 1x SYBR Green (Invitrogen) in PBS. The samples were then incubated for 30 
minutes on a platform Titramax 101 shaker (Heidolph) at 950rpm while protected from 
light. Post-incubation, 150µL of PBS was added to each well to dilute unbound SYBR Green 
dye. A control consisting of uninfected RBCs was also prepared in parallel and treated in the 
same manner as listed above.  
 Samples were analyzed with an Attune Nxt Flow Cytometer (Thermo Fisher 
Scientific). With a 50µL acquisition volume, 250µL total sample volume, and a running speed 
of 25µL/minute with 10,000 total events were collected within the R2 gate. 
 For flow cytometer gating, the R1 gate used forward-scatter area by side-scatter area 
to identify total RBCs from the sample. The R2 gate used forward-scatter height to identify 
single cells, and the R3 gate was used to measure parasitemia using fluorescence from the 
SYBR Green staining of parasite DNA (ratio of SYBR Green positive cells to total cells).  
 





The loss of the apicoplast was confirmed via PCR with primers specific for a gene 
within the nuclear (Lactate Dehydrogenase), apicoplast (SufB), and mitochondrial (Cox1) 
genomes (Table 2-1). Failure to amplify a gene from the apicoplast genome, while 
amplifying genes from the nuclear and mitochondrial genomes would indicate loss of the 
organelle (30). To collect samples for PCR, approximately 100µL of a resuspended parasite 
culture at ~5-10% parasitemia was placed in a 90°C heat block for 2 minutes, and then 
frozen at -20°C. For the PCR reaction, 1µL of the parasite sample was added to reactions 
with a 50µL total volume. Reactions were conducted using a Veriti 96 well thermal cycler 
(Applied Biosystems) and Phusion High-Fidelity DNA polymerase (Thermo Fisher 
Scientific). PCR products were separated by size on a 1.5% agarose gel stained with ethidium 
bromide. The parental PfMev line was always used as a positive control for apicoplast 
detection. 
 
The PCR reaction volumes were as follows:  
 
Water 34.5µL 
5x Phusion HF buffer 10µL 
Forward primer (10 µM)1.5µL 
Reverse primer (10 µM) 1.5µL 
dNTPs (10mM) 1µL 
Phusion polymerase 0.5µL 
parasite lysate 1µL 
Total volume 50µL 
 
The PCR program was as follows: 
 
95°C 3.5 minutes 
95°C 30 seconds 
63°C 30 seconds 
72°C 1 minute 
72°C 4 minutes 
4°C ∞ 
 






Live cell epifluorescent microscopy 
For sample preparation, 100µL of parasite culture with a hematocrit of 1% and a 
parasitemia between 8-10% was obtained. Parasites were stained with 30nM mitoTracker 
CMX-Ros (Invitrogen) and 1µg/mL 4′, 6-diamidino-2-phenylindole (DAPI), and incubated 
for 30 minutes at 37°C. Cells were then pelleted via mini-centrifuge (Fischer Scientific) for 
10 seconds, and the media was aspirated and the cells were resuspended in 100µL of CMA 
media and incubated for 5 minutes at 37°C. This was done three times to wash the cells, 
with the cells being resuspended in 20µL of CMA and then pipetted onto slides and sealed 
with wax (2 parts paraffin, 1 part Vaseline) for observation on a Zeiss AxioImager M2 
microscope. A series of images spanning 5µm were acquired with 0.2µm spacing and images 
were deconvolved with VOLOCITY software (PerkinElmer) to report a single combined z -
stack image.  
 
PfMev parasite immunofluorescence (IFA) microscopy 
For analysis of PfMev parasites via IFA, slides were first prepared by creating 6 wells 
on a glass slide using a Super Pap Pen Liquid Blocker (Ted Pella, Inc.), followed by the 
addition of 30µL of 1:10 .1% poly-L-Lysine solution (Sigma-Aldrich) in water to each well, 
and allowed to dry for 30 minutes. Next, 500µL of the PfMev parasite line at a hematocrit of 
2% and a parasitemia between ~5-10% was obtained and spun down at 500G for 1 minute, 
and resuspended in 300µL of a 1:1 solution of 4% PFA, .0075% GA, PBS to fix the cells. 
40µL of the cells were then immediately pipetted into each well and incubated at room 
temperature for 30 minutes. Cells were permeabilized by aspirating the fixation solution and 





added, with the cells incubated at room temperature for 10 minutes. This solution was then 
aspirated and then cells were washed again with 45µL 1x PBS. This solution was aspirated, 
and then a solution of .1g/L NaBH4 in 1x PBS was added to the cells, after which they were 
incubated at room temperature for 10 minutes to reduce the cells. This solution was then 
aspirated and the cells were washed with 45µL 1x PBS. This solution was then aspirated and 
then a solution of 3% (30g/L) BSA in 1x PBS was added as a blocking agent, and then 
allowed to incubate at room temperature for 2 hours. This solution was then aspirated, and 
the cells were washed with 45µL 1x PBS. That solution was aspirated and a 40µL solution 
containing the primary antibodies was added. This solution contained 500µL 3% BSA in 1x 
PBS with 1µL pAB anti-ACP (JHR72 rat, pool) and 1µL pAB anti-GFP (JH915 rabbit, 
3g/L). Slides were then incubated at 4°C overnight (~14-16 hours). This solution was then 
aspirated and washed with 45µL 1x PBS 3 times, and then washed once with 3% (30g/L) 
BSA in 1x PBS. This solution was then aspirated and a 40µL solution containing the 
secondary antibodies was added. This solution contained 1mL 3% BSA in 1x PBS with 1µL 
anti-Rabbit Alexa 594 and 3µL anti-rat Alexa488. After this solution was added the slides 
were incubated at room temperature in the dark, protected from light for 2 hours. This 
solution was then aspirated, and the then washed with 45µL 1x PBS 3 times. Slides were 
then sealed with Gold DAPI antifade (Life Technologies) under a coverslip sealed with nail 
polish. Slides were then viewed using a Zeiss AxioImager M2 microscope. A series of images 
spanning 5µm were acquired with 0.2µm spacing and images were deconvolved with 
VOLOCITY software (PerkinElmer) to report a single combined z -stack image.  
 





A PfMev culture was synchronized through magnetic purification (55) and 
immediately used to seed two identical 20mL cultures at 2% hematocrit and ~2% 
parasitemia. Parasite cultures were cultured in media containing 25µM fosmidomycin (50x 
IC50) and supplemented with either 50µM [12C]-mevalonate (Sigma-Aldrich, cat. #M4667) or 
[2-13C]-mevalonate (Sigma-Aldrich, cat. #486604), and incubated for 48 hours, equivalent to 
one parasite lifecycle, to allow for incorporation of the label. After 48 hours, the parasitemia 
had reached ~9% and the parasites were isolated via magnetic purification, resuspended in 
12mL CMA, and quantified using a hemocytometer, with ~8x107 parasites purified from 
each culture.  
Metabolite extraction was conducted following a previously established protocol (56). 
Briefly, the isolated parasites were pelleted via centrifugation using a Megafuge 1.0R 
(Heraeus) at 4,000rpm for 5 minutes at room temperature, followed by the aspiration of the 
supernatant. The parasite pellet was then snap frozen on dry ice, and stored at -80°C before 
extraction. For metabolite extraction, the pellet was thawed on ice and 600µL of 100% 
methanol cooled on dry ice was added, and then incubated on dry ice for 15 minutes with 
intermittent vortexing. Lysed parasites were then centrifuged in a Biofuge pico 
microcentrifuge (Heraeus) at 13,000rpm for 5 minutes at 4°C and the supernatant was 
transferred to a separate tube and stored on dry ice. To the original tube containing the pellet, 
600µL of ice cold 80% methanol/20% H2O was added, and the pellet was broken up by 
pipetting up and down with intermittent vortexing. The tube was then tip sonicated (Vibra-
Cell, Sonics & Materials Inc.) on ice for 15 seconds with 0.5 second on/off cycles at 20% 
amplitude. This was done twice, with a 30 second pause between sonication cycles. Insoluble 
material was then pelleted by centrifugation at 13,000rpm for 5 minutes at 4°C. The resulting 





dried at room temperature under nitrogen gas until fully evaporated and stored at -80°C. On 
the day of analysis, dried samples were resuspended in 100µL of ice cold solvent A (2mM 
ammonium phosphate and 2mM hexylamine in H2O) and then incubated on ice for ~1.5 
hours with intermittent vortexing. The sample was then centrifuged at 13,000rpm for 5 
minutes at 4°C, and the supernatant was transferred to a fresh tube for metabolite analysis.   
Metabolites were detected using a Dionex Ultimate 3000 uHPLC system coupled to 
a TSQ Vantage Triple Stage Quadrupole (QQQ) mass spectrometer (Thermo Fisher 
Scientific) using a Hypersil-GOLD C18 column (3µm, 100mm x 1mm, Thermo Fischer 
Scientific) at a flow rate of 0.4mL/min. Solvent A was 2mM ammonium phosphate and 
2mM hexylamine in H2O and Solvent B was 100% acetonitrile. The following gradient was 
used: 0-2 minutes at 9% B, 2-15.5 minutes linearly increasing from 9% to 100% B, 15.6-17.6 
minutes at 100% B, and 17.7-31.7 minutes at 9% B. 
In order to optimize detection of IPP, we started by analyzing a chemical standard. 
For this we injected 10µL of 5µM IPP (Sigma) in 90% mobile phase A, and 10% mobile 
phase B (100% acetonitrile). The detection method relied on selected reaction monitoring 
(SRM) in negative ion mode to monitor the transition (m/z 244.9 à 79.0), in which the 
parent ion (244.9m/z) is selected for and fragmented, and the daughter ion fragment is 
detected (79.0m/z), indicative of the loss and detection of phosphate from IPP (36). The 
retention time of the IPP standard was found to be ~11.7 seconds. For sample analysis, 
40µL of sample was injected. In order to detect IPP we monitored the above-mentioned 
transition (m/z 244.9 à 79.0). However, parasites supplemented with [13C]-mevalonate 
should produce [13C]-labeled IPP, shifting the molecular mass by one Dalton to (m/z) 245.9. 
Thus, for samples extracted from parasite cultures supplemented with [12C]-mevalonate or 





79.0). The same SRM technique was used to look for downstream isoprenoid products, 
specifically farnesyl pyrophosphate (FPP). Using previously published methods, we 
monitored the transition (m/z 381.0 → 79) for unlabeled FPP (36). Since FPP is formed 
from three isoprenoid precursors, the mass of labeled FPP should be shifted by three 
Daltons to (m/z) 384.0. Thus, we also monitored both transitions (m/z 381.0 → 79) and 
(m/z 384.0 → 79) in the labeled and unlabeled samples. 
 
Generation of the Cas9 gene deletion construct 
Cas9 mediated gene deletion constructs were generated using modified versions of 
the pUF1-Cas9 and pL6-eGFP plasmids, which were generously provided by Dr. Jose-Juan 
Lopez-Rubio, approximately following methods previously described (38) [12]. The pL6-
eGFP plasmid was modified to contain ligation independent cloning (LIC) sites. The 3’ LIC 
was modified to contain a NgoMIV restriction site, while the 5’ LIC was modified to contain 
a NotI restriction site. Additionally, the plasmid backbone was modified to remove a BsaI 
site within the AmpR E. coli drug resistance cassette, and the BtgZI restriction sites were 
replaced with BsaI sites. The resulting plasmid was renamed pL8. The pUF1-Cas9 plasmid 
was modified as well, to generate a plasmid that was are calling pCasG.  
To generate the DXPR deletion construct, homology arms of ~300-600bp for 
DXPR were amplified using the homology arm (HA) 1 and 2 forward and reverse primers 
(Table 2-1) from blood-stage P. falciparum NF54-attb gDNA. HA1 and HA2 primers were 
designed to contain ~15bp overhangs for insertion into the cut pL8 plasmid using In-Fusion 
(Clontech) cloning methods. The pL8 plasmid containing the hDHFR drug resistance 
cassette for selection and contains flanking endonuclease sites for insertion of the homology 





HA2. Digests with either endonuclease were also treated with recombinant shrimp alkaline 
phosphatase (rSAP) and then ethanol precipitated before insertion of the homology arms. 
The pL8 plasmid also contains a guide RNA (gRNA) expression cassette. For insertion of 
the gRNA sequence the plasmid was digested with BsaI and also treated with rSAP, and then 
ethanol precipitated. Guide RNA sequences were synthesized as oligos (Table 2-2), 
annealed, and inserted into the pL8 via In-Fusion cloning. 
 
P. falciparum transfections for gene deletion 
 Transfections were conducted as previously described (53, 54). Briefly, 400µL of red 
blood cells were washed with 5mL of CytoMix and resuspended in 400µL of CytoMix. The 
red blood cells were then electroporated with 75µg each of the pUF1-Cas9 and pL8-DXPR 
knock out plasmids (38). The electroporated RBCs were then mixed with ~2.5mL PfMev 
parasites synchronized as schizonts at 1% hematocrit and ~10% parasitemia and given 
10mL CMA with 50µM mevalonate. After 48 hours, transfectants were selected with 0.75µM 
DSM1, 2.5nM WR99210, and 50µM mevalonate for seven days. After seven days, the 
parasites were switched to media containing only 50µM mevalonate. Infected red blood cells 
(iRBC) were first observed between 17 and 30 days after beginning drug selection. Once 
parasites were observed, the medium was switched to 2.5nM WR99210 and 50µM 
mevalonate.  
 
Confirmation of knockout genotype 
In order to screen for integration and successful gene knockout, in addition to the 
presence of any contaminating residual wild type parasites, a set of six primers were used: 





designed to screen for integration and gene disruption at the 5’ and 3’ ends (Δ5’ and Δ3’) in 
addition to 5’ and 3’ regions of the WT gene (5’ and 3’). The same reactions were also 
performed on the parental PfMev line concurrently as a control. Samples for PCR were 
collected when the parasitemia reached been 5-10%, as determined by Giemsa stain. 
Approximately 100µL of a resuspended parasite culture was placed in a heat block at 90°C 
for 2 minutes and stored at -20°C. For the PCR reaction, 1µL of the parasite sample was 
added to reactions with a 50µL total volume. Reactions were conducted using a Veriti 96 
well thermal cycler (Applied Biosystems) and Phusion High-Fidelity DNA polymerase 
(Thermo Fisher Scientific). PCR products were separated on a 1.5% agarose gel stained with 
ethidium bromide for visualization.  
The PCR reaction volumes were as follows:  
 
Water 34.5µL 
5x Phusion HF buffer 10µL 
Forward primer (10 µM)1.5µL 
Reverse primer (10 µM) 1.5µL 
dNTPs (10mM) 1µL 
Phusion polymerase 0.5µL 
parasite lysate 1µL 
Total volume 50µL 
 
The PCR program was as follows: 
 
95°C 3.5 minutes 
95°C 30 seconds 
62°C 1 minute 
62°C 4 minutes 
4°C ∞ 
 
(steps 2 and 3 were repeated 35 times) 
A diagram of the primer combinations and DNA agarose gel used to screen for gene 






Lane Primer Combination Parasite Line 
1.  Δ5’ 5’F, pL8 HA1R  
Gene deletion line 2.  Δ3’ pL8 HA2 F, 3’R 
3.  5’ WT 5’F, 5’ WT R 
4.  3’ WT 3’ WT F, 3’R 
5.  Δ5’ 5’F, pL8 HA1R  
PfMev parental line 6.  Δ3’ pL8 HA2 F, 3’R 
7.  5’ WT 5’F, 5’ WT R 








































Figure 2-1 Plasmid pMPC-aSFG used to generate the PfMev parasite line 
NF54-attb parasites were transfected with the pINT (integrase) and pMPC-aSFG plasmids, 
in order to integrate the pMPC-aSFG plasmid into the attb locus of the NF54 attb line. 
Parasites possessing the pMPC-aSFG plasmid were selected with fosmidomycin in the 
presence of mevalonate. Expression of the mevalonate pathway and apicoplast SFG (api-


























Figure 2-2 Diagram of the endogenous (MEP) and engineered (Mev) isoprenoid 
pathways 
A.) Plasmodium parasites contain the endogenous MEP isoprenoid precursor pathway within 
the apicoplast. For the MEP pathway pyruvate and glyceraldehyde 3-phosphate (G3P) are 
joined together by DOXP synthase (DXS) to form 1-Deoxy-D-xylulose 5-phosphate 
(DOXP). DOXP is then converted by DOXP reductoisomerase (DXPR) to form 2-C-
methylerythritol 4-phosphate (MEP), which is in turn converted by 2-C-methyl-D-erythritol 
4-phosphate cytidylyltransferase (CDP-ME Synthase) to form 4-diphosphocytidyl-2-C-
methylerythritol (CDP-ME). CDP-ME is then converted by 4-diphosphocytidyl-2-C-methyl-
D-erythritol kinase (CDP-ME kinase) to form 4-diphosphocytidyl-2-C-methyl-D-erythritol 
2-phosphate (CDP-MEP). CDP-MEP is converted by 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate synthase (MEc-PP Synthase) to form 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate (MEc-PP). MEc-PP is then converted by HMB-PP synthase to form (E)-





HMB-PP reductase to form Isopentenyl pyrophosphate (IPP) and Dimethylallyl 
pyrophosphate (DMAPP). 
PfMev parasites were engineered to convert mevalonate into IPP/DMAPP through the 
expression of four enzymes from the mevalonate pathway. In this engineered pathway, 
mevalonate is converted by mevalonate kinase (MVA kinase) to form mevalonate-5-kinase 
(MVA-P). MVA-P is then converted by phosphomevalonate kinase (MVA-P kinase) to form 
mevalonate-5-pyrophosphate (MVA-PP). MVA-PP is then converted by mevalonate-5-
pyrophosphate decarboxylase (MVA-PP decarboxylase) to form IPP, which can also be 
converted into DMAPP by isopentenyl pyrophosphate isomerase (IPP isomerase). 
B.) Diagram of the parasite cell showing that the endogenous MEP pathway is localized with 
the apicoplast organelle of the parasite, with IPP and DMAPP presumably being exported 
out of the organelle. We engineered the PfMev parasites to express four enzymes from the 
MVA pathway, which are expressed in the cytosol of the parasite and metabolize exogenous 













Figure 2-3 Growth of PfMev parasites treated with fosmidomycin and mevalonate 
PfMev parasites were treated with 25µM fosmidomycin (50x IC50), and supplemented with 
100µM, 50µM, 25µM, 10µM, or 0µM mevalonate, with growth compared to an untreated 
control. PfMev parasites grew to wild-type levels in the presence of a typically lethal 
concentration of fosmidomycin with as little as 10µM mevalonate indicating usage of the 
engineered mevalonate pathway for the generation of essential isoprenoid precursors. PfMev 
parasites treated with 25µM fosmidomycin not supplemented with mevalonate failed to 
grow. Data from duplicate experiments conducted in quadruplicate are shown with error 
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Figure 2-4 Fluorescent labeling of the apicoplast organelle in PfMev parasites and 
confirmation via co-localization 
Figure 2-4 Fluorescent labeling of the apicoplast organelle in PfMev parasites and 
confirmation via co-localization 
A.) Live fluorescence microscopy of the PfMev line expressing the signal sequence and 
transit peptide from ACP fused to SFG (api-SFG, green), the mitochondria was stained with 
MitoTracker (red), and nuclear DNA was stained with DAPI (blue).  
B.) Immunofluorescence co-localization of api-SFG with the apicoplast marker ACP, with α-
ACP (green), α-GFP (red), with nuclear DNA stained with DAPI (blue) in fixed PfMev 
parasites.  











Figure 2-5 Generation and characterization of an apicoplast-minus PfMev parasite 
line 
A.) Attempted detection of nuclear, mitochondrial, and apicoplast genomes via PCR 
amplification of LDH (nuclear), SufB (apicoplast), and Cox1 (mitochondrial) genes from 
PfMev parasites treated with 100nM azithromycin and 50µM mevalonate for one week (red), 
in addition to an untreated control (blue). Failure to amplify SufB in PfMev parasites treated 
with azithromycin/mevalonate indicates loss of the apicoplast organelle.  
B.) Live fluorescence microscopy of PfMev parasites after treatment with 100nM 
azithromycin and 50µM mevalonate for one week, showing a disrupted organelle phenotype, 
with multiple discrete vesicles instead of a single intact organelle structure. The apicoplast is 
labeled with the api-SFG protein (green), the mitochondrion is stained with MitoTracker 





C.) Immunofluorescence co-localization of api-SFG with the apicoplast marker ACP, with α-
GFP (red), α-ACP (green), with nuclear DNA stained with DAPI (blue) in fixed apicoplast 
minus PfMev parasites.  
























Figure 2-6 Mevalonate titration of apicoplast minus PfMev parasites 
Growth curve of apicoplast minus PfMev parasites grown in the presence of 100µM, 50µM, 
10µM, 2.5µM, and 0µM mevalonate. The growth of untreated (apicoplast positive) PfMev 
parasites was also measured in the presence of 50µM or 0µM mevalonate as a control. 
Supplementation with as little as 10µM mevalonate restored the growth of apicoplast 
negative parasites to near wild-type levels. Data from duplicate experiments conducted in 
quadruplicate are shown with error bars representing the standard error of the mean (SEM). 
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Figure 2-7 Metabolic labeling of PfMev parasites with [2-13C]-mevalonate 
 
PfMev parasite cultures were treated with 25µM fosmidomycin (50x IC50) and supplemented 
with either 50µM [12C]-mevalonate or [2-13C]-mevalonate for 48 hours. Metabolites were 
extracted and analyzed via targeted liquid-chromatography mass spectrometry (LC-MS).  





A.) Detection of IPP/DMAPP (black) in parasites treated with 50µM mevalonate and 25µM 
fosmidomycin, with attempted detection of mass-shifted IPP/DMAPP (red).  
B.) Detection of mass-shifted IPP/DMAPP (red) in parasites treated with 50µM [2-13C]-
mevalonate and 25µM fosmidomycin, with attempted detection of IPP/DMAPP (black).  
C.) Detection of FPP (black) in parasites treated with 50µM mevalonate and 25µM 
fosmidomycin, with attempted detection of mass-shifted FPP (red).  
D.) Detection of mass-shifted FPP (red) in parasites treated with 50µM [2-13C]-mevalonate 







































Figure 2-8 Deletion of an apicoplast essential gene using Cas9 mediated gene editing 
A.) Confirmation of DXPR gene deletion via PCR showing the expected 5’ and 3’ 
integration of the selection cassette. Parasites were also screened for the unmodified 5’ and 
3’ loci to detect if there were any residual wild-type parasites (red) and compared to a control 
(blue).  
B.) PfMev ΔDXPR parasites were screened for the presence of the nuclear (LDH), 
apicoplast (SufB), and mitochondrial (Cox1) genomes via PCR (red), and compared to a 
control (blue). Both lines showed the presence of nuclear, apicoplast and mitochondrial 
genomes, indicating deletion of DXPR does not result in organelle loss. 
C.) Live epifluorescent microscopy of the PfMev ΔDXPR parasites showing the presence of 
an intact organelle. This parasite line is expressing api-SFG (green), and is also stained with 





D.) PfMev ΔDXPR parasites grown in the presence of 50µM mevalonate (blue) or no 
mevalonate (red). The reliance of PfMev ΔDXPR parasites on mevalonate for growth 


























Table 2-1 Primer sequences used for amplifying DXPR homology arms 
 
Primer Name Primer Sequence 
DXPR HA1 F GCCACGAGCGGCCTCCATTGAAAGAAGAAAAAATAACG 
DXPR HA1 R AAGCGCAGCGGCCCCTTCATCACCACACAATATTATAGG 
DXPR HA2 F CGACAGACGCCGGGGTTATAGAAACCCATTTTTTATTTGA 








































Table 2-2 Guide RNA (gRNA) oligo sequences 
 
Oligo Name Oligo Sequence 
DXPR gRNA F TAAGTATATAATATTTATGATGAATAAAGGTTTAGGTTTTAGAGCTAGAA 












































Table 2-3 Primer sequences used for DXPR KO confirmation 
 
Primer Name Primer Sequence 
pl8insHA1F GCTATTTAGGTGACACTATAGAATACTCAAGC 
pl8insHA2R AATCTAGAATTCGACAGACGCCGG 
DXPR 5' F CTATTAATGATTTAGTAATAAATAATACATCAAAATGTG 
DXPR 3'R GTATTTTATTTTTTTTTGTACTATGAAGAATTATGTTTG 
DXPR 5' WT R CCTTGAAAAGAATCAATACCAATAACTATTTTATC 





































Table 2-4 Primer sequences used for determining apicoplast presence 
 
Primer Name Primer Sequence 
Lactate Dehydrogenase (LDH) F GGAGATGTAGTTTTGTTCGATATTG 
Lactate Dehydrogenase (LDH) R CTTGTAAAGGGATACCACCTACAG 
SufB F CATGTAGCTATAGTAGAAATAATAGTAAAAGATTATGG 
SufB R GACTCTGAAATACTTAAACCACGTTGC 
Cox1 F CTTCATCTTTAAGAATAATTGCACAAGAAAATGTAAATC 
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The Essentiality and Role of the SUF Iron-Sulfur Cluster Biosynthetic Pathway in 




































- The growth curves for each deletion line were generated by Hans Liu  






The apicoplast is essential for Plasmodium falciparum. However, it has been shown that 
blood-stage parasites can survive without this organelle as long as the isoprenoid precursor 
isopentenyl pyrophosphate (IPP) is supplemented. While this suggests that IPP is the only 
indispensable product of the organelle during this stage, other pathways within the 
apicoplast play accessory functions to its production, or are involved in the maintenance and 
replication of the organelle and thus are also required for blood-stage parasite survival. 
Previous work showed that the SUF iron-sulfur cluster biosynthetic pathway within the 
organelle is required for blood-stage parasite survival in addition to being essential for the 
maintenance of the apicoplast. However, the roles that the individual iron-sulfur cluster 
dependent proteins play in apicoplast maintenance has remained unknown. To help answer 
this question we utilized our PfMev parasite line, which provides a metabolic bypass that 
allows for the deletion of essential apicoplast-specific proteins. Genetic deletions in this line 
also allowed us to determine the importance of these genes in apicoplast maintenance by 
analyzing the resulting organelle phenotype. Through a series of genetic deletions, we have 
been able to determine that a number of iron-sulfur cluster dependent proteins are required 
for the survival of blood-stage parasites, while others are dispensable. However, individually 
none of the predicted apicoplast-resident iron-sulfur cluster dependent proteins are required 
for the maintenance of the organelle. We went on to demonstrate that additionally, none of 
the nuclear encoded genes involved in iron-sulfur cluster generation are required for 
organelle maintenance either, with the exception of the cysteine desulfurase SufS. These 
results contradict previous findings showing that SufC is required for organelle maintenance. 
We found that the requirement for SufS in apicoplast maintenance is not driven by its 





generation of sulfur for use by MnmA, a tRNA modifying enzyme predicted to be present 




With increasing resistance to current front-line antimalarials there is a crucial need to 
find new therapeutic interventions with novel mechanisms of action (1, 2). In efforts to find 
new potential drug targets, the apicoplast organelle within the parasite has often been 
considered because it is necessary for parasite survival and contains unique biochemical 
pathways dissimilar from the human host (3). While the production of the isoprenoid 
precursors isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) are 
thought to be the only essential products of the apicoplast in the blood-stage of Plasmodium 
falciparum parasites (4), the organelle remains an attractive source of drug targets due to other 
resident pathways playing essential accessory functions (5). One such essential pathway in 
the apicoplast is the SUF iron-sulfur cluster biosynthetic pathway, responsible for the 
generation of iron-sulfur cluster cofactors within the organelle (6). Previous work has shown 
that the SUF pathway is likely essential for blood-stage parasite survival, since the genes 
involved in this pathway are refractory to deletion (7). Additional work has shown that the 
pathway appears to be essential for the maintenance of the apicoplast organelle, based on 
results generated through the expression of a SufC dominant negative mutant (6).  
 Iron-sulfur clusters are cofactors composed of inorganic sulfur and iron, and are 
ubiquitous in nature, being found in organisms within every domain of life (8, 9). Iron-sulfur 
cluster cofactors are extremely versatile and can serve a variety of functions including single 





Iron-sulfur clusters are typically generated within eukaryotes by the iron-sulfur cluster 
formation (ISC) pathway, residing within the mitochondrion (10, 11). The ISC pathway 
generates iron-sulfur clusters for proteins within the mitochondrion in addition to exporting 
the sulfur component to the cytosolic iron-sulfur protein assembly (CIA) pathway, forming 
iron-sulfur clusters for transfer to proteins within the cytosol and other subcellular locations, 
such as the nucleus (12, 13). Prokaryotic organisms can also contain the ISC iron-sulfur 
cluster assembly pathway, as well as the sulfur utilization factor (SUF) pathway (14). 
However, some eukaryotic cells, such as those that contain a chloroplast or plastid, typically 
possess their own self-contained SUF iron-sulfur cluster assembly pathway within the 
organelle, inherited from a cyanobacterial endosymbiont ancestor (15, 16).  
 Plasmodium parasites are believed to possess the ISC, CIA, and SUF pathways (17, 
18). The activity and localization of these pathways is believed to replicate what has been 
found in other systems, with the ISC pathway being localized to the mitochondrion (6, 19), 
generating iron-sulfur clusters for usage within the organelle, in addition to transferring 
sulfur to the cytosolic iron-sulfur protein assembly (CIA) machinery for the generation and 
transfer of iron-sulfur clusters for usage in other areas within the cell (17). The SUF system 
is believed to reside within the apicoplast and generates iron-sulfur clusters exclusively for 
proteins within that organelle (6, 20, 21).  
 Fe-S cluster biosynthesis is organized in three main steps: sulfur acquisition, cluster 
assembly, and cluster transfer. For the SUF pathway sulfur is acquired through the cysteine 
desulfurase SufS, which mobilizes sulfur from L-cysteine resulting in a bound persulfide 
(22). SufE interacts with SufS increasing the cysteine desulfurase activity (23) and also 
acquires sulfur from SufS and transfers it to SufB of the SufBCD iron-sulfur cluster 





formation (25) with the ATPase activity of SufC being essential for the accumulation of iron 
(26). SufA and NifU (SufU) have been shown to receive iron-sulfur clusters from the 
SufBCD complex (27) and transfer them to downstream target proteins (28, 29). 
 In Plasmodium, all components of the SUF system are nuclear encoded and trafficked 
to the organelle with the exception of SufB, which is encoded by the ~35kb apicoplast 
organellar genome (30). The activity of multiple components of the SUF pathway from 
Plasmodium have been confirmed. The cysteine desulfurase activity of SufS and its interaction 
with SufE have been confirmed and localized (6, 21). SufB and SufC have been shown to 
interact (31) and the ATPase activity of SufC has been shown to be present and essential (6, 
31). Additionally, SufA has been demonstrated to interact with SufB of the SufBCD 
complex and accept iron-sulfur clusters (32), with NifU (SufU) also believed to accept and 
transfer iron-sulfur clusters (33).  
 As mentioned previously, the apicoplast can be disrupted in blood-stage P. falciparum 
parasites as long as they are supplemented with 200µM of IPP (4). Our lab has previously 
taken advantage of this apicoplast chemical bypass system, using it to investigate the role and 
importance of iron-sulfur cluster biogenesis through the generation of a SufC (K140A) 
dominant negative mutant (6). The expression of SufC (K140A), containing a point 
mutation designed to ablate the essential ATPase activity of SufC (26), was reliant on IPP 
supplementation for survival and resulted in the disruption and loss of the apicoplast 
organelle. This demonstrated that SufC is not only an essential protein, but is also required 
for the maintenance of the organelle (6). By extension, these results also suggest that the 
SUF pathway and the formation and utilization of iron-sulfur clusters is also essential for 





 While the generation of a SufC (K140A) dominant negative mutant suggested that 
iron-sulfur cluster biosynthesis is required for the maintenance of the apicoplast, the ultimate 
mechanism by which it is responsible for this process has not been elucidated. However, the 
only proposed function of the SUF pathway is the generation of iron-sulfur cluster cofactors 
for usage by five predicted apicoplast localized target proteins: lipoic acid synthase (LipA) 
involved in the lipoylation of pyruvate dehydrogenase (PDH) (34, 35), MiaB predicted to 
function as a tRNA modifying enzyme (36–40), IspG and IspH involved in the last two 
steps of the MEP isoprenoid precursor production pathway (37, 41), and ferredoxin (Fd) 
which is part of the ferredoxin/ferredoxin NADP+ reductase (FNR) redox system within 
the apicoplast (42–44) (Figure 3-1). Thus, we hypothesized that inhibition of iron-sulfur 
cluster formation likely results in the disruption of the apicoplast due to the loss of function 
of one of the downstream enzymes that has been deprived of its essential iron-sulfur cluster 
cofactor.  
 In order to better determine the ultimate mechanism by which iron-sulfur clusters 
are required for apicoplast maintenance, our goal was to delete each of the five proposed 
iron-sulfur cluster dependent proteins. As outlined in chapter 2 of this thesis, we developed 
an alternative apicoplast bypass in the form of the PfMev parasite line, and demonstrated 
that we can use this line to generate deletions of essential apicoplast-specific genes and 
analyze the resulting apicoplast phenotype. Thus, we used this line for the generation of all 
targeted genetic deletions.  
 We were successful in generating deletions of all of the proposed iron-sulfur cluster 
dependent proteins, but found that individually, none were required for the maintenance of 
the apicoplast. We searched for additional potential apicoplast localized iron-sulfur cluster 





approaches, and were ultimately unsuccessful. Thus, we went on to delete each component 
of the SUF pathway, with the exception of SufB encoded within the apicoplast organelle 
genome, to better determine which SUF proteins are required for apicoplast maintenance. 
We found that both iron-sulfur-cluster transfer, mediated by SufA and NifU, and iron-sulfur 
cluster formation, mediated by the SufBCD complex are not required for the maintenance of 
the organelle. These results contradict what has been previously found with the SufC 
dominant negative mutant, but more conclusively demonstrate that iron-sulfur clusters are 
not required for apicoplast maintenance. 
 Surprisingly, we did find that the SufS cysteine desulfurase of the SUF pathway is 
required for apicoplast maintenance, suggesting that a pathway reliant on sulfur, other than 
the SUF pathway is required for organelle maintenance. Upon further analysis, we found that 
the cysteine desulfurase activity of SufS is likely required for apicoplast maintenance due to 
its role in generating sulfur for tRNA modifications mediated by the putative tRNA 
modifying enzyme 5-methylaminomethyl-2-thiouridylate methyltransferase, also referred to 
as MnmA.  
 Overall, the work outlined here provides multiple insights into the apicoplast 
resident SUF iron-sulfur cluster biosynthetic pathway and the proteins dependent on these 
cofactors, and their roles in parasite survival and organelle maintenance. We have 
demonstrated that iron-sulfur cluster usage and generation are required for parasite survival, 
but not for organelle maintenance. We additionally discovered that the SufS cysteine 
desulfurase enzyme of this pathway is required for organelle maintenance, but not due to its 
role in iron-sulfur cluster biogenesis, but instead by its likely role in sulfur generation for its 








Iron Sulfur Cluster Dependent Proteins are not Required for Apicoplast Maintenance  
 Having the proof of concept that the PfMev line is a viable platform to generate 
deletions of essential apicoplast-specific genes, we wanted to use this system to follow up on 
previous results demonstrating that the generation of a SufC (K140A) dominant negative 
mutant results in disruption of the apicoplast (6). We hypothesized that the ultimate 
mechanism by which iron-sulfur clusters are required for apicoplast maintenance is due to 
the loss of function of one of the iron-sulfur cluster dependent proteins. Thus, we generated 
deletions of each of the proposed iron-sulfur cluster dependent proteins within the organelle 
including LipA, MiaB, IspG, IspH, and Fd. For each targeted gene, a series of tests were 
performed to confirm the genetic deletion, ascertain whether the gene is required for blood-
stage parasite survival, and to determine if the gene is essential for the maintenance of the 
apicoplast, following what had been done previously for DXPR as outlined in chapter 2 of 
this thesis.  
 Of the predicted iron-sulfur cluster containing proteins, we first targeted the gene 
encoding lipoate synthase (LipA) (PF3D7_1344600) for disruption. LipA is responsible for 
the lipoylation of the PDH E2 subunit (34, 45), enabling it to generate acetyl-CoA for usage 
by the FASII pathway (46). While the FASII pathway is dispensable for blood-stage parasites 
(46, 47), LipA has remained refractory to deletion (48). Thus, in order to determine if LipA 
is essential for blood-stage parasite survival and potentially apicoplast maintenance we 
deleted the gene in the PfMev line using Cas9-mediated editing (49), under continuous 
supplementation with 50µM mevalonate. We were successful in knocking out LipA and 





the recombinant locus (Δ5’ and Δ3’), in addition to screening for the potential presence of 
any wild type parasites as well, at the 5’ and 3’ loci. We also conducted these same reactions 
using the PfMev parental line as a control (Figure 3-2a). We went on to determine whether 
this gene deletion resulted in disruption of the apicoplast by attempting to PCR amplify SufB 
from the apicoplast genome, in addition to lactate dehydrogenase (LDH) from the nuclear 
genome and cytochrome C oxidase (Cox1) from the mitochondrial genome as PCR controls, 
as previously described (50). We were successful in amplifying SufB, demonstrating that the 
apicoplast genome was still present (Figure 3-2b). We went on to confirm the phenotype of 
the apicoplast using live epifluorescent microscopy and found that the apicoplast remained 
intact in the LipA deletion line (Figure 3-2c). We additionally found that LipA is not 
required for blood-stage parasite survival by demonstrating that ΔLipA parasites continue to 
grow in the absence of mevalonate supplementation (Figure 3-2d). 
 We next targeted the gene encoding MiaB (PF3D7_0622200) for deletion. MiaB is 
predicted to be an iron-sulfur cluster dependent tRNA modifying enzyme within the 
apicoplast (36, 37), and is believed to potentially assist in the read-through of a premature 
stop codon in the RpoC2 gene within the apicoplast genome (30, 37). However, we were 
successful in deleting MiaB in the PfMev parasites under continuous supplementation with 
50µM mevalonate and were able to show that this gene is not required for organelle 
maintenance or replication. Additionally, we were able to demonstrate that this gene is also 
dispensable in blood-stage parasites, as it is not reliant on mevalonate for growth (Figure 3-
3).  
 We next moved on to deleting IspG (PF3D7_1022800) and IspH (PF3D7_0104400) 
of the MEP pathway. IspG and IspH are involved in the last two steps of the MEP 





production of IPP and DMAPP within the parasite, we reasoned that they were likely to be 
essential, but we wanted to determine if they are also required for apicoplast maintenance. 
To answer this question, we targeted both for deletion in the PfMev line under continuous 
supplementation with 50µM mevalonate and were able to confirm that both are essential for 
blood-stage parasite survival, as evidenced by their reliance on exogenous mevalonate for 
parasite growth and survival. We then analyzed their potential role in apicoplast maintenance 
by attempting to amplify SufB from the apicoplast genome, and examining the morphology 
of the apicoplast via live epifluorescence microscopy. We found that the organelle genome 
was still present and that the apicoplast remained intact in both the ΔIspG (Figure 3-4) and 
ΔIspH (Figure 3-5) parasites, indicating that these genes are not required for apicoplast 
maintenance.   
 We finally targeted ferredoxin (Fd) (PF3D7_1318100) and ferredoxin reductase 
(FNR) (PF3D7_0623200) for deletion in the PfMev line. As discussed previously, the 
generation of a SufC (K140A) dominant negative mutant resulted in disruption of the 
apicoplast (6). In that publication the authors speculated that the ultimate mechanism by 
which the dominant negative mutant resulted in disruption of the apicoplast was likely due 
to the loss of function of the Fd/FNR redox system (6). The Fd/FNR redox system is the 
only known redox system within the apicoplast, which is believed to deliver reducing power 
to IspG, LipA, and MiaB in addition to other proteins within the SUF pathway (37, 42, 51, 
52). Thus, we went on to test this hypothesis by attempting to delete both Fd and FNR in 
the PfMev line under continuous supplementation with 50µM mevalonate. We successfully 
deleted both genes and found that both Fd and FNR are required for blood-stage parasite 





resulted in disruption of the apicoplast, demonstrating that these genes are not required for 
organelle maintenance.   
 Through the findings described above, we were successful in determining which 
predicted apicoplast-specific iron-sulfur cluster dependent proteins are required for blood-
stage parasite survival. However, these results demonstrate that the individual deletion of any 
of the proposed iron-sulfur cluster dependent proteins did not result in disruption of the 
apicoplast.  
 
Searching for Additional Apicoplast Iron-Sulfur Cluster Dependent Proteins 
  Deletion of any of the individual predicted iron-sulfur cluster dependent proteins did 
not replicate the phenotype seen with the SufC (K140A) dominant negative mutant (6). This 
led us to believe that there may be additional apicoplast resident iron-sulfur cluster 
dependent proteins that are playing essential roles in apicoplast maintenance that have not 
yet been annotated or discovered. In order to search for additional apicoplast trafficked iron-
sulfur cluster containing proteins we downloaded the amino acid sequences of every known 
and putative protein of the P. falciparum 3D7 genome through PlasmoDB (53). We then ran 
the amino acid sequences through the program MetalPredator, which is a program designed 
to predict iron-sulfur cluster binding proteins (54). Through this program we were able to 
generate a list of all of the predicted iron-sulfur cluster binding proteins (Table 3-1). We 
then ran this list of proteins through PlasmoAP, a program designed to predict the 
likelihood of a given protein being trafficked to the apicoplast (55). Finally, we checked if the 
genes are predicted to be essential through prior work done using forward genetic screens in 
P. berghei (56) and P. falciparum (57). However, after this analysis we found no candidate genes 





apicoplast and were likely to be essential proteins. Thus, we were unable to identify any other 
potential apicoplast localized iron-sulfur-cluster dependent proteins that represented viable 
targets to pursue further through the generation of additional genetic knockouts or other 
methods.  
 
Iron-Sulfur Cluster Transfer is not Required for Apicoplast Maintenance  
 The previous genetic deletions were all done individually, leading to the possibility 
that the loss of the apicoplast may be due to a combinatorial effect from multiple iron-sulfur 
cluster dependent genes lacking their required cofactors. There also still remained the 
possibility that there may be additional apicoplast localized iron-sulfur cluster dependent 
proteins that are essential for organelle maintenance that our previous bioinformatic analysis 
did not identify. Thus, in an effort to address these questions we attempted to delete the 
genes involved in iron-sulfur cluster transfer in order to prevent all apicoplast proteins from 
acquiring iron-sulfur-cluster cofactors.  
 Two genes are proposed to be involved in iron-sulfur cluster transfer within the 
apicoplast, SufA (PF3D7_0522700) and NifU (SufU) (PF3D7_0921400). In E. coli both 
SufA and NfuA (a homolog of NifU) have been shown to receive iron-sulfur clusters from 
the SufBCD iron-sulfur cluster assembly complex (27) and transfer those clusters to 
downstream target enzymes (28, 29). Some of this activity has been confirmed in Plasmodium, 
showing interactions between SufA and SufB of the SufBCD complex (32). Both SufA and 
NifU have been previously localized to the apicoplast, and have been shown individually to 
be dispensable at every stage of the parasite lifecycle in P. berghei (7, 33). However, this work 
has not been replicated in P. falciparum. Thus, we targeted both of these genes for deletion in 





both SufA and NifU are dispensable for P. falciparum blood-stage parasite survival, and that 
parasite growth was unaffected by the removal of mevalonate. Additionally, we were able to 
show that neither SufA (Figure 3-8) or NifU (Figure 3-9) are required for apicoplast 
maintenance or replication by assaying for the presence of the apicoplast genome and 
determining the morphology of the organelle. This reproduces previous results in P. berghei 
also demonstrating that individually SufA (7) and NifU (33) are not essential.  
 It has been hypothesized that SufA and NifU are functionally redundant and are 
both able to recognize all potential substrate proteins (7, 33). In other organisms it has been 
shown that detrimental effects are only observed when more than one of the cluster transfer 
genes are targeted for deletion (58). Thus, in order to determine if iron-sulfur cluster transfer 
is essential for apicoplast maintenance we generated a double knockout of SufA and NifU. 
The deletion of both of these genes should continue to allow for the formation of iron-
sulfur clusters through the actions of SufS/SufE and the SufBCD complex, but inhibit the 
transfer of those clusters to any downstream proteins that receive these cofactors. We were 
successful in generating ΔSufA/ΔNifU PfMev parasite lines, and found that together these 
genes are essential for blood-stage parasite survival. However, these genetic deletions did not 
result in the disruption of the apicoplast (Figure 3-10).  
 Taken together, these data suggest that SufA and NifU are functionally redundant as 
indicated by the lack of phenotype observed upon the individual deletion of either gene (58). 
The essentiality of SufA and NifU together suggests that iron-sulfur cluster transfer is 
required for the survival of blood-stage parasites. However, the observation that 
ΔSufA/ΔNifU PfMev parasite lines retain the apicoplast suggests that iron-sulfur cluster 
transfer or usage is not required for apicoplast maintenance. Additionally, these results 





that are essential for organelle maintenance, since the ΔSufA/ΔNifU double deletion should 
presumably prevent the transfer of iron-sulfur clusters to all apicoplast proteins.  
 
Iron Sulfur Cluster Formation is not Required for Apicoplast Maintenance  
 Since the transfer or usage of iron-sulfur clusters is not essential for apicoplast 
maintenance, we wanted to determine at which point inhibition of the SUF pathway would 
result in disruption of the organelle. It was previously demonstrated that the expression of a 
SufC (K140A) dominant negative mutant resulted in apicoplast disruption. The introduction 
of the K140A point mutation abolishes the ATPase activity of SufC, which is essential for 
iron acquisition and cluster formation in vivo (26, 59). However, the work outlined up to this 
point has only involved deletion of the iron-sulfur cluster dependent proteins and iron-sulfur 
cluster transfer proteins. Thus, it remains a possibility that iron-sulfur cluster formation, but 
not transfer or usage is required for organelle maintenance. This may be the case due to 
previous work showing that iron-sulfur cluster formation may be essential for iron 
homeostasis (60–63). Thus, we next sought to determine whether interfering with the iron-
sulfur cluster assembly complex may result in apicoplast disruption. 
 The SufBC2D complex is predicted to form from a SufBC dimer and a SufDC dimer 
(64), with SufC transiently dimerizing upon hydrolyzing ATP (25). It has previously been 
demonstrated that SufD is required for iron incorporation into the complex in vivo (26, 65), 
and thus should play an essential role in iron-sulfur cluster formation. Thus, we attempted to 
delete SufD (PF3D7_1103400) of the SufBCD iron-sulfur cluster assembly complex. Using 
the PfMev line we were successful in deleting SufD, and found it to be essential for blood-
stage parasite survival as evidenced by its reliance on mevalonate for growth. However, 





 This finding demonstrating that SufD is not required for organelle maintenance, but 
is essential for parasite survival suggests that the process of iron-sulfur cluster formation 
itself is not required for the maintenance of the apicoplast. The requirement of SufD for 
iron-sulfur cluster formation is supported by prior work in other systems (26). However, 
SufB and SufD are paralogs, sharing 17% sequence identity in E. coli (66), and 21% identity 
in P. falciparum. It is predicted that SufD arose from a gene duplication event of SufB, with 
ancestral iron-sulfur cluster assembly complexes consisting of only SufB and SufC (67). 
Indeed there are many organisms that contain genes for SufC and SufB, but lack SufD (67). 
It has even been shown that organisms that contain SufD are capable of forming SufB2C2 
complexes (16, 68). Thus, in order to confirm the essentiality of iron-sulfur cluster 
formation, we targeted the SufC ATPase for deletion.  
 Using the PfMev line we were successful in generating a SufC (PF3D7_1413500) 
deletion line. We were able to determine that SufC is essential for blood-stage parasite 
survival, but is not required for apicoplast maintenance or replication (Figure 3-12). The 
deletion of SufC resulted in a similar phenotype as that seen for the deletion of SufD, 
helping to further support the finding that iron-sulfur cluster formation is not required for 
organelle maintenance. Additionally, we went on to more conclusively establish that iron-
sulfur cluster formation is not required for organelle maintenance by generating a dual 
deletion of both SufC and SufD in the PfMev line. While SufE has previously been shown 
to only transfer sulfur from SufS to SufB in the presence of SufC (24), and both SufC and 
SufD have been demonstrated to perform critical functions in iron acquisition and iron-
sulfur cluster assembly (26), we wanted to eliminate as many components of the SufBCD 
cluster assembly complex to eliminate any doubt that iron-sulfur cluster formation is 





are able to knockout, since SufB is encoded by the apicoplast organelle genome (30), and 
current genetic tools make organelle genome modification unfeasible. However, we were 
successful in generating a ΔSufC/ΔSufD dual deletion in the PfMev parasite line, and found 
that even when both components were deleted they were required for blood-stage survival, 
but were not essential for apicoplast maintenance (Figure 3-13). Thus, these results more 
conclusively demonstrate that iron-sulfur cluster formation is not required for apicoplast 
maintenance.  
 
SufE is Required for Parasite Survival, but is not Essential for Apicoplast 
Maintenance 
 Having established that iron-sulfur cluster formation is not required for apicoplast 
maintenance, we continued to move up in the SUF pathway to determine if sulfur 
acquisition and transfer is essential for apicoplast maintenance. Thus, we chose to delete 
SufE (PF3D7_0206100), which has previously been characterized as a sulfur transfer 
protein, and has been shown to accept sulfur from SufS and transfer it to SufB of the 
SufBCD complex (24, 69). Additionally, SufE has been shown to increase the cysteine 
desulfurase activity of SufS up to 8 fold (23), and in other systems up to 50 fold (22). SufE 
has been shown to be essential for iron-sulfur cluster synthesis in E. coli (23, 24). In 
Plasmodium, SufE is predicted to be essential due to the inability to generate SufE deletion 
lines (7). Using the PfMev line we were successful in generating a genetic knock out of SufE, 
and found the gene to be essential for parasite survival, but found that it is not required for 
apicoplast maintenance (Figure 3-14).  
 





 As mentioned previously, SufS (PF3D7_0716600) is an apicoplast resident cysteine 
desulfurase (6, 21), that acquires sulfide through the conversion of L-cysteine to L-alanine 
(69). SufS has been shown to then transfer this sulfide to SufE, which in turn transfers it to 
SufB of the SufBCD complex for iron-sulfur cluster formation (24). As outlined in the work 
above, we were able to demonstrate that SufE is required for parasite survival, but is not 
essential for organelle maintenance. While SufE has previously been shown to play a role in 
sulfur transfer between SufS and SufB (24), in addition to increasing the cysteine desulfurase 
activity of SufS (23), it does not appear to be absolutely required for cysteine desulfurase 
activity. SufS in the absence of SufE still displays a basal cysteine desulfurase activity (23), 
and it may be possible that its activity can be enhanced by other interacting partners besides 
SufE. Some organisms lack SufE altogether, demonstrating that its activity may not be 
essential for the cysteine desulfurase activity of SufS (70). Additionally, in other systems 
cysteine desulfurase enzymes have been shown to be required for other pathways in addition 
to iron-sulfur cluster formation including the biosynthesis of thiamine, biotin, lipoic acid, 
molybdopterin, and tRNA modifications (71), and the transfer of sulfur between SufS and 
the target proteins likely does not require SufE (72–74). We were successful in deleting SufS 
in the PfMev line and found the gene to be essential for blood-stage parasite survival, in 
addition to being essential for apicoplast maintenance (Figure 3-15). These results suggest 
that the cysteine desulfurase activity of SufS is essential for apicoplast maintenance, but its 
role in that process is likely not due to its function in generating sulfur for usage by the SUF 
iron-sulfur cluster formation pathway.  
 





 The previous results demonstrate that SufS is required for apicoplast maintenance. 
However, none of the genes involved in iron-sulfur cluster generation, transfer, or usage are 
required for this process. This suggests that the reliance on sulfur for organelle maintenance 
is not driven by its requirement for iron-sulfur cluster generation, but instead by a separate 
pathway. As mentioned above, cysteine desulfurase enzymes can also be involved in the 
biosynthesis of thiamine, biotin, lipoic acid, molybdopterin, and sulfur containing tRNA 
modifications (71). Having analyzed which of these pathways are present within the parasite, 
likely to be localized to the apicoplast, and potentially essential for the survival of the 
parasite, the only pathway that potentially fit this description was tRNA thiolation, mediated 
by a putative MnmA (37). While this gene has not been investigated or characterized in 
Plasmodium, MnmA has previously been predicted to be localized to the apicoplast (37), with 
its activity being reliant on a cysteine desulfurase (75). 
 After searching the genome of P. falciparum, we found a gene that potentially 
possesses MnmA activity, that is currently annotated as a tRNA methyltransferase 
(PF3D7_1019800). Using the apicoplast targeting prediction algorithm PlasmoAP, the gene 
product is likely trafficked to the apicoplast (76). Additionally, further analysis of the protein 
sequence shows that there is a domain present that shows homology to the bacterial MnmA, 
with eukaryotic homologs typically termed TrmU or Mtu1, which act as a tRNA-specific 2-
thiouridylase involved in the 2-thiolation of the wobble base uridine at position 34 (U34) of 
tRNA(Lys), tRNA(Glu) and tRNA(Gln), generating the s2U34 tRNA modification (77). This 
modification has been shown to improve reading frame maintenance, with its absence 
responsible for a growth defect in bacteria, attributed to potential translational frameshifting 
(78–81). In order to determine if the s2U34 tRNA modification, potentially catalyzed by the 





deleted this gene in the PfMev parasite line and found this gene to be essential for blood-
stage survival in addition to being required for apicoplast maintenance (Figure 3-16). 
Overall, these results suggest that the ultimate reason why SufS is required for apicoplast 
maintenance is likely due to its role in sulfur generation for utilization by the putative MnmA 
gene for tRNA modification.  
 
CONCLUSIONS AND DISCUSSION  
 
Previous work using the IPP chemical bypass system (4), showed that the apicoplast 
organelle becomes disrupted when the SufC (K140A) dominant negative mutant is expressed 
(6). This work suggested that iron-sulfur cluster biosynthesis is required for organelle 
maintenance, but a more refined etiology was not provided. The ultimate mechanism by 
which the SufC (K140A) dominant negative mutant resulted in organelle loss was suggested 
to be due to the loss of function of one or more of the five proposed iron-sulfur cluster 
containing proteins within the organelle, with ferredoxin being hypothesized as the most 
likely candidate (6). To capitalize on these insights, we individually deleted each of the five 
proposed iron-sulfur cluster dependent proteins in the apicoplast, including LipA, MiaB, 
IspG, IspH, and Fd using the PfMev parasite line described in chapter 2 of this thesis. We 
determined the role of each protein in parasite survival and in the maintenance of the 
apicoplast, as summarized in Table 3-2.  
 We first targeted lipoic acid synthase (LipA) for deletion. As described previously, 
LipA is predicted to be an apicoplast-resident iron-sulfur cluster dependent protein (35, 46, 
82), involved the lipoylation of the apicoplast-resident pyruvate dehydrogenase (PDH) 





octanoyltransferase LipB, which transfers an octanoyl group from ACP onto the E2 subunit 
of apicoplast resident pyruvate dehydrogenase (PDH) (34, 45, 46). LipA is responsible for 
the insertion of two sulfur atoms into the octanoyl moiety of PDH, converting it to the 
active lipoylated form of the enzyme (34, 35, 83). Lipoate functions as an essential cofactor 
of PDH, which converts pyruvate into acetyl-CoA, which in turn is utilized by the type II 
fatty acid biosynthetic pathway (FASII) within the apicoplast (46). Previous attempts to 
delete LipA in P. falciparum have been unsuccessful (48). However, genes relevant to the 
activity and function of LipA, such as LipB (84), the E1α subunit of PDH (85), and multiple 
components of the FASII pathway (46, 47) have been amenable to deletion in blood-stage P. 
falciparum parasites, suggesting that LipA should be able to be deleted as well. As detailed 
above, we were successful in deleting LipA and found it to be not essential for the growth of 
blood-stage parasites. The deletion was generated in the PfMev bypass line under 
supplementation with 50µM mevalonate. However, upon the removal of mevalonate, the 
ΔLipA parasites continued to grow at a rate similar to those with supplementation with 
50µM mevalonate, demonstrating the dispensability of the gene in blood-stage parasites.  
 We next targeted MiaB for deletion. In P. falciparum MiaB (PF3D7_0622200) is 
predicted to be another apicoplast-resident iron-sulfur cluster containing enzyme (36–38). 
MiaB is predicted to function as a tRNA modifying enzyme, acting downstream of another 
tRNA modifying enzyme MiaA (PF3D7_1207600) (37). MiaA is a tRNA 
isopentenyltransferase, transferring the isopentenyl group from DMAPP to the N6-nitrogen 
of adenine at base 37 of the target tRNA, to form the modification (i6A37) (39, 40). MiaB is 
then predicted to function as a tRNA methylthiotransferase (38), catalyzing the 
methylthiolation of the i6A37 base, further modifying it to generate the 2-methylthio-N6-





tRNA modification generated by MiaA and MiaB is involved in increasing translational 
fidelity, reducing frameshifting, assisting in stop codon suppression, and reading frame 
maintenance (81, 87–89). These modifications are also present in tRNAs within chloroplast 
organelles, and are required for tRNA ribosome binding (90, 91). The apicoplast organelle 
genome contains an internal stop codon in the RpoC2 gene (30), and the MiaA/MiaB 
modification was previously predicted to be essential for the translation of this gene (37). 
MiaA is involved in tRNA isopentenylation reliant on DMAPP (92), produced within the 
organelle. However, previous work suggested that isoprenoid biosynthesis is not essential for 
organelle maintenance (50). Our work certainly confirms this conclusion since the deletions 
of MEP pathway enzymes DXS, DXPR, IspG, or IspH did not result in loss of the 
apicoplast. Formation of i6A37 tRNA would only be possible in these deletion lines if 
supplemented isoprenoid precursors were able to enter the apicoplast from the cytosol. 
MiaA and MiaB have been proven to be non-essential in other systems such as E. coli (93) 
and we found MiaB to not be essential in our system as well. Based on our results, we found 
that the deletion of MiaB had no discernible detrimental effect on the growth of blood-stage 
parasites. 
 We moved on to delete IspG and IspH, two proteins predicted to contain iron-
sulfur-clusters and localize to the apicoplast (37, 42, 94, 95). IspG and IspH are responsible 
for the last two steps of isoprenoid precursor production (37, 41), with IspG predicted to 
catalyze the conversion of methylerythritol cyclic diphosphate (MEcPP) to (E)-4-hydroxy-3-
methylbut-2-enyl diphosphate (HMBPP) (96), followed by IspH which converts HMBPP 
into IPP and DMAPP (42, 97). Previous work reported in the chapter 2 of this thesis 
demonstrated that DXPR, which catalyzes the second step in the MEP pathway, is essential 





the same phenotype to be shared by ΔIspG and ΔIspH parasites, however, there was the 
possibility that another phenomenon, such as the buildup of a toxic substrate, could lead to 
apicoplast disruption in these lines. Ultimately, this proved not to be the case, and the MEP 
pathway enzymes IspG, IspH, and DXPR all are essential for parasite survival, but are not 
required for apicoplast maintenance. 
 Ferredoxin is another apicoplast-resident iron-sulfur cluster dependent protein (42) 
involved in the apicoplast Fd/FNR redox system (43), the only known redox system present 
in the apicoplast (44, 52, 98). FNR harvests two electrons (through hydride transfer) from 
NADPH and uses these electrons to reduce two Fd proteins (one electron each), which in 
turn deliver reducing power throughout the organelle (52). Fd has been demonstrated to 
function as an electron donor to IspH (42), and is also believed to deliver reducing power to 
multiple other enzymes and pathways within the organelle, such as IspG, LipA, MiaB, and 
other proteins within the SUF iron-sulfur cluster generation pathway (37, 42, 51, 52). It was 
hypothesized that loss of the Fd iron-sulfur cluster would lead to redox dysfunction, DNA 
damage, and loss of the organelle (6). In E. coli, loss of the Fd/FNR system led to increased 
sensitivity to oxidative stress (50, 99). However, while we found that Fd and FNR are both 
essential for parasite survival, we found that neither are required for the maintenance of the 
organelle. Since redox homeostasis should be critical for organelle maintenance, these results 
suggest that there could be some other mechanisms for maintaining redox balance and 
oxidative defense.  
 Our results showed that all of the known apicoplast iron-sulfur cluster proteins can 
be individually deleted without loss of the organelle. It remained possible that other 
undiscovered iron-sulfur proteins existed, or that the combined loss of multiple iron-sulfur 





only two proposed iron-sulfur cluster transfer proteins, SufA and NifU, both individually 
and together. These proteins should be required for transferring the clusters formed by the 
SufBCD complex to all target proteins (7, 33, 100). Thus, loss of the transfer proteins should 
behave like a functional deletion of all iron-sulfur proteins, including any that have yet to be 
discovered. We found that individually SufA and NifU are dispensable, however, the 
simultaneous deletion of both SufA and NifU demonstrated that together they are required 
for parasite survival. These data support previous findings suggesting that they are 
functionally redundant, as parasites lacking either can complete the entire parasite lifecycle in 
P. berghei (7, 33). Our results indicate that SufA and NifU are likely the only iron-sulfur 
cluster transfer proteins within the organelle, since the deletion of both results in parasite 
death. Dual deletion, however, did not result in the disruption of the apicoplast. Thus, 
functional loss of all apicoplast iron-sulfur cluster proteins does not trigger disruption of the 
organelle.  
 There do not appear to be any other iron storage proteins located in the apicoplast. 
The iron-sulfur cluster assembly machinery may have an important role in sequestering free 
iron and sulfide, which would be toxic otherwise. This hypothesis is supported by previous 
researching demonstrating the importance of iron-sulfur cluster generation in iron 
homeostasis and metabolism (60–63). Thus, we chose to delete SufD and SufC of the 
SufBCD iron-sulfur cluster assembly complex (26). As mentioned above SufD is a paralog 
of SufB, with SufB being encoded by the apicoplast organellar genome (37, 67, 101), with its 
activity being essential for iron acquisition and cluster formation (26). We were successful in 
individually deleting SufD and SufC, and while they were shown to be essential for parasite 
survival, neither was required for organelle maintenance. Consistent with this result, we 





demonstrating that the SufBCD complex is not essential for organelle maintenance, and thus 
likely not required for iron homeostasis and metabolism in the organelle. 
 Our results make it clear that iron-sulfur cluster generation, transfer or usage is not 
required for organelle maintenance. The discrepancy in the results between the SufC 
dominant negative mutant and SufC genetic deletion are not immediately clear. For one, the 
mechanisms of gene disruption were different, with the previous method relying on a SufC 
(K140A) dominant negative mutant. This method relied on the exogenous expression of a 
second copy of the gene containing the point mutation, with its expression controlled by 
either the ribosomal L2 (RL2) or calmodulin promoters (50). Overexpression of the protein 
could have led to general toxicity as has been observed by others (6), however, expression of 
the native SufC using the same promoters (RL2 and calmodulin) did not lead to toxicity and 
apicoplast loss (50). In our current work, protein overexpression is not an issue because we 
targeted proteins for deletion. Additionally, the method of bypass was different in the 
previous work and what is outlined here, with the previous dominant negative mutant 
expression relying on the exogenous supplementation with 200 µM IPP. The effect of this 
concentration of IPP on parasite fitness over the time-course needed for this experiment 
(>30 days) has not been studied, however, the isomer of IPP, DMAPP has been shown to 
toxic to parasites (4). Our method relies on supplementation with only 50µM mevalonate, 
and while this has not been experimentally confirmed, this may be better tolerated by the 
parasite. As far as how the previous phenotype manifested, it is unclear, but may be a 
combinatorial effect of increased protein trafficking to the organelle as well as the metabolic 
bypass method, but it is clear that the resulting phenotype was not due to SufC being 





 We completed our investigation of the SUF pathway by targeting the sulfur 
acquisition step catalyzed by SufS and SufE. We attempted to knockout SufE, which is an 
accessory partner to SufS, and functions as a sulfur transfer protein. Once sulfur is liberated 
from L-cysteine by SufS, the persulfide sulfur is transferred from SufS to SufE (69). SufE 
can then in turn transfer it to SufB of the SufBCD complex, with analysis showing that there 
is no transfer of sulfur directly from SufS to SufB (24), and thus SufE is required for this 
process. Additionally, bacterial SufE has been shown to enhance the cysteine desulfurase 
activity of SufS, increasing its activity up to 50-fold (22). Similar experiments have been 
conducted analyzing the P. falciparum proteins and found that SufS cysteine desulfurase 
activity was enhanced up to 17-fold by the addition of SufE (21). We were successful in 
deleting SufE and SufS in P. falciparum, and showed that both proteins are required for 
parasite survival, consistent with their roles in iron-sulfur cluster synthesis. However, SufS 
proved to be essential for apicoplast maintenance while SufE was not. While SufE has been 
shown to enhance the cysteine desulfurase activity of SufS, it does not appear to be 
absolutely required for its activity (21). SufS may be capable of liberating and transferring 
sulfur to other pathways within the organelle that are essential for its maintenance, 
independent of SufE. In addition to iron-sulfur cluster assembly there are other pathways 
that rely on sulfur harvested from L-cysteine by cysteine desulfurases, such as the 
biosynthesis of thiamine, biotin, lipoic acid, molybdopterin, in addition to the sulfur 
modifications of tRNAs (71). We analyzed each of these potential pathways to determining 
if they are likely to be present in P. falciparum, and if their activity is likely to be required for 
apicoplast maintenance.  
 The current model of thiamine biosynthesis relies on the joining of 5-(2-





pyrophosphate (HMP-PP) by the enzyme ThiE (102), with an additional pathway for 
thiamine scavenging (102, 103). The biosynthesis of THZ is the step in thiamine 
biosynthesis reliant on cysteine desulfurase activity, and parasites have been shown to 
survive in thiamine depleted media as long as HMP is supplemented, suggesting that the 
parasites can synthesize THZ, but not HMP (102). However, multiple enzymes involved in 
THZ synthesis including ThiG/H/L have not been identified in Plasmodium species (102, 
104), and should be required for its biosynthesis (105, 106). Additionally, there is a pathway 
present for the scavenging of THZ, as evidenced by the presence of the ThiM (102, 107). 
The biosynthesis of THZ does require a cysteine desulfurase, and while it is currently unclear 
what proteins are involved in this pathway or if this pathway is present in the parasite at all, a 
potential role for SufS cannot be ruled out. However, thiamine biosynthesis is unlikely to 
play a role in apicoplast maintenance. Within the parasite, thiamine is predicted to be used by 
transketolase, 3-methyl-2-oxobutanoate dehydrogenase (BCKDK), and 2-oxoglutarate 
dehydrogenase (OxoDH) outside of the apicoplast, and by 1-deoxy-D-xylose phosphate 
synthase (DXS) and the E1 subunit of the pyruvate dehydrogenase (PDH) complex within 
the apicoplast (107, 108). The dependent enzymes outside of the apicoplast are unlikely to 
play a role in organelle maintenance, and of the dependent enzymes within the apicoplast, 
both have been deleted and have been shown to not be required for organelle maintenance. 
The PDH E1α subunit has previously been deleted and was demonstrated to not be essential 
for blood-stage survival (85). Additionally, as outlined in chapter 4 of this manuscript, we 
deleted DXS and found the gene to be essential for parasite survival but not for organelle 
maintenance. Thus, overall it appears unlikely that SufS has a key role in thiamine 






 Other pathways potentially reliant on a cysteine desulfurase include lipoic acid and 
biotin biosynthesis. For lipoic acid biosynthesis, LipA is predicted to be an iron-sulfur cluster 
dependent protein that catalyzes the conversion of PDH E2 bound octanoate into lipoate 
through the addition of two sulfur atoms (34, 46). Within the parasite, the only enzymes 
predicted to be reliant on lipoic acid include the branched-chain alpha-ketoacid 
dehydrogenase (BCDH), alpha-ketoglutarate dehydrogenase (KDH), and the glycine 
cleavage system within the mitochondria (109), and the PDH E2 subunit within the 
apicoplast (46). However, due to LipA being an iron-sulfur cluster dependent protein, in 
addition to the above demonstration that deletion of the gene has no discernible effect on 
apicoplast morphology, LipA is clearly not responsible for organelle maintenance. For biotin 
biosynthesis the final step typically involves the conversion of dethiobiotin into biotin by 
biotin synthase (BioB), an iron-sulfur cluster dependent protein (110, 111). However, acetyl-
CoA carboxylase (ACC) is the only protein predicted to be biotinylated within the parasite 
(104), and it has been demonstrated to not be essential for the blood-stage survival of the 
parasite (112). Furthermore, the parasite is predicted to scavenge biotin (113), and lacks the 
ability to synthesize it on their own (104). Thus, for these reasons lipoate and biotin 
biosynthesis are unlikely to be responsible for apicoplast maintenance.  
 Additionally, another pathway reliant on cysteine desulfurase is the biosynthesis of 
molybdopterin (71). However, the enzymes involved in the production of this cofactor are 
not likely to be present in P. falciparum based on bioinformatic analysis of the parasite 
genome (114).  
 When analyzing which pathways may be present in the apicoplast and playing a role 
in the maintenance of the organelle, the pathway that appeared to be the most likely was 





position 8 on the tRNA, or the 2-thiouridine (s2U) modification at position 34 of the tRNA 
(71). The s4U modification typically relies on IscS and ThiL of the thiamine biosynthetic 
pathway (115–117). However, Plasmodium does not have a ThiL, and instead contains the 
homologous thiamine phosphate kinase (TPK) (37, 107), which is believed to act solely 
within the cytosol of the parasite (118). The s2U modification relies on MnmA (119), which 
has previously been predicted to be localized to the apicoplast organelle (37).  
 MnmA is an 5-methylaminomethyl-2-thiouridylate methyltransferase enzyme 
involved in the 2-thiouridine modification (s2) of position 2 of the pyrimidine ring at the 
wobble base position (U34) of tRNAGluUUC, tRNAGlnUUG, and tRNALysUUU (75), helping to 
generate the mnm5s2U34 tRNA modification (77). While requiring sulfur, this modification 
has been shown to occur independently of iron-sulfur clusters (120). This modification 
typically occurs in parallel to modifications mediated by the MnmE/MnmG complex, which 
catalyzes the addition of an aminomethyl or carboxymethylaminomethyl group to the C5 
position at the U34 wobble base of tRNAGluUUC, tRNAGlnUUG, tRNALysUUU, tRNALeuUAA, 
tRNAArgUCU, and tRNAGlyUCC (121, 122). In E. coli, the tRNAGluUUC and tRNALysUUU can then 
be further converted into a 5-methylaminomethyl (mnm5) group by MnmC (121). However, 
while MnmE and MnmG are evolutionarily conserved, MnmC is not, with some organisms 
lacking this gene (123). This appears to be the case in P. falciparum, with genes sharing a high 
sequence homology to the E. coli MnmA (PF3D7_1019800), MnmE (PF3D7_0817100), and 
MnmG (PF3D7_1244000) present in the parasite genome. Additionally, each of these genes 
are predicted to likely be trafficked to the apicoplast (76), and predicted to be essential as 
determined by the forward genetic screen conducted by Dr. John Adams (57). With the 
MnmA and MnmG also predicted to be essential in P. berghei, as predicted by a separate 





MnmA is likely to be present in the apicoplast and essential for its maintenance, as evidenced 
through its deletion in the PfMev line. Additionally, it appears that other proteins involved in 
this pathway are present and essential in the P. falciparum apicoplast organelle as well.  
 In the MnmA pathway in E. coli, sulfur is typically liberated by IscS and the 
transferred through the Tus sulfur relay system (TusABCDE) to MnmA for modification of 
the tRNA (74). While MnmA is conserved, TusBCD and E are often not found in numerous 
organisms (124) and it has been shown that this modification can occur independent of the 
Tus system (72). Additionally, the liberation of sulfur for usage by MnmA has been shown to 
be generated by other cysteine desulfurases besides IscS, such as yrvO in B. subtilis (72), or by 
NifS within the mitochondria (77), and SufS is predicted to fulfill this role in T. parva (125). 
These modified tRNAs are also believed to be present within chloroplasts (126). 
 MnmA shows extreme evolutionary conservation, being present even in the most 
reduced bacterial genomes (127), and is even hypothesized to also be responsible for the 
retention of SufS and IscS, due to the lack of conservation of the other pathways that would 
be reliant on these enzymes (128). The (x)nm5S2U34 modification is also conserved in the 
mitochondrial and chloroplast organelles (126), with the eukaryotic homolog of MnmA, 
Mtu, having been shown to be essential for mitochondrial translation and organelle 
biogenesis (129–131). While MnmA has been shown to not be essential in E. coli or S. 
enterica, MnmA deletion mutants do display a slower growth phenotype (75, 126) and 
MnmA/MnmE double mutants in E. coli and S. enterica demonstrated that these genes 
together are critical for growth (122, 126). The reduction in growth is believed to be caused 
by an increase in missense errors (126).  
 While the specific role the putative MnmA is playing in the apicoplast of P. falciparum 





to be important in other systems for tRNA ribosome binding (132), the recognition of 
wobble codons (133, 134), reading frame maintenance (78), and reducing +1 +2 frameshifts 
(81, 135). Additionally, tRNA modifications in general are ubiquitous and critical for 
translation across all domains of life (136). Due to P. falciparum presumably encoding all of 
the tRNAs needed for translation within the apicoplast genome itself (30), there is likely no 
import of tRNAs into the organelle. Thus, all modifications of the apicoplast tRNAs must 
also likely occur within the organelle as well. Previous work showed that ribosome binding 
and wobble codon recognition was prevented with hypomodified tRNALysUUU, but was 
restored upon S2U34 modification (132, 133). This suggests that there may be a minimal set 
of tRNA modifications required for translation, with the S2U34 modification potentially 
being one of them. This hypothesis is supported by the retention of MnmA in extremely 
reduced bacterial genomes (127, 137–139).  
 Overall, this work has helped to better elucidate the biochemistry and roles of the 
various components of the SUF pathway and the downstream proteins reliant on it. We have 
been able to demonstrate which are essential for parasite survival and which are required for 




P. falciparum culture and maintenance 
Unless otherwise noted, blood-stage P. falciparum parasites were cultured in human 
erythrocytes at 1% hematocrit in a 10mL total volume of CMA (complete medium with 
Albumax) medium containing RPMI 1640 media with L-glutamine (USBiological Life 





hypoxanthine, 5g/L Albumax II (Life Technologies) and 25µg/mL gentamicin. Cultures 
were maintained in gassed flasks (94% N2, 3% O2, 3% CO2) and incubated in sealed 25cm2 
flasks at 37°C. 
 
Generation of P. falciparum transfection constructs for gene deletion 
 Homology arms of ~300-600bp for each gene were amplified using the homology 
arm (HA) 1 and 2 forward and reverse primers corresponding to each gene (Table 3-3) 
from blood-stage P. falciparum NF54-attb gDNA. HA1 and HA2 primers were designed to 
contain ~15bp overhangs for insertion into the cut the pL8, pRS or pRSng plasmids using 
In-Fusion (Clontech) ligation independent cloning methods. The pRS and pRSng are 
modified versions of the pL8 plasmid. The pRS plasmid contains a synthetic LacZ cassette 
flanked by two BsaI sites to allow for blue/white colony screening within the site used for 
guide RNA insertion. The pRSng plasmid has the guide RNA expression cassette removed 
entirely, reliant on gRNA expression from the paired pCasG plasmid, which also contains 
the gene encoding the Cas9 enzyme.  
For generation of the deletion constructs, the pL8 and pRS(ng) plasmids were 
digested with NotI for insertion of HA1, and with NgoMIV for HA2. Digests with either 
endonuclease were also treated with recombinant shrimp alkaline phosphatase (rSAP) and 
then ethanol precipitated before insertion of the homology arms. The pL8, pRS, and pCasG 
plasmids contain a guide RNA (gRNA) expression cassette. Guide RNA sequences were 
synthesized as oligos (Table 3-5), annealed, and inserted into the pL8, pRS, or pCasG 
plasmids via In-Fusion cloning after being digested with BsaI and also treated with rSAP, 





The SufA/NifU double knock-out construct was generated by cutting the existing 
pRSng SufA plasmid with BamHI and HindIII in the presence of rSAP and ethanol 
precipitating it. The blasticidin deaminase drug resistance cassette was then amplified from a 
separate plasmid containing the sequence, using the primers listed in Table 3-8 (pRsBSD F 
and pRsBSD R). The amplicon was then ethanol precipitated and inserted into the cut 
plasmid using In-Fusion cloning.  
 
P. falciparum transfections for Gene Deletion 
  Transfections were conducted as previously described (140, 141). Briefly, 400µL of 
red blood cells were washed with 5mL of CytoMix and resuspended in 340µL of CytoMix. 
The red blood cells were then electroporated with 75µg each of the pUF1-Cas9 and pL8-
gene specific knock out plasmids (49) or the pCasG and pRS(ng) gene specific plasmids. The 
electroporated RBCs were then mixed with ~2.5mL of 10mL PfMev parasites synchronized 
as schizonts at 1% hematocrit and ~10% parasitemia and given 10mL CMA with 50µM 
mevalonate. After 48 hours, transfectants were selected with 1.5µM DSM1, 2.5nM 
WR99210, and 50µM mevalonate for seven days. After seven days, the parasites were 
switched to media containing only 50µM mevalonate. Infected red blood cells (iRBC) were 
first observed between 17 and 30 days after beginning drug selection. Once parasites were 
observed the medium was switched to 2.5nM WR99210 and 50µM mevalonate.  
 For generation of the double SufA/NifU double knockout ΔSufA parasites were 
transfected following the above mentioned standard protocol with the NifU gene-specific 
pRSng and pCasG plasmids, with the pRSng plasmid having been modified to contain the 
BSD drug resistance cassette. Parasites were then selected for 7 days with 2.5ng/mL 





seven days, the media was switched to 50µM mevalonate and 2.5nM WR99210 until 
parasites were seen ~20-25 days post selection, after which they were maintained on media 
containing 2.5ng/mL blasticidin, 2.5nM WR99210, and 50µM mevalonate. 
 
Confirmation of knockout genotype 
In order to screen for integration and successful gene knockout, in addition to the 
presence of any contaminating residual wild type parasites, a set of six primers were used: 
5’F, 3’R, pL8 HA1 R, pL8 HA2F, 5’ WT R and 3’ WT F (Table 3-6). These primers were 
designed to screen for integration and gene disruption at the 5’ and 3’ ends (Δ5’ and Δ3’) in 
addition to 5’ and 3’ regions of the WT gene (5’ and 3’). The same reactions were also 
performed on the parental PfMev line concurrently as a control. Samples for PCR were 
collected when the parasitemia reached been 5-10%, as determined by Giemsa stain. 
Approximately 100µL of a resuspended parasite culture was placed in a heat block at 90°C 
for 2 minutes and stored at -20°C. For the PCR reaction, 1µL of the parasite sample was 
added to reactions with a 50µL total volume. Reactions were conducted using a Veriti 96 
well thermal cycler (Applied Biosystems) and Phusion High-Fidelity DNA polymerase 
(Thermo Fisher Scientific). PCR products were separated on a 1.5% agarose gel stained with 
ethidium bromide for visualization.  
 




5x Phusion HF buffer 10µL 
Forward primer (10 µM)1.5µL 
Reverse primer (10 µM) 1.5µL 
dNTPs (10mM) 1µL 
Phusion polymerase 0.5µL 





Total volume 50µL 
 
The PCR program was as follows: 
 
95°C 3.5 minutes 
95°C 30 seconds 
62°C 1 minute 
62°C 4 minutes 
4°C ∞ 
 
(steps 2 and 3 were repeated 35 times) 
 
Confirmation of apicoplast loss 
The loss of the apicoplast was confirmed via PCR with primers specific for a gene 
within the nuclear (Lactate Dehydrogenase), apicoplast (SufB), and mitochondrial (Cox1) 
genomes (Table 3-7). Failure to amplify a gene from the apicoplast genome, while 
amplifying genes from the nuclear and mitochondrial genomes would indicate loss of the 
organelle [31]. To collect samples for PCR, approximately 100µL of a resuspended parasite 
culture at ~5-10% parasitemia was placed in a 90°C heat block for 2 minutes, and then 
frozen at -20°C. For the PCR reaction, 1µL of the parasite sample was added to reactions 
with a 50µL total volume. Reactions were conducted using a Veriti 96 well thermal cycler 
(Applied Biosystems) and Phusion High-Fidelity DNA polymerase (Thermo Fisher 
Scientific). PCR products were separated by size on a 1.5% agarose gel stained with ethidium 
bromide. The parental PfMev line was always used as a positive control for apicoplast 
detection. 
 
The PCR reaction volumes were as follows:  
 
Water 34.5µL 





Forward primer (10 µM)1.5µL 
Reverse primer (10 µM) 1.5µL 
dNTPs (10mM) 1µL 
Phusion polymerase 0.5µL 
parasite lysate 1µL 
Total volume 50µL 
 
The PCR program was as follows: 
 
95°C 3.5 minutes 
95°C 30 seconds 
63°C 30 seconds 
72°C 1 minute 
72°C 4 minutes 
4°C ∞ 
 
(steps 2-4 were repeated 35 times) 
 
Live cell epifluorescent microscopy 
For sample preparation, 100µL of parasite culture with a hematocrit of 1% and a 
parasitemia between 8-10% was obtained. Parasites were stained with 30nM MitoTracker 
CMX-Ros (Invitrogen) and 1µg/mL 4, 6-diamidino-2-phenylindole (DAPI), and incubated 
for 30 minutes at 37°C. Cells were then pelleted via mini-centrifuge (Fischer Scientific) for 
10 seconds, and the media was aspirated and the cells were resuspended in 100µL of CMA 
media and incubated for 5 minutes at 37°C. This was done three times to wash the cells, 
with the cells being resuspended in 20µL of CMA and then pipetted onto slides and sealed 
with wax (2 parts paraffin, 1 part Vaseline) for observation on a Zeiss AxioImager M2 
microscope. A series of images spanning 5µm were acquired with 0.2µm spacing and images 
were deconvolved with VOLOCITY software (PerkinElmer) to report a single combined z -
stack image.  
 





For each of the PfMev deletion lines, the parasitemia was determined via Gimesa 
stain, with the appropriate amount of the parental culture removed to seed quadruplicate 
samples with or without mevalonate. This volume was resuspended in a total of 10mL CMA 
and centrifuged at 1,600rcf at room temperature (~25°C) for 5 minutes, washed a second 
time with an additional 10mL CMA, and then resuspended in the appropriate volume of 
CMA, and then split equally into two tubes. To one of the tubes, the appropriate volume of 
a 10mM stock of mevalonate was added to bring to final concentration to 50µM mevalonate. 
Parasites were seeded in a 96-well plate at 0.5% starting parasitemia, 2% hematocrit, and at a 
total volume of 250µL per well in quadruplicate. Additionally, 150µL of the appropriate 
media was replaced in each well on days 1, 2, and 3. Parasite samples were collected every 24 
hours for four days, and the parasitemia was counted via SYBR green staining and flow-
cytometry as outlined below. 
 
Flow cytometry for parasite growth curve determination  
Growth curves were generated by staining parasites with SYBR Green and counting 
parasitemia via flow cytometry. In order to setup the growth curve, the parasitemia of the 
starting culture was determined via Giemsa stain. Based on the determined parasitemia the 
culture was used to seed a 96-well flat bottom cell culture plate (Corning) at a 0.5% starting 
parasitemia and 2% hematocrit, at a total volume of 250µL in quadruplicate. In order to 
minimize evaporation and edge effects, the surrounding wells were filled with 250µL of 
1mM EDTA. Plates were incubated in chambers gassed with 94% N2, 3% O2, 3% CO2 for 1 
minute and 15 seconds, and incubated at 37°C.  
Parasite samples were collected immediately after seeding and analyzed via flow 





Samples collected on days 1-3 were diluted 1:10 in phosphate-buffered saline (PBS) and 
stored in a 96-well plate (Corning) at 4°C. We have previously verified that storage under 
these conditions and subsequent staining with SYBR Green reflects accurate parasitemia 
values.  
 On day 4 parasites were stained with SYBR Green by transferring 1µL of parasite 
culture, or 10µL of the 1:10 dilutions (the day 1-3 samples), to a 96-well plate containing 
100µL of 1x SYBR Green (Invitrogen) in PBS. The samples were then incubated for 30 
minutes on a platform Titramax 101 shaker (Heidolph) at 950rpm while protected from 
light. Post-incubation, 150µL of PBS was added to each well to dilute unbound SYBR Green 
dye. A control consisting of uninfected RBCs was also prepared in parallel and treated in the 
same manner as listed above.  
 Samples were analyzed with an Attune Nxt Flow Cytometer (Thermo Fisher 
Scientific). With a 50µL acquisition volume, 250µL total sample volume, and a running speed 
of 25µL/minute with 10,000 total events were collected within the R2 gate. 
 For flow cytometer gating, the R1 gate used forward-scatter area by side-scatter area 
to identify total RBCs from the sample. The R2 gate used forward-scatter height to identify 
single cells, and the R3 gate was used to measure parasitemia using fluorescence from the 
SYBR Green staining of parasite DNA (ratio of SYBR Green positive cells to total cells).  
 
Parasite cloning through limiting dilution  
Single cloning of each parasite line was carried out via limiting dilution. For each 
parasite line, the type of media used for the dilution and media change is the same as that 
within the flask from which the sample is derived. The parasitemia for each culture was 





(iRBCs) per µL of culture. Based on the this iRBC concentration, a sample consisting of 
1,000 iRBCs/µL in media was prepared. This sample was then diluted 1:10 thrice 
sequentially, yielding a parasite sample with a final concentration of 1 iRBC/µL. Then, a 2% 
hematocrit media was deposited into row A of a 96-well flat bottom cell culture plate 
(Corning, cat. #3595) at 200µL per well, followed by the diluted parasite sample at 100µL 
per well. Finally, a 1:3 serial dilution was carried out from row to row starting form row A 
and all the way down to row H. The prepared plate was placed into a Modular Incubator 
Chamber (Billups-Rothenberg Inc.), and gassed with 92% N2, 3% O2, 5% CO2 for 1 min and 
15 seconds prior to incubation at 37°C.  
After seeding on day 0, the media was changed on days 5, 7, 9, 12, and 14. On days 5 
and 12, a 0.5% hematocrit media was used; on days 7, 9, and 14, pure media (without any 
blood) was used. On day 16, selected iRBC-positive wells that are the most dilute (i.e., 
closest to row H) were picked and transferred into a 24-well flat bottom cell culture plate 
(Corning, cat. #S3524) at 2% hematocrit and 1mL total volume per well. The 24-well plate 
was then maintained and routinely monitored. Upon reaching a high enough parasitemia 
(~8%), the content within the well was transferred into a 75cm2 sealed cell culture flask and 
further maintained. For each cloned parasite line, the genotype and the (nuclear, apicoplast, 



















Figure 3-1 Iron-sulfur cluster assembly and transfer in the apicoplast 
Iron-sulfur cluster assembly takes place in three steps: sulfur acquisition, cluster assembly 
and cluster transfer. Sulfur acquisition is mediated by the cysteine desulfurase SufS along 
with SufE. Sulfur is transferred by SufE to the SufBCD cluster assembly complex. Fe-S 
clusters are handed off to SufA or NifU, which transfer the Fe-S clusters to the terminal 





















Figure 3-2 Characterization of the PfMev ΔLipA parasite line 
A.) Genotyping PCR confirming deletion of the LipA locus, as compared to WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔLipA parasite line, indicating presence of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔLipA parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔLipA parasites cultured with or without 50µM mevalonate.  















Figure 3-3 Characterization of the PfMev ΔMiaB parasite line 
A.) Genotyping PCR confirming deletion of the MiaB locus, as compared to WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔMiaB parasite line, indicating presence of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔMiaB parasite line. This parasite line is 
expressing api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔMiaB parasites cultured with or without 50µM mevalonate.  














Figure 3-4 Characterization of the PfMev ΔIspG parasite line 
A.) Genotyping PCR confirming deletion of the IspG locus, as compared to WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔIspG parasite line, indicating presence of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔIspG parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔIspG parasites cultured with or without 50µM mevalonate.  















Figure 3-5 Characterization of the PfMev ΔIspH parasite line 
A.) Genotyping PCR confirming deletion of the IspH locus, as compared to WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔIspH parasite line, indicating presence of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔIspH parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔIspH parasites cultured with or without 50µM mevalonate.  














Figure 3-6 Characterization of the PfMev ΔFd parasite line 
A.) Genotyping PCR confirming deletion of the Fd locus, as compared to WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔFd parasite line, indicating presence of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔFd parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔFd parasites cultured with or without 50µM mevalonate.  
















Figure 3-7 Characterization of the PfMev ΔFNR parasite line 
A.) Genotyping PCR confirming deletion of the FNR locus, as compared to WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔFNR parasite line, indicating presence of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔFNR parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
















Table 3-1 List of potential iron-sulfur cluster binding proteins in P. falciparum 3D7 
 










PF3D7_0910800 Cytosolic Fe-S cluster 
assembly factor NBP35 
++ ++ Essential Slow 
PF3D7_1344600 Lipoyl synthase ++ ++ Dispensable Essential 
PF3D7_0921400 NifU-like scaffold 
protein 
++ ++ Dispensable Essential 
PF3D7_1103400 SufD Fe-S cluster 
assembly protein SufD 
++ ++ Essential Essential 
PF3D7_0716600 SufS cysteine 
desulfurase 
++ ++ Slow Slow/ 
Dispensable  
PF3D7_0522700 SufA iron-sulfur 
assembly protein 
++ ++ Dispensable Essential 
PF3D7_1318100 ferredoxin ++ ++ Essential Slow/ 
Dispensable  




+ ++ Essential Essential 
PF3D7_0910900 DNA primase large 
subunit 
- ++ Essential Essential 




- ++ Essential Slow/ Essential 
PF3D7_1454500 ISU iron-sulfur cluster 
assembly protein 
- ++ Essential Essential 
PF3D7_0207200 IscA1 iron-sulfur 
assembly protein 
- ++ Essential Essential 
PF3D7_0727200 NFS cysteine 
desulfurase 
- ++ Essential Slow/ Essential 
PF3D7_0720400 Apoptosis-inducing 
factor 
- ++ NA Dispensable  
PF3D7_0614800 Endonuclease III 
homologue 





PF3D7_1220500 ribosome biogenesis 
protein TSR3 
- ++ NA Essential 
PF3D7_1361600 Fe-S assembly protein 
IscX 
- ++ NA Essential 
PF3D7_1439400 Cytochrome b-c1 
complex subunit Rieske 
- ++ NA Dispensable  
PF3D7_0927300 Fumarate hydratase - ++ NA Essential 
PF3D7_1212800 Iron-sulfur subunit of 
succinate dehydrogenase 
- ++ Dispensable Dispensable  
PF3D7_0709200 Glutaredoxin-like 
protein 
- ++ Dispensable Dispensable  
PF3D7_0416700 CDGSH iron-sulfur 
domain-containing 
protein 
- ++ Dispensable Dispensable  
PF3D7_0930900 NifU-like protein - ++ Dispensable Dispensable  
PF3D7_1306300 SAM dependent 
methyltransferase 
- ++ Dispensable Dispensable  
PF3D7_API0470
0 
SufB Fe-S cluster 
assembly protein SufB 
- ++ NA NA 
PF3D7_1472700 DNA-directed RNA 
polymerase, alpha 
subunit 
+ + NA Essential 
PF3D7_1406900 Radical SAM protein - + Essential Essential 
PF3D7_0322500 IscA2 iron-sulfur 
assembly protein 
- + NA Dispensable  
PF3D7_0824600 Fe-S cluster assembly 
protein DRE2 
- - Essential Essential 
PF3D7_1017000 DNA polymerase delta 
catalytic subunit 
- - Essential Essential 
PF3D7_0934100 TFIIH basal 
transcription factor 
complex helicase XPD 
subunit 
- - Essential Essential 
PF3D7_1128500 Fe-S cluster assembly 
protein 
- - Essential Essential 
PF3D7_1227800 Elongator complex 
protein 3 
- - Essential Dispensable/Sl
ow 
PF3D7_1022900 CDGSH iron-sulfur 
domain-containing 
protein 





PF3D7_0524900 tRNA-YW synthesizing 
protein 
- - Essential Dispensable  
PF3D7_1458700 Exonuclease V, 
mitochondrial 
- - Slow Essential 
PF3D7_1238800 Acyl-CoA synthetase - - Slow Essential 
PF3D7_1435300 NAD(P)H-dependent 
glutamate synthase 
- - Slow Dispensable 
PF3D7_0606900 Glutaredoxin-like 
protein 
- - Slow Essential 
PF3D7_1408400 FANCJ-like helicase - - Slow Essential 
PF3D7_1143300 DNA-directed RNA 
polymerases I and III 
subunit RPAC1 
- - NA Essential 
PF3D7_0515800 BolA-like protein - - NA Essential 
PF3D7_1415200 DNA-directed RNA 
polymerases I and III 
subunit RPAC2 
- - NA Essential 
PF3D7_1413800 Diphthamide 
biosynthesis protein 1 
- - NA Slow/ 
Dispensable  
PF3D7_0923000 DNA-directed RNA 
polymerase II subunit 
RPB3 
- - NA Essential 
PF3D7_0614200 Cytosolic Fe-S cluster 
assembly factor NAR1 
- - NA Essential 
PF3D7_1324500 DEAD box helicase - - NA Essential 
PF3D7_0302700 CDGSH iron-sulfur 
domain-containing 
protein 
- - NA Essential 
PF3D7_1129500 A/G-specific adenine 
glycosylase 
- - Dispensable Dispensable  




- - NA Dispensable  
PF3D7_1368200 ABC transporter E 
family member 1 








Figure 3-8 Characterization of the PfMev ΔSufA parasite line 
A.) Genotyping PCR confirming deletion of the SufA locus, as compared with WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔSufA parasite line, indicating presence of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔSufA parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔSufA parasites cultured with or without 50µM mevalonate.  















Figure 3-9 Characterization of the PfMev ΔNifU parasite line 
A.) Genotyping PCR confirming deletion of the NifU locus, as compared with WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔNifU parasite line, indicating presence of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔNifU parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔNifU parasites cultured with or without 50µM mevalonate.  














Figure 3-10 Characterization of the PfMev ΔSufA/NifU parasite line 
A.) Genotyping PCR confirming deletion of the SufA locus in the PfMev ΔSufA/ΔNifU 
line, as compared with WT parasites 
B.) Genotyping PCR confirming deletion of the NifU locus in the PfMev ΔSufA/ΔNifU 
line, as compared with WT parasites 
C.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔSufA/ΔNifU parasite line, indicating presence of the apicoplast organelle 
genome.  
D.) Live fluorescence microscopy of the PfMev ΔSufA/ΔNifU parasite line. This parasite 
line expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
E.) Growth curve of PfMev ΔSufA/ΔNifU parasites supplemented with either 50µM or 
0µM mevalonate. 








Figure 3-11 Characterization of the PfMev ΔSufD parasite line 
A.) Genotyping PCR confirming deletion of the SufD locus, as compared with WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔSufD parasite line, indicating presence of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔSufD parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔSufD parasites cultured with or without 50µM mevalonate.  














Figure 3-12 Characterization of the PfMev ΔSufC parasite line 
A.) Genotyping PCR confirming deletion of the SufC locus, as compared with WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔSufC parasite line, indicating presence of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔSufC parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔSufC parasites cultured with or without 50µM mevalonate.  

















Figure 3-13 Characterization of the PfMev ΔSufC/SufD parasite line 
A.) Genotyping PCR confirming deletion of the SufC locus in the ΔSufC/SufD line, as 
compared with WT parasites 
B.) Genotyping PCR confirming deletion of the SufD locus in the ΔSufC/SufD line, as 
compared with WT parasites 
C.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔSufC/ΔSufD parasite line, indicating presence of the apicoplast organelle 
genome. 
D.) Live fluorescence microscopy of the PfMev ΔSufC/SufD parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
E.) Growth curve of PfMev ΔSufC/SufD parasites supplemented with either 50µM or 0µM 
mevalonate 







Figure 3-14 Characterization of the PfMev ΔSufE parasite line 
A.) Genotyping PCR confirming deletion of the SufE locus, as compared with WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔSufE parasite line, indicating presence of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔSufE parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔSufE parasites cultured with or without 50µM mevalonate.  
















Figure 3-15 Characterization of the PfMev ΔSufS parasite line 
A.) Genotyping PCR confirming deletion of the SufS locus, as compared with WT parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We were unsuccessful in 
amplifying SufB from the PfMev ΔSufS parasite line, indicating loss of the apicoplast 
organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔSufS parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔSufS parasites cultured with or without 50µM mevalonate.  












Figure 3-16 Characterization of the PfMev ΔMnmA parasite line 
A.) Genotyping PCR confirming deletion of the MnmA locus, as compared with WT 
parasites 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We were unsuccessful in 
amplifying SufB from the PfMev ΔSufS parasite line, indicating loss of the apicoplast 
organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔMnmA parasite line. This parasite line 
expresses api-SFG (green), and is also stained with mitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔMnmA parasites cultured with or without 50µM mevalonate.  











Table 3-2 Resulting apicoplast-specific gene deletion phenotypes 
 
Gene ID Gene Name  Phenotype 
PF3D7_1344600 LipA Nonessential 
PF3D7_0622200 MiaB Nonessential 
PF3D7_1022800 IspG Essential 
PF3D7_0104400 IspH Essential 
PF3D7_1318100 Ferredoxin (Fd) Essential 
PF3D7_0623200 Ferredoxin reductase (FNR) Essential  
PF3D7_0522700 SufA Nonessential 
PF3D7_0921400 NifU Nonessential 
See above SufA + NifU Essential 
PF3D7_1103400 SufD Essential 
PF3D7_1413500 SufC Essential 
PF3D7_0206100 SufE Essential 
PF3D7_0716600 SufS Essential and Maintenance  



































Table 3-3 Primer sequences used to amplify homology arms for genetic knock outs  
Primer Name Primer Sequence 
SufS HA1 F GCCACGAGCGGCGCTTAATAAATATTTTCTATTATGTCAT 
SufS HA1 R AAGCGCAGCGGCATTATATTATTTCTTCATTTTATTACC 
SufS HA2 F CGACAGACGCCGGTAGTAATATAATAACTAATGTTTCTAA 
SufS HA2 R GGCCACCAGCCGGTGTGTTATAAAAATATATGGATATCC  
MiaB HA1 F GCCACGAGCGGCCTTAGCAGGAGGAGGAACGTATTAC 
MiaB HA1 R AAGCGCAGCGGCCTAAATGGGTCCATGTTATTATCTGTAG 
MiaB HA2 F CGACAGACGCCGGTTTTTCTGATATAGAAAATGAATATTG 
MiaB HA2R GGCCACCAGCCGGTACGCACCCACATACAATAATTTTTAT 
Fd HA1 F GCCACGAGCGGCCACCAAAAAGGCTATTGCATCAATAAAC  
Fd HA1 R AAGCGCAGCGGCCTCAAAAATAATTTACTCTTTTGGCTTC  
Fd HA2 F CGACAGACGCCGGTAGTTGTTCTACATGCGCAGCAAAAT  
Fd HA2 R GGCCACCAGCCGGAGGAAATTTTATCATTCCCCATTTCAA 
FNR HA1 F GCCACGAGCGGCCTGAAAATTCGTTTCGTCTTTATCTTGT 
FNR HA1 R AAGCGCAGCGGCCTTCCAAATATTTAAAGAGACCAT 
FNR HA2 F CGACAGACGCCGGTGCACATGGATATTTTAATTTACCA 
FNR HA2 R GGCCACCAGCCGGTCATGACTTTTCAAAATATCCATAAC 
LipA HA1 F GTGCCACGAGCGGCCCCCATCCCTTTTTTACTTGTATATC 
LipA HA1 R TTAAGCGCAGCGGCCCAGCTACATGAAACCAGTCTG 
LipA HA2 F TTCGACAGACGCCGGGCTAGTCATTTTGCTAAAACAGTAG 
LipA HA2 R ATGGCCACCAGCCGGCGAACTAAAGGGCCGCTG 
IspH HA1 F GTGCCACGAGCGGCCATGTCAGTTACCACATTTTGTTC 
IspH HA1 R TTAAGCGCAGCGGCCCTTATCTGTTCTTGTTTTCCGAAG 
IspH HA2 F TCGACAGACGCCGGGATTGTGCACTTATCGTACAAAAACT 





IspG HA1 F GTGCCACGAGCGGCCTCCCAACACGAGAAGTAGTTATTG 
IspG HA1 R TTAAGCGCAGCGGCCCTACCATACCTAATGGTGTATCTCC 
IspG HA2 F TTCGACAGACGCCGGGCAGGAAGTTGTTTGATGGAT 
IspG HA2 R TGGCCACCAGCCGGCAATTTATCACAAGCTTCTTCCTCAG 
SufA HA1 F GCCACGAGCGGCCACCAAAAAGGCTATTGCATCAATAAAC  
SufA HA1 R AAGCGCAGCGGCCTCAAAAATAATTTACTCTTTTGGCTTC  
SufA HA2 F CGACAGACGCCGGTAGTTGTTCTACATGCGCAGCAAAAT  
SufA HA2 R GGCCACCAGCCGGAGGAAATTTTATCATTCCCCATTTCAA 
NifU HA1 F GCCACGAGCGGCCGAACGGTTCAGGTAAAATTTAGAAAAA 
NifU HA1 R AAGCGCAGCGGCCCTAAGGTTTTTCACATACACAAAAAAA 
NifU HA2 F CGACAGACGCCGGGTTCCCTACATTAACTGTTAATTTTGA 
NifU HA2 R GGCCACCAGCCGGTCCTTTTATTTATTTGTTTGTTTGTTT 
SufC HA1 F GCCACGAGCGGCCTATGCATCCTTTTGAAACCCTTCAACT 
SufC HA1 R AAGCGCAGCGGCCTTGTTATTTTCCATATGCACGACATTC 
SufC HA2 F CGACAGACGCCGGAGGAGAAAAAAAAAGAAATGAAATATT 
SufC HA2 R GGCCACCAGCCGGCTATTCCTTAAGAAATTGAGAGTACCCC 
SufD HA1 F GCCACGAGCGGCCTTTGATTATGTTGAGAGTAAACATTGG 
SufD HA1 R AAGCGCAGCGGCCAAATGGGTAGCATTATTAATCTTTAGA 
SufD HA2 F CGACAGACGCCGGATGGATTCTCAAGAATTTGTTTAGAAG 
SufD HA2 R GGCCACCAGCCGGGTGATTTGCACATTCTATATCACTTGG 
SufE HA1 F GCCACGAGCGGCCTTGTTTTCGGGCATACCATTTAATATGC 
SufE HA1 R AAGCGCAGCGGCCTGGAGATTACTGAAAAATAAATTGGAGTCA 
SufE HA2 F CGACAGACGCCGGCAGGGGTGTCAATCGGTAGTATATATTTAC 
SufE HA2 R GGCCACCAGCCGGTGTCCATATTCTTCAATATATTGGTGCAGA 
MnmA HA1 F GCCACGAGCGGCCATCATTTTGTAAATCTATTAAGGTCACACA 





MnmA HA2 F CGACAGACGCCGGAGGGGAAATTACCTGCATGTATAAAAAAG 















































Table 3-4 Oligonucleotides designed for In-Fusion insertion of gRNA sequences 
  
Name Oligonucleotide Sequence 
SufS gRNA F TAAGTATATAATATTAAATTTAAACCATTGTTATAGTTTTAGAGCTAGAA 
SufS gRNA R TTCTAGCTCTAAAACTATAACAATGGTTTAAATTTAATATTATATACTTA 
MiaB gRNA F TAAGTATATAATATTTGCTTATCAACATCTTCCTCGTTTTAGAGCTAGAA 
MiaB gRNA R TTCTAGCTCTAAAACGAGGAAGATGTTGATAAGCAAATATTATATACTTA 
Fd gRNA F TAAGTATATAATATTTTACCATATAGTTGTAGGGGGTTTTAGAGCTAGAA 
Fd gRNA R TTCTAGCTCTAAAACCCCCTACAACTATATGGTAAAATATTATATACTTA 
FNR gRNA F TAAGTATATAATATTTATTTGGAAGGCCATACTTGGTTTTAGAGCTAGAA 
FNR gRNA R TTCTAGCTCTAAAACCAAGTATGGCCTTCCAAATAAATATTATATACTTA 
LipA gRNA F TAAGTATATAATATTAGAGATGATTTACCAGATGGGTTTTAGAGCTAGAA 
LipA gRNA R TTCTAGCTCTAAAACCCATCTGGTAAATCATCTCTAATATTATATACTTA 
IspH gRNA F TAAGTATATAATATTTACACAAACCACACTAAGTAGTTTTAGAGCTAGAA 
IspH gRNA R TTCTAGCTCTAAAACTACTTAGTGTGGTTTGTGTAAATATTATATACTTA 
IspG gRNA F TAAGTATATAATATTACCATTAGGTATGGTAGAATGTTTTAGAGCTAGAA 
IspG gRNA R TTCTAGCTCTAAAACATTCTACCATACCTAATGGTAATATTATATACTTA 
SufA gRNA F TAAGTATATAATATTAGTAATGATTTAATTAGTGGGTTTTAGAGCTAGAA 
SufA gRNA R TTCTAGCTCTAAAACCCACTAATTAAATCATTACTAATATTATATACTTA 
NifU gRNA F TAAGTATATAATATTTGTCATATTGTAAGATGCTAGTTTTAGAGCTAGAA 
NifU gRNA R TTCTAGCTCTAAAACTAGCATCTTACAATATGACAAATATTATATACTTA 
SufC gRNA F TAAGTATATAATATTGTTAATTATGGATTTAGTGGGTTTTAGAGCTAGAA 
SufC gRNA R TTCTAGCTCTAAAACCCACTAAATCCATAATTAACAATATTATATACTTA 
SufD gRNA F TAAGTATATAATATTAGTAATAGTGGACTAGTTAAGTTTTAGAGCTAGAA 
SufD gRNA R TTCTAGCTCTAAAACTTAACTAGTCCACTATTACTAATATTATATACTTA 
SufE gRNA F TAAGTATATAATATTATATAATCTACACATAACAGGTTTTAGAGCTAGAA 





MnmA gRNA F TAAGTATATAATATTACAATATAAAATGGATAGAGGTTTTAGAGCTAGAA 



















































Table 3-5 Primer sequences used for confirmation of gene deletions 
 
Primer Name Primer Sequence 
pl8insHA1R TACAAAATGCTTAAGCGCAGCGGCC 
pl8insHA2F CATATTTATTAAATCTAGAATTCGACAGACGCCG 
SufS 5’F CAGAAAATGAGTGAGTTTTATAAAAAGGAAAACTC 
SufS 3’R CAATTTGCTGTGCCAAATATTTGATTTC 
SufS 5’WT R CCATATAACAATGGTTTAAATTTATATTTTGATG 
SufS 3’ WT F CCAGATATATTAATAACATCTGGTCATAAATTTTG 
MiaB 5’F GATATTAAATGGGAAAGCAAAACTTATAAGTTTTTTATTC 
MiaB 3’R GTGATACATTTTCAAATATCTCCATATCTTTTTCTG 
MiaB 5’ WT R GATGTTGATAAGCATTCCAAGTCATATTCTC 
MiaB 3’ WT F GGATGTGCTCATAATAGTTCAGATTCTG 
Fd 5'F CTGGTATATTATAGTTTATATTTAATAAGAAAAGGGC 
Fd 3'R GGTAGCGAAGTTAATACATACACATATATATATGTG 
Fd 5' WT R CGAATGTAATGAAGATGAATATATATTAGATGCTAG 
Fd 3' WT F GGTAGCGAAGTTAATACATACACATATATATATGTG 
FNR 5’ F GAGAAGTTTTCTTTATATCATCCTATTTTTTTTGTCATAT 
FNR 3’ R AACTAGTACACCTCAACGTGCACCCTT 
FNR 5’ WT R CCTGAACAATAACCATAATTTGTAATATTGGGAG 
FNR 3’ WT F GTGGTATTATACCTTACTATAATGAACTTGATAATAATCC 
LipA 5' F CCTACATAAACTGTAATGTTTCAATATGACC 
LipA 3' R GGTTAACTAAATTTTTTATAAAATATTCACCTGC 
LipA 5' WT R GTGCTTCTTCACATACGGTATGTAAG 
LipA 3' WT F CTTTCAATACAGCTAAAGCTATATGTGAATG 
IspH 5' F CCAGTAAGCAAAATATATCCATTCTGTATAC 





IspH 5' WT R GGGTACATATATATTTTTCGATTCCCATC 
IspH 3' WT F CCATTAAATAAAAAGTTATTCTATGTTACACAAACC 
IspG 5' F CTAAATGAAGAAGGGAATTCTTCAAAAAAG 
IspG 3' R CATATTCAATTTATGGATCTTTCCATTTG 
IspG 5' WT R CAATACATAAATCAGAAAACTCAAAAGCC 
IspG 3' WT F GTATTAATAACCAGAAGAATTAATGAACTTTTACAATC 
SufA 5'F CTTTTTTCTCCTTTTAATATTAAAAAGAAAAAAG 
SufA 3'R CCTAAAGATATATATTTATGTGTTATCTTATATATTTTTG 
SufA 5' WTR GCTCTTATTGTTATATAAAAATGTTTTTGGAG 
SufA 3' WTF GATATAGAACGAAATTGAAGAAGATGATTATATAC 
NifU 5'F ATACGAAATGAAATTAGTTTTTTAATAATATATTTATACC 
NifU 3'R CGTTAATGTGGAGAAAATTCAAAGACCTAC 
NifU 5' WTR CGAAATTATTTTGTATAAATAACACCTTTGC 
NifU 3' WTF CACACAACGTTAAAAATGAAATAACAGAAAG 
SufE 5’F CATTTCATTCATTTTGGTAGTTAAAAAGAAAAGG 
SufE 3’R TCATTTTATTAAAAACATATTTCATTTAATTTGTAAGA 
SufE 5’WT R CATGAGCATATTATATATAAAACAAAGAAATGTGC 
SufE 3’ WT F CCTGATAAACATAAAATTAGACAAAATCAAGTTTTGG 
SufC 5’F GGGATTTGTCATACATATAAATATGTATAAAAAGGTCC 
SufC 3’R TAAGTACAAAATAATATCATATGTACATTATAAAATCCAC 
SufC 5’WT R CTTCTTCTAAATTTTTTAATAAAGATAATCTATCCATATC 
SufC 3’ WT F GAGATAAGTGTAAGTGAATTTAATTTAATGATGATAGAAG 
SufD 5’F GTGTATATAATTTTTTGAAAAAAATGATTTAGCTAACACA 
SufD 3’R CAGATATTCCTCTTGTCATTAATGAGAAGATTGG 
SufD 5’WT R GTGTTTTCTCTTCATTTTGATGTCTATAGTTTTTTATAC 





MnmA 5’F CTACTTTGATGTTTTTTTATTTTTGCACATTTTATG 
MnmA 3’R GGTATTTTTTATTTGCTCATGTTTAAATCATTTATCTG 
MnmA 5’WT R CTTTATACTATTGTTTCTTTGTTCGTCTTCATCAATTTG 











































Table 3-6 Primer sequences used to detect genes from the nuclear and organellar 
genomes 
 
Primer Name Primer Sequence 
LDH F GGAGATGTAGTTTTGTTCGATATTG 
LDH R CTTGTAAAGGGATACCACCTACAG 
SufB F CATGTAGCTATAGTAGAAATAATAGTAAAAGATTATGG  
SufB R GACTCTGAAATACTTAAACCACGTTGC 
Cox1 F CTTCATCTTTAAGAATAATTGCACAAGAAAATGTAAATC 




































Table 3-7 Primer sequences used to generate the pRSng SufA (BSD) plasmid 
 
Primer Name Primer Sequence 
pRsBSD F ACCTAATAGAAATATATCAGGATCCATGGCAAAACCTTTG 















































1.  Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop 
Med Hyg 64:12–7. 
2.  Dondorp MA, Nosten F, Yi P, Das D, Phyo PA, Tarning J, Lwin MK, Ariey F, 
Hanpithakpong W, Lee JS, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim 
P, Herdman T, An S Sen, Yeung S, Singhasivanon P, Day JNP, Lindegardh N, 
Socheat D, White JN. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N 
Engl J Med 361:455–467. 
3.  Lim L, McFadden GI. 2010. The evolution, metabolism and functions of the 
apicoplast. Philos Trans R Soc Lond B Biol Sci 365:749–63. 
4.  Yeh E, DeRisi LJ. 2011. Chemical rescue of malaria parasites lacking an apicoplast 
defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol 9. 
5.  Mukherjee A, Sadhukhan CG. 2016. Anti-malarial Drug Design by Targeting 
Apicoplasts: New Perspectives. J pharmacopuncture 19:7–15. 
6.  Gisselberg EJ, Dellibovi-Ragheb AT, Matthews AK, Bosch G, Prigge TS. 2013. The 
suf iron-sulfur cluster synthesis pathway is required for apicoplast maintenance in 
malaria parasites. PLoS Pathog 9. 
7.  Haussig MJ, Matuschewski K, Kooij ATW. 2014. Identification of vital and 
dispensable sulfur utilization factors in the Plasmodium apicoplast. PLoS One 9. 
8.  Fontecave M. 2006. Iron-sulfur clusters: ever-expanding roles. Nat Chem Biol 2:171–
174. 
9.  Johnson CD, Dean RD, Smith DA, Johnson KM. 2003. Structure, function, and 
formation of biological iron-sulfur clusters. Annu Rev Biochem 74:247–281. 
10.  Lill R. 2009. Function and biogenesis of iron-sulphur proteins. Nature 460:831–838. 
11.  Lill R, Mühlenhoff U. 2004. Iron-sulfur protein biogenesis in eukaryotes: components 
and mechanisms. Annu Rev Cell Dev Biol 22:457–486. 
12.  Stehling O, Lill R. 2013. The role of mitochondria in cellular iron-sulfur protein 
biogenesis: mechanisms, connected processes, and diseases. Cold Spring Harb 
Perspect Biol 5. 
13.  Sharma KA, Pallesen JL, Spang JR, Walden EW. 2010. Cytosolic iron-sulfur cluster 
assembly (CIA) system: factors, mechanism, and relevance to cellular iron regulation. 
J Biol Chem 285:26745–26751. 
14.  Fontecave M, Ollagnier-de-Choudens S. 2008. Iron–sulfur cluster biosynthesis in 






15.  Balk J, Pilon M. 2011. Ancient and essential: the assembly of iron–sulfur clusters in 
plants. Trends Plant Sci 16:218–226. 
16.  Takahashi Y, Tokumoto U. 2002. A third bacterial system for the assembly of iron-
sulfur clusters with homologs in archaea and plastids. J Biol Chem 277:28380–28383. 
17.  Dellibovi-Ragheb AT, Gisselberg EJ, Prigge TS. 2013. Parasites FeS up: iron-sulfur 
cluster biogenesis in eukaryotic pathogens. PLoS Pathog 9. 
18.  Seeber F. 2002. Biogenesis of iron-sulphur clusters in amitochondriate and 
apicomplexan protists. Int J Parasitol 32:1207–1217. 
19.  Sato S, Rangachari K, Wilson MRJ. 2003. Targeting GFP to the malarial 
mitochondrion. Mol Biochem Parasitol 130:155–158. 
20.  Ellis EK, Clough B, Saldanha WJ, Wilson JR. 2001. Nifs and Sufs in malaria. Mol 
Microbiol 41:973–981. 
21.  Charan M, Singh N, Kumar B, Srivastava K, Siddiqi IM, Habib S. 2014. Sulfur 
mobilization for Fe-S cluster assembly by the essential SUF pathway in the Plasmodium 
falciparum apicoplast and its inhibition. Antimicrob Agents Chemother 58:3389–3398. 
22.  Loiseau L, Ollagnier-de-Choudens S, Nachin L, Fontecave M, Barras F. 2003. 
Biogenesis of Fe-S cluster by the bacterial Suf system: SufS and SufE form a new type 
of cysteine desulfurase. J Biol Chem 278:38352–38359. 
23.  Outten WF, Wood JM, Munoz MF, Storz G. 2003. The SufE protein and the 
SufBCD complex enhance SufS cysteine desulfurase activity as part of a sulfur 
transfer pathway for Fe-S cluster assembly in Escherichia coli. J Biol Chem 278:45713–
45719. 
24.  Layer G, Gaddam AS, Ayala-Castro NC, Ollagnier-de Choudens S, Lascoux D, 
Fontecave M, Outten WF. 2007. SufE transfers sulfur from SufS to SufB for iron-
sulfur cluster assembly. J Biol Chem 282:13342–13350. 
25.  Hirabayashi K, Yuda E, Tanaka N, Katayama S, Iwasaki K, Matsumoto T, Kurisu G, 
Outten WF, Fukuyama K, Takahashi Y, Wada K. 2015. Functional Dynamics 
Revealed by the Structure of the SufBCD Complex, a Novel ATP-binding Cassette 
(ABC) Protein That Serves as a Scaffold for Iron-Sulfur Cluster Biogenesis. J Biol 
Chem 290:29717–29731. 
26.  Saini A, Mapolelo TD, Chahal KH, Johnson KM, Outten WF. 2010. SufD and SufC 
ATPase activity are required for iron acquisition during in vivo Fe-S cluster formation 
on SufB. Biochemistry 49:9402–9412. 
27.  Chahal KH, Dai Y, Saini A, Ayala-Castro C, Outten WF. 2009. The SufBCD Fe-S 






28.  Gupta V, Sendra M, Naik GS, Chahal KH, Huynh HB, Outten WF, Fontecave M, de 
Choudens S. 2009. Native Escherichia coli SufA, coexpressed with SufBCDSE, purifies 
as a [2Fe-2S] protein and acts as an Fe-S transporter to Fe-S target enzymes. J Am 
Chem Soc 131:6149–6153. 
29.  Py B, Gerez C, Angelini S, Planel R, Vinella D, Loiseau L, Talla E, Brochier-Armanet 
C, Garcia Serres R, Latour J-M, Ollagnier-de Choudens S, Fontecave M, Barras F. 
2012. Molecular organization, biochemical function, cellular role and evolution of 
NfuA, an atypical Fe-S carrier. Mol Microbiol 86:155–171. 
30.  Wilson RJ, Denny PW, Preiser PR, Rangachari K, Roberts K, Roy A, Whyte A, Strath 
M, Moore DJ, Moore PW, Williamson DH. 1996. Complete gene map of the plastid-
like DNA of the malaria parasite Plasmodium falciparum. J Mol Biol 261:155–72. 
31.  Kumar B, Chaubey S, Shah P, Tanveer A, Charan M, Siddiqi IM, Habib S. 2011. 
Interaction between sulphur mobilisation proteins SufB and SufC: evidence for an 
iron-sulphur cluster biogenesis pathway in the apicoplast of Plasmodium falciparum. Int J 
Parasitol 41:991–999. 
32.  Pala RZ, Saxena V, Saggu SG, Yadav KS, Pareek PR, Kochar KS, Kochar KD, Garg 
S. 2016. Structural and functional characterization of an iron-sulfur cluster assembly 
scaffold protein-SufA from Plasmodium vivax. Gene 585:159–165. 
33.  Haussig MJ, Matuschewski K, Kooij ATW. 2013. Experimental Genetics of 
Plasmodium berghei NFU in the Apicoplast Iron-Sulfur Cluster Biogenesis Pathway. 
PLoS One 8. 
34.  Wrenger C, Müller S. 2004. The human malaria parasite Plasmodium falciparum has 
distinct organelle-specific lipoylation pathways. Mol Microbiol 53:103–113. 
35.  Thomsen-Zieger N, Schachtner J, Seeber F. 2003. Apicomplexan parasites contain a 
single lipoic acid synthase located in the plastid. FEBS Lett 547:80–6. 
36.  Pierrel F, Björk RG, Fontecave M, Atta M. 2002. Enzymatic modification of tRNAs: 
MiaB is an iron-sulfur protein. J Biol Chem 277:13367–13370. 
37.  Ralph SA, van Dooren GG, Waller RF, Crawford MJ, Fraunholz MJ, Foth BJ, 
Tonkin CJ, Roos DS, McFadden GI. 2004. Tropical infectious diseases: metabolic 
maps and functions of the Plasmodium falciparum apicoplast. Nat Rev Microbiol 2:203–
16. 
38.  Hernández HL, Pierrel F, Elleingand E, García-Serres R, Huynh BH, Johnson MK, 
Fontecave M, Atta M. 2007. MiaB, a Bifunctional Radical- S- Adenosylmethionine 
Enzyme Involved in the Thiolation and Methylation of tRNA, Contains Two 





39.  Moore JA, Poulter CD. 1997. Escherichia coli Dimethylallyl Diphosphate:tRNA 
Dimethylallyltransferase:  A Binding Mechanism for Recombinant Enzyme †. 
Biochemistry 36:604–614. 
40.  Leung CH, Chen Y, Winkler EM. 1997. Regulation of substrate recognition by the 
MiaA tRNA prenyltransferase modification enzyme of Escherichia coli K-12. J Biol 
Chem 272:13073–13083. 
41.  Saggu SG, Garg S, Pala RZ, Yadav KS, Kochar KS, Kochar KD, Saxena V. 2017. 
Characterization of 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (IspG) 
from Plasmodium vivax and it’s potential as an antimalarial drug target. Int J Biol 
Macromol 96:466–473. 
42.  Röhrich CR, Englert N, Troschke K, Reichenberg A, Hintz M, Seeber F, Balconi E, 
Aliverti A, Zanetti G, Köhler U, Pfeiffer M, Beck E, Jomaa H, Wiesner J. 2005. 
Reconstitution of an apicoplast-localised electron transfer pathway involved in the 
isoprenoid biosynthesis of Plasmodium falciparum. FEBS Lett 579:6433–6438. 
43.  Balconi E, Pennati A, Crobu D, Pandini V, Cerutti R, Zanetti G, Aliverti A. 2009. 
The ferredoxin-NADP+ reductase/ferredoxin electron transfer system of Plasmodium 
falciparum. FEBS J 276:3825–3836. 
44.  Vollmer M, Thomsen N, Wiek S, Seeber F. 2001. Apicomplexan parasites possess 
distinct nuclear-encoded, but apicoplast-localized, plant-type ferredoxin-NADP+ 
reductase and ferredoxin. J Biol Chem 276:5483–5490. 
45.  Jordan WS, Cronan EJ. 2003. The Escherichia coli lipB gene encodes lipoyl 
(octanoyl)-acyl carrier protein: protein transferase. J Bacteriol 185:1582–1589. 
46.  Foth JB, Stimmler ML, Handman E, Crabb SB, Hodder NA, McFadden IG. 2005. 
The malaria parasite Plasmodium falciparum has only one pyruvate dehydrogenase 
complex, which is located in the apicoplast. Mol Microbiol 55:39–53. 
47.  van Schaijk LBC, Kumar STR, Vos WM, Richman A, van Gemert G-J, Li T, Eappen 
GA, Williamson CK, Morahan JB, Fishbaugher M, Kennedy M, Camargo N, Khan 
MS, Janse JC, Sim LK, Hoffman LS, Kappe ISH, Sauerwein WR, Fidock AD, 
Vaughan MA. 2014. Type II fatty acid biosynthesis is essential for Plasmodium 
falciparum sporozoite development in the midgut of Anopheles mosquitoes. Eukaryot 
Cell 13:550–559. 
48.  Günther S, Storm J, Müller S. 2009. Plasmodium falciparum: organelle-specific 
acquisition of lipoic acid. Int J Biochem Cell Biol 41:748–752. 
49.  Ghorbal M, Gorman M, Macpherson CR, Martins RM, Scherf A, Lopez-Rubio J-J. 
2014. Genome editing in the human malaria parasite Plasmodium falciparum using the 
CRISPR-Cas9 system. Nat Biotechnol 32:819–21. 





suf iron-sulfur cluster synthesis pathway is required for apicoplast maintenance in 
malaria parasites. PLoS Pathog 9:e1003655. 
51.  Seeber F, Soldati-Favre D. 2010. Metabolic Pathways in the Apicoplast of 
Apicomplexa. Int Rev Cell Mol Biol 281:161–228. 
52.  Seeber F, Aliverti A, Zanetti G. 2005. The plant-type ferredoxin-NADP+ 
reductase/ferredoxin redox system as a possible drug target against apicomplexan 
human parasites. Curr Pharm Des 11:3159–72. 
53.  Bahl A, Brunk B, Crabtree J, Fraunholz JM, Gajria B, Grant RG, Ginsburg H, Gupta 
D, Kissinger CJ, Labo P, Li L, Mailman DM, Milgram JA, Pearson SD, Roos SD, 
Schug J, Stoeckert JC, Whetzel P. 2003. PlasmoDB: the Plasmodium genome resource. 
A database integrating experimental and computational data. Nucleic Acids Res 
31:212–215. 
54.  Valasatava Y, Rosato A, Banci L, Andreini C. 2016. MetalPredator: a web server to 
predict iron-sulfur cluster binding proteomes. Bioinformatics 32:2850–2852. 
55.  Foth JB, Ralph AS, Tonkin JC, Struck SN, Fraunholz M, Roos SD, Cowman FA, 
McFadden IG. 2003. Dissecting apicoplast targeting in the malaria parasite Plasmodium 
falciparum. Science 299:705–708. 
56.  Schwach F, Bushell E, Gomes AR, Anar B, Girling G, Herd C, Rayner JC, Billker O. 
2015. PlasmoGEM, a database supporting a community resource for large-scale 
experimental genetics in malaria parasites. Nucleic Acids Res 43:D1176-82. 
57.  Zhang M, Wang C, Otto TD, Oberstaller J, Liao X, Adapa SR, Udenze K, Bronner 
IF, Casandra D, Mayho M, Brown J, Li S, Swanson J, Rayner JC, Jiang RHY, Adams 
JH. 2018. Uncovering the essential genes of the human malaria parasite Plasmodium 
falciparum by saturation mutagenesis. Science 360:eaap7847. 
58.  Lu J, Yang J, Tan G, Ding H. 2008. Complementary roles of SufA and IscA in the 
biogenesis of iron-sulfur clusters in Escherichia coli. Biochem J 409:535–543. 
59.  Nachin L, Loiseau L, Expert D, Barras F. 2003. SufC: an unorthodox cytoplasmic 
ABC/ATPase required for [Fe-S] biogenesis under oxidative stress. EMBO J 22:427–
437. 
60.  Schilke B, Voisine C, Beinert H, Craig E. 1999. Evidence for a conserved system for 
iron metabolism in the mitochondria of Saccharomyces cerevisiae. Proc Natl Acad Sci U S 
A 96:10206–11. 
61.  Uhrigshardt H, Singh A, Kovtunovych G, Ghosh M, Rouault TA. 2010. 
Characterization of the human HSC20, an unusual DnaJ type III protein, involved in 
iron–sulfur cluster biogenesis. Hum Mol Genet 19:3816–3834. 





Copper stress affects iron homeostasis by destabilizing iron-sulfur cluster formation 
in Bacillus subtilis. J Bacteriol 192:2512–24. 
63.  Ye H, Rouault TA. 2010. Human iron-sulfur cluster assembly, cellular iron 
homeostasis, and disease. Biochemistry 49:4945–56. 
64.  Wollers S, Layer G, Garcia-Serres R, Signor L, Clemancey M, Latour J-M, Fontecave 
M, Ollagnier de Choudens S. 2010. Iron-sulfur (Fe-S) cluster assembly: the SufBCD 
complex is a new type of Fe-S scaffold with a flavin redox cofactor. J Biol Chem 
285:23331–41. 
65.  Nachin L, El Hassouni M, Loiseau L, Expert D, Barras F. 2001. SoxR-dependent 
response to oxidative stress and virulence of Erwinia chrysanthemi: the key role of 
SufC, an orphan ABC ATPase. Mol Microbiol 39:960–72. 
66.  Pérard J, Ollagnier de Choudens S. 2018. Iron–sulfur clusters biogenesis by the SUF 
machinery: close to the molecular mechanism understanding. JBIC J Biol Inorg Chem 
23:581–596. 
67.  Boyd ES, Thomas KM, Dai Y, Boyd JM, Outten FW. 2014. Interplay between 
Oxygen and Fe–S Cluster Biogenesis: Insights from the Suf Pathway. Biochemistry 
53:5834–5847. 
68.  Wada K, Sumi N, Nagai R, Iwasaki K, Sato T, Suzuki K, Hasegawa Y, Kitaoka S, 
Minami Y, Outten FW, Takahashi Y, Fukuyama K. 2009. Molecular Dynamism of 
Fe–S Cluster Biosynthesis Implicated by the Structure of the SufC2–SufD2 Complex. 
J Mol Biol 387:245–258. 
69.  Ollagnier-de-Choudens S, Lascoux D, Loiseau L, Barras F, Forest E, Fontecave M. 
2003. Mechanistic studies of the SufS-SufE cysteine desulfurase: evidence for sulfur 
transfer from SufS to SufE. FEBS Lett 555:263–267. 
70.  Huet G, Daffe M, Saves I. 2005. Identification of the Mycobacterium tuberculosis SUF 
Machinery as the Exclusive Mycobacterial System of [Fe-S] Cluster Assembly: 
Evidence for Its Implication in the Pathogen’s Survival. J Bacteriol 187:6137–6146. 
71.  H. M, N. E. 2002. Bacterial cysteine desulfurases: their function and mechanisms. 
Appl Microbiol Biotechnol 60:12–23. 
72.  Black KA, Dos Santos PC. 2015. Abbreviated Pathway for Biosynthesis of 2-
Thiouridine in Bacillus subtilis. J Bacteriol 197:1952–62. 
73.  Palenchar PM, Buck CJ, Cheng H, Larson TJ, Mueller EG. 2000. Evidence that ThiI, 
an enzyme shared between thiamin and 4-thiouridine biosynthesis, may be a 
sulfurtransferase that proceeds through a persulfide intermediate. J Biol Chem 
275:8283–6. 





Sulfur Relay by Multiple Sulfur Mediators Involved in Thiouridine Biosynthesis at 
tRNA Wobble Positions. Mol Cell 21:97–108. 
75.  and RK, Lauhon* CT. 2003. MnmA and IscS Are Required for in Vitro 2-Thiouridine 
Biosynthesis in Escherichia coli†. 
76.  Cilingir G, Broschat SL, Lau AOT. 2012. ApicoAP: The First Computational Model 
for Identifying Apicoplast-Targeted Proteins in Multiple Species of Apicomplexa. 
PLoS One 7:e36598. 
77.  Umeda N, Suzuki T, Yukawa M, Ohya Y, Shindo H, Watanabe K, Suzuki T. 2005. 
Mitochondria-specific RNA-modifying enzymes responsible for the biosynthesis of 
the wobble base in mitochondrial tRNAs. Implications for the molecular 
pathogenesis of human mitochondrial diseases. J Biol Chem 280:1613–24. 
78.  Nilsson K, Lundgren HK, Hagervall TG, Björk GR. 2002. The cysteine desulfurase 
IscS is required for synthesis of all five thiolated nucleosides present in tRNA from 
Salmonella enterica serovar typhimurium. J Bacteriol 184:6830–5. 
79.  Agris PF. 1991. Wobble position modified nucleosides evolved to select transfer 
RNA codon recognition: a modified-wobble hypothesis. Biochimie 73:1345–9. 
80.  Ogle JM, Brodersen DE, Clemons WM, Tarry MJ, Carter AP, Ramakrishnan V. 2001. 
Recognition of Cognate Transfer RNA by the 30S Ribosomal Subunit. Science (80- ) 
292:897–902. 
81.  Urbonavicius J, Qian Q, Durand JM, Hagervall TG, Björk GR. 2001. Improvement 
of reading frame maintenance is a common function for several tRNA modifications. 
EMBO J 20:4863–4873. 
82.  Cicchillo MR, Lee K-H, Baleanu-Gogonea C, Nesbitt MN, Krebs C, Booker JS. 2004. 
Escherichia coli lipoyl synthase binds two distinct [4Fe-4S] clusters per polypeptide. 
Biochemistry 43:11770–11781. 
83.  Miller RJ, Busby WR, Jordan WS, Cheek J, Henshaw FT, Ashley WG, Broderick BJ, 
Cronan EJ, Marletta AM. 2000. Escherichia coli LipA is a lipoyl synthase: in vitro 
biosynthesis of lipoylated pyruvate dehydrogenase complex from octanoyl-acyl carrier 
protein. Biochemistry 39:15166–15178. 
84.  Günther S, Wallace L, Patzewitz E-M, McMillan JP, Storm J, Wrenger C, Bissett R, 
Smith KT, Müller S. 2007. Apicoplast lipoic acid protein ligase B is not essential for 
Plasmodium falciparum. PLoS Pathog 3. 
85.  Cobbold SA, Vaughan AM, Lewis IA, Painter HJ, Camargo N, Perlman DH, 
Fishbaugher M, Healer J, Cowman AF, Kappe SHI, Llinás M. 2013. Kinetic flux 
profiling elucidates two independent acetyl-CoA biosynthetic pathways in Plasmodium 





86.  Esberg B, Leung HC, Tsui HC, Björk GR, Winkler ME. 1999. Identification of the 
miaB gene, involved in methylthiolation of isopentenylated A37 derivatives in the 
tRNA of Salmonella typhimurium and Escherichia coli. J Bacteriol 181:7256–65. 
87.  Thompson MK, Gottesman S. 2014. The MiaA tRNA modification enzyme is 
necessary for robust RpoS expression in Escherichia coli. J Bacteriol 196:754–761. 
88.  Connolly DM, Winkler ME, Connolly DM, Winkler ME, Bacteriol J. 1991. Structure 
of Escherichia coli K-12 miaA and Characterization of the Mutator Phenotype Caused 
by miaA Insertion Mutations Previously, we reported several unusual relationships 
between the 2-methylthio-N6-(A2-isopentenyl)adeno-sine-37 (ms2i6A-37) tRNA 
modification and spontaneous mutagenesis in Escherichia coli. 
89.  Petrullo LA, Gallagher PJ, Elseviers D. 1983. The role of 2-methylthio-N6-
isopentenyladenosine in readthrough and suppression of nonsense codons in 
Escherichia coli. Mol Gen Genet 190:289–94. 
90.  Hall RH. 1970. N6-(delta 2-isopentenyl)adenosine: chemical reactions, biosynthesis, 
metabolism, and significance to the structure and function of tRNA. Prog Nucleic 
Acid Res Mol Biol 10:57–86. 
91.  Persson BC, Esberg B, Olafsson O, Björk GR. 1994. Synthesis and function of 
isopentenyl adenosine derivatives in tRNA. Biochimie 76:1152–60. 
92.  Lamichhane TN, Blewett NH, Maraia RJ. 2011. Plasticity and diversity of tRNA 
anticodon determinants of substrate recognition by eukaryotic A37 
isopentenyltransferases. RNA 17:1846–1857. 
93.  Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita 
M, Wanner BL, Mori H. 2006. Construction of Escherichia coli K-12 in-frame, single-
gene knockout mutants: the Keio collection. Mol Syst Biol 2:2006.0008. 
94.  Zepeck F, Gräwert T, Kaiser J, Schramek N, Eisenreich W, Bacher A, Rohdich F. 
2005. Biosynthesis of isoprenoids. purification and properties of IspG protein from 
Escherichia coli. J Org Chem 70:9168–9174. 
95.  Lee M, Gräwert T, Quitterer F, Rohdich F, Eppinger J, Eisenreich W, Bacher A, 
Groll M. 2010. Biosynthesis of isoprenoids: crystal structure of the [4Fe-4S] cluster 
protein IspG. J Mol Biol 404:600–610. 
96.  Xiao Y, Zahariou G, Sanakis Y, Liu P. 2009. IspG enzyme activity in the 
deoxyxylulose phosphate pathway: roles of the iron-sulfur cluster. Biochemistry 
48:10483–10485. 
97.  Altincicek B, Duin EC, Reichenberg A, Hedderich R, Kollas A-K, Hintz M, Wagner 
S, Wiesner J, Beck E, Jomaa H. 2002. LytB protein catalyzes the terminal step of the 






98.  Mulo P. 2011. Chloroplast-targeted ferredoxin-NADP+ oxidoreductase (FNR): 
Structure, function and location. Biochim Biophys Acta - Bioenerg 1807:927–934. 
99.  Krapp RA, Rodriguez ER, Poli OH, Paladini HD, Palatnik FJ, Carrillo N. 2002. The 
flavoenzyme ferredoxin (flavodoxin)-NADP(H) reductase modulates NADP(H) 
homeostasis during the soxRS response of Escherichia coli. J Bacteriol 184:1474–1480. 
100.  Sendra M, Ollagnier de Choudens S, Lascoux D, Sanakis Y, Fontecave M. 2007. The 
SUF iron-sulfur cluster biosynthetic machinery: Sulfur transfer from the SUFS-SUFE 
complex to SUFA. FEBS Lett 581:1362–1368. 
101.  Arisue N, Hashimoto T, Mitsui H, Palacpac QNM, Kaneko A, Kawai S, Hasegawa M, 
Tanabe K, Horii T. 2012. The Plasmodium apicoplast genome: conserved structure and 
close relationship of P. ovale to rodent malaria parasites. Mol Biol Evol 29:2095–2099. 
102.  Wrenger C, Eschbach M-L, Müller IB, Laun NP, Begley TP, Walter RD. 2006. 
Vitamin B1 de novo synthesis in the human malaria parasite Plasmodium falciparum 
depends on external provision of 4-amino-5-hydroxymethyl-2-methylpyrimidine. Biol 
Chem 387:41–51. 
103.  Chan XWA, Wrenger C, Stahl K, Bergmann B, Winterberg M, Müller IB, Saliba KJ. 
2013. Chemical and genetic validation of thiamine utilization as an antimalarial drug 
target. Nat Commun 4:2060. 
104.  Müller S, Kappes B. 2007. Vitamin and cofactor biosynthesis pathways in Plasmodium 
and other apicomplexan parasites. Trends Parasitol 23:112–21. 
105.  Webb E, Claas K, Downs DM. 1997. Characterization of thiI, a new gene involved in 
thiazole biosynthesis in Salmonella typhimurium. J Bacteriol 179:4399–402. 
106.  Gralnick J, Webb E, Beck B, Downs D. 2000. Lesions in gshA (Encoding gamma-L-
glutamyl-L-cysteine synthetase) prevent aerobic synthesis of thiamine in Salmonella 
enterica serovar typhimurium LT2. J Bacteriol 182:5180–7. 
107.  Bozdech Z, Ginsburg H. 2005. Data mining of the transcriptome of Plasmodium 
falciparum: the pentose phosphate pathway and ancillary processes. Malar J 4:17. 
108.  Müller IB, Hyde JE, Wrenger C. 2010. Vitamin B metabolism in Plasmodium falciparum 
as a source of drug targets. Trends Parasitol 26:35–43. 
109.  Allary M, Lu JZ, Zhu L, Prigge ST. 2007. Scavenging of the cofactor lipoate is 
essential for the survival of the malaria parasite Plasmodium falciparum. Mol Microbiol 
63:1331–1344. 
110.  Ugulava NB, Gibney BR, Jarrett JT. 2001. Biotin synthase contains two distinct iron-
sulfur cluster binding sites: chemical and spectroelectrochemical analysis of iron-
sulfur cluster interconversions. Biochemistry 40:8343–51. 





biotin synthase: dissociation and reassociation of iron during conversion of [2Fe-2S] 
to [4Fe-4S] clusters. Biochemistry 39:5206–14. 
112.  Goodman DC, Mollard V, Louie T, Holloway AG, Watson GK, McFadden IG. 2014. 
Apicoplast acetyl Co-A carboxylase of the human malaria parasite is not targeted by 
cyclohexanedione herbicides. Int J Parasitol 44:285–289. 
113.  Dellibovi-Ragheb TA, Jhun H, Goodman CD, Walters MS, Ragheb DRT, Matthews 
KA, Rajaram K, Mishra S, McFadden GI, Sinnis P, Prigge ST. 2018. Host biotin is 
required for liver stage development in malaria parasites. Proc Natl Acad Sci U S A 
115:E2604–E2613. 
114.  Carlton JM, Angiuoli S V., Suh BB, Kooij TW, Pertea M, Silva JC, Ermolaeva MD, 
Allen JE, Selengut JD, Koo HL, Peterson JD, Pop M, Kosack DS, Shumway MF, 
Bidwell SL, Shallom SJ, van Aken SE, Riedmuller SB, Feldblyum T V., Cho JK, 
Quackenbush J, Sedegah M, Shoaibi A, Cummings LM, Florens L, Yates JR, Raine 
JD, Sinden RE, Harris MA, Cunningham DA, Preiser PR, Bergman LW, Vaidya AB, 
van Lin LH, Janse CJ, Waters AP, Smith HO, White OR, Salzberg SL, Venter JC, 
Fraser CM, Hoffman SL, Gardner MJ, Carucci DJ. 2002. Genome sequence and 
comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. 
Nature 419:512–519. 
115.  Mueller EG, Buck CJ, Palenchar PM, Barnhart LE, Paulson JL. 1998. Identification 
of a gene involved in the generation of 4-thiouridine in tRNA. Nucleic Acids Res 
26:2606–10. 
116.  Kambampati R, Lauhon CT. 1999. IscS is a sulfurtransferase for the in vitro 
biosynthesis of 4-thiouridine in Escherichia coli tRNA. Biochemistry 38:16561–8. 
117.  Kambampati R, Lauhon CT. 2000. Evidence for the transfer of sulfane sulfur from 
IscS to ThiI during the in vitro biosynthesis of 4-thiouridine in Escherichia coli tRNA. J 
Biol Chem 275:10727–30. 
118.  Eschbach M-L, Müller IB, Gilberger T-W, Walter RD, Wrenger C. 2006. The human 
malaria parasite Plasmodium falciparum expresses an atypical N-terminally extended 
pyrophosphokinase with specificity for thiamine. Biol Chem 387:1583–91. 
119.  Sullivan MA, Cannon JF, Webb FH, Bock RM. 1985. Antisuppressor mutation in 
Escherichia coli defective in biosynthesis of 5-methylaminomethyl-2-thiouridine. J 
Bacteriol 161:368–76. 
120.  Čavužić M, Liu Y. 2017. Biosynthesis of Sulfur-Containing tRNA Modifications: A 
Comparison of Bacterial, Archaeal, and Eukaryotic Pathways. Biomolecules 7. 
121.  Moukadiri I, Garzón M-J, Björk GR, Armengod M-E. 2014. The output of the tRNA 
modification pathways controlled by the Escherichia coli MnmEG and MnmC enzymes 






122.  Armengod ME, Meseguer S, Villarroya M, Prado S, Moukadiri I, Ruiz-Partida R, 
Garzón MJ, Navarro-González C, Martínez-Zamora A. 2014. Modification of the 
wobble uridine in bacterial and mitochondrial tRNAs reading NNA/NNG triplets of 
2-codon boxes. RNA Biol 11:1495–1507. 
123.  Moukadiri I, Villarroya M, Benítez-Páez A, Armengod M-E. 2018. Bacillus subtilis 
exhibits MnmC-like tRNA modification activities. RNA Biol 15:1167–1173. 
124.  KOTERA M, BAYASHI T, HATTORI M, TOKIMATSU T, GOTO S, MIHARA 
H, KANEHISA M. 2010. COMPREHENSIVE GENOMIC ANALYSIS OF 
SULFUR-RELAY PATHWAY GENES, p. 104–115. In Genome Informatics 2010. 
IMPERIAL COLLEGE PRESS. 
125.  Gardner MJ, Bishop R, Shah T, de Villiers EP, Carlton JM, Hall N, Ren Q, Paulsen 
IT, Pain A, Berriman M, Wilson RJM, Sato S, Ralph SA, Mann DJ, Xiong Z, Shallom 
SJ, Weidman J, Jiang L, Lynn J, Weaver B, Shoaibi A, Domingo AR, Wasawo D, 
Crabtree J, Wortman JR, Haas B, Angiuoli S V, Creasy TH, Lu C, Suh B, Silva JC, 
Utterback TR, Feldblyum T V, Pertea M, Allen J, Nierman WC, Taracha ELN, 
Salzberg SL, White OR, Fitzhugh HA, Morzaria S, Venter JC, Fraser CM, Nene V. 
2005. Genome Sequence of Theileria parva, a Bovine Pathogen That Transforms 
Lymphocytes. Science (80- ) 309:134–137. 
126.  Nilsson K, Jäger G, Björk GR. 2017. An unmodified wobble uridine in tRNAs 
specific for Glutamine, Lysine, and Glutamic acid from Salmonella enterica Serovar 
Typhimurium results in nonviability—Due to increased missense errors? PLoS One 
12:e0175092. 
127.  Bjork GR, Ericson JU, Gustafsson CED, Hagervall TG, Jonsson YH, Wikstrom PM. 
1987. Transfer RNA Modification. Annu Rev Biochem 56:263–285. 
128.  McCutcheon JP, Moran NA. 2011. Extreme genome reduction in symbiotic bacteria. 
129.  Zhang Q, Zhang L, Chen D, He X, Yao S, Zhang Z, Chen Y, Guan M-X. 2018. 
Deletion of Mtu1 (Trmu) in zebrafish revealed the essential role of tRNA 
modification in mitochondrial biogenesis and hearing function. Nucleic Acids Res 
46:10930–10945. 
130.  Wang X, Yan Q, Guan M-X. 2010. Combination of the loss of cmnm5U34 with the 
lack of s2U34 modifications of tRNALys, tRNAGlu, and tRNAGln altered 
mitochondrial biogenesis and respiration. J Mol Biol 395:1038–48. 
131.  Wu Y, Wei F-Y, Kawarada L, Suzuki T, Araki K, Komohara Y, Fujimura A, Kaitsuka 
T, Takeya M, Oike Y, Suzuki T, Tomizawa K. 2016. Mtu1-Mediated Thiouridine 
Formation of Mitochondrial tRNAs Is Required for Mitochondrial Translation and Is 
Involved in Reversible Infantile Liver Injury. PLOS Genet 12:e1006355. 
132.  ASHRAF SS, SOCHACKA E, CAIN R, GUENTHER R, MALKIEWICZ A, 





binding. RNA 5:S1355838299981529. 
133.  Yarian C, Marszalek M, Sochacka E, Malkiewicz A, Guenther R, Miskiewicz A, Agris 
PF. 2000. Modified nucleoside dependent Watson-Crick and wobble codon binding 
by tRNALysUUU species. Biochemistry 39:13390–5. 
134.  Vendeix FAP, Murphy F V., Cantara WA, Leszczyńska G, Gustilo EM, Sproat B, 
Malkiewicz A, Agris PF. 2012. Human tRNALys3UUU Is Pre-Structured by Natural 
Modifications for Cognate and Wobble Codon Binding through Keto–Enol 
Tautomerism. J Mol Biol 416:467–485. 
135.  Brégeon D, Colot V, Radman M, Taddei F. 2001. Translational misreading: a tRNA 
modification counteracts a +2 ribosomal frameshift. Genes Dev 15:2295–306. 
136.  Diwan GD, Agashe D. 2018. Wobbling Forth and Drifting Back: The Evolutionary 
History and Impact of Bacterial tRNA Modifications. Mol Biol Evol 35:2046–2059. 
137.  Grosjean H, Breton M, Sirand-Pugnet P, Tardy F, Thiaucourt F, Citti C, Barré A, 
Yoshizawa S, Fourmy D, de Crécy-Lagard V, Blanchard A. 2014. Predicting the 
Minimal Translation Apparatus: Lessons from the Reductive Evolution of Mollicutes. 
PLoS Genet 10:e1004363. 
138.  McCutcheon JP, Moran NA. 2012. Extreme genome reduction in symbiotic bacteria. 
Nat Rev Microbiol 10:13–26. 
139.  Gil R, Peretó J. 2015. Small genomes and the difficulty to define minimal translation 
and metabolic machineries. Front Ecol Evol 3:123. 
140.  Nkrumah JL, Muhle AR, Moura AP, Ghosh P, Hatfull FG, Jacobs RW, Fidock AD. 
2006. Efficient site-specific integration in Plasmodium falciparum chromosomes 
mediated by mycobacteriophage Bxb1 integrase. Nat Methods 3:615–621. 
141.  Spalding DM, Allary M, Gallagher RJ, Prigge TS. 2010. Validation of a modified 
method for Bxb1 mycobacteriophage integrase-mediated recombination in Plasmodium 
falciparum by localization of the H-protein of the glycine cleavage complex to the 
mitochondrion. Mol Biochem Parasitol 172:156–160. 
142.  Zhang M, Wang C, Otto TD, Oberstaller J, Liao X, Adapa SR, Udenze K, Bronner 
IF, Casandra D, Mayho M, Brown J, Li S, Swanson J, Rayner JC, Jiang RHY, Adams 
JH. 2018. Uncovering the essential genes of the human malaria parasite Plasmodium 













































- The PfMev PDH E2 deletion mutant was generated by Dr. Krithika Rajaram, and the 
PfMev DXS deletion mutant was generated by Bobby Kwan 
- All growth curves were generated by Hans Liu 
- PyrKII E. coli purification and enzyme activity assays were conducted by Cyrianne Keutcha 
- Microarray analysis of the PyrKII-CLD line was conducted by the Johns Hopkins 






 In this chapter, we determined which genes involved in carbon backbone 
metabolism within the apicoplast are essential for the maintenance of the organelle. In order 
to determine this, we made knockouts of the genes involved in this pathway in our PfMev 
bypass line under mevalonate supplementation and then determined the resulting organellar 
phenotypes. We demonstrated that deletion of the inner triosephosphate transporter (iTPT), 
responsible for the import of three-carbon phosphates, was essential for the maintenance of 
the organelle. We were also able to show that pyruvate kinase II (PyrKII), the sole predicted 
source of pyruvate and ATP within the apicoplast, was essential for the maintenance of the 
organelle as well. The pyruvate generated by PyrKII is subsequently fed into the MEP 
isoprenoid precursor pathway as well as the FASII fatty acid biosynthetic pathway. Deletion 
of enzymes within these pathways did not result in organelle disruption, suggesting that the 
utilization of pyruvate is not required for the maintenance of the organelle. This suggests 
that the essentiality of PyrKII for apicoplast maintenance is instead driven by its ability to 
generate ATP. Given this, we went on to further characterize this enzyme by determining 
the substrate specificity of recombinant purified PyrKII against various NDPs and dNDPs 
to determine which nucleotide triphosphates might be supplied by PyrKII. Through this 
work we were able to determine that PyrKII does not have a high level of substrate 
specificity, indicating that it may be capable of generating all NTPs and dNTPs within the 
organelle. We also generated a parasite line that allows for the conditional mislocalization of 
PyrKII, and used this line to examine how loss of PyrKII affects transcription within the 
apicoplast and disruption of the organelle. We were able to show that upon mislocalization 
of PyrKII there was a rapid decrease in transcript level within the apicoplast that far 





essential for organelle maintenance due to its role in nucleotide triphosphate generation 




The apicoplast is a plastid organelle present in most Apicomplexa species (1). The 
apicoplast is an organelle surrounded by four membranes, a result of its evolutionary origin 
resulting from a secondary endosymbiotic process. In the first endosymbiotic event, the 
chloroplast of an algal cell was formed from an engulfed cyanobacterium (2). The algal cell 
was then phagocytosed, and lost all of its cellular contents except for its chloroplast 
organelle (3),(4). Over the course of endosymbiosis the apicoplast has become extremely 
reduced in terms of the biochemical processes present within the organelle in addition to the 
genetic material that it possesses (5). However, the P. falciparum apicoplast has kept some of 
its own genetic material in the form of a reduced 35kb organellar genome that encodes a full 
set of tRNAs, rRNAs, and just a few proteins (6). The remainder, and majority, of 
apicoplast-specific proteins are now encoded within the nucleus of the parasite and 
trafficked to the organelle, likely resulting from multiple gene transfer events that have 
occurred over the course of endosymbiosis (7–9). Due to the unique eubacterial origin of the 
organelle, the apicoplast retains some bacterial-like pathways that are highly dissimilar from 
that of the human host, making it an attractive source of potential drug targets (10).   
 In Plasmodium falciparum malaria parasites, the apicoplast is home to the FASII fatty 
acid and MEP (methylerythritol phosphate) isoprenoid precursor biosynthetic pathways, in 
addition to containing its own iron-sulfur cluster machinery, and sharing the heme 





stage of the parasite lifecycle (11–14), it appears that the only essential product of the 
organelle during the asexual blood-stage of the parasite is the isoprenoid precursor 
isopentenyl pyrophosphate (IPP) (15). However, enzymes within the MEP pathway are not 
the only potential apicoplast blood-stage drug targets. There are over 400 proteins predicted 
to be trafficked to the apicoplast, representing ~7% of the parasite genome (16–20), many of 
which are likely involved in accessory pathways that are required to support isoprenoid 
production by producing substrates or cofactors, and others that are essential for the 
maintenance and replication of the organelle that houses these pathways. 
 In order to fuel the metabolic pathways in the apicoplast, sources of reducing power, 
carbon skeletons, and energy in the form of nucleotide triphosphates are required. Other 
plastid organelles, such as chloroplasts, can generate these products through photosynthesis 
and export them (21, 22). However, when not exposed to light, chloroplasts must import the 
resources needed for the anabolic processes that occur within the organelle (23, 24). Since 
the apicoplast is non-photosynthetic, it has been referred to as a plastid ‘in the dark’ and is 
reliant on the cell to provide these resources (25).  
 The way in which the apicoplast acquires energy and reducing power remains 
unknown. While chloroplasts can acquire carbon backbones, energy, and reducing power 
through the import of glucose-6-phosphate and its breakdown by glycolytic (26) or pentose 
phosphate pathways (27), it does not appear that this occurs in P. falciparum, since the 
apicoplast does not seem to contain the proteins required to import or breakdown hexose or 
pentose sugars (16). Additionally, chloroplasts can also import ATP in exchange for ADP 
with ATP/ADP antiporters (24, 28), but these transporters have not been found to be 





carbon backbone, energy, and reducing power needs solely through the import and 
metabolism of 3-carbon phosphates generated by parasite glycolysis (16, 29). 
 Three-carbon phosphates are imported by two different transporters, the inner triose 
phosphate transporter (iTPT), which is embedded in the inner apicoplast membrane, with its 
trafficking directed by a N-terminal signal and transit peptide, as well as the outer triose 
phosphate transporter (oTPT), embedded in the outer apicoplast membrane, which lacks a 
targeting sequence (30, 31). These transporters have been biochemically characterized ex vivo 
and have been shown to be capable of importing triose phosphate compounds including 
phosphoenolpyruvate (PEP), dihydroxyacetone phosphate (DHAP), and 3-phosphoglyceric 
acid (3PGA), which it exchanges for inorganic phosphate (Figure 4-1) (29). Previous work 
investigated the essentiality of these transporters in P. berghei, and found oTPT to be 
essential, while iTPT was dispensable in blood-stage parasites, but was required in mosquito 
and liver stage parasites (32). Based on these results, it was hypothesized that there may be 
some functional redundancy between iTPT and oTPT (32). However, the essentiality or 
potential redundancy of these transporters has not been determined in P. falciparum parasites.  
 The import of three carbon phosphates is critical for metabolism within the 
apicoplast. Imported DHAP, mediated by iTPT/oTPT (29), is believed to interact with 
triose phosphate isomerase (TPI) as a substrate to generate GA3P (16), which is then fed 
into the MEP isoprenoid pathway for the production of essential isoprenoid precursors (33). 
Additionally, DHAP is also believed to be converted by glycerol phosphate dehydrogenase 
(GpdA) to form glycerol-3-phosphate (G3P) for phospholipid biosynthesis within the 
apicoplast (16, 34). DHAP may also be involved in the generation of reducing power within 
the organelle. One hypothesized source of reducing power is a triose phosphate isomerase 





DHAP is converted by TPI to form GA3P, which in turn is converted into 1,3-
diphosphoglycerate (1,3-DPGA) by GAPDH, reducing NAD+ to NADPH in the process 
(35, 36). The 1,3-DPGA can then presumably be exchanged for DHAP by the triose 
phosphate transporters, creating an electron shuttle (35). A putative TPI has been found and 
is predicted to localize to the apicoplast, but only a single GAPDH has been found (37) and 
does not appear to localize to the apicoplast (38). This is in contrast to the related parasite 
species Toxoplasma gondii which has an apicoplast GAPDH and cytosolic GAPDH (36), and 
presumably has a functional apicoplast TPI/GAPDH cycle. However, it has yet to be 
determined if this cycle is present and active in P. falciparum. In general, the source of 
reducing power in the apicoplast remains unclear. 
 Another three-carbon phosphate imported into the apicoplast is 
phosphoenolpyruvate (PEP) (29). PEP is believed to be used along with ADP as substrates 
by the enzyme pyruvate kinase II (PyrKII), which transphosphorylates PEP to ADP to 
generate the products pyruvate and ATP (8, 39, 40). As the name implies, there are two 
pyruvate kinase enzymes within Plasmodium, one within the cytosol, Pyruvate kinase I (PyrKI) 
(41), and another within the apicoplast called pyruvate kinase II (PyrKII) (42). In eukaryotes, 
pyruvate kinase plays a key role in glycolysis, catalyzing the final step of this pathway, and is 
also one of the key control points of glycolysis (43). In Apicomplexan parasites such as T. 
gondii and P. falciparum, two isoforms of pyruvate kinase have been found, that are referred to 
as Type-I and Type-II isozymes, or PyrKI and PyrKII (39, 42). PyrKI is found within the 
cytoplasm and plays a typical glycolytic role, while PyrKII has been found to localize to both 
the mitochondria and apicoplast in T. gondii and solely to the apicoplast in P. falciparum (39, 
42). Within the apicoplast of P. falciparum PyrKII provides the only predicted source of both 





pathways (33), and becomes incorporated into fatty acid and isoprenoid products (44). The 
ATP generated presumably powers all energy requiring reactions within the organelle and 
provides adenine bases for RNA synthesis. It is not clear how the apicoplast acquires the 
other NTPs for RNA synthesis and other reactions since apicoplast transporters for NMPs 
or NDPs have not been described and there is no other predicted source of NTPs within the 
organelle (16). The activity of the T. gondii PyrKII has been characterized in vitro and shows a 
near-exclusive substrate preference for GDP instead of using ADP (39). Researchers have so 
far been unable to produce recombinant P. falciparum PyrKII in E. coli, and its substrate 
specificity remains unknown (42). 
 The import of PEP and DHAP by the triose phosphate transporters and their 
conversion by the PyrKII and TPI provides the substrates required for the FASII and MEP 
anabolic pathways, and presumably supplies energy and reducing power for apicoplast 
metabolism. Although carbon metabolism appears to be an essential process, the importance 
of these proteins in parasite survival or the maintenance of the apicoplast in P. falciparum has 
not been elucidated. Thus, we utilized the PfMev apicoplast bypass parasite line described in 
chapter 2 of this thesis to determine the required roles of the apicoplast carbon metabolism 
proteins. As demonstrated in chapters 2 and 3 of this thesis, the PfMev parasite line allows 
for the deletion of essential apicoplast resident genes, while under mevalonate 
supplementation. The PfMev parasite line also contain a fluorescently labeled apicoplast, 
which enables us to determine the impact a given gene deletion has on the organellar 
phenotype (15). We have previously shown that deletion of essential apicoplast-resident 
genes, such as DXPR has no discernible effect on the morphology of the organelle. 
However, other genetic disruptions, such as SufS and MnmA, can result in breakdown of the 





organelle (45). In the work outlined this chapter, we utilized the PfMev line to interrogate 
carbon metabolism within the apicoplast through a series of genetic deletions, and have been 
able to determine which genes are required for blood-stage parasite survival, in addition to 
determining which are essential for the maintenance of the apicoplast organelle.  
 Our results show that PyrKII, an enzyme believed to be the sole source of pyruvate 
and ATP in the organelle (16), is essential for apicoplast maintenance. Deletion of iTPT, the 
transporter responsible for the PEP substrate (29) used by PyrKII replicated the phenotype, 
helping to confirm the original finding. To assess the importance of the pyruvate generated 
from PyrKII for apicoplast metabolism, we deleted the two enzymes predicted to use the 
pyruvate generated by PyrKII. We deleted the PDH (pyruvate dehydrogenase) E2 subunit, 
responsible for the generation of acetyl-CoA from pyruvate (46), and found that it was 
dispensable. This replicates what has been shown previously through deletions of other 
enzymes in the FASII pathway (47). We also deleted DXS (DOXP synthase), which is 
responsible for the condensation of pyruvate and G3P to form DOXP in the MEP pathway. 
We found that while DXS is essential for parasite growth, it is not needed for maintenance 
of the apicoplast organelle. These data indicate that pyruvate generated by PyrKII is not 
required for the maintenance of the organelle. Instead the requirement of PyrKII for 
apicoplast maintenance is likely driven by its role in generating ATP (or NTP) products.  
 Given these results we went on to further characterize the PyrKII enzyme by 
determining the substrate specificity of recombinant purified PyrKII against various NDPs 
and dNDPs. While PyrKII was most active against ADP and GDP, it was also found to be 
active against all NDPs and dNDPs that were tested, and did not show a high level of 
substrate specificity. Thus, this led us to hypothesize that the deletion of PyrKII resulted in 





substrates, such as energy consuming reactions (ATP), protein translation (GTP), mRNA 
production (NTPs), and DNA replication (dNTPs). Based on the hypothesis that mRNA 
levels may decline as a result of PyrKII deletion we generated a parasite line that would allow 
us to controllably knockdown PyrKII and measure the rate of loss of mRNA levels via 
microarray as a proxy for measuring the change in NTP production. Using this approach, we 
found that apicoplast mRNA levels decreased rapidly (over the course of hours) while the 
organelle itself remained intact for much longer (~4 days), helping to support the conclusion 




The goal of this work is to interrogate the role and necessity of genes involved in 
carbon metabolism within the apicoplast. In order to accomplish this, we began by 
attempting to delete these genes in our PfMev line under mevalonate supplementation, 
which should allow for the deletion of essential apicoplast-specific genes. A given genetic 
deletion should give us two pieces of information. First, it should allow us to determine if 
the gene is essential by testing whether the deletion line is reliant on mevalonate for growth 
and survival. Second, it should allow us to determine if the gene is required for the 
maintenance or replication of the apicoplast organelle. Previous genetic disruptions of 
essential genes localized in the apicoplast have shown no discernable phenotype, such as the 
deletion of DXPR, while others such as SufS or MnmA have proven to be essential for the 
maintenance or replication of the organelle (48).  
 





Triose phosphates imported into the apicoplast are predicted to be substrates for 
PyrKII and TPI. As mentioned above, imported DHAP is predicted to be used as a 
substrate by TPI to generate GA3P, which is fed into the MEP isoprenoid pathway for the 
generation of isoprenoid precursors (33). In order to determine the importance of TPI 
within the apicoplast, in addition to the parasite overall, we attempted to delete this gene in 
the PfMev parasite line under constant supplementation with 50µM mevalonate using Cas9-
mediated genome editing (49, 50). Through this approach we were successful in deleting the 
TPI gene. Once parasites were obtained the presence of recombinant parasites containing 
the genetic deletion were confirmed using PCR by screening for integration at the 5’ and 3’ 
ends of the locus (Δ5’ and Δ3’), in addition to screening for the original locus (5’ and 3’) to 
determine if there was any contamination by residual wild type parasites. These same 
reactions were also used to screen the PfMev parental line as a control for the PCR reactions 
(Figure 4-2a). We went on to characterize the ΔTPI line by determining whether the gene 
disruption resulted in the loss of the organelle by screening for the presence or absence of 
the apicoplast organelle genome using PCR techniques that have been previously described 
(45). We attempted to amplify SufB from the apicoplast genome, as well as lactate 
dehydrogenase (LDH) from the nuclear genome and cytochrome C oxidase (Cox1) from the 
mitochondrial genome as PCR controls, as previously described (48). We were able to 
amplify SufB, indicating that the apicoplast organellar genome is intact (Figure 4-2b). Using 
epifluorescent microscopy, we observed an intact apicoplast organelle in ΔTPI parasites 
(Figure 4-2c), confirming that deletion of TPI does not affect organelle morphology. 
Additionally, when we removed the mevalonate supplement from the growth medium, there 
was no significant change in parasite growth, demonstrating that TPI is not essential for 





TPI was previously believed to play a potentially essential role in converting DHAP 
to GA3P for usage by the MEP isoprenoid pathway (16). However, the ability to delete TPI 
may be explained by the relative lack of substrate specificity by the triosephosphate 
transporters (oTPT and iTPT), which have been shown to be capable of importing PEP, 
DHAP, and 3PGA (29) and may be capable of importing other 3-carbon phosphate 
compounds as well, as seen in homologous transporters found in chloroplast membranes 
(51). Thus, TPI may be dispensable in blood-stage parasites due to the ability of these 
transporters to directly import GA3P for the MEP pathway. Additionally, TPI was thought 
to potentially play an important role in the generation of reducing power (NADPH) in the 
organelle along with a hypothetical GAPDH (16). The successful deletion of TPI and the 
failure to identify a candidate apicoplast GAPDH makes it more likely that this cycle is not 
present in malaria parasites (16). 
 
Deletion of Pyruvate Kinase II 
We next targeted the apicoplast PyrKII for deletion since it is predicted to be the 
sole source of pyruvate in the organelle, and should be required for the FASII and MEP 
pathways (16). We were successful in deleting PyrKII in PfMev parasites under mevalonate 
supplementation and confirmed the deletion by PCR (Figure 4-3a). When assaying for the 
presence of the apicoplast, we were able to amplify genes from the nuclear and 
mitochondrial genomes, but were unable to amplify SufB, consistent with loss of the 
apicoplast genome due to disruption of the organelle (Figure 4-3b). Using live 
epifluorescent microscopy, we observed multiple vesicles throughout the cell instead of the 
discrete intact structure that is typically seen in wild type parasites (15, 48), further 





Additionally, when we removed the mevalonate supplement from the growth medium, there 
was a rapid reduction in parasite growth, demonstrating that PyrKII is an essential protein 
(Figure 4-3d). These data suggest that PyrKII is an essential gene required for blood-stage 
parasite survival, and is also essential for the maintenance of the apicoplast organelle. 
However, based on these results the mechanism by which PyrKII was essential for 
apicoplast maintenance remained unclear, and could be due to its enzymatic activity or some 
other essential binding or structural role.  
 
Attempted Deletion of the Inner and Outer Triose Phosphate Transporters 
We next attempted to delete the inner and outer triose phosphate transporters 
(iTPT/oTPT) since these proteins are responsible for importing the PyrKII substrate PEP 
into the apicoplast (29). If the enzymatic activity of PyrKII is indeed essential for organelle 
maintenance, then these transporters, either individually or together, should also be required. 
Previous deletions in P. berghei showed iTPT to be dispensable in blood-stage parasites, while 
oTPT was essential (32). Using the PfMev line we were successful in deleting iTPT under 
mevalonate supplementation (Figure 4-4a). When assessing the apicoplast phenotype we 
observed results similar that of the ΔPyrKII parasite line including loss of the apicoplast 
organelle genome (Figure 4-4b) and accumulation of multiple vesicles instead of an intact 
apicoplast organelle (Figure 4-4c). The apicoplast disruption phenotype shared by ΔPyrKII 
and ΔiTPT parasite lines is consistent with the hypothesis that iTPT is needed to import 
PEP to support PyrKII activity which is essential for apicoplast maintenance. Additionally, 
upon removal of mevalonate there was a rapid inhibition of parasite growth, indicating that 





previous found in P. berghei in which the deletion did not cause significant growth defects 
(32).  
 Using the same techniques, we also attempted to delete oTPT, but were unsuccessful 
after multiple attempts (Table 4-1). These results are somewhat similar to those seen in P. 
berghei, in which the attempted deletion was apparently successful, but did not survive 
beyond a few replicative cycles, suggesting that the gene is essential for blood-stage survival 
(32). However, in our case, we should have been able to delete oTPT in the presence of the 
mevalonate bypass as long as oTPT has a role that is limited to apicoplast function. It could 
be that the molecular techniques we used were not designed in a way that facilitated 
successful deletion of the gene. Although, another possibility is that oTPT has an essential 
role for the parasite beyond its function associated with the apicoplast. While oTPT has been 
localized to the apicoplast (31) it still remains a possibility that a small portion of the protein 
may be located elsewhere in the cell. Regardless of where it is located, our results suggest 
that oTPT plays an essential role in parasite survival in parasites that cannot be bypassed 
with mevalonate.   
 
The Role of Pyruvate in the Apicoplast 
 Our results so far implicate PyrKII enzymatic activity in apicoplast maintenance and 
suggest that one of the PyrKII products, pyruvate or ATP, is responsible for this 
phenomenon. We first investigated the role of pyruvate by targeting enzymes for deletion 
within the only two pathways predicted to use pyruvate as a substrate, the FASII and MEP 
pathways. All of the carbon in fatty acids synthesized by the FASII pathway comes from 
acetyl-CoA which is produced by PDH (pyruvate dehydrogenase) (46), with the production 





FASII pathway enzymes showed that this pathway is dispensable in blood-stage parasites 
(12, 54). Subunits of the PDH complex were also shown to be dispensable in P. yoelli (E1α 
and E3) (55) and P. falciparum (E1α) (56). Although these results are quite convincing, the 
PDH E2 subunit, which forms the catalytic core of the PDH complex, has not been 
successfully deleted in any parasite species. We targeted the PDH E2 subunit for deletion, 
and confirmed deletion via PCR as previously described (Figure 4-5a). We also 
characterized the PDH E2 deletion line using the previously described apicoplast genome 
PCR and epifluorescent microscopy techniques, and found that the parasites retained the 
apicoplast genome and contained a discrete intact organellar structure (Figure 4-5b and c). 
We also found that the deletion line grows normally when the mevalonate supplement is 
removed from the growth medium, showing that PDH E2 is dispensable in blood-stage 
parasites (Figure 4-5d). Taken together, these results show that the PDH E2 is dispensable 
in blood-stage parasites, consistent with what has been seen previously in deletions of other 
genes involved in the FASII pathway (12, 54–56). If pyruvate is essential for apicoplast 
maintenance, PDH and the FASII pathway are not the reason why. 
 The MEP isoprenoid pathway is the only other pathway within the apicoplast 
believed to be reliant on pyruvate. The first enzyme in this pathway, DOXP synthase (DXS), 
mediates the first step of the MEP pathway, converting pyruvate along with GA3P into 1-
deoxy-D-xylulose 5-phosphate (DOXP) (44, 57). However, beyond its role in isoprenoid 
production, DXS may be playing a yet to be discovered role in the maintenance of the 
organelle. In order to determine the role and essentiality of this enzyme, we deleted it in the 
PfMev parasite line under mevalonate supplementation. We confirmed the deletion via PCR, 
as previously described (Figure 4-6a). Upon assessing the apicoplast phenotype we were 





apicoplast organelle via epifluorescent microscopy (Figure 4-6c). We also found that ΔDXS 
parasites are mevalonate-dependent, demonstrating that DXS is an essential enzyme (Figure 
4-6d). These results show that DXS is essential for parasite survival, but is not required for 
the maintenance of the apicoplast. This phenotype is consistent with the effects of the MEP 
pathway inhibitor fosmidomycin which kills parasites but can be bypassed with IPP without 
disrupting the apicoplast organelle (48). Taken together, our results targeting PDH E2 and 
DXS show that the enzymes predicted to use pyruvate can be deleted without loss of the 
apicoplast. This suggests that the enzymatic activity of PyrKII that is essential for organelle 
maintenance is likely to be the generation of ATP, or other nucleotide triphosphates, rather 
than the generation of pyruvate.  
 
Enzymatic Characterization of Purified Recombinant P. falciparum PyrKII 
 Due to the deletion of enzymes within the pathways known to be reliant on pyruvate 
not replicating the apicoplast loss phenotype seen with the deletion of PyrKII, this suggests 
that the essential product of PyrKII that is required for organelle maintenance is the 
generation of ATP, or potentially the generation of many or all NTPs and dNTPs within the 
organelle. Thus, in order to investigate the generation of nucleotide triphosphates by PyrKII, 
we produced pure recombinant protein for enzymatic assays. It was previously reported that 
the P. falciparum PyrKII enzyme cannot be produced in E. coli (42), so we generated a codon 
harmonized version of the gene to overcome problems with protein translation, and 
appended an N-terminal maltose binding protein (MBP) to increase the solubility and 
folding of recombinant PyrKII. The MBP-PyrKII fusion protein was purified by amylose 
affinity chromatography and cleaved with tobacco etch virus (TEV) protease to remove the 





10mg of pure PyrKII per liter of E. coli culture. We measured enzymatic activity using a 
lactate dehydrogenase (LDH) coupled spectrophotometric assay that tracks the consumption 
of NADH by LDH as it converts pyruvate generated by PyrKII to lactate (58). Using a 
saturating level of ADP (3mM), we determined that the KM for PEP was 0.61±0.09mM and 
we subsequently used a saturating level of PEP (5mM) to assess the kinetic parameters of 
nucleotide diphosphate substrates. Our results indicate that PyrKII is fairly nonspecific and 
converts all of the NDPs and dNDPs that we tested into the corresponding triphosphates 
(Table 4-2). In comparison, the kcat/Km values for the T. gondii PyrKII were 337-fold 
higher for GDP than for ADP (39). However, for the P. falciparum PyrKII, the preference for 
GDP over ADP was less than l-fold, and the greatest difference in activity between GDP 
and dCDP only differed by 38-fold. These results indicate that PyrKII does not have a high 
substrate specificity and may have an important role in nucleotide metabolism. Currently, 
there is no other known source of dNTPs or NTPs within the apicoplast of malaria 
parasites, neither the enzymes responsible for their generation, nor the transporters capable 
of importing them (16).  
 
Inducible Knock Down of PyrKII using the TetR DOZI System 
Genetic deletion of PyrKII in the PfMev line offers information on the terminal 
effect of the loss of the gene, which results in disruption of the organelle. In order to study 
the chain of events, and thus potential mechanism leading to loss of the organelle, we 
needed to generate a controllable system to remove PyrKII from the apicoplast. To 
accomplish this, we tagged the endogenous PyrKII gene with a C-terminal aptamer array 
that is part of the TetR-DOZI tetracycline-on system that has previously been developed for 





plasmid pMG74 immediately after the PyrKII gene, adding the aptamer array and other 
elements (such as the expression cassette to produce the TetR-DOZI fusion protein and the 
blasticidin S-deaminase drug selection marker) to the 3’ end of the PyrKII gene. Parasites 
were selected with blasticidin and maintained in the permissive state with 0.5µM aTc 
(anhydrotetracycline). Once generated, we then assayed the line to determine what effect the 
knockdown of PyrKII would have on parasite growth (Figure 4-7). These results show that 
upon removal of aTc, there is a rapid reduction in parasite growth, occurring during the 
second parasite intraerythrocytic growth cycle, confirming that PyrKII is an essential protein. 
However, importantly the PyrKII-TetR-DOZI line also gives us a controllable system in 
which to better investigate the importance of PyrKII in parasite survival and organelle 
maintenance and replication.  
 
Conditional Localization of PyrKII 
We also developed a separate conditional PyrKII line in which we replaced the 
apicoplast trafficking region of the endogenous PyrKII with an artificial conditional 
localization domain (CLD) (60). This system allows for the mislocalization of PyrKII, which 
will, upon the addition of the ligand Shield1, be secreted into the parasitophorous vacuole 
instead of being trafficked to the apicoplast (60). We also tested the CLD-PyrKII line by 
adding Shield1 and measuring the growth of the parasite line. The addition of Shield1 
resulted in a rapid reduction of parasite growth (Figure 4-8). The reduction in growth was 
more rapid than that found with the PyrKII-TetR-DOZI line (Figure 4-7), and thus we 
used this line in subsequent experiments investigating the effect that PyrKII loss has on 






Tracking Loss of the Apicoplast Post-mislocalization of PyrKII 
 Based on the previous genetic knockout of PyrKII we know that deletion of the 
gene in the PfMev line results in loss of the organelle. However, this only gives us an 
endpoint result and does not give us information on the rate of potential NTP/dNTP loss 
or the kinetics of organelle disruption. We hypothesized that if PyrKII was indeed involved 
in NTP/dNTP production, then mislocalization would result in a rapid reduction of NTPs 
and that this could be detected by measuring the levels of mRNA transcripts generated from 
the organelle genome. We also hypothesized that if PyrKII were involved in NTP/dNTP 
production then the reduction in apicoplast mRNA levels post-mislocalization would occur 
much more rapidly than the loss of the organelle, as opposed to apicoplast mRNA levels 
being reduced because of organelle loss. Thus, we first wanted to determine the kinetics of 
apicoplast loss following mislocalization of PyrKII. In order to accomplish this, we 
synchronized the CLD-PyrKII line and added Shield1 to ring stage parasites and determined 
the apicoplast morphology at ~24 hour intervals for 5 days. We observed the pattern of api-
SFG fluorescence and found that disruption of the organelle occurred primarily after 4-5 
days, or during the transition between the second and third lifecycle of the parasite (Figure 
4-9). The percentage of parasites containing an intact organelle was ~90-100% at the 0, 16, 
40, and 64-hour time points, and then dropped precipitously in the transition between the 
second and third 48-hour growth cycle. Approximately 25% of parasites contain an intact 
apicoplast at the 88-hour (day 4) time point, and less than 5% of parasites containing an 
intact apicoplast at the 110-hour (day 5) time point (Figure 4-10). 
 





 Loss of the apicoplast primarily occurred 4-5 days after mislocalization of PyrKII. 
We hypothesized that apicoplast transcript levels would be reduced much faster, if PyrKII is 
playing a critical role in NTP production, which would be required for the generation of new 
mRNA transcripts within the organelle. Thus, in order to determine the kinetics of 
apicoplast transcript loss we replicated the same procedure used to determine the phenotype 
of the organelle mentioned above. CLD-PyrKII parasites were synchronized and Shield1 
was added to ring stage parasites. Parasites were collected every 8 hours for 48 hours and 
analyzed via microarray. We found that mislocalization of PyrKII triggers a rapid reduction 
in apicoplast transcript levels, beginning to occur within the first ~8-16 hours (Figure 4-11). 
The reduction in apicoplast transcript levels happens much more rapidly than the disruption 
of the organelle, which occurs between the second and third parasite growth cycle after 
mislocalization of PyrKII. Thus, disruption of apicoplast gene transcription is a very early 
consequence of interfering with PyrKII activity. This finding is consistent with the 
hypothesis that PyrKII is involved the production of NTPs, which are required for mRNA 
production within the organelle.  
 
CONCLUSIONS AND DISCUSSION 
 
 Through the work outlined in this thesis chapter we explored the roles of apicoplast 
proteins predicted to be involved in the import and metabolism of three carbon sugars in the 
apicoplast organelle. The apicoplast is thought to meet its carbon backbone, energy, and 
reducing power needs through the import of 3-carbon phosphates using the inner and outer 
triose phosphate transporters (iTPT and oTPT) (16, 29). We were successful in deleting 





apicoplast. These findings contradict previous results, which found this gene to be 
dispensable in blood-stage P. berghei parasites (32). What is driving this discrepancy is unclear, 
but may be due to differences in the metabolic requirements or modes of substrate import 
into the apicoplast between blood-stage P. berghei and P. falciparum parasites. However, our 
results are consistent with forward genetic screens conducted by Oliver Billker in P. berghei 
suggesting that this gene is essential (61), and by John Adams in P. falciparum showing that 
disruption causes a large reduction in fitness (62). While iTPT can transport PEP and DHAP 
(63), the reason that it is required for organelle maintenance is most likely to be the 
utilization of PEP by PyrKII for the generation of NTPs. Imported DHAP may be used by 
the phospholipid biosynthetic pathway or the MEP pathway, however, deletions of genes 
involved in these pathways do not result in disruption of the apicoplast (34).  
 Additionally, we attempted to delete the outer triose phosphate transporter (oTPT), 
but failed after multiple attempts. The reason for this failure is unclear. It may be due to 
inefficiencies associated with the design of the guide RNA or repair construct. Alternatively, 
it may be due to the inability of the oTPT deletion to be bypassed by mevalonate 
supplementation in the PfMev line because it is playing an essential role in the parasite 
beyond the function of the apicoplast. These results are consistent with what has been 
previously shown, in which the gene could not be deleted in P. berghei (32), and also appears 
to be essential as determined by a forward genetic screen in P. falciparum (62). However, even 
if the gene is essential, we should have been able to delete it in the presence of our 
mevalonate bypass as long as it’s essential function is exclusively associated with the 
apicoplast. 
 PyrKII is a central player in apicoplast carbon metabolism and is involved in 





Through our work here we were able to show that PyrKII is an essential gene that is 
required for blood-stage parasite survival and the maintenance of the apicoplast organelle. 
We went on to investigate the mechanism by which PyrKII is essential for apicoplast 
maintenance by deleting genes in the two pathways predicted to be reliant on pyruvate 
within the apicoplast, including DXS from the MEP pathway and the PDH E2 subunit from 
the FASII pathway. While the deletion of DXS demonstrated that this gene is essential for 
parasite survival, it was shown to not be required for the maintenance of the organelle, 
reproducing what we found when deleting the DXPR, IspG, and IspH enzymes, which are 
also components of this pathway. We additionally deleted the E2 subunit of PDH, which is 
involved in the conversion of pyruvate into acetyl-CoA and the generation of NADH within 
the apicoplast (64). While PDH provides the only predicted source of NADH, and 
potentially all reducing power within the organelle (16, 46), we were able to demonstrate that 
this gene is dispensable in blood-stage parasites. This replicates what has been seen 
previously with the deletion of another PDH subunit in P. falciparum (52). Overall, the result 
that the deletion of enzymes within the two pathways predicted to be reliant on pyruvate 
within the apicoplast did not replicate the organelle-loss phenotype seen with the deletion of 
PyrKII suggested that the generation or usage of pyruvate within the apicoplast is not 
required for organelle maintenance.  
 We found that the activity of PyrKII that is essential for organelle maintenance is 
instead likely due to its role in the generation of nucleoside triphosphates. While PyrKII 
generates the only predicted source of energy in the apicoplast, it may also be involved in the 
generation of all NTPs and dNTPs within the organelle, since there is no other predicted 
source for these compounds within the apicoplast (16). This activity would not be totally 





specific in their use of purine or pyrimidine nucleoside substrates (65–69). In other systems, 
pyruvate kinase enzymes have been shown to play an important role in nucleoside 
triphosphate generation, and are potentially able to function as a nucleoside diphosphate 
kinase (66). Through our work outlined in this chapter, we were able to demonstrate that 
PyrKII has a relatively low substrate specificity, with only a slightly higher activity against 
purine nucleotide substrates. These data indicate that PyrKII may be capable of generating 
any or all NTPs and dNTPs within the apicoplast. Additionally, using transcript abundance 
within the apicoplast as a proxy for measuring NTP levels within the organelle, we were able 
to demonstrate that mislocalization of PyrKII results in the rapid loss of transcripts within 
the apicoplast. The drop in transcript levels began within ~8 hours, which far preceded 
disruption of the apicoplast, which was not observed until ~88-110 hours after 
mislocalization. The rapid loss of apicoplast transcript levels upon removal of PyrKII from 
the organelle suggests that PyrKII may be playing an important role in NTP generation 
within the apicoplast. Loss of the NTP generating activity of PyrKII is the likely cause of 
subsequent apicoplast disruption.  
 Within the apicoplast the ferredoxin/ferredoxin reductase system is the only known 
redox system within the organelle, and is believed to deliver reducing power to LipA, NifU, 
MiaB, IspG and IspH (16, 70–72). The generation and utilization of reducing power within 
the apicoplast has been predicted to be essential for parasite survival (10). We were able to 
confirm this by demonstrating that the deletion of either component of the 
ferredoxin/ferredoxin reductase system results in parasite death, as outlined in chapter 3 of 
this thesis. However, the source of reducing power within the apicoplast has remained 
unclear. One hypothesized source has been a triose phosphate isomerase (TPI), working 





TPI would convert DHAP into GA3P, which would be used by GAPDH to generate 1,3-
diphosphoglycerate (1,3-DPGA) with the concomitant production of NADPH (35, 36). 
However, we were able to demonstrate that TPI is dispensable in blood-stage parasites, and 
the single GAPDH in malaria parasites has been localized to the cytosol (38). This is the only 
predicted source of NADPH within the apicoplast, and due to the apparent absence of 
GAPDH from the organelle, the apicoplast is predicted to rely entirely on NADH for 
reducing power (16). The only predicted source of NADH, and thus potentially all reducing 
power within the organelle is the PDH complex, converting pyruvate into acetyl-CoA, and 
forming NADH from in the process (73). However, we have been able to demonstrate that 
PDH is dispensable for blood-stage parasite survival, replicating what had been seen 
previously with deletions of other PDH subunits in P. falciparum (52). Thus, the source of 
reducing power within the apicoplast remains a mystery, and cannot be attributed exclusively 
to TPI or PDH.  
 TPI is also believed to provide the MEP pathway with carbon backbones through 
the conversion of DHAP to GA3P (16). While the MEP pathway is essential, we have 
demonstrated that TPI is dispensable. The dispensability of TPI can potentially be attributed 
to the lack of specificity of the upstream iTPT/oTPT transporters. Homologous 
transporters in plant plastids are relatively nonspecific and can import various triose 
phosphate compounds (51). The P. falciparum iTPT and oTPT triose phosphate transporters 
were also demonstrated to be relative nonspecific when tested in vitro, capable of importing 
3PGA, a compound not predicted to be used within the organelle (29). Thus, it is possible 
that the iTPT/oTPT transporters can import GA3P directly, bypassing the need for the 





 Through the work outlined here we have been able to draw numerous conclusions 
about the metabolic requirements of the apicoplast organelle during the asexual stage of the 
parasite. We were able to demonstrate that PyrKII is essential for apicoplast maintenance 
and replication. The requirement of PyrKII for this process is apparently not due to its role 
in the generation of pyruvate, as evidenced by pathways reliant on pyruvate not being 
essential for this process, but instead can likely be attributed to the role of PyrKII in NTP 
production. Additionally, PyrKII may potentially be responsible for the generation of all 
NTPs and dNTPs within the apicoplast due to the relative lack of specificity of the enzyme, 
and the rapid loss of apicoplast transcript levels upon removal of the enzyme, occurring 
within the same intraerythrocytic growth cycle that the mislocalization was induced. This is 
also bolstered by the lack of any other identified sources of NTPs/dNTPs within the 
apicoplast. Additionally, we were able to demonstrate that TPI is dispensable for blood-stage 
survival, suggesting an alternate source of GA3P, such as the direct import of the metabolite. 
The dispensability of TPI also suggests that it is unlikely to play a role in the generation of 
reducing power; this is supported by previous findings demonstrating that the required 
partner enzyme, GAPDH, is not localized to the apicoplast. The dispensability of PDH, the 
only other potential source of reducing power opens up further questions, as to what the 
source of reducing power is within organelle, which remains an open question. Furthermore, 
we were unable to delete oTPT, after numerous attempts, potentially suggestive of an 
essential function beyond its current known role in importing three-carbon phosphate 








P. falciparum culture and maintenance 
 Unless otherwise noted, blood-stage P. falciparum parasites were cultured in human 
erythrocytes at 1% hematocrit in a 10mL total volume of CMA (complete medium with 
AlbuMAX) medium containing RPMI 1640 media with L-glutamine (USBiological Life 
Sciences), supplemented with 25mM HEPES, 0.2% sodium bicarbonate, 12.5µg/ml 
hypoxanthine, 5g/L Albumax II (Life Technologies) and 25µg/mL gentamicin. Cultures 
were maintained in gassed flasks (94% N2, 3% O2, 3% CO2) and incubated in sealed 25cm2 
flasks at 37°C. 
 
Generation of Cas9 gene deletion constructs 
Cas9 mediated gene deletion constructs were generated generally following methods 
previously described (49). Briefly, homology arms of ~300-600bp for each gene were 
amplified using the homology arm (HA) 1 and 2 forward and reverse primers corresponding 
to each gene (Table 4-3) from blood-stage P. falciparum NF54-attb gDNA. HA1 and HA2 
primers were designed to contain ~15bp overhangs for insertion into the cut the pL8 or 
pRSng plasmids using In-Fusion (Clontech) cloning methods. The pL8 and pRSng plasmids 
contain the hDHFR drug resistance cassette for selection, which is flanked by endonuclease 
sites for insertion of the homology arms. The pL8 or pRSng plasmids were digested with 
NotI for insertion of HA1, and with NgoMIV for HA2. Digests with either endonuclease 
were also treated with recombinant shrimp alkaline phosphatase (rSAP) and then ethanol 
precipitated. The pL8 and pCasG plasmids also contain a guide RNA (gRNA) expression 
cassette. For insertion of the gRNA sequence, the plasmids were digested with BsaI and also 





oligos (Table 4-4), annealed, and inserted into the pL8 or pCasG plasmids via In-Fusion 
cloning. 
 
P. falciparum transfections for gene deletion 
 Transfections were conducted as previously described (74, 75). Briefly, 400µL of red 
blood cells were washed with 5mL of CytoMix and resuspended in 400µL of CytoMix. The 
red blood cells were then electroporated with 75µg each of the pUF1-Cas9 and pL8 gene 
specific knock out plasmids or the pCasG and pRSng gene specific knock out plasmids (49). 
The electroporated RBCs were then mixed with ~2.5mL PfMev parasites synchronized as 
schizonts at 1% hematocrit and ~10% parasitemia and given 10mL CMA with 50µM 
mevalonate. After 48 hours, transfectants were selected with 0.75µM DSM1, 2.5nM 
WR99210, and 50µM mevalonate for seven days. After seven days, the parasites were 
switched to media containing only 50µM mevalonate. Infected red blood cells (iRBC) were 
first observed between 17 and 30 days after beginning drug selection. Once parasites were 
observed, the medium was switched to 2.5nM WR99210 and 50µM mevalonate.  
 
Confirmation of knockout genotype 
In order to screen for integration and successful gene knockout, in addition to the 
presence of any contaminating residual wild type parasites, a set of six primers were used: 
5’F, 3’R, pL8 HA1 R, pL8 HA2F, 5’ WT R and 3’ WT F (Table 4-5). These primers were 
designed to screen for integration and gene disruption at the 5’ and 3’ ends (Δ5’ and Δ3’) in 
addition to 5’ and 3’ regions of the WT gene (5’ and 3’). The same reactions were also 
performed on the parental PfMev line concurrently as a control. Samples for PCR were 





Approximately 100µL of a resuspended parasite culture was placed in a heat block at 90°C 
for 2 minutes and stored at -20°C. For the PCR reaction, 1µL of the parasite sample was 
added to reactions with a 50µL total volume. Reactions were conducted using a Veriti 96 
well thermal cycler (Applied Biosystems) and Phusion High-Fidelity DNA polymerase 
(Thermo Fisher Scientific). PCR products were separated on a 1.5% agarose gel stained with 
ethidium bromide for visualization.  
 
The PCR reaction volumes were as follows:  
 
parasite lysate 1µl 
5x Phusion HF buffer 10µl 
Forward primer (10 µM)1.5µl 
Reverse primer (10 µM) 1.5µl 
dNTPs (10mM)  1µl 
Phusion polymerase 0.5µl 
Water 34.5µl 
Total volume 50µl 
 
The PCR program was as follows: 
 
95°C 3.5 minutes 
95°C 30 seconds 
62°C 1 minute 
62°C 4 minutes 
4°C stable 
 
(steps 2 and 3 were repeated 35 times) 
 
Confirmation of apicoplast loss 
The loss of the apicoplast was confirmed via PCR with primers specific for a gene 
within the nuclear (Lactate Dehydrogenase), apicoplast (SufB), and mitochondrial (Cox1) 
genomes (Table 4-6). Failure to amplify a gene from the apicoplast genome, while 
amplifying genes from the nuclear and mitochondrial genomes would indicate loss of the 





culture at ~5-10% parasitemia was placed in a 90°C heat block for 2 minutes, and then 
frozen at -20°C. For the PCR reaction, 1µL of the parasite sample was added to reactions 
with a 50µL total volume. Reactions were conducted using a Veriti 96 well thermal cycler 
(Applied Biosystems) and Phusion High-Fidelity DNA polymerase (Thermo Fisher 
Scientific). PCR products were separated by size on a 1.5% agarose gel stained with ethidium 
bromide. The parental PfMev line was always used as a positive control for apicoplast 
detection. 
 
The PCR reaction volumes were as follows:  
 
parasite lysate 1µl 
5x Phusion HF buffer 10µl 
Forward primer (10 µM)1.5µl 
Reverse primer (10 µM) 1.5µl 
dNTPs (10mM)  1µl 
Phusion polymerase 0.5µl 
Water 34.5µl 
Total volume 50µl 
 
The PCR program was as follows: 
 
95°C 3.5 minutes 
95°C 30 seconds 
63°C 30 seconds 
72°C 1 minute 
72°C 4 minutes 
4°C stable 
 
(steps 2-4 were repeated 35 times) 
 
Live cell epifluorescent microscopy 
For sample preparation, 100µL of parasite culture with a hematocrit of 1% and a 
parasitemia between 8-10% was obtained. Parasites were stained with 30nM mitoTracker 





for 30 minutes at 37°C. Cells were then pelleted via mini-centrifuge (Fischer Scientific) for 
10 seconds, and the media was aspirated and the cells were resuspended in 100µL of CMA 
media and incubated for 5 minutes at 37°C. This was done three times to wash the cells, 
with the cells being resuspended in 20µL of CMA and then pipetted onto slides and sealed 
with wax (2 parts paraffin, 1 part Vaseline) for observation on a Zeiss AxioImager M2 
microscope. A series of images spanning 5µm were acquired with 0.2µm spacing and images 
were deconvolved with VOLOCITY software (PerkinElmer) to report a single combined z -
stack image.  
 
Testing mevalonate dependence in PfMev deletion mutants via growth curve 
For each of the PfMev deletion lines, the parasitemia was determined via Gimesa 
stain, with the appropriate amount of the parental culture removed to seed quadruplicate 
samples with or without mevalonate. This volume was resuspended in a total of 10 mL CMA 
and centrifuged at 1,600rcf at room temperature (~25°C) for 5 minutes, washed a second 
time with an additional 10 mL CMA, and then resuspended in the appropriate volume of 
CMA, and then split equally into two tubes. To one of the tubes, the appropriate volume of 
a 10mM stock of mevalonate was added to bring to final concentration to 50 µM 
mevalonate. Parasites were seeded in a 96-well plate at 0.5% starting parasitemia, 2% 
hematocrit, and at a total volume of 250µL per well in quadruplicate. Additionally, 150µL of 
the appropriate media was replaced in each well on days 1, 2, and 3. Parasite samples were 
collected every 24 hours for four days, and the parasitemia was counted via SYBR green 
staining and flow-cytometry as outlined below. 
 





Growth curves were generated by staining parasites with SYBR Green and counting 
parasitemia via flow cytometry. In order to setup the growth curve, the parasitemia of the 
starting culture was determined via Giemsa stain. Based on the determined parasitemia the 
culture was used to seed a 96-well flat bottom cell culture plate (Corning) at a 0.5% starting 
parasitemia and 2% hematocrit, at a total volume of 250µL in quadruplicate. In order to 
minimize evaporation and edge effects, the surrounding wells were filled with 250µL of 
1mM EDTA. Plates were incubated in chambers gassed with 94% N2, 3% O2, 3% CO2 for 1 
minute and 15 seconds, and incubated at 37°C.  
Parasite samples were collected immediately after seeding and analyzed via flow 
cytometry to verify the starting parasitemia and then collected every 24 hours thereafter. 
Samples collected on days 1-3 were diluted 1:10 in phosphate-buffered saline (PBS) and 
stored in a 96-well plate (Corning) at 4°C. We have previously verified that storage under 
these conditions and subsequent staining with SYBR Green reflects accurate parasitemia 
values.  
 On day 4 parasites were stained with SYBR Green by transferring 1µL of parasite 
culture, or 10µL of the 1:10 dilutions (the day 1-3 samples), to a 96-well plate containing 
100µL of 1x SYBR Green (Invitrogen) in PBS. The samples were then incubated for 30 
minutes on a platform Titramax 101 shaker (Heidolph) at 950rpm while protected from 
light. Post-incubation, 150µL of PBS was added to each well to dilute unbound SYBR Green 
dye. A control consisting of uninfected RBCs was also prepared in parallel and treated in the 
same manner as listed above.  
 Samples were analyzed with an Attune Nxt Flow Cytometer (Thermo Fisher 
Scientific). With a 50µL acquisition volume, 250µL total sample volume, and a running speed 





 For flow cytometer gating, the R1 gate used forward-scatter area by side-scatter area 
to identify total RBCs from the sample. The R2 gate used forward-scatter height to identify 
single cells, and the R3 gate was used to measure parasitemia using fluorescence from the 
SYBR Green staining of parasite DNA (ratio of SYBR Green positive cells to total cells).  
 
Generation of the PyrKII E. coli Expression Vector 
The P. falciparum PyrKII was codon harmonized for expression in E. coli cells. The 
PyrKII gene was synthesized consisting of amino acids 42-745 of the protein. This region 
corresponds to what we predict to be the mature full-length protein, post-processing of the 
signal/transit peptide. The PyrKII gene was then amplified from the plasmid containing the 
codon harmonized sequence using the primers listed in Table 4-7. The amplicon was then 
inserted into the EcoRI and HindIII sites in the pMAL-cHT expression vector (76) using 
ligation independent cloning (In-Fusion, Clontech). The pMAL-cHT expression vector 
generates a fusion protein tagging the PyrKII protein with an N-terminal MBP (maltose 
binding protein) followed by a TEV (Tobacco Etch Virus) protease site and a six-histidine 
tag.  Cleavage with TEV protease liberates histidine-tagged PyrKII (76).   
 
Expression and Purification of Recombinant PyrKII from E.coli 
The pMAL-cHT PyrKII expression plasmid was transformed into BL21 Star (DE3) 
E. coli cells (ThermoFisher) also harboring the pRIL plasmid from BL21-CodonPlus-RIL 
cells (Agilent), that we refer to as *RIL cells. The fusion protein was expressed in *RIL cells 
grown in LB medium, and shaken at 220 rpm at 37°C until an OD600 of 0.6 was reached. 
At this point, expression was induced with 0.4mM isopropyl β-thiogalactoside (IPTG) and 





 Cells were isolated via centrifugation and then lysed with 20mM Tris-HCl at pH 7.5, 
100mM KCl, 1mg/mL lysozyme (Sigma), 2.5mg/mL DNAse I (Sigma), and 100mM PMSF. 
Cells were then sonicated at 40% amplitude for 30 seconds two times, and then pelleted via 
centrifugation. The MBP-PyrKII protein was then purified from the resulting lysate using a 
5mL MBPTrap HP column (GE Healthcare). The protein was eluted with 100mM maltose. 
The resulting protein was then cleaved with TEV protease and further purified using a 5mL 
HisTrap column (GE Healthcare). The protein was then eluted with an imidazole gradient, 
and peak fractions were collected, pooled, and concentrated for storage in 20mM Tris-HCl 
(pH 7.5), 100mM KCl, 10% glycerol at -80 °C. The PyrKII protein concentration was 
determined by a Bradford assay using bovine serum albumin as a standard. The purity of 
recombinant pyruvate kinase was analyzed by electrophoresis on a 4-12% acrylamide gel, and 
detected by Coomassie Brilliant Blue staining. 
 
PyrKII Enzyme Assays 
The activity of the PyrKII protein was determined by a continuous assay coupled to 
lactate dehydrogenase (LDH), as previously described (39). Pyruvate generated by PyrKII is 
converted into lactate by LDH  with concomitant oxidation of NADH, which can be 
monitored via spectrophotometer at 340nm. The standard reaction mixture for assaying 
PyrKII activity contained 1µL of the PyrKII enzyme, 5mM PEP (neutralized to pH 7), 
10mM MgCl2, 0.2mM NADH, 2 units of rabbit muscle lactate dehydrogenase (Sigma), 
26.5mM Tris-HCl at pH 7.5, and 50mM KCl. Appropriate dilution of PyrKII enzyme was 
made to ensure that the reaction remained in the linear range over the complete time course. 
All reactions were initiated by adding a given NDP or dNDP. The concentrations assayed 





250µM, 500µM, 1.02mM, 1.01mM, and 3mM. CDP, UDP, TDP, dATP, dGDP, dCTP, and 
dTDP were assayed at concentrations between 0mM to 6mM, specifically at 0mM, 128µM, 
254µM, 510µM, 1.08mM, 2.07mM, 4.05mM, and 6.03mM. All reactions were carried out in 
final volume of 100µL in triplicate in a 96-well plate, and monitored for 20 minutes. The 
initial enzyme velocity was calculated from a tangent that was fitted to the reaction curve. 
Kinetic parameters were calculated using Prism (GraphPad).  
 
Generation of the TetR-DOZI PyrKII Parasite Line 
The PyrKII TetR-DOZI line was generated as previously described (59). Briefly, the 
pMG74 plasmid was used, generously sent to us by the laboratory of Dr. Jacquin Niles. The 
pMG74 plasmid encodes the TetR-DOZI system, which allows for the inducible 
knockdown of a gene through the removal of aTc. This method relies on the insertion of the 
entire linearized pMG74 plasmid immediately following the gene to be knocked down. This 
work by generating two homology arms corresponding to the 3’ end of the gene, and 
another corresponding to the 3’ UTR, which are separated by endonuclease cut-site, such as 
EcoRV. The gene of interest is then cut with a gene-specific gRNA, using the linearized 
gene-specific pMG74 plasmid as a repair template. This results in the insertion of the entire 
pMG74 plasmid, which generates a C-terminal HA and flag tag that will become appended 
to the 3’ end of the gene, followed by an aptamer array. This aptamer array is part of the 
TetR-DOZI system which is encoded elsewhere within the inserted plasmid. 
 The gene-specific pMG74 line was generated by using the primers in Table 4-8. 
Briefly, the PyrKIItet HA1 F and PyrKIItet HA1 R primers were used to amplify the region 
of the gene corresponding to homology arm 1 (HA1), and the PyrKIItet HA2 F and 





homology arm 2 (HA2). The amplicons were then ethanol precipitated and a small amount 
from each was used as a template for another PCR reaction, this time using PyrKIItet HA2 
F and PyrKIItet HA1 R primers to join the two fragments together, containing the 
intervening EcoRV site. The resulting amplicon was then ethanol precipitated. The pMG74 
plasmid was then cut with AscI and AatII restriction enzymes in the presence of rSAP, and 
ethanol precipitated. The HA1/HA2 fragment was then inserted into this plasmid using In-
Fusion (Clontech) cloning methods. The resulting pMG74 plasmid was validated and then 
linearized with EcoRV for transfection into PfMev parasites.  
 Insertion of the pMG74 plasmid also relies on cutting of the genetic region using a 
gene-specific gRNA encoded by the pCasG plasmid. The pCasG plasmid was digested as 
previously described, with BsaI and also treated with rSAP. Guide RNAs were synthesized 
as oligos and (Table 4-4), annealed, and inserted in the pCasG plasmid via In-Fusion 
cloning. 
 The linearized PyrKII pMG74 plasmid along with the genetic-specific pCasG 
plasmid were co-transfected into the PfMev line, using the same transfection protocol as 
described previously. The parasites were then selected for 7 days with 2.5ng/mL blasticidin, 
1.5µM DSM1, and 0.5µM aTc. After 7 days, the drug pressure was removed and the 
parasites were cultured with CMA media, and continuously cultured in the presence of 
0.5µM aTc. Resulting parasites were single-cloned following the single-cloning methods 
listed later this section. 
 
Magnetic purification and synchronization of parasite cultures 
Parasite lines were synchronized via magnetic purification, isolating late-stage 





mixed stage culture at ~5-10% parasitemia and 1% hematocrit through a MACS LS column 
(Miltenyi BioTec) placed in a custom-made magnet with a field strength of about ~8,000g 
The column was washed with 1mL CMA, and the parasites were eluted with 1mL of the 
appropriate media (in the absence of a magnet) into a flask containing 9mL pre-warmed 
media and 200µL of 50% hematocrit blood to generate a synchronized culture at 1% 
hematocrit. 
 
TetR-DOZI PyrKII Growth Curve 
Growth curves for the TetR-DOZI PyrKII line were conducted using cultures that 
had been synchronized using magnetic purification, as mentioned above, 6 hours prior to 
seeding. Once the parasite lines were synchronized, the parasitemia was counted via Giemsa 
stain in order to determine how much culture was needed to seed wells at the desired 
parasitemia. Once this was calculated, the required volume was removed from the parental 
flask and transferred to a 15mL conical tube, and CMA media pre-warmed to 37°C was 
added until a final volume of 10mL was reached. The culture was then centrifuged at 
1,600xg at room temperature (~25°C) for 5 minutes. The media was aspirated, and the pellet 
was resuspended in 10mL of CMA. The washing was done an additional time to ensure 
removal of any residual aTc from the parental culture. The culture was then resuspended in 
the appropriate volume required for seeding. This volume was then split in half, with one 
half receiving 0.5µM aTc, while the other did not. Parasites from both conditions were then 
seeded in a 96-well flat bottom cell culture plate (Corning) at a starting parasitemia of 0.5% 
at 2% hematocrit, at a total volume of 250µL in quadruplicate. For each well, 150µL of the 
appropriate media was replaced daily. Parasite samples were collected every 24 hours and 





 On day 4 of the growth curve, 1/10th of the culture was used to seed another 96-well 
plate with identical growth and culture conditions as the original plate to show the growth 
kinetics of the lines after a 1:10 cut. This helped to remove any dead parasite that may have 
been detected and counted as a parasite via flow cytometry (which would artificially raise the 
parasitemia count). These 1:10 cut cultures were then treated in the same manner as 
previously mentioned, with samples being collected every 24 hours and 150µL of the 
appropriate media replaced daily until day 8.  
 
Generation of the PyrKII Conditional Localization Line 
The conditional localization domain was added to the endogenous PyrKII enzyme 
using CRISPR-Cas9 genome editing techniques, and relied on markerless selection. To 
engineer this line two constructs were created, a pCasG plasmid, and a repair template 
plasmid. The pCasG plasmid expresses the Cas9 enzymes and a gene-specific gRNA. The 
pCasG plasmid was digested as previously described, with BsaI and also treated with rSAP. 
Guide RNAs were synthesized as oligos and (Table 4-4), annealed, and inserted in the 
pCasG plasmid via In-Fusion cloning. 
The repair construct was generated by first synthesizing a piece of DNA that 
corresponded to the first 250 nucleotides of 5’UTR of the PyrKII gene, ending immediately 
before the start codon. This was immediately followed by the conditional localization 
domain, that had been previously generated and validated (60), followed by a BsaI type IIs 
restriction site for the insertion of the PyrKII genetic sequence corresponding to what we 
predict to be the start of the PyrKII protein after processing of the signal and transit peptide, 
and thus begins at the 42nd amino acid. The 5’ UTR and genetic region of PyrKII included in 





insertion of an N-terminal CLD into the endogenous PyrKII gene sequence. For insertion 
of the PyrKII genetic sequence, the above-mentioned plasmid was digested with BsaI in the 
presence of rSAP and then ethanol precipitated. The PyrKII genetic region was then 
amplified using the primers in Table 4-9 (PyrKII HA2 F, and PyrKII HA2 F), and inserted 
into the cut plasmid via In-Fusion cloning. This sequence was then validated and inserted 
into the pRSng plasmid, by first cutting the plasmid with NotI, and then ethanol 
precipitating it. The entire genetic region containing the 5’ UTR, CLD and PyrKII genetic 
sequence was then amplified with the primers listed in Table 4-9 (PyrKII pRSHA1F, and 
PyrKII pRSHA2R), and then inserted into the previously cut pRSng plasmid. 
 The pRSng-PyrKII-CLD plasmid along with the genetic-specific pCasG plasmid 
were co-transfected into the PfMev line, using the same transfection protocol as described 
previously. The parasites were then selected for 14 days with 1.5µM DSM1 and 2.5nM 
WR99210. After 14 days, the drug pressure was removed and the parasites were cultured 
with CMA media. The insertion of the CLD was validated using the primers listed in Table 
4-10. This method looked for insertion of the CLD as well as the potential presence of any 
contaminating wild-type parasites. Insertion at the 5’ end was done by pairing the 
PyrKcld.5.F and CLD.R primers. Insertion at the 5’ end was done by pairing the 
PyrKcld.3.R and CLD.F primers. The presence of any residual wild-type parasites was 
screened at the 5’ end of the PyrKII gene by pairing the PyrKcld.5.F and PyrkcldWT.5.R, 
and screened at the 3’ end of the gene by pairing the Pyrkcld.wt.3.F and PyrKcld.3.R 
primers. These reactions were also replicated for the parental PfMev line as a control. These 
PCR reactions were conducted on the lines, but there was still some contaminating wild-type 
parasites. Thus, the parasites were single-cloned following the below mentioned methods, 





line of parasites that contained the conditional localization domain on the N-terminal end of 
the PyrKII gene.  
 
Parasite cloning through limiting dilution  
Single cloning of the PyrKII TetR-DOZI and CLD lines were carried out via limiting 
dilution. For each parasite line, the type of media used for the dilution and media change is 
the same as that within the flask from which the sample is derived. The parasitemia for each 
culture was determined using Giemsa staining, and used to calculate the number of infected 
RBCs (iRBCs) per µL of culture. Based on the iRBC concentration, a sample consisting of 
1,000 iRBCs/µL in media was prepared. This sample was then diluted 1:10 three times 
sequentially, yielding a parasite sample with a final concentration of 1 iRBC/µL. Then, a 2% 
hematocrit media was pipetted into row A of a 96-well flat bottom cell culture plate 
(Corning) at 200µL per well, followed by the diluted parasite sample at 100uL per well. 
Finally, a 1:3 serial dilution was carried out from row to row starting from row A and all the 
way down to row H. The prepared plate was placed into a Modular Incubator Chamber 
(Billups-Rothenberg Inc.), and gassed with 92% N2, 3% O2, 5% CO2 for 1 min and 15 
seconds prior to incubation at 37°C.  
After seeding on day 0, the media was changed on days 5, 7, 9, 12, and 14. On days 5 
and 12, a 0.5% hematocrit media was used; on days 7, 9, and 14, pure media (without any 
blood) was used. On day 16, selected iRBC-positive wells that are the most dilute (i.e., 
closest to row H) were picked and transferred into a 24-well flat bottom cell culture plate 
(Corning) at 2% hematocrit and 1mL total volume per well. The 24-well plate was then 
maintained and routinely monitored. Upon reaching a high enough parasitemia (~8%), the 





maintained. For each cloned parasite line, the genotype confirmed via PCR using the above-
mentioned primer sets.  
 
CLD-PyrKII Growth Curve 
 The growth curve for the CLD-PyrKII line was conducted identically as described 
for the TetR-DOZI line (vide ante), with the exception that the parental line was not washed, 
as there was no need to remove any ligand. Additionally, once parasite cultures were split, 
one culture received 500nM Shield1, while the other did not.  
 
CLD-PyrKII Sample Collection for Microarray 
 A mixed stage CLD-PyrKII line at ~5-10% parasitemia was synchronized via 
magnetic purification as detailed above. Six hours post synchronization, the parasitemia of 
the culture was counted in order to determine the volume required for seeding. The 
determined volume was taken from the parental flask and used to seed a 50mL culture flask 
at 1% parasitemia and 2% hematocrit with 500nM Shield1, with this point considered as 
time 0.  
 To collect the sample at each time point, 5mL of the culture was taken and 
transferred to a 15mL conical tube, which was then centrifuged at 1,600g at room 
temperature (~25°C) for 5 minutes. The media was then aspirated and ~100µL of the 
pelleted cells were transferred to a 1.5mL cryo tube and snap frozen by submerging the tube 
in a slurry of dry ice and 70% ethanol and stored at -80°C until the samples were processed 
for microarray analysis. Samples were collected for microarray analysis every 8 hours for 56 





parasite growth was not hindered by the lack of nutrients, the media was replaced with the 
appropriate volume of pre-warmed media containing 500nM Shield1 at 16, and 40 hours.  
 Samples were sent to the Johns Hopkins Genomic Analysis and Sequencing Core 
Facility for microarray analysis using Agilent microarray chip AMADID 037237. This same 
experiment was conducted three separate times, and the data shown are based on averages 
of the data collected.  
 
Tracking apicoplast loss via live epi-fluorescent microscopy 
While the above experiment was being conducted the morphology of the apicoplast 
was also tracked by taking 100µL samples from the culture for analysis via live epifluorescent 
microscopy at times 0, 16, 40, 64, 88, and 110 hours. For each of these time points the 
parasites were prepared for analysis via microscopy following the same protocol listed as 
above, including staining with DAPI and mitoTracker CMX-Ros (Invitrogen). For each time 
point, images were collected using the same method as listed above, for a minimum of 15 
parasite cells. The images were processed and deconvolved using the same methods as listed 
above. Apicoplast morphology was assessed by visual inspection to determine whether the 
apicoplast was intact or disrupted multiple discrete vesicles. Parasitized cells in which the 
status of the apicoplast was unclear, such as with late stage schizont parasites were discarded 
















Figure 4-1 Carbon metabolism in the apicoplast 
Carbon backbones are imported into the apicoplast organelle in the form of 3-carbon 
phosphates by the apicoplast membrane outer triose phosphate transporter (oTPT) and 
inner triose phosphate transporter (iTPT). Pyruvate kinase II (PyrKII) converts substrates 
phosphoenolpyruvate (PEP) and adenosine diphosphate (ADP) into products pyruvate and 
adenosine triphosphate (ATP). Pyruvate is used by the FASII fatty acid biosynthesis pathway 
as well as the MEP isoprenoid precursor pathway.  
Triose phosphate isomerase (TPI) converts dihydroxyacetone phosphate (DHAP) into 
glyceraldehyde-3-phosphate (GA3P), which is also required for the isoprenoid precursor 














Figure 4-2 Characterization of the PfMev ΔTPI parasite line 
A.) Genotyping PCR confirming the deletion of TPI, with amplification demonstrating 
integration at the Δ5’ and Δ3’ loci, and lack of wild type parasites due to failure to amplify at 
the wild type 5’ and 3’ loci, as compared to the parental control.  
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔTPI parasite line, indicating retention of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔTPI parasite line. This parasite line 
expresses api-SFG (green), and is also stained with MitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔTPI parasites cultured with or without 50µM mevalonate.  













Figure 4-3 Characterization of the PfMev ΔPyrKII parasite line 
A.) Genotyping PCR confirming the deletion of PyrKII, with amplification demonstrating 
integration at the Δ5’ and Δ3’ loci, and lack of wild type parasites due to failure to amplify at 
the wild type 5’ and 3’ loci, as compared to the parental control.  
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We failed to amplify SufB from 
the PfMev ΔPyrKII parasite line, indicating loss of the apicoplast organelle genome.  
C.) Live fluorescence microscopy of the PfMev ΔPyrKII parasite line. This parasite line 
expresses api-SFG (green), and is also stained with MitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔPyrKII parasites cultured with or without 50µM mevalonate.  













Figure 4-4 Characterization of the PfMev ΔiTPT parasite line 
A.) Genotyping PCR confirming the deletion of iTPT, with amplification demonstrating 
integration at the Δ5’ and Δ3’ loci, and lack of wild type parasites due to failure to amplify at 
the wild type 5’ and 3’ loci, as compared to the parental control.  
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We failed to amplify SufB from 
the PfMev ΔiTPT parasite line, indicating loss of the apicoplast organelle genome.  
C.) Live fluorescence microscopy of the PfMev ΔiTPT parasite line. This parasite line 
expresses api-SFG (green), and is also stained with MitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔiTPT parasites cultured with or without 50µM mevalonate.  










Plasmids Time of selection Successful? 
Puf1-Cas9/pL8-oTPT-HA1/2+g (14s16) 31 days No 
Puf1-Cas9/pL8-oTPT-HA1/2+g (20s16) 40 days No 
Puf1-Cas9/pL8-oTPT-HA1/2+g (27s16) 40 days No 
Puf1-Cas9/pL8-oTPT-HA1/2+g (3o16) 40 days No 
Puf1-Cas9/pL8-oTPT-HA1/2+g (31o16) 40 days No 
Puf1-Cas9/pL8-oTPT-HA1/2+g (8n16) 40 days No 
Puf1-Cas9/pL8-oTPT-HA1/2+g (28n16) 40 days No 
 
Table 4-1 oTPT deletion transfection attempts 
We attempted to knockout the outer triose phosphate transporter (oTPT) gene. In none of 






































Figure 4-5 Characterization of the PfMev ΔPDH E2 parasite line 
A.) Genotyping PCR confirming the deletion of PDH E2, with amplification demonstrating 
integration at the Δ5’ and Δ3’ loci, and lack of wild type parasites due to failure to amplify at 
the wild type 5’ and 3’ loci, as compared to the parental control.  
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔPDH E2 parasite line, indicating retention of the apicoplast organelle 
genome. 
C.) Live fluorescence microscopy of the PfMev ΔPDH E2 parasite line. This parasite line 
expresses api-SFG (green), and is also stained with MitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔPDH E2 parasites cultured with or without 50µM mevalonate.  










Figure 4-6 Characterization of the PfMev ΔDXS parasite line 
A.) Genotyping PCR confirming the deletion of DXS, with amplification demonstrating 
integration at the Δ5’ and Δ3’ loci, and lack of wild type parasites due to failure to amplify at 
the wild type 5’ and 3’ loci, as compared to the parental control.  
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We successfully amplified SufB 
from the PfMev ΔDXS parasite line, indicating retention of the apicoplast organelle genome. 
C.) Live fluorescence microscopy of the PfMev ΔDXS parasite line. This parasite line 
expresses api-SFG (green), and is also stained with MitoTracker (red) and DAPI (blue). 
D.) Growth curve of PfMev ΔDXS parasites cultured with or without 50µM mevalonate.  










Substrate Kcat  (min-1) KM (mM) Kcat/KM (mM-1 min-1) Organism 





GDP 400 +/-45 0.10 +/-0.05 5,670 
CDP 440 +/-70 1.00 +/-0.10 430 
UDP 250 +/-40 0.80 +/-0.20 310 
dADP 400 +/-30 0.40 +/-0.05 1058 
dGDP 90 +/-5 0.30 +/-0.50 321 
dCDP 80 +/-5 0.50 +/-0.10 150 
ADP 2850 +/-80 8.0 +/-0.40 360 T. gondii 
GDP 6600+/-240 0.05 +/-0.006 121,320 
 
Table 4-2 Enzyme kinetics of pure recombinant PyrKII as compared to T. gondii 
PyrKII 
Activity of PyrKII was measured using various NPDs and dNDPs as substrates. Values are 
reported for the kinetic parameters Kcat, KM, and Kcat/KM (catalytic efficiency).  















































Figure 4-7 Growth of the PfMev PyrKII TetR-DOZI line under permissive and non-
permissive knockdown conditions 
Synchronized PfMev PyrKII TetR-DOZI parasites were seeded at 0.5% parasitemia and 
cultured without the mevalonate supplement in the permissive (with aTc) or non-permissive 
(no aTc) conditions for 8 days. Parasites were collected daily and parasitemia was determined 
via flow cytometry. Upon the removal of aTc, parasites exhibit a decrease in growth, which 
was more pronounced after the cultures are cut 1:10 on day 4. Error bars represent the 

































Figure 4-8 Growth of the PfMev PyrKII-CLD line under permissive and non-
permissive conditional localization conditions 
Synchronized PfMev PyrKII-CLD parasites were seeded at 0.5% parasitemia and cultured 
without the mevalonate supplement in the permissive (no Shield1) or non-permissive 
(500nM Shield1) conditions for 8 days. Parasites were collected daily and parasitemia was 
determined via flow cytometry. Upon the addition of Shield1, parasites exhibit a rapid 
decrease in growth, which can be seen clearly by day 3, but is more pronounced after the 
cultures are cut 1:10 on day 4. Error bars represent the standard error of the mean from two 













Figure 4-9 Tracking apicoplast disruption in PyrKII-CLD parasites via live 
epifluorescent microscopy 
Live fluorescence microscopy of the PfMev PyrKII-CLD parasite line after Shield1 
treatment. This parasite line expresses api-SFG (green), and is also stained with MitoTracker 
(red) and DAPI (blue). The above images are representative images of the state of the 
apicoplast organelle at the corresponding time points. Each day, a minimum 15 microscopy 
images were taken to determine apicoplast morphology (intact or disrupted), with average 
values from three independent experiments displayed in the previous graph. 

















Figure 4-10 Quantifying apicoplast disruption in PyrKII-CLD parasites via live 
epifluorescent microscopy 
Graph of the percentage of disrupted apicoplast organelles in synchronized PyrKII-CLD 
parasite lines after Shield1 treatment. Each day a minimum 15 microscopy images were taken 
to determine apicoplast morphology (intact or disrupted) based on api-SFG fluorescence. 
The percentage of parasites containing an intact apicoplast dropped precipitously between 
the second and third growth cycle of the parasite, corresponding to the 64 and 88-hour time 







































Figure 4-11 Measuring apicoplast transcript levels in Shield1-treated PyrKII-CLD 
parasites 
Synchronized ring-stage PyrKII-CLD parasites were treated with of Shield1, with samples 
collected every 8 hours for 48 hours to be used for microarray analysis. The intensity 
background corrected average mRNA levels of genes encoded by the apicoplast organelle 
genome were compared to an untreated control line as well as a IPP-dependent apicoplast 






















Table 4-3 Primer sequences used to amplify homology arms for genetic knock outs 
 
Primer Name Primer Sequence 
PyrKII HA1 F GCCACGAGCGGCCTATGATAAATTTTATAAGCAAGGAAG 
PyrKII HA1 R AAGCGCAGCGGCCTGTTTTGGTTACCTAATGAATTC 
PyrKII HA2 F CGACAGACGCCGGTTTCTGTATTCCTAATATGATTATGCC 
PyrKII HA2 R GGCCACCAGCCGGTAAATTGGATAAATTCGTTTCGATTC 
iTPT HA1 F GCCACGAGCGGCCCATATAAATATTATGCCTTGCCCAACC 
iTPT HA1 R AAGCGCAGCGGCCTTCCTATTAATTTGTGAAGGACGTTTG 
iTPT HA2 F CGACAGACGCCGGGTGCTGGTGCTATTAGTTTTGTTCATA 
iTPT HA2 R GGCCACCAGCCGGCTGTGCTTGCAACAGCATGTGTAATAT 
oTPT HA1 F GCCACGAGCGGCCGTAGTTATTTTATTACGTGAGACCTCA 
oTPT HA1 R AAGCGCAGCGGCCGGATTTTTTTCATTCCACTTATCCAAT 
oTPT HA2 F CGACAGACGCCGGGTGCAACCTTATCAAATTTTGGTTCAT 
oTPT HA2R GGCCACCAGCCGGAATGTCATCGTTAAAATGCCACAATTC 
TPI HA1 F GCCACGAGCGGCCCCATTATGGTGATATTTGTTCATCTTG 
TPI HA1 R AAGCGCAGCGGCCGTTCATCATGGGTTAATATATTTTCCA 
TPI HA2 F CGACAGACGCCGGTGCTATAGGTACAGGACAACCTGTATC 
TPI HA2 R GGCCACCAGCCGGCACAGGGAAAATATGCTAATGATCTAC 
PDH E2 HA1 F GCCACGAGCGGCCCGTGGAAGCATTTGATGAAGGTATAAC 
PDH E2 HA1 R AAGCGCAGCGGCCTCCACTTCTATGGTGCTTTTATCATCC 
PDH E2 HA2 F CGACAGACGCCGGATTACCAGATTCTCTATTAACTCCTGT 
PDH E2 HA2 R GGCCACCAGCCGGCAATACTTCCAATATTTGTGCCGATTG 
DXS HA1 F GCCACGAGCGGCCGAATAGGTTGTCAAGGAAAAATTCGTTATG 
DXS HA1 R AAGCGCAGCGGCCATTAGCTAGTTTGTCCTGTTCATGTGAC 
DXS HA2 F CGACAGACGCCGGTGGTTTAACAGGTGGAATGGC 





Table 4-4 Oligonucleotides designed for In-Fusion insertion of gRNA sequences 
 
Primer Name Primer Sequence 
PyrKII gRNA F TAAGTATATAATATTAATTTAATTGTACCCTGTTTGTTTTAGAGCTAGAA 
PyrKII gRNA R TTCTAGCTCTAAAACAAACAGGGTACAATTAAATTAATATTATATACTTA 
iTPT gRNA F TAAGTATATAATATTTCTATTATCTGTTATTGCTAGTTTTAGAGCTAGAA 
iTPT gRNA R TTCTAGCTCTAAAACTAGCAATAACAGATAATAGAAATATTATATACTTA 
oTPT gRNA F TAAGTATATAATATTATTTTACTTGGATAGCTTTTGTTTTAGAGCTAGAA  
oTPT gRNA R TTCTAGCTCTAAAACAAAAGCTATCCAAGTAAAATAATATTATATACTTA 
TPI gRNA F TAAGTATATAATATTTAATCATAGCCTTTGAGCCAGTTTTAGAGCTAGAA 
TPI gRNA R TTCTAGCTCTAAAACTGGCTCAAAGGCTATGATTAAATATTATATACTTA 
PDH E2 gRNA F TAAGTATATAATATTGTTAATATAGGAAATGCATTGTTTTAGAGCTAGAA 
PDH E2 gRNA R TTCTAGCTCTAAAACAATGCATTTCCTATATTAACAATATTATATACTTA  
DXS gRNA F TAAGTATATAATATTATTGCTATTATAGGAGATGGGTTTTAGAGCTAGAA 
DXS gRNA R TTCTAGCTCTAAAACCCATCTCCTATAATAGCAATAATATTATATACTTA 
PyrKIITetR gRNA F TAAGTATATAATATTCCATGTCTAACAAATTAGCAGTTTTAGAGCTAGAA 
PyrKIITetR gRNA R TTCTAGCTCTAAAACTGCTAATTTGTTAGACATGGAATATTATATACTTA 
PyrKIICLD gRNA F TAAGTATATAATATTTCCATTGCCAGAACCTACAAGTTTTAGAGCTAGAA 
































Table 4-5 Primer sequences used for confirmation of gene deletions 
 
Primer Name Primer Sequence 
pl8insHA1R TACAAAATGCTTAAGCGCAGCGGCC 
pl8insHA2F CATATTTATTAAATCTAGAATTCGACAGACGCCG 
PyrKII 5' F GTTAATTGCATAAAAAAGAATAACAAACATATTGC 
PyrKII 3'R CCATCATTTGTGTTGCTACAATTACTGG 
PyrKII 5' WT R CCTTTTTTACTATATAATTTTCCACCTGTTAAAACTTGTA 
PyrKII 3' WT F GGGTACAATTAAATTATCCAGAATTAATAAAGAATGC 
iTPT 5’F GCTTATATTGTAAACAATGATTGTTATTGC 
iTPT 3’R CAAGAGAATATACAAATGTTCCACCAAC 
iTPT 5’WT R GGAATAGAAAAAACGGGTATATTAAATGC 
iTPT 3’ WT F CCTTAATCAAAGGATTCCAAAAATACG 
oTPT 5’F TCCTTACACATATTACAAAGTATTTAAAAGGA 
oTPT 3’R GACTAAAACGATTTCTTAAATGTCAAAAGG 
oTPT 5’ WT R ACCAAAATGAACAAATATATGACATACAC 
oTPT 3’ WT F CCTTATTAATTATTGTAGGTGGTGTTGTTTG 
TPI 5'F GTGTATAATATTATGGGATTTAATATATATATGTGTG 
TPI 3'R GGAAGTCACGAAATAAAATTAAAAAAAAAAAAAGAATC 
TPI 5' WT R GCTTCCTCTTTTGATAAATAGCATTTCC 
TPI 3' WT F CCATATTTTATTTTCCCCAGCTTATC 
PDH E2 5'F GCCAGCTCTATCTAGTACCATGACG 
PDH E2 3'R CGCTGCTGCATGGGATCCATAG 
PDH E2 5' WT R GTCTAAATCTACGAACTGTCCTTCCTTGAC 
PDH E2 3' WT F CCGTTCCAGTGTTCCGTGTTACTC 
DXS 5'F GAACTTTGTACCAGTTGTTCTATACATTCTCC 
DXS 3'R CGATTTTTTTGTACGTACATGAAGAACAGTAGC 
DXS 5' WT R GTGCAATTTTTTTTTTTATAGGCCTTATGCAG 

















Table 4-6 Primer sequences used to detect genes from the nuclear and organellar 
genomes 
 
Primer Name Primer Sequence 
LDH F GGAGATGTAGTTTTGTTCGATATTG 
LDH R CTTGTAAAGGGATACCACCTACAG 
SufB F CATGTAGCTATAGTAGAAATAATAGTAAAAGATTATGG  
SufB R GACTCTGAAATACTTAAACCACGTTGC 
Cox1 F CTTCATCTTTAAGAATAATTGCACAAGAAAATGTAAATC 



































Table 4-7 Primer sequences used to amplify harmonized PyrKII for In-Fusion 
insertion into the pMAL-cHT expression plasmid 
 
Primer Name Primer Sequence 
PfPyrKIIpMAL F ATCACCATCACGAATTCATGGGCAGTGGAAACGGCTCAGG 
PfPyrKIIpMAL R CGGCCAGTGCCAAGCTTAGTTGGTGAGGCACGGCTGACAC 
 






























































































Table 4-9 Primer sequences used for generation of the PyrKII-CLD line 
 
Primer Name Primer Sequence 
PyrKII HA2F TTGCTAAAGTTAGAAGGTTCTGGCAATGGATCGGGGGATT 
PyrKII HA2R TTACGCCGCGGCCGCCATCTATACCATTTAAGTATAATTT 
PyrKII pRSHA1F GCGGCCGTGCCACGAGCGGCCGACGCGTAAAGTAAATGAT 









































Table 4-10 Insertion validation primers for the PfPyrKII-CLD line 
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The survival of blood-stage P. falciparum parasites has long been known to rely on the 
vitamin pantothenate, which is metabolized by a series of enzymes to generate Coenzyme A 
(CoA). All of the enzymes involved in this pathway are predicted to reside in the cytosol 
except for the last enzyme in the pathway, dephospho-CoA kinase (DPCK), which is 
predicted to localize to the apicoplast organelle. This enzyme should be essential for the 
production of CoA and the survival of blood-stage parasites, which makes its putative 
localization in the apicoplast interesting. Previous work demonstrated that the apicoplast can 
be disrupted in blood-stage parasites, if isopentenyl pyrophosphate (IPP) is supplemented in 
the growth medium. This has been interpreted as IPP production being the only essential 
function of the apicoplast during this stage. In the work described here, we confirmed that 
DPCK is indeed localized to the apicoplast organelle. We were unable to delete the gene 
encoding DPCK, even in the presence of an apicoplast bypass system, unless we first 
expressed the E. coli DPCK (EcDPCK) to complement the loss of the parasite enzyme. 
Ultimately, we were able to demonstrate that DPCK activity is required for parasite survival, 
and that DPCK remains functional and essential in ‘apicoplast negative’ parasites that 
contain a disrupted apicoplast organelle. Taken together, these results show that the 
apicoplast is an essential source of CoA in blood-stage malaria parasites. CoA also appears to 
be required in the apicoplast for the 4’-phosphopantetheine modification of the acyl-carrier 
protein (ACP). Both ACP and ACP Synthase (ACP-S), the enzyme that catalyzes the 
modification of ACP, are essential for parasite survival and organelle maintenance. Thus, 
ACP modified with the 4’-phosphopantetheine group from CoA has an essential non-
canonical function in the apicoplast outside of its known role in the FasII fatty acid 








P. falciparum parasites rely on exogenous pantothenate (vitamin B5) (1, 2), which they 
use for the de novo synthesis of Coenzyme A (CoA) (3). Within the parasite, CoA functions as 
an essential cofactor used for a variety of biosynthetic pathways (4), including the generation 
of acetyl-CoA, fatty acid biosynthesis and modification, and cellular oxidation and 
metabolism (5). The CoA biosynthetic pathway has been considered an attractive source of 
drug targets, with studies showing that pantothenate analogs inhibit this pathway and are 
effective in inhibiting the growth of the asexual red blood cell (RBC) stage of the parasite (6–
8).  
In Plasmodium, pantothenate is imported into the infected red blood cell (iRBC) via 
the new permeability pathway (NPP) transporter (9), diffuses across the parasitophorous 
vacuole (10), and then crosses the parasite plasma membrane through the pantothenate 
transporter (PAT) (11–13). Once inside the parasite, pantothenate is converted into CoA 
through a series of five enzyme-mediated steps. The first four enzymes, including 
pantothenate kinase 1 or 2 (PanK1/2), phosphopantothenoylcysteine synthase (PPCS), 
phosphopantothenoylcysteine decarboxylase (PPCDC), and phosphopantetheine 
adenylyltransferase (PPAT) are believed to be localized to the cytosol of the parasite (4). 
However, the last step of this pathway, involving the conversion of dephospho-CoA to CoA 
by the dephospho-CoA kinase (DPCK) enzyme is predicted to occur within the apicoplast 
of the parasite (Figure 5-1) (14).  
All of these enzymes have been targeted for deletion in Plasmodium yoelli, and it was 





survival, while the last two enzymes in this pathway, PPAT and DPCK, appear to be 
essential (12, 15, 16). However, in P. falciparum PAT was refractory to deletion (11). The 
dispensability or essentiality of these genes was explained by a potential alternate CoA 
biosynthetic route in which pantetheine is imported and phosphorylated by PanK1 or 
PanK2 to form 4′ phosphopantetheine, which is used directly by PPAT to form dephospho-
CoA, bypassing PPCS and PPCDC (15). While parasites are able to tolerate the deletion of 
multiple enzymes within the pathway, it still represents a viable drug target that is deserving 
of further investigation.  
The last enzyme in this pathway, DPCK, is predicted to localize to the apicoplast due 
to the presence of a N-terminal bipartite apicoplast trafficking peptide (14). The CoA 
generated within the apicoplast is then presumably exported out of the organelle for 
utilization throughout the rest of the cell, by a transporter that is yet to be identified. Within 
the apicoplast, CoA is predicted to be used to modify the acyl-carrier protein (ACP) with a 
4-phosphopantethine cofactor (17). This modification is catalyzed by ACP synthase (ACP-
S), and is required to form the mature and biologically active form of ACP (4, 17). ACP 
plays a central role in the FasII pathway within the apicoplast (14, 18), however this pathway 
has been demonstrated to be nonessential in blood-stage parasites (19, 20).  
It has previously been demonstrated that the apicoplast organelle can be disrupted in 
blood-stage P. falciparum parasites if supplemented with sufficient quantities of isoprenoid 
precursor isopentenyl pyrophosphate (IPP) (21). Parasites with a disrupted apicoplast lose 
the 35kb apicoplast genome and no longer contain an intact organelle, instead accumulating 
vesicles throughout the cell (21, 22). One interpretation of this result is that IPP is the only 
essential product generated by the apicoplast during the blood-stage of the parasite. 





the apicoplast (14). Thus, disruption of the apicoplast should require supplementation with 
CoA as well as IPP if DPCK is an essential apicoplast enzyme whose product, CoA, is 
needed by the rest of the cell. 
The vast majority of apicoplast-specific proteins are encoded within the nucleus (23), 
and then trafficked to the apicoplast through the recognition of an N-terminal hydrophobic 
signal peptide followed by a positively charged transit peptide (24). This bipartite peptide is 
necessary and sufficient to target proteins, such as the green-fluorescent protein (GFP) to 
the apicoplast (25). The signal peptide mediates co-translational import into the endoplasmic 
reticulum and is cleaved, exposing the transit peptide which mediates vesicular trafficking to 
the organelle (26–28). When the apicoplast is disrupted, there is an accumulation of vesicles 
throughout the cell (21, 22) that have been shown to contain nuclear-encoded apicoplast 
proteins (26). Thus, it remains a possibility that the vesicles that accumulate in parasites 
containing a disrupted apicoplast contain apicoplast-specific proteins that are biochemically 
active and fulfilling their functional role in the cell.  
Through the work described here, we attempted to generate a genetic knockout of 
DPCK, and were unsuccessful, even when using an apicoplast metabolic bypass , suggesting 
that DPCK is playing an essential role in the parasite beyond its potential function within the 
apicoplast. However, we were successful in deleting the endogenous P. falciparum DPCK, 
when complementing the parasite with the E. coli DPCK (EcDPCK), helping to both 
confirm its functionality as a DPCK enzyme, and providing additional evidence that it is 
likely to be essential. We provided further evidence that DPCK activity is essential for 
parasite survival by knocking down the complemented EcDPCK in the ΔDPCK line, which 
resulted in the inhibition of parasite growth. We also showed that DPCK is present and 





demonstrated that CoA is likely needed within the apicoplast for the 4-phosphopanthethine 
modification of ACP by ACP-S. We found that both ACP and ACP-S are essential for 
parasite survival and organelle maintenance, suggesting that these proteins have an essential 





DPCK Localization to the Apicoplast Organelle 
In P. falciparum, DPCK is predicted to localize to the apicoplast (14), however this 
has yet to be experimentally confirmed. In order to determine the localization of DPCK we 
took advantage of certain features of the PfMev parasite line that we generated previously. 
Namely, PfMev parasites are engineered to express a more stable green fluorescent protein, 
super-folder green (SFG), which is directed to the apicoplast by the trafficking peptide of the 
P. falciparum acyl-carrier protein, fluorescently labeling the organelle (api-SFG). Systems such 
as these have been used previously to visualize the apicoplast (21, 22, 29). Thus, we 
generated a construct to express the P. falciparum DPCK containing a C-terminal mCherry 
tag, under the control of the calmodulin promoter. The entire construct was then integrated 
into the genome of PfMev parasites that had been further modified to contain an additional 
attb site within the p230p locus of the genome using attP/attB recombination (30, 31). We 
then analyzed the resulting line using live epifluorescent microscopy. Upon analysis, we 
observed co-localization of the api-SFG and mCherry signals, indicating that DPCK is 






DPCK is Not Amenable to Genetic Deletion Even in the Presence of Exogenous 
Mevalonate and CoA 
 Using the PfMev line, we attempted to delete DPCK using Cas9-mediated genome 
editing methods (32) under continuous supplementation with 50µM mevalonate, which 
should allow DPCK to be deleted even if it is essential for apicoplast function. However, we 
failed to delete DPCK in six independent attempts, suggesting that DPCK is essential for 
parasite survival and likely fulfills a metabolic requirement outside of the apicoplast. We also 
tried direct supplementation with CoA, since CoA has been shown to rescue the growth of 
parasites that have been treated with inhibitors that are thought to target CoA biosynthesis 
(33, 34). We were also not successful in deleting DPCK in two additional attempts using 
both 50µM mevalonate and 5mM CoA as culture medium supplements (Table 5-2). This 
result seems to suggest that DPCK is either essential for some function that does not 
involve CoA, or that the parasites are unable to scavenge CoA. However, it is not clear from 
previous supplementation experiments whether parasites can scavenge intact CoA (33, 34). 
In these experiments, CoA may have broken down into components like pantetheine or 4′ 
phosphopantetheine and then taken up by the parasites. If 4′ phosphopantetheine can be 
scavenged, it can be used directly by PPAT and DPCK, bypassing the other CoA synthesis 
pathway enzymes and their inhibitors. Since DPCK is the last enzyme in the pathway, only 
acquisition of intact CoA would rescue deletion of the enzyme. 
 
DPCK Can be Knocked Out if Complemented With the E. coli DPCK in the 
Apicoplast 
 Since our previous knockout attempts were inconclusive, we wanted to determine if 





the apicoplast. Thus, we generated an expression construct in which we appended the signal 
and transit peptide of P. falciparum ACP to the N-terminus of the E. coli DPCK (EcDPCK), 
along with a C-terminal mCherry tag to confirm trafficking of the protein to the apicoplast 
(Figure 5-3a). The expression of this gene was controlled by the calmodulin promoter, and 
the construct was integrated into the genome using attP/attB integration in the PfMev 
p230p attb line. The resulting parasite line (PfMev Api-EcDPCK-mCherry) was then 
analyzed by live fluorescent microscopy. We found that the mCherry signal was co-localized 
with the api-SFG signal, demonstrating that the E. coli DPCK was being expressed and 
trafficked to the apicoplast (Figure 5-3b). Upon confirming this, we again targeted the 
endogenous DPCK for deletion, with the same construct previously used unsuccessfully in 
attempts to delete this gene in non-complemented PfMev parasites. However, this time in 
the complemented PfMev Api-EcDPCK-mCherry line, we were successful in deleting 
DPCK. We confirmed the deletion of this gene using PCR (Figure 5-3c). We then analyzed 
this line again using live epifluorescent microscopy and confirmed that the api-SFG and 
mCherry signals continued to be co-localized in the apicoplast (Figure 5-3d). These results 
indicate that EcDPCK can complement the loss of the parasite DPCK. Since the E. coli 
DPCK (encoded by the coaE gene) has already been biochemically characterized (35), 
complementation further indicates that the parasite DPCK has dephospho-CoA kinase 
enzymatic activity. 
 
The E. coli DPCK is Present and Active in the Vesicles of Parasites Containing a 
Disrupted Apicoplast Organelle  
Once we generated the DPCK knockout line expressing the apicoplast localized E. 





EcDPCK enzyme could be active in the vesicles resulting from disruption of the apicoplast 
organelle. Thus, we treated the PfMev Api-EcDPCK-mCherry ΔDPCK line with 100nM 
azithromycin in the presence of 50µM mevalonate for 7 days. After azithromycin treatment, 
we were no longer able to detect the presence of the apicoplast genome by PCR, indicating 
that the organelle had been disrupted (Figure 5-4a). We then analyzed this line by live 
epifluorescent microscopy and observed the presence of multiple vesicular bodies in the 
parasites, consistent with loss of the single apicoplast organelle (Figure 5-4b). Both the api-
SFG and mCherry signals remained co-localized (Figure 5-4b), indicating that the E. coli 
DPCK was present and active in the vesicles of the parasite.  
 
DPCK Can be Knocked Out if Complemented with the E. coli DPCK in the Cytosol 
It is not clear why the last step of CoA synthesis occurs in the apicoplast . Within the 
apicoplast, CoA is an important cofactor needed for the FASII fatty acid biosynthetic 
pathway (36), however, this pathway is dispensable in blood-stage parasites (19, 20). We have 
previously failed to delete DPCK under mevalonate supplementation, suggesting that CoA is 
essential for processes outside of the apicoplast organelle. However, we could delete DPCK 
in a parasite line expressing E. coli DPCK in the apicoplast organelle. This raised the 
question of whether CoA has to be produced in the apicoplast, potentially being required for 
within the organelle for maintenance or replication, or whether it could be produced in the 
cytosol. In order to determine this, we generated a second complementation parasite line in 
which we expressed the E. coli DPCK protein with a C-terminal mCherry tag, but did not 
append a N-terminal trafficking peptide to the construct (Figure 5-5a). 
We were successful in integrating the EcDPCK-mCherry cytosolic expression 





and observed a pattern of mCherry fluorescence consistent with cytosolic protein expression 
(Figure 5-5b). Using this parasite line, we were successful in deleting the endogenous 
DPCK gene under supplementation with 50µM mevalonate (Figure 5-5c). We then 
analyzed the resulting apicoplast phenotype to determine whether deletion of DPCK had 
any effect on the maintenance or replication of the organelle. PCR analysis indicated that the 
apicoplast genome is present in the knockout line (Figure 5-5d), and we observed intact 
apicoplast morphology via epifluorescent microscopy (Figure 5-5e). Additionally, we 
removed mevalonate from the culture medium and found that these parasites continued to 
grow and replicate, demonstrating that CoA production within the apicoplast is not required 
for organelle maintenance or parasite survival. Taken together, these results indicate that 
either CoA is not needed in the apicoplast, or that the organelle has the ability to import 
CoA from the cytosol. 
 
Knockdown of E. coli DPCK in ΔDPCK Parasites Results in a Modest Growth 
Defect 
Our results so far strongly suggest that DPCK is an essential gene, but they are not 
entirely conclusive since they are based on the failure to delete DPCK unless EcDPCK is 
expressed. In order to demonstrate that DPCK activity is essential, we took advantage of the 
TetR-DOZI knockdown system, which inhibits the translation of the target protein in the 
absence of the tetracycline analog aTc (anhydrotetracycline) (37). We also used a new 
conditional localization domain (CLD) approach that does not affect protein trafficking to 
the apicoplast until a CLD binding ligand (Shield1) is added to the parasite culture, causing 
the targeted protein to be secreted to the parasitophorous vacuole (38). Using both of these 





an N-terminal CLD and a C-terminal mCherry tag for visualization, followed by an aptamer 
array providing binding sites for the tetR-DOZI fusion protein to bind and silence mRNA 
transcripts. The expression was controlled by a calmodulin promoter, with the construct also 
containing the TetR-DOZI system, required for the function of the knockdown (Figure 5-
6a) (37). We were successful in integrating this construct into the genome of the PfMev 
p230p attb parasite line using attP/attB integration, with the resulting line being named 
PfMev CLD-EcDPCK-mCherry-apt (aptamer). We confirmed expression of the protein 
using live epifluorescent microscopy (Figure 5-6b), and found it to be localized to the 
apicoplast as expected. We then went on to delete the endogenous DPCK gene in this line, 
confirming the successful deletion of the gene by PCR (Figure 5-6c), and generating what 
we called the PfMev-CLD-EcDPCK-mCherry-apt ΔDPCK line. 
After validating that the E. coli DPCK-mCherry protein was being appropriately 
expressed (Figure 5-7a), we confirmed the functionality of the individual knockdown 
systems through the removal of aTc (Figure 5-7b), the addition of Shield1 (Figure 5-7c), or 
the simultaneous removal of aTc and the addition of Shield1 (Figure 5-7d). Analysis of 
mCherry signal after 48 hours of treatment under these conditions indicated that the TetR-
DOZI knockdown and the CLD systems were both functional. The removal of aTc resulted 
in a highly diminished mCherry signal, consistent with knockdown of the protein. The 
addition of Shield1 resulted in mislocalization of the protein away from the apicoplast, 
confirming the functionality of the CLD. In the non-permissive state with both systems 
applied (aTc removed and Shield1 added), we were not able to detect mCherry signal. We 
conducted a growth assay under this non-permissive condition and tracked growth over 6 
days. We observed a modest effect on parasite growth, with the parasitemia differing by 





conducted in singlicate, as an initial proof of concept to test whether DPCK may be 
essential. The reduced growth of the PfMev EcDPCK-mCherry-apt ΔDPCK line upon the 
removal of aTc and addition of Shield1 suggested that DPCK is playing an important role in 
parasite growth.  
 
Knockdown of E. coli DPCK in ΔDPCK Parasites is Exacerbated Under Limiting 
Concentrations of Pantothenate 
The mild growth inhibition of PfMev EcDPCK-mCherry-apt ΔDPCK parasites 
grown in the non-permissive state may be partially explained by strong overexpression of 
EcDPCK by the calmodulin promoter. Thus, even if the knockdown and CLD approaches 
were effective in reducing EcDPCK levels in the apicoplast, there still may be enough 
enzyme activity to sustain parasite growth, albeit at a reduced level. We reasoned that we 
could further reduce DPCK activity and parasite growth by limiting that amount of 
pantothenate in the growth medium. Thus, we determined the minimal concentration of 
pantothenate that is required to sustain parasite growth to near wild type levels. RPMI-1640 
parasite growth medium contains is approximate 1µM pantothenate; we titrated the 
concentration of pantothenate and found that as little as 100nM was sufficient to restore 
parasite growth to near wild-type levels. Parasites failed to replicate at concentrations of less 
than 10nM pantothenate (Figure 5-9). This gave us a starting point to test additional 
pantothenate concentrations within the range required for parasite growth. Thus, we next 
measured growth of the PfMev EcDPCK-mCherry-apt ΔDPCK parasite line under 
permissive and non-permissive conditions, with pantothenate supplemented at 
concentrations of 100nM, 50nM, 25nM, and 10nM, supplemented with 0nM as a negative 





that parasites supplemented with as little as 50nM pantothenate grew at near wild type levels 
under permissive conditions, and essentially failed to replicated under non-permissive 
conditions. It should be noted that both of these pantothenate titration experiments were 
done in singlicate as initial ranging experiments. Thus, we ran one additional experiment 
measuring the growth of the PfMev EcDPCK-mCherry-apt ΔDPCK parasite line under the 
permissive and non-permissive conditions in the presence of 50nM pantothenate with an 
appropriate number of technical and biological replicates. Under limiting pantothenate 
concentrations we saw a severe defect in parasite replication in the non-permissive 
condition. These results demonstrate that DPCK activity is essential for parasite growth 
(Figure 5-11). 
 
DPCK is Present and Active in Disrupted Apicoplast Vesicles and is Essential for 
Parasite Survival 
It is not clear whether apicoplast-localized DPCK could continue to function if the 
organelle becomes disrupted. This would require the enzyme to be expressed and functional 
in the vesicles that result from apicoplast disruption, and these vesicles would have to 
provide the appropriate biochemical environment. To explore this question, we treated the 
PfMev CLD-EcDPCK-mCherry-apt ΔDPCK line with 100nM azithromycin in the presence 
of 50µM mevalonate for seven days. Azithromycin treatment resulted in the formation of 
multiple punctate vesicles containing fluorescent signals corresponding to both api-SFG and 
mCherry, indicating that EcDPCK is produced and trafficked to the vesicles in apicoplast 
disrupted parasites (Figure 5-12a). We were no longer able to detect the presence of the 
apicoplast genome by PCR in these parasites, confirming that the organelle had been 





of the EcDPCK is essential for parasite survival, and thus induced the dual knockdown and 
CLD systems in the presence of 50µM mevalonate and the reduced level of 50nM 
pantothenate. Based on these results, we found that parasites grew poorly in the non-
permissive condition, indicating that EcDPCK is essential for parasite survival in apicoplast 
disrupted parasites (Figure 5-13). These results reinforced the finding that DPCK activity 
within the apicoplast is essential for parasite growth, and demonstrated that the vesicles 
resulting from apicoplast disruption can contain essential processes despite the absence of an 
intact organelle. 
 
ACP is Essential for Blood-Stage Parasite Survival and Apicoplast Maintenance 
We showed thus far that CoA synthesis is essential, but we next wanted to know 
whether CoA is specifically required in the apicoplast. Pyruvate dehydrogenase (PDH) uses 
CoA to generate acetyl-CoA within the apicoplast, however this activity has previously been 
demonstrated to be dispensable in blood-stage parasites (39). Within the apicoplast, ACP 
synthase (ACP-S) uses CoA and catalyzes the posttranslational modification of ACP with a 
4’-phosphopantetheine cofactor (4, 17, 40). ACP is known to function in the FASII fatty 
acid biosynthetic pathway (36), and although this pathway is dispensable in blood-stage 
parasites (19, 20), ACP itself has not been targeted for deletion.  
In order to test the potential essentiality of ACP within the with the apicoplast, we 
attempted to delete this gene in the PfMev parasite line using Cas9-mediated editing (32), 
under continuous supplementation with 50µM mevalonate. We were successful in knocking 
out ACP, and confirmed the deletion using PCR (Figure 5-14a). Surprisingly, PCR analysis 
indicated that the organellar genome was no longer present in the ACP deletion line (Figure 





microscopy images, confirming the loss of the organelle (Figure 5-14c). Consistent with 
these findings, the ΔACP parasite line relies on mevalonate for survival, and these parasites 
fail to grow in its absence. These results demonstrate the ACP is not only essential for the 
blood-stage survival of the parasite, but is additionally required for the maintenance and 
replication of the organelle. Due to the dispensability of other components of the FASII 
pathway ACP must be essential for a previously unpredicted and essential non-canonical 
function.  
 
ACP Synthase is Essential for Blood-Stage Parasite Survival and Apicoplast 
Maintenance 
 Our previous results show that ACP is essential, but this does not necessarily mean 
that CoA or the 4’-phosphopantethine modification of ACP is required. To investigate the 
importance of this posttranslational modification, we attempted to delete ACP-S in the 
PfMev parasite line under continuous supplementation with 50µM mevalonate. We were 
successful in deleting this gene, confirming the knockout using PCR (Figure 5-15a). We 
observed a phenotype similar that of the ΔACP parasite line including loss of the apicoplast 
organelle genome (Figure 5-15b), accumulation of multiple vesicles (Figure 5-15b), and 
dependence on mevalonate supplementation for survival. These results indicate that ACP-S 
and its substrate CoA are likely required in the apicoplast for the 4’-phosphopantethine 
modification of ACP, and that this posttranslational modification is essential for organelle 
maintenance and parasite survival.  
 





While the multiple deletions of genes within the FASII pathway demonstrated that 
this pathway is dispensable for blood-stage parasite survival (19, 20) the first enzyme in the 
pathway, FabD, has not been targeted for deletion (18). FabD catalyzes the transfer of the 
malonyl group from malonyl-CoA to ACP, to form malonyl-ACP (36). It is possible that 
FabD generates malonyl-ACP or another acyl-ACP species that has an important role in 
apicoplast maintenance. To investigate these possibilities, we targeted FabD for deletion and 
confirmed the deletion via PCR (Figure 5-16a). Unlike the ΔACP and ΔACP-S parasite 
lines, we could detect the apicoplast organellar genome in the ΔFabD line (Figure 5-16b), 
and found that the apicoplast remained intact in this line (Figure 5-16c). Additionally, we 
found that ΔFabD parasites grow without mevalonate supplementation, demonstrating that 
FabD is not required for blood-stage parasite survival. Thus, the essential role of holo-ACP 
in the apicoplast does not rely on acylation by FabD, and is instead seemingly due to a 
previously unpredicted non-canonical activity.  
 
CONCLUSIONS AND DISCUSSION 
 
 Through the work outlined here we have been able to confirm that the generation of 
CoA is essential for parasite survival. We have also been able to demonstrate that the last 
enzyme in the CoA synthesis pathway, DPCK, is located in the apicoplast, and confirmed its 
function as a DPCK through complementation with the E. coli enzyme. We were also able to 
demonstrate that DPCK likely remains present and active in the vesicles of a parasite 
containing a disrupted organelle. Furthermore, we have been able to show that CoA is likely 
needed within the apicoplast for its utilization by ACP-S to modify ACP with a 4-





and the maintenance of the organelle, likely related to some unpredicted non-canonical 
activity unrelated to their previously described role in the FASII pathway. As mentioned 
previously, P. falciparum parasites are reliant on the supplementation of exogenous 
pantothenate, which they use to generate CoA (3). The enzymes involved in this process 
include PanK1/2, PPCS, PPCDC, and PPAT within the cytosol, with the final step mediated 
by DPCK within the apicoplast (4, 14). Most of these enzymes have been targeted for 
deletion in P. yoelli, and all except for the last two (PPAT and DPCK) are dispensable for 
blood-stage parasite survival (12, 15, 16). This pathway has not been investigated to the same 
degree in other species of Plasmodium, such as P. berghei or P. falciparum, but previous forward 
genetic screens attempting to determine gene essentiality have been instructive (41, 42). The 
results from these screens are not totally concordant with what has been found previously, 
but mostly confirm that the initial steps in the CoA biosynthetic pathway are likely to be 
dispensable, and that DPCK is likely to be essential (Table 5-2). As stated previously, the 
dispensability of the upstream enzymes involved in this pathway is likely related to the ability 
of parasites to use pantetheine or 4′-phosphopantetheine directly; PPAT and DPCK would 
then be required to form dephospho-CoA and CoA, respectively (15).  
 
Table 5-1 Predicted essentiality of genes via forward genetic screens 
 
Gene Name ID # PiggyBac PlasmoGem 
PAT PF3D7_0206200 Dispensable Not studied 
PanK1 PF3D7_1420600 Essential Dispensable 
PanK2 PF3D7_1437400 Dispensable  Dispensable 
PPCS PF3D7_1102400 Dispensable Dispensable 
PPCS2 PF3D7_0412300 Dispensable Absent in P. berghei 
PPCDC PF3D7_0816100 Essential Dispensable 
PPAT PF3D7_0704700 Dispensable Not studied 
DPCK PF3D7_1443700 Essential Essential 





ACP-S PF3D7_0420200 Essential Not studied 
FabD PF3D7_1312000 Essential Dispensable 
 
 
While the P. falciparum DPCK has been predicted to be one of the few enzymes 
within the pantothenate pathway that is absolutely required for parasite survival, it has not 
been well studied. DPCK is predicted to reside within the apicoplast, performing the 
essential function of CoA generation for the parasite. However, P. falciparum DPCK had 
previously not been localized or functionally characterized, and its essentiality had not been 
demonstrated. Through the work outlined here, we were able to localize DPCK to the 
apicoplast organelle. This was accomplished by expressing a second copy of the DPCK with 
a C-terminal mCherry tag, which co-localized with the apicoplast marker api-SFG when 
analyzed via live epifluorescent microscopy, indicating apicoplast localization. We were also 
able to demonstrate that DPCK is likely functioning as a DPCK, by complementing the 
parasite with E. coli DPCK. This complementation not only helped to functionally validate 
DPCK, but also helped confirm its essentiality, since deletion of the endogenous DPCK was 
only successful when completed with the expression of EcDPCK. The essentiality of DPCK 
was more conclusively shown through the knockdown of the complemented EcDPCK in a 
ΔDPCK line. In this knockdown line EcDPCK was under the control of a CLD to alter its 
trafficking to the parasitophorous vacuole (PV) instead of the apicoplast, in addition to 
containing a C-terminal aptamer array that allowed for knockdown of the protein upon the 
removal of aTc. This knockdown and mislocalization resulted in a reduction of parasite 
growth, which was dramatically exacerbated by limiting the concentration of pantothenate in 
the culture medium, confirming the essentiality of the gene. Additionally, DPCK could not 
be knocked out even when supplied with 5mM of exogenous CoA, indicating that the 





It had been previously hypothesized that DPCK is apicoplast localized and essential 
for parasite survival (14, 15), and our work shows that both of these predictions are true. 
However, previous work also demonstrated that the apicoplast can be disrupted if parasites 
are supplemented with sufficient concentrations of IPP (21). The resulting disrupted 
apicoplast phenotype has been characterized, with the normally discrete intact structure of 
the organelle no longer seen, but instead there appears to be an accumulation of vesicles 
throughout the cell (21, 22). This can be visualized by tagging a green fluorescent protein 
with an N-terminal apicoplast-specific signal and transit peptide, to direct its trafficking to 
the organelle (24, 25). Additionally, the ~35kb apicoplast genome becomes lost in this 
process as well, which can be confirmed via PCR (22). Once parasites have reached this 
disrupted apicoplast state, they are entirely reliant on IPP supplementation for survival, and 
can continue to survive and replicate in perpetuity as long as IPP is provided (21). These 
results have been described as proof that IPP is the only essential product generated by the 
apicoplast during the blood-stage of the parasite. However, when the apicoplast is disrupted, 
nuclear-encoded apicoplast-specific proteins are still presumably being made. Based our own 
transcriptomic analysis of apicoplast negative parasites, it appears that there is no significant 
difference in the transcription of nuclear-encoded apicoplast-specific proteins that would be 
trafficked to the organelle. Additionally, previous work suggests that apicoplast trafficked 
proteins are still being translated, packaged, and sent out into the cell, but accumulate due to 
the destination organelle no longer being present (26). It is assumed that the all proteins and 
pathways once active in the intact organelle are no longer functional once the organelle has 
become disrupted. However, this conclusion is hard to reconcile with the need for CoA 
generated in the apicoplast. CoA is needed outside of the organelle and it does not make 





results show that DPCK plays an essential role within the organelle that cannot by bypassed 
with apicoplast metabolic bypass systems. This was demonstrated through the localization of 
DPCK to the apicoplast, along with the multiple failed attempts to delete DPCK, even in the 
presence of exogenous mevalonate. Furthermore, we demonstrated that the vesicles of a 
parasite containing a disrupted organelle continue to be biochemically active. This was 
shown through the continued survival and co-localization of DPCK-mCherry with the api-
SFG apicoplast marker in parasites containing a disrupted organelle, indicating that it 
remained biochemically active within these vesicles. We were also able to demonstrate that 
the DPCK activity within these vesicles is essential, since parasites grow poorly when DPCK 
is knocked down and mislocalized, even in the presence of mevalonate, fueling the 
apicoplast metabolic bypass. While the exact mechanism is unclear, the likely scenario is that 
DPCK is present and active within the vesicles, and there are functional transporters 
embedded within the membrane of the vesicles that are allowing for the import of substrates 
and the export of the product CoA for usage throughout the cell. One could further 
speculate that the environmental conditions (pH, redox potential, ion concentration) are also 
maintained in the vesicles at levels compatible with enzymatic activity. 
We investigated whether CoA is essential for apicoplast function in addition to 
requirements outside of the organelle. We found that ACP and ACP-S, and likely CoA, are 
essential for apicoplast maintenance, but it is not clear why they are required in the organelle. 
ACP-S is involved in catalyzing the addition of a 4’-phosphopantetheine prosthetic group to 
ACP, converting the apo form of the protein to the functional mature form of the protein 
(holo-ACP) (4, 17). ACP was shown to function in the FASII fatty acid biosynthetic pathway 
(14, 18), with FabD first catalyzing the transfer of a malonyl group from malonyl-CoA to 





modification of acyl-ACP. FabH condenses malonyl-ACP and acetyl-CoA to form 
acetoacetyl-ACP (36). These steps are followed by the elongation stage of FASII in which 
fatty acids are extended by the enzymes FabF, FabG, FabZ and FabI (43). However, after a 
series of knockouts in Plasmodium it was concluded that the pathway is not required in blood-
stage parasites (44, 45). With knockouts of ACC (46), FabF (20), FabI (44), and the PDH 
E1α subunit (39) in P. falciparum showing no clear deleterious effects in blood-stage parasites. 
Thus, the essential role of ACP and ACP-S is likely not related to their role in the FASII 
pathway.  
It is likely that ACP and ACP-S have some secondary function yet to be elucidated 
that is required both for parasite survival in addition to apicoplast maintenance. It is possible 
that both proteins have secondary functions, while ACP has a similar secondary structure to 
the other acyl carrier proteins and acyl carrier protein-like domains (47) it has been shown to 
have additional enzymatic activity in vitro, being able to function as a malonyl-transferase (48) 
in addition to showing the ability to self-acylate (49). In regards to ACP-S, it appears to be 
bifunctional, containing a metal-dependent hydrolase domain (50). Additionally, the 4-
phosphopanthethine modification has been shown to increase the stability of ACP, which 
may be important for any cryptic role that ACP may be playing (47). In other organisms, 
ACP has been shown to be important for additional roles beyond fatty acid biosynthesis. In 
Saccharomyces cerevisiae, ACP, and specifically the 4’-phosphopantetheine prosthetic group, was 
shown to play an important role in iron-sulfur cluster biosynthesis in mitochondria (51). The 
S. cerevisiae ACP has been shown to interact and form a complex with ISD11, the cysteine 
desulfurase NFS1, and ISCU (51, 52). However, this may not be the case in the P. falciparum 
apicoplast. The P. falciparum ACP and S. cerevisiae ACP are evolutionarily distinct, and found 





(22). The P. falciparum homologs of the proteins found within the mitochondria of S. cerevisiae 
are found in the mitochondrion of P. falciparum including ISD11 (53), ISCU 
(PF3D7_1454500) (54) and NFS1 (55). In the closely related species T. gondii, ACP has also 
been shown to be essential for parasite survival and organelle maintenance (56), but that has 
been assumed to be due to its role in fatty acid biosynthesis, which is not required in P. 
falciparum. However, it is possible that ACP is playing an essential role in T. gondii parasites 
and other apicomplexan species that is unrelated to fatty acid biosynthesis as well.  
Expression of cytosolic EcDPCK complemented the deletion of apicoplast DPCK. 
This deletion did not result in the loss of the apicoplast. This is surprising since the deletions 
of ACP and ACP-S result in the loss of the organelle, and it seems that CoA would be 
needed within the apicoplast for the 4’-phosphopantethine modification of ACP. Thus, it is 
possible that the CoA generated within the cytosol by EcDPCK may be able to be imported 
back into the apicoplast. Presumably, there is one or more transporters that bring 
dephospho-CoA into the apicoplast and export CoA during the normal operation of the 
apicoplast. These transporters may either be sufficiently nonspecific, or have the ability to 
work in reverse to bring CoA into the organelle, allowing production of CoA in the cytosol 
to fulfill requirements in the apicoplast.  
Overall, the work here demonstrated that DPCK is an essential apicoplast-localized 
protein that is required for parasite survival and whose activity cannot be bypassed with IPP. 
We also found that the vesicles of parasites with disrupted apicoplast organelles continue to 
be biochemically active, at least in the case of DPCK. Additionally, it is likely that CoA is 
required within the apicoplast as the 4’-phosphopantethine modification of ACP by ACP-S 
is essential for organelle maintenance and parasite survival, and that this essentiality is not 








P. falciparum culture and maintenance 
Unless otherwise noted, blood-stage P. falciparum parasites were cultured in human 
erythrocytes at 1% hematocrit in a 10mL total volume of CMA (complete medium with 
AlbuMAX) medium containing RPMI 1640 media with L-glutamine (USBiological Life 
Sciences), supplemented with 25mM HEPES, 0.2% sodium bicarbonate, 12.5µg/mL 
hypoxanthine, 5g/L Albumax II (Life Technologies) and 25µg/mL gentamicin. Cultures 
were maintained in gassed flasks (94% N2, 3% O2, 3% CO2) and incubated in sealed 25cm2 
flasks at 37°C. 
 
Generation of the P. falciparum DPCK localization line 
 In order to determine the subcellular localization of the P. falciparum DPCK protein 
we generated a plasmid for the expression of DPCK followed by a C-terminal mCherry tag 
for visualization in the cell. Due to DPCK containing an intron the gene was amplified from 
P. falciparum cDNA using the primers listed in Table 5-3. This amplicon was then ethanol 
precipitated and inserted into a plasmid containing a bi-directional Cam/HOP promoter, 
promoting the expression of the hDHFR drug selection cassette on the other end. This 
plasmid (Cam Api-EcDPCK-mCherry, described below) also already contained the mCherry 
sequence, and we were able to generate the C-terminal mCherry tag by digesting the vector 
with AvrII and BsiWI in the presence of rSAP, ethanol precipitating the plasmid, and then 






Live cell epifluorescent microscopy 
For sample preparation, 100µL of parasite culture with a hematocrit of 1% and a 
parasitemia between 8-10% was obtained. Parasites were stained with 30nM mitoTracker 
CMX-Ros (Invitrogen) and 1µg/mL 4′, 6-diamidino-2-phenylindole (DAPI), and incubated 
for 30 minutes at 37°C. Cells were then pelleted via mini-centrifuge (Fischer Scientific) for 
10 seconds, and the media was aspirated and the cells were resuspended in 100µL of CMA 
media and incubated for 5 minutes at 37°C. This was done three times to wash the cells, 
with the cells being resuspended in 20µL of CMA and then pipetted onto slides and sealed 
with wax (2 parts paraffin, 1 part Vaseline) for observation on a Zeiss AxioImager M2 
microscope. A series of images spanning 5µm were acquired with 0.2µm spacing and images 
were deconvolved with VOLOCITY software (PerkinElmer) to report a single combined z -
stack image.  
 
Confirmation of apicoplast genome loss 
The loss of the apicoplast was confirmed via PCR with primers specific for a gene 
within the nuclear (Lactate Dehydrogenase), apicoplast (SufB), and mitochondrial (Cox1) 
genomes (Table 5-4). Failure to amplify a gene from the apicoplast genome, while 
amplifying genes from the nuclear and mitochondrial genomes would indicate loss of the 
organelle (53). To collect samples for PCR, approximately 100µL of a resuspended parasite 
culture at ~5-10% parasitemia was placed in a 90°C heat block for 2 minutes, and then 
frozen at -20°C. For the PCR reaction, 1µL of the parasite sample was added to reactions 
with a 50µL total volume. Reactions were conducted using a Veriti 96 well thermal cycler 
(Applied Biosystems) and Phusion High-Fidelity DNA polymerase (Thermo Fisher 





bromide. The parental PfMev line was always used as a positive control for apicoplast 
detection. 
 
The PCR reaction volumes were as follows:  
 
Water 34.5µL 
5x Phusion HF buffer 10µL 
Forward primer (10 µM)1.5µL 
Reverse primer (10 µM) 1.5µL 
dNTPs (10mM)  1µL 
Phusion polymerase 0.5µL 
parasite lysate 1µL 
Total volume 50µL 
 
The PCR program was as follows: 
 
95°C 3.5 minutes 
95°C 30 seconds 
63°C 30 seconds 
72°C 1 minute 
72°C 4 minutes 
4°C ∞ 
 
(steps 2-4 were repeated 35 times) 
 
Generation of the PfMev EcDPCK complementation lines 
The E. coli complementation constructs were generated in plasmids containing the 
Cam/HOP promoter. The hDHFR drug resistance cassette was inserted into the plasmid by 
being amplified from another plasmid containing the cassette using primers shown in Table 
5-5 (hDHFR F and hDHFR R). The plasmid was cut with BamHI and HindIII in the 
presence of rSAP, and then ethanol precipitated. The hDHFR gene was then amplified, 
ethanol precipitated, and then inserted into the cut plasmid using In-Fusion cloning.  
The E. coli DPCK gene was synthesized and codon optimized for expression in P. 





which was cut with AvrII and BsiWI in the presence of rSAP and then ethanol precipitated. 
The E. coli DPCK gene was then amplified using the primers in Table 5-5 (EcDPCK F and 
EcDPCK R), ethanol precipitated, and inserted into the cut plasmid using In-Fusion cloning 
to generate a sequence that would encode the E. coli DPCK with a C-terminal mCherry 
protein. This whole sequence was then lifted and inserted into the Cam/HOP plasmid 
containing the hDHFR drug resistance cassette mentioned above by cutting the plasmid with 
AvrII and AflII in the presence of rSAP and ethanol precipitating it. The entire E. coli 
DPCK-mCherry gene was then amplified from this plasmid that contained the sequence 
using the primers in Table 5-5 (CamEcDpmCry F and CamEcDpmCry R), and then ethanol 
precipitated and inserted into the cut plasmid using In-Fusion cloning.  
For the generation of the apicoplast localized E. coli DPCK-mCherry protein the 
aforementioned pLN plasmid containing the E. coli DPCK-mCherry gene was cut with 
AvrII in the presence of rSAP and ethanol precipitated. The N-terminal signal and transit 
peptide, corresponding to the first 55 amino acids from the P. falciparum ACP protein was 
then amplified from a separate plasmid containing the sequence using the primers in Table 
5-5 (pLN.Api55 F and pLN.Api55 R), ethanol precipitated and then inserted upstream of 
the EcDPCK-mCherry sequence using infusion cloning. This entire gene sequence, 
containing the Api55 sequence, E. coli DPCK and mCherry was then inserted into the 
plasmid containing the Cam/HOP promoter and hDHFR sequence as mentioned above. 
This was done by cutting the plasmid with AvrII and AflII in the presence of rSAP and 
ethanol precipitating the plasmid. The Api-EcDPCK-mCherry gene was then amplified using 
the primers in Table 5-5 (CamApEcDpmC F and CamApEcDpmC R) 
The previous EcDPCK-mCherry and Api-EcDPCK-mCherry plasmids both contain 





which contains an attb site at the p230 locus of the parasite genome, generously provided by 
Dr. Krithika Rajaram (Johns Hopkins Bloomberg School of Public Health). This allowed for 
integration of these plasmids into the genome of this parasite line using bxb1 integration. In 
order to generate these lines transfections were conducted using the above-mentioned 
protocol using the EcDPCK-mCherry or Api-EcDPCK-mCherry plasmids along with the 
pINT plasmid encoding the bxb1 integrase and selected with 2.5nM WR99210 for 7 days, 
after which point drug pressure was removed. Infected RBCs were then observed ~20-25 
days post transfection, at which point 2.5nM WR99210 was added back, with the parasites 
maintained in the presence of this drug.  
 
Generation of P. falciparum transfection constructs for gene deletion 
Homology arms of ~300-600bp for each gene were amplified using the homology 
arm (HA) 1 and 2 forward and reverse primers corresponding to each gene (Table 5-6) 
from blood-stage P. falciparum NF54-attb gDNA. HA1 and HA2 primers were designed to 
contain ~15bp overhangs for insertion into the cut the pRS(ng) or pL8 plasmid using In-
Fusion (Clontech) cloning methods. The pRS(ng) and pL8 plasmids contain the hDHFR 
drug resistance cassette for selection and contains flanking endonuclease sites for insertion 
of the homology arms. The pRS(ng) or pL8 plasmid was digested with NotI for insertion of 
HA1, and with NgoMIV for HA2. Digests with either endonuclease were also treated with 
recombinant shrimp alkaline phosphatase (rSAP).  
The pCasG, pRS, and pL8 plasmids contain a guide RNA (gRNA) expression cassette. 
Guide RNA sequences were synthesized as oligos (Table 5-7), annealed, and inserted into 
the pCasG, pRS, or pL8 plasmids via In-Fusion cloning after the plasmids were digested 






P. falciparum transfections for gene deletion 
 Transfections were conducted as previously described (31, 57). Briefly, 400µL of red 
blood cells were washed with 5mL of CytoMix and resuspended in 400µL of CytoMix. The 
red blood cells were then electroporated with 75µg each of the pUF1-Cas9 and pL8 gene 
specific knock out plasmids or the pCasG and pRS(ng) gene specific knock out plasmids 
(32). The electroporated RBCs were then mixed with ~2.5mL PfMev parasites synchronized 
as schizonts at 1% hematocrit and ~10% parasitemia and given 10mL CMA with 50µM 
mevalonate. After 48 hours, transfectants were selected with 1.5µM DSM1, 2.5nM 
WR99210, and 50µM mevalonate for seven days. After seven days, the parasites were 
switched to media containing only 50µM mevalonate. Infected red blood cells (iRBC) were 
first observed between 17 and 30 days after beginning drug selection. Once parasites were 
observed, the medium was switched to 2.5nM WR99210 and 50µM mevalonate.  
 
Confirmation of knockout genotype 
In order to screen for integration and successful gene knockout, in addition to the 
presence of any contaminating residual wild type parasites, a set of six primers were used: 
5’F, 3’R, pL8 HA1 R, pL8 HA2F, 5’ WT R and 3’ WT F (Table 5-8). These primers were 
designed to screen for integration and gene disruption at the 5’ and 3’ ends (Δ5’ and Δ3’) in 
addition to 5’ and 3’ regions of the WT gene (5’ and 3’). The same reactions were also 
performed on the parental PfMev line concurrently as a control. Samples for PCR were 
collected when the parasitemia reached been 5-10%, as determined by Giemsa stain. 





for 2 minutes and stored at -20°C. For the PCR reaction, 1µL of the parasite sample was 
added to reactions with a 50µL total volume. Reactions were conducted using a Veriti 96 
well thermal cycler (Applied Biosystems) and Phusion High-Fidelity DNA polymerase 
(Thermo Fisher Scientific, cat. #F530L). PCR products were separated on a 1.5% agarose 
gel stained with ethidium bromide for visualization.  
 
The PCR reaction volumes were as follows:  
 
Water 34.5µL 
5x Phusion HF buffer 10µL 
Forward primer (10 µM)1.5µL 
Reverse primer (10 µM) 1.5µL 
dNTPs (10mM)  1µL 
Phusion polymerase 0.5µL 
parasite lysate 1µL 
Total volume 50µL 
 
The PCR program was as follows: 
 
95°C 3.5 minutes 
95°C 30 seconds 
62°C 1 minute 
62°C 4 minutes 
4°C ∞ 
 
(steps 2 and 3 were repeated 35 times) 
 
Generation of the PfMev CLD-EcDPCK-mCherry-apt parasite line 
 In order to generate the CLD-EcDPCK-mCherry-apt plasmid, the Cam Api-
EcDPCK-mCherry plasmid was used as a starting point. This plasmid was digested with 
AvrII and BspEI in order to remove the signal and transit peptide sequence from ACP used 
to target the protein to the apicoplast, and was ethanol precipitated. The conditional 
localization domain was then amplified from another plasmid that contained this sequence 





The plasmid (pPB1) used for the generation of the PfMev CLD-EcDPCK-mCherry-apt was 
graciously provided by Dr. Krithika Rajaram (Johns Hopkins Bloomberg School of Public 
Health). This plasmid contains a bi-directional Cam/HOP promoter, with one end 
promoting the expression of the tetR-DOZI system in addition to the BSD drug resistance 
marker. The other end contained an aptamer array that can be appended to the inserted gene 
of interest. The above-mentioned CLD-EcDPCK-mCherry gene sequence was amplified 
using the same CLD F primer along with the EcDPCK CLD R primer (Table 5-9), gel 
purified, and then inserted in to the pPB1 plasmid using In-Fusion cloning. For insertion, 
the pPB1 plasmid had been previously digested with AvrII and PspOMI in the presence of 
rSAP and ethanol precipitated. This plasmid also contains an attP site, thus, in order to 
generate the PfMev CLD-EcDPCK-mCherry-apt the PfMev p230pattb parasites were 
transfected with this plasmid, along with the pINT plasmid encoding the bxb1 integrase for 
attb/attP integration.  Parasites were transfected following the standard protocol and 
selected with 2.5ng/mL blasticidin for seven days, after which drug pressure was removed. 
Parasites were observed via Giemsa stain ~20-25 days later, at which point parasites were 
again cultured in the presence of 2.5ng/mL blasticidin. 
 
Deletion of DPCK in the PfMev EcDPCK-mCherry, PfMev Api-EcDPCK-mCherry, 
and PfMev CLD-EcDPCK-mCherry-apt lines 
A DPCK specific pL8 plasmid was generated using the above-mentioned protocol. 
This plasmid contains a hDHFR drug resistance cassette, which was removed by digesting 
the plasmid with BamHI and HindIII in the presence of rSAP and ethanol precipitating it. 
The blasticidin deaminase drug resistance cassette was then amplified from a separate 





amplicon was then ethanol precipitated and inserted into the cut plasmid using In-Fusion 
cloning.  
The PfMev EcDPCK-mCherry and PfMev Api-EcDPCK-mCherry lines were then 
transfected with pL8-DPCK (BSD) plasmid along with the pUF1-Cas9 plasmid following 
the standard transfection procedure listed above. The parasites were selected with 2.5ng/mL 
blasticidin and 1.5µM DSM1 for seven days, also in the presence of 2.5nM WR99210 which 
selected for the previously integrated drug resistance cassette. After seven days, the 
2.5ng/mL blasticidin and 1.5µM DSM1 drug pressure was removed. Infected red blood cells 
were then typically seen after ~20-25 days. After parasites were observed the cultures were 
then maintained in the presence of 2.5nM WR99210 and 2.5ng/mL blasticidin.  
For deletion of DPCK in the PfMev CLD-EcDPCK-mCherry-apt, since the line was 
selected for, using 2.5ng/mL blasticidin, due to the presence of the BSD drug selectable 
marker, the original pL8 plasmid containing the DPCK homology arms flanking the hDHFR 
drug selectable marker was used. These parasites were transfected with the pL8-DPCK 
(hDHFR) plasmid along with the pUF1-Cas9 plasmid following the standard transfection 
procedure listed above. The parasites were selected with 2.5nM WR99210 and 1.5µM DSM1 
for seven days, also in the presence of 2.5ng/mL blasticidin which selected for the 
previously integrated drug resistance cassette. After seven days, the 2.5nM WR99210 and 
1.5µM DSM1 drug pressure was removed. Infected red blood cells were then typically seen 
after ~20-25 days. After parasites were observed the cultures were then maintained in the 
presence of 2.5nM WR99210 and 2.5ng/mL blasticidin. Parasites were continuously cultured 
in the presence of 0.5µM aTc from the moment of transfection and onward to allow for 






Growth curve for the PfMev CLD-EcDPCK-mCherry-apt ΔDPCK line 
(+aTc/+Shield1) 
 The PfMev CLD-EcDPCK-mCherry-apt ΔDPCK line was maintained in CMA 
media with 0.5µM aTc. To begin the growth curve the PfMev CLD-EcDPCK-mCherry-apt 
ΔDPCK parasite was washed to remove the aTc. This was done by spinning the cells at 
1,600rcf, aspirating the media, and adding 10mL of CMA, repeating this four times. These 
parasites were then used to seed two separate 75cm2 flasks, each at 1% hematocrit in a 10mL 
total volume of CMA media, and a starting parasitemia of ~0.5%. One flask was 
supplemented with 0.5µM aTc, representing the uninduced condition, while the other was 
treated with 0.5µM Shield1, representing the induced condition. The appropriate media was 
replaced approximately every 24 hours, at which point a blood-film was made, and the 
parasitemia was determined via Giemsa stain. On day four of this growth curve the 
parasitemia was cut 1:10. This experiment was done in singlicate as an initial proof of 
concept experiment in support of Figure 5-11. 
 
Pantothenate titration growth curve  
Pantothenate free media was generated, consisting of RPMI 1640 media with L-
glutamine, and without pantothenate (USBiological Life Sciences), supplemented with 
25mM HEPES, 0.2% sodium bicarbonate, 12.5µg/mL hypoxanthine, 5g/L Albumax II (Life 
Technologies) and 25µg/ml gentamicin. PfMev parasites were washed to remove the 
pantothenate. This was done by spinning the cells at 1,600rcf, aspirating the media, and 
adding 10mL of pantothenate free-media, repeating this four times. Parasites were then 
seeded in a 24-well plate at 2% hematocrit, a starting parasitemia of 0.5%, and 1mL of 





in CMA. Pantothenate was then added back to the wells containing pantothenate-free media 
at concentrations of 1nM, 10nM, 100nM, or 1µM, with one well receiving no pantothenate. 
The appropriate media was replaced approximately every 24 hours, at which point a blood-
film was made, and the parasitemia was determined via Giemsa stain. On day three of this 
growth curve the parasitemia was cut 1:10. This experiment was done in singlicate as an 
initial ranging experiment in support of Figure 5-11. 
 
Pantothenate titration for the PfMev CLD-EcDPCK-mCherry-apt ΔDPCK line 
(+aTc/+Shield1) 
The PfMev CLD-EcDPCK-mCherry-apt ΔDPCK line was regularly maintained with 
media containing 2.5nM WR99210 and 2.5ng/mL blasticidin with 0.5µM aTc. This parasite 
culture was then washed to remove the pantothenate and aTc from the culture. This was 
done by spinning the cells at 1,600rcf, aspirating the media, and adding 10mL of 
pantothenate free-media, repeating this four times. Parasites were then seeded in a 24-well 
plate at 2% hematocrit, a starting parasitemia of 0.5%, and 1mL of pantothenate free media, 
with the exception of one condition in which parasites were grown in CMA. Pantothenate 
was then added back to the wells containing pantothenate-free media at concentrations of 
10nM, 25nM, 50nM, or 100nM, with one well receiving no pantothenate. These conditions 
were set up in duplicate, in order to test permissive and non-permissive conditions at each 
concentration of pantothenate. Thus, parasites were either supplemented with 0.5µM aTc, 
representing the permissive condition, or with 0.5µM Shield1, representing the non-
permissive condition. The appropriate media was replaced approximately every 24 hours. 





stain. On day four of this growth curve the culture was cut 1:10. This experiment was done 
in singlicate as an initial ranging experiment in support of Figure 5-11.  
 
Growth curve for the PfMev CLD-EcDPCK-mCherry-apt ΔDPCK line 
(+aTc/+Shield1) under limiting pantothenate concentrations 
The PfMev CLD-EcDPCK-mCherry-apt ΔDPCK line was washed with 
pantothenate free media in order to remove the aTc and pantothenate. This was done by 
spinning the cells at 1,600rcf, aspirating the media, and adding 10mL of pantothenate free-
media, repeating this four times. Parasitemia was determined via Giemsa stain, with that 
culture then used to seed a 96-well flat bottom cell culture plate (Corning) at a 0.5% starting 
parasitemia, 2% hematocrit, and a total volume of 250µL per well in quadruplicate. 
Pantothenate free media was used, as described above, with pantothenate then added back 
to a concentration of 50nM. Two conditions were tested, with parasites either being 
supplemented with 0.5µM aTc, representing the permissive condition, or with 0.5µM 
Shield1, representing the non-permissive condition. The appropriate media was replaced 
approximately every 24 hours, at which point samples were collected for analysis via flow 
cytometry as outlined below. On day four of this growth curve the parasitemia was cut 1:10. 
In order to minimize evaporation and edge effects, the surrounding wells were filled with 
250µL of 1mM EDTA. The plates were incubated in a Modular Incubator Chamber gassed 
with 94% N2, 3% O2, 3% CO2 for 1 minute and 15 seconds, and incubated at 37°C. This 
experimental setup was also used to generate a growth curve for the apicoplast minus PfMev 
CLD-EcDPCK-mCherry-apt ΔDPCK parasite line, the only difference being the addition of 






Inducing apicoplast loss in the PfMev CLD-EcDPCK-mCherry-apt ΔDPCK parasite 
line 
The PfMev CLD-EcDPCK-mCherry-aptamer ΔDPCK line was cultured in media 
containing 100nM azithromycin in the presence of 50µM mevalonate for 7 days. After 7 
days, the parasites were cultured continuously in the presence of 50µM mevalonate. Loss of 
the apicoplast was confirmed via PCR using the methods described above.  
 
Testing mevalonate dependence in PfMev deletion mutants via growth curve 
For each of the PfMev deletion lines, the parasitemia was determined via Gimesa 
stain, with the appropriate amount of the parental culture removed to seed quadruplicate 
samples with or without mevalonate. This volume was resuspended in a total of 10mL CMA 
and centrifuged at 1,600rcf at room temperature (~25°C) for 5 minutes, washed a second 
time with an additional 10mL CMA, and then resuspended in the appropriate volume of 
CMA, and then split equally into two tubes. To one of the tubes, the appropriate volume of 
a 10mM stock of mevalonate was added to bring to final concentration to 50µM mevalonate. 
Parasites were seeded in a 96-well plate at 0.5% starting parasitemia, 2% hematocrit, and at a 
total volume of 250µL per well in quadruplicate. Additionally, 150µL of the appropriate 
media was replaced in each well on days 1, 2, and 3. Parasite samples were collected every 24 
hours for four days, and the parasitemia was counted via SYBR green staining and flow-
cytometry as outlined below. 
 
Flow cytometry for parasite growth curve determination  
Growth curves were generated by staining parasites with SYBR Green and counting 





starting culture was determined via Giemsa stain. Based on the determined parasitemia the 
culture was used to seed a 96-well flat bottom cell culture plate (Corning) at a 0.5% starting 
parasitemia and 2% hematocrit, at a total volume of 250µL in quadruplicate. In order to 
minimize evaporation and edge effects, the surrounding wells were filled with 250µL of 
1mM EDTA. Plates were incubated in chambers gassed with 94% N2, 3% O2, 3% CO2 for 1 
minute and 15 seconds, and incubated at 37°C.  
Parasite samples were collected immediately after seeding and analyzed via flow 
cytometry to verify the starting parasitemia and then collected every 24 hours thereafter. 
Samples collected on days 1-3 were diluted 1:10 in phosphate-buffered saline (PBS) and 
stored in a 96-well plate (Corning) at 4°C. We have previously verified that storage under 
these conditions and subsequent staining with SYBR Green reflects accurate parasitemia 
values.  
 On day 4 parasites were stained with SYBR Green by transferring 1µL of parasite 
culture, or 10µL of the 1:10 dilutions (the day 1-3 samples), to a 96-well plate containing 
100µL of 1x SYBR Green (Invitrogen) in PBS. The samples were then incubated for 30 
minutes on a platform Titramax 101 shaker (Heidolph) at 950rpm while protected from 
light. Post-incubation, 150µL of PBS was added to each well to dilute unbound SYBR Green 
dye. A control consisting of uninfected RBCs was also prepared in parallel and treated in the 
same manner as listed above.  
 Samples were analyzed with an Attune Nxt Flow Cytometer (Thermo Fisher 
Scientific). With a 50µL acquisition volume, 250µL total sample volume, and a running speed 
of 25µL/minute with 10,000 total events were collected within the R2 gate. 
 For flow cytometer gating, the R1 gate used forward-scatter area by side-scatter area 





single cells, and the R3 gate was used to measure parasitemia using fluorescence from the 




















































Figure 5-1 Generation of CoA and utilization in the apicoplast 
P. falciparum parasites are believed to be reliant on scavenged pantothenate to generate CoA. 
The generation of CoA occurs through a series of enzymes within the cytosol (PanK, PPCS, 
PPCDC, and PPAT). The final step involving the conversion of dephospho-CoA to CoA by 
DPCK is believed to occur within the apicoplast. CoA is utilized within the organelle to 
modify apo-ACP into holo-ACP, which is involved in the FASII fatty acid biosynthesis 
pathway. The CoA produced within the apicoplast is also believed to be exported for 















Figure 5-2 Co-localization of DPCK-mCherry with apicoplast marker api-SFG 
Live fluorescent microscopy of four different PfMev parasites expressing api-SFG (green), 
the P. falciparum DPCK-mCherry protein (red), and also stained with DAPI (blue).                    


























40 days 50µM mev. No 
pUF1-Cas9/pL8-DPCK-HA1/2+g 
(8N16) 
40 days 50µM mev. No 
pUF1-Cas9/pL8-DPCK-HA1/2+g 
(16N16) 
40 days 50µM mev. No 
pUF1-Cas9/pL8-DPCK-HA1/2+g 
(28N16) 
40 days 50µM mev. No 
pUF1-Cas9/pL8-DPCK-HA1/2+g 
(5j17) 









Table 5-2 DPCK Transfection Attempts 
We attempted to knockout the dephospho-CoA kinase (DPCK) gene in the PfMev parasite 
line in the presence of 50µM mevalonate. In none of the six independent transfections were 
we successful in deleting the DPCK gene, even in the two attempts in which the parasites 





























Figure 5-3 E. coli DPCK complementation in the apicoplast and deletion of DPCK 
A.) Construct used to express E. coli DPCK in the apicoplast with an N-terminal signal 
sequence from ACP, and a C-terminal mCherry tag. 
B.) Live epifluorescence microscopy of PfMev parasites expressing api-SFG (green), the Api-
EcDPCK-mCherry construct (red), and also stained with DAPI (blue).                    
C.) Genotyping PCR confirming the deletion of the endogenous DPCK, with amplification 
demonstrating integration at the Δ5’ and Δ3’ loci, and lack of wild type parasites due to 
failure to amplify at the wild type 5’ and 3’ loci, as compared to the parental control.  
D.) Live epifluorescence microscopy of the PfMev Api-EcDPCK-mCherry ΔDPCK parasite 
line expressing api-SFG (green), the Api-EcDPCK-mCherry construct (red), and also stained 
with DAPI (blue), with co-localization seen between the api-SFG and Api-EcDPCK-







Figure 5-4 Azithromycin treatment of PfMev-asfg Api-Ec-DPCK-mCherry ΔDPCK 
parasites 
A.) Live epifluorescence microscopy of the PfMev Api-EcDPCK-mCherry ΔDPCK line 
treated with 1x azithromycin for 7 days under supplementation with 50µM mevalonate. This 
parasite line expresses api-SFG (green), the Api-EcDPCK-mCherry construct (red), and is 
also stained with DAPI (blue). The api-SFG and Api-EcDPCK-mCherry proteins appear to 
be co-localized in these parasites after apicoplast disruption. 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We failed to amplify SufB from 
the PfMev Api-Ec-DPCK-mCherry ΔDPCK parasites, indicating loss of the apicoplast 
organellar genome.  














Figure 5-5 E. coli DPCK complementation in the cytosol and deletion of DPCK 
A.) Construct used to express the E. coli DPCK protein with a C-terminal mCherry tag in the 
cytosol of the PfMev parasite line. 
B.) Live epifluorescence microscopy of the PfMev EcDPCK-mCherry line. This parasite line 
is expressing api-SFG (green), the EcDPCK-mCherry construct (red), and also stained with 
DAPI (blue).  
C.) Genotyping PCR confirming the deletion of the endogenous DPCK, with amplification 
demonstrating integration at the Δ5’ and Δ3’ loci, and lack of wild type parasites due to 
failure to amplify at the wild type 5’ and 3’ loci, as compared to the parental control.  
D.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We were successful in 





continuous supplementation with 50µM mevalonate, indicating retention of the apicoplast 
organelle genome.  
E.) Live epifluorescence microscopy of the PfMev api-SFG EcDPCK-mCherry ΔDPCK 
line. This parasite line expresses api-SFG (green), the EcDPCK-mCherry construct (red), and 
is also stained with DAPI (blue).  










































Figure 5-6 Generation of the PfMev CLD-EcDPCK-mCherry-aptamer line and 
deletion of DPCK 
A.) Construct used to generate PfMev CLD-EcDPCK-mCherry-aptamer parasite line 
B.) Live epifluorescence microscopy of the PfMev CLD-EcDPCK-mCherry-aptamer line. 
This parasite line is expressing api-SFG (green), the CLD-EcDPCK-mCherry protein (red), 
and also stained with DAPI (blue). 
C.) Genotyping PCR confirming the deletion of the endogenous DPCK, with amplification 
demonstrating integration at the Δ5’ and Δ3’ loci, and lack of wild type parasites due to 
failure to amplify at the wild type 5’ and 3’ loci, as compared to the parental control. 















Figure 5-7 Testing protein knockdown and mislocalization in the PfMev CLD-
EcDPCK-mCherry-apt parasite line 
A.) The PfMev CLD-EcDPCK-mCherry-apt parasite line grown in the presence of 0.5µM 
aTc. 
B.) The PfMev CLD-EcDPCK-mCherry-apt parasite line grown in the absence of aTc for 48 
hours. 
C.) The PfMev CLD-EcDPCK-mCherry-apt parasite line grown in the presence of 0.5µM 
aTc, and in the presence of 0.5µM Shield1 for 48 hours. 
D.) The PfMev CLD-EcDPCK-mCherry-apt parasite line grown in the absence of aTc, and 
in the presence of 0.5µM Shield1 for 48 hours. 











Figure 5-8 Growth of the PfMev CLD-EcDPCK-mCherry-apt ΔDPCK parasite line 
under permissive and non-permissive conditions 
Growth curve of the PfMev-CLD-EcDPCK-mCherry-aptamer ΔDPCK parasite line grown 
either in the permissive state (absence of 0.5µM aTc and the presence of 0.5µM Shield1), or 
the non-permissive state (presence of 0.5µM aTc and the absence 0.5µM Shield1). Parasites 
were seeded at ~0.5% parasitemia and then cut 1:10 on day 4. Parasites had the media 
exchanged every 24 hours, at which time a blood film was made, and parasitemia was 
determined via Giemsa stain. This experiment was done in singlicate as an initial proof of 






























Figure 5-9 Titration of pantothenate affecting the growth of the PfMev parasite line 
PfMev parasites were seeded at ~0.5% parasitemia and grown in media containing either 
0nM, 1nM, 10nM, 100nM, or 1µM of pantothenate, also with parasites grown in CMA as a 
control. Parasite media was refreshed every 24 hours, at which time a blood film was made, 
and parasitemia was determined via Giemsa stain. All parasite cultures were cut 1:10 on day  
3. This experiment was done in singlicate as an initial ranging experiment in support of the 
































Figure 5-10 Titration of pantothenate affecting the growth of the PfMev CLD-
EcDPCK-mCherry-apt ΔDPCK parasite line under permissive and non-permissive 
conditions 
Growth curve of the PfMev CLD-EcDPCK-mCherry-aptamer ΔDPCK parasite line grown 
either in the presence of 0.5µM aTc and the absence 0.5µM Shield1 (permissive condition, 
blue), or the absence of 0.5µM aTc and the presence of 0.5µM Shield1 (non-permissive 
condition, red). Parasites were also grown at varying concentrations of pantothenate, 
including either 10nM, 25nM, 50nM, 100nM, or grown in 0nM pantothenate as a negative 
control, and CMA as a positive control. Parasites were seeded at ~0.5% parasitemia, with 
media exchanged every 24 hours. Every 48 hours a blood film was made, and parasitemia 
was determined via Giemsa stain. All parasite cultures were cut 1:10 on day 4. These 
experiments were done in singlicate as an initial ranging experiment in support of the final 








Figure 5-11 Growth curve of PfMev CLD-EcDPCK-mCherry-apt ΔDPCK parasite 
line under permissive and non-permissive conditions at 50nM pantothenate 
Growth curve of the PfMev CLD-EcDPCK-mCherry-apt ΔDPCK parasite line grown either 
in the presence of 0.5µM aTc and the absence 0.5µM Shield1 (permissive condition, blue), or 
the absence of 0.5µM aTc and the presence of 0.5µM Shield1 (non-permissive condition, 
red). All parasite lines were also grown at a concentration of 50nM pantothenate. Parasites 
were collected during daily media exchanges for determination of parasitemia by flow 
cytometry. Parasite cultures were cut 1:10 on day 4. Error bars represent the SEM of 




































Figure 5-12 Azithromycin treatment of PfMev CLD-EcDPCK-mCherry-apt ΔDPCK 
parasite line 
A.) Live epifluorescence microscopy of the apicoplast negative PfMev CLD-EcDPCK-
mCherry-apt ΔDPCK line post treatment with 100nM azithromycin in the presence of 
50µM mevalonate. This parasite line expresses Api-SFG (green), the CLD-EcDPCK-
mCherry construct (red), and is also stained with DAPI (blue). Images are 10µM long by 
10µM wide. 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We were unsuccessful in 
amplifying SufB from the PfMev CLD-EcDPCK-mCherry-apt ΔDPCK parasite line after 
treatment with 100nM azithromycin in the presence of 50µM mevalonate, indicating 















Figure 5-13 Growth curve of the azithromycin-treated PfMev CLD-EcDPCK-
mCherry-aptamer ΔDPCK parasite line under permissive and non-permissive 
conditions at 50nM pantothenate 
Growth curve of the PfMev CLD-EcDPCK-mCherry-aptamer ΔDPCK parasite line 
containing a disrupted apicoplast, grown either in the presence of 0.5µM aTc and the 
absence 0.5µM Shield1 (permissive condition, blue), or the absence of 0.5µM aTc and the 
presence of 0.5µM Shield1 (non-permissive condition, red). All parasite lines were also 
grown at a concentration of 50nM pantothenate and 50µM mevalonate. Parasites were 
collected during daily media exchanges for determination of parasitemia by flow cytometry. 
Parasite cultures were cut 1:10 on day 4. Error bars represent the SEM of duplicate 







Figure 5-14 Characterization of the PfMev ΔACP parasite line 
A.) Genotyping PCR confirming the deletion of ACP, with amplification demonstrating 
integration at the Δ5’ and Δ3’ loci, and lack of wild type parasites due to failure to amplify at 
the wild type 5’ and 3’ loci, as compared to the parental control.  
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We failed to amplify SufB from 
the PfMev ΔACP parasite line, indicating loss of the apicoplast organelle genome.  
C.) Live fluorescence microscopy of the PfMev ΔACP parasite line. This parasite line is 
expressing api-SFG (green), and is also stained with MitoTracker (red), and DAPI (blue).  














Figure 5-15 Characterization of the PfMev ΔACP-S parasite line 
A.) Genotyping PCR confirming the deletion of ACP-S, with amplification demonstrating 
integration at the Δ5’ and Δ3’ loci, and lack of wild type parasites due to failure to amplify at 
the wild type 5’ and 3’ loci, as compared to the parental control. 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We failed in attempting to 
amplify SufB from the PfMev ΔACP-S parasite line, indicating loss of the apicoplast 
organelle genome.  
C.) Live fluorescence microscopy of the PfMev ΔACP-S parasite line. This parasite line is 
expressing api-SFG (green), and is also stained with MitoTracker (red), and DAPI (blue). 










Figure 5-16 Characterization of the PfMev ΔFabD parasite line 
A.) Genotyping PCR confirming the deletion of FabD, with amplification demonstrating 
integration at the Δ5’ and Δ3’ loci, and lack of wild type parasites due to failure to amplify at 
the wild type 5’ and 3’ loci, as compared to the parental control. 
B.) PCR detection of the lactate dehydrogenase, SufB, and Cox1 genes from the nuclear (N), 
apicoplast (A), and mitochondrial (M) genomes, respectively. We were successful in 
amplifying SufB from the PfMev ΔFabD parasite line, indicating retention of the apicoplast 
organelle genome.  
C.) Live fluorescence microscopy of the PfMev ΔFabD parasite line. This parasite line is 
expressing api-SFG (green), and is also stained with MitoTracker (red), and DAPI (blue). 






























































Table 5-4 Primer used for detecting the nuclear and organellar genomes 
 
Primer Name Primer Sequence 
LDH F GGAGATGTAGTTTTGTTCGATATTG 
LDH R CTTGTAAAGGGATACCACCTACAG 
SufB F CATGTAGCTATAGTAGAAATAATAGTAAAAGATTATGG  
SufB R GACTCTGAAATACTTAAACCACGTTGC 
Cox1 F CTTCATCTTTAAGAATAATTGCACAAGAAAATGTAAATC 





































Table 5-5 Primers for the generation of the E. coli complementation plasmids 
 
Primer Name Primer Sequence 
hDHFR F CCTAATAGAAATATATCAGGATCCATGCATGGTTCGCTAAACT 
hDHFR R AATCTATTATTAAATAAGCTTAATCATTCTTCTCATATACTTCA 
EcDPCK F CCTAATAGAAATATATCACCTAGGATGAGGTATATAGTTGCCTTAACGGGAGG 
EcDPCK R CCTCCTCGCCCTTGCTCGTACGCGGTTTTTCCTGTGAGACAAACTGC 
CamEcmCry F TTTTAATTTTTTTTACAACCTAGGATGAGGTATATAGTTGCCT 
CamEcmCry R TATATTATATAACTCGACCTTAAGCTCGAGTTACTTGTACAGCTCGTCC 
pLN.Api55 F GAAATATATCACCTAGGATGAAGATCTTATTACTTTGTATAAT 
pLN.Api55 R AACTATATACCTCATCCTAGGATGTGGGTTTTTATTTTTTATC 
CamApEcDpmC F TTAATTTTTTTTACAACCTAGGATGAAGATCTTATTACTTTGT 
CamApEcDpmC R TATATTATATAACTCGACCTTAAGCTCGAGTTACTTGTACAGCTCGTCC 
pRsBSD F ACCTAATAGAAATATATCAGGATCCATGGCAAAACCTTTG 


























Table 5-6 Primer sequences used for amplifying homology arms 
  
Primer Name Primer Sequence 
ACP HA1 F GCCACGAGCGGCCTGAAGTATATATCCACGTCCATAACAG 
ACP HA1 R AAGCGCAGCGGCCCCATCTTTTTGTGTATTTTTAAAAGCT 
ACP HA2 F CGACAGACGCCGGGGTACAAAAAAATAAAATGATACACAA 
ACP HA2 R GGCCACCAGCCGGGGGATACATTTTAACAAAGAAGAAATA 
ACP-S HA1 F GCCACGAGCGGCCCCAGGAGTTCACACACATAATAGATTG 
ACP-S HA1 R AAGCGCAGCGGCCATTCGGCATTTGTTTTTGTATTCAATG 
ACP-S HA2 F CGACAGACGCCGGGAGGGGTCAATAAATTGTTTTCCAATA 
ACP-S HA2 R GGCCACCAGCCGGACCCTCTACCAATAGATTTGACGATAG 
FabD HA1 F GCCACGAGCGGCCACACTCACACTCACACTCACATTATCC 
FabD HA1 R AAGCGCAGCGGCCACGACCCTATCTTATTTGTATTCTCCT 
FabD HA2 F CGACAGACGCCGGGTGGAAAACCAGAATCTATGGATTATC 
































gRNA F TAAGTATATAATATTAATGAACTCAAATTTTACCAGTTTTAGAGCTAGAA 
ACP 
gRNA R TTCTAGCTCTAAAACTGGTAAAATTTGAGTTCATTAATATTATATACTTA 
ACP-S 
gRNA F TAAGTATATAATATTTAAAATATTGAACCCACGAGGTTTTAGAGCTAGAA 
ACP-S 
gRNA R TTCTAGCTCTAAAACCTCGTGGGTTCAATATTTTAAATATTATATACTTA 
FabD 
gRNA F TAAGTATATAATATTGATAGAAAATTTGGTTTATGGTTTTAGAGCTAGAA  
FabD 






























Table 5-8 Primer sequences used for confirmation of gene deletions 
  
Primer Name Primer Sequence 
pl8insHA1R TACAAAATGCTTAAGCGCAGCGGCC 
pl8insHA2F CATATTTATTAAATCTAGAATTCGACAGACGCCG 
ACP 5' F CCTATGTTTGTGTACTTTTTTTTTTCCCC 
ACP 3'R CATACATAAATATATGAACATTTTTATAAAGAGGTAAC 
ACP 5' WT R GGTTGCTTCTTTTCTTTTTTAATATTTGTAAG 
ACP 3' WT F CCCATCTAGCTCTTTAAAAAGTACTTTTG 
ACP-S 5’F GTAATATTTGTGGATATATATTTCTTTACATACCTTGC 
ACP-S 3’R CCTAATTGTCTAGCTATTTTTTTTGCTTTG 
ACP-S 5’WT R GTAATATCATTTCTCTTACAAAAAGAAGATAAAATATTC 
ACP-S 3’ WT F CAGAACAAGTTGTAATGTTTATGATATTAGTGTTG 
FabD 5’F GAGAAGATATATTAAAAGAGAAATTTTTTTTTTTTTTTCG 
FabD 3’R CTTTAAAATATAAAATATACTTTTTTTGTCAATTTGTAAG 
FabD 5’ WT R TTCCTTTTATATCTTTATTTACACTAACATTATGTCTAAG 























Table 5-9 Primers used for the generation of the CLD-EcDPCK-mCherry-apt line 
 
Primer Name Primer Sequence 
CLD F TTAATTTTTTTTACAACCTAGGATGAAGATCTTATTACTTTGTATAATTTTT
CT 
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Future Applications of the PfMev Line 
 The creation and utilization of the PfMev apicoplast bypass line was critical to much 
of the work outlined in this thesis, offering an exceedingly user-friendly platform in which to 
investigate essential biochemical processes within the apicoplast. This line represents a 
significant improvement to the previously used IPP chemical bypass system due to the 
reduced cost, the greater chemical stability of the molecule used for supplementation, in 
addition to the ability for apicoplast-negative parasites to easily survive cryopreservation and 
grow at wild-type levels under mevalonate supplementation. The ability to cryopreserve is 
especially critical, as it allows for the future analysis of lines that are generated either within 
the lab of origin or throughout the scientific community, in addition to making larger-scale 
and longer-term experiments more tenable. Furthermore, the method in which the PfMev 
line was generated did not rely on any of the currently used drug resistance cassettes, 
allowing for the application of previously established plasmid systems and the ability to 
conduct experiments that rely on multiple selection cassettes. We hope that these 
improvements will result in the wide-spread adoption of this line, and help in furthering 
research into the apicoplast organelle.  
 We were able to demonstrate that the PfMev line can be used for the facile deletion 
of essential apicoplast-specific genes, in addition to offering a read-out of the resulting 
apicoplast phenotype, due to the fluorescent labelling of the organelle. This allows for the 
determination of which apicoplast-specific genes are essential for parasite survival, in 
addition to being able to determine which are required for the maintenance of the organelle. 
As mentioned previously, there have been no published genetic deletions of any essential 
apicoplast-specific genes since the development of the chemical bypass system, likely due to 





were successful in deleting multiple apicoplast-specific genes, and were able to determine 
their requirement for parasite survival and the maintenance of the organelle. While we were 
able to do this for over 20 genes, this represents a just a small fraction of the over ~400 
proteins that are predicted to be trafficked to the organelle that could still be explored [36]–
[39].  
 There are likely to be tens or even hundreds of apicoplast-specific genes that are 
essential for apicoplast maintenance or replication that are yet to be discovered and 
characterized. Many of these are likely to be playing essential roles within the apicoplast, 
critical to processes such as transcription, translation, organelle genome replication, protein 
trafficking to the organelle, protein import and processing, the import and export of 
biomolecules, the generation of essential cofactors, and the replication and division of the 
organelle, among others. However, of the ~400 proteins predicted to be trafficked to the 
organelle [36]–[39], approximately half are annotated as having no known function, 
highlighting how much more work there is to be done in investigating this unusual organelle 
(6). To this end, the PfMev line could help elucidate which apicoplast-specific genes are 
required for parasite survival and organelle maintenance using a higher-throughput method 
than targeted gene deletions, such as a forward genetic screen. Forward genetic screens have 
already been adapted for use in P. falciparum including PiggyBac insertional mutagenesis (7) 
and chemical mutagenesis screens (8).  
 The PfMev line could also be used for drug target identification and validation, by 
screening compound libraries against P. falciparum parasites and determining which display 
differential drug activity in the presence or absence of mevalonate supplementation. This 
would help in better elucidating the mechanism of action of the drug, by determining if the 





absence of mevalonate would provide a measure of the apicoplast-specificity of any 
particular drug. Efforts such as these have been attempted already using the IPP chemical 
bypass system, in a screen against a limited number of compounds (9). However, the 
reduced cost of mevalonate and greater ease of usage with the PfMev line would make 
screening much larger compound libraries more feasible.  
 Furthermore, the parasite line that we used to generate the PfMev line is not 
competent in generating infectious gametocytes. Future efforts could introduce this bypass 
system into a line capable of forming gametocytes. This could allow for the investigation of 
apicoplast-specific genes in other stages of the parasite lifecycle, including 
gametocytogenesis, the various mosquito stages, including gamete activation, and formation 
of the zygote, ookinete, oocyst, or sporozoite, in addition to the liver stage of the parasite.   
 
Iron-sulfur Cluster Biosynthesis, Sulfur Utilization, and tRNA Modification within 
the Apicoplast 
 The impetus for this work was originally driven by the finding that the expression of 
a SufC (K140A) dominant negative mutant resulted in the disruption of the apicoplast under 
IPP supplementation (10). We wanted to follow up on this by attempting to determine the 
ultimate mechanism by which the loss of iron-sulfur clusters results in this phenotype by 
making targeted deletions of the iron-sulfur cluster dependent proteins. However, we 
determined that none of the iron-sulfur cluster dependent proteins, and that none of the 
proteins in the SUF iron-sulfur cluster biosynthetic pathway, with the exception of the 
cysteine desulfurase SufS, are required for the maintenance of the apicoplast. We then 





while iron-sulfur clusters are not essential for apicoplast maintenance, the generation of 
sulfur by SufS, and its utilization by the tRNA modifying enzyme MnmA likely is.  
 These results obviously contradicted what was previously found, which suggested 
that iron-sulfur cluster biosynthesis and SufC were required for the maintenance and 
replication of the apicoplast. While the results of the previous work are not in question, the 
mechanism by which expression of the SufC (K140A) dominant negative mutant resulted in 
loss of the organelle is unclear. It was speculated in chapter 3 of this thesis that this may be 
due to the detrimental effects associated with high concentrations of IPP or through other 
potential mechanisms. However, in comparison to a dominant negative mutant, the genetic 
deletion of SufC clearly illustrates that its biochemical activity is not required for the 
maintenance of the organelle. Furthermore, we were able to demonstrate that iron-sulfur 
cluster generation in general is not essential for organelle maintenance through the deletion 
of additional proteins within the SUF pathway. This clarification is likely important to the 
field, as this paper has been cited over 50 times since it was originally published.  
 In this work, we targeted all of the predicted iron-sulfur cluster dependent proteins, 
in addition to all of the nuclear-encoded components of the SUF pathway for deletion in our 
PfMev line under mevalonate supplementation. We were able to conclusively demonstrate 
which of these proteins are essential for blood-stage parasite survival, in addition to which 
are required for organelle maintenance and replication. Through these deletions we were also 
able to generate important insights into this pathway, more conclusively showing that the 
SufA and NifU iron-sulfur cluster transfer proteins are functionally redundant as previously 
hypothesized (11, 12). We additionally were also able to demonstrate that SufE is likely not 
necessarily required for the cysteine desulfurase activity of SufS, or the transfer of sulfur to 





 Our results suggest that the requirement of SufS for organelle maintenance is not 
driven by its requirement for iron-sulfur cluster biosynthesis, but instead its ability to 
generate sulfur for another purpose. In general, sulfur generated by cysteine desulfurase 
enzymes can be utilized by a variety of biochemical pathways, such as the biosynthesis of 
thiamine, biotin, lipoic acid, molybdopterin, in addition to the sulfur modifications of tRNAs 
(13). Our bioinformatic analysis and genetic studies indicate that the essentiality of the 
parasite SufS is most likely driven by its role in generating sulfur for usage by the tRNA 
modifying enzyme MnmA.  
 As mentioned previously in this work, MnmA is an extremely conserved gene, 
present even in the most reduced bacterial genomes (14–17). tRNA modifications in general 
are ubiquitous throughout life, and play a critical role in protein translation (18–20). The 
apicoplast of P. falciparum is interesting in this regard because it produces all of the required 
tRNAs needed for translation within the organelle, and is not predicted to import any 
additional tRNAs (21). Thus, all tRNA modifications are likely to occur within the organelle, 
making the apicoplast an interesting system in which to study the minimal set of tRNA 
modifications required for accurate translation in vivo. Within the apicoplast the tRNA 
modifying enzymes MiaA and MiaB are predicted to be present, as described previously (1). 
MnmA is also predicted to be present within the apicoplast (1). MnmA in many bacterial 
organisms is part of a larger tRNA modification pathway involving the additional enzymes 
MnmC, MnmE, and MnmG (22, 23). In addition to MnmA, MnmE and MnmG are also 
predicted to be present within the P. falciparum genome. All three enzymes are predicted to 
be trafficked to the apicoplast (5), and are also predicted to be essential as determined by a 
forward genetic screen conducted by Dr. John Adams (7). MnmA and MnmG are also 





Thus, further investigation into these enzymes and the tRNA modifications present within 
the apicoplast represent an important area of further research.  
 It should be noted that many of these conclusions are largely speculative due to the 
fact that the putative P. falciparum MnmA (PF3D7_1019800) has not been functionally 
validated, and its activity as tRNA-specific 2-thiouridylase has not been proven 
biochemically. In fact, the putative P. falciparum MnmA is currently annotated as a tRNA 
methyltransferase in PlasmoDB. In order to validate the activity of this enzyme, future 
experiments could express the putative P. falciparum MnmA in MnmA deficient E. coli and 
attempt to detect the nucleobases that should be modified by this enzyme using LC-MS (25). 
Additionally, this protein could be used to complement MnmA deficient E. coli, which 
should rescue their slow-growth phenotype if it is able to compensate for the activity of the 
deleted endogenous MnmA (25). The P. falciparum MnmA also merits further research, due 
to the potential complexity of the protein. The E. coli MnmA is 368 amino acids in length, 
while the P. falciparum MnmA is 1,084 amino acids in length. While there is a domain within 
putative the P. falciparum MnmA that shows homology to other MnmA proteins, this 
represents just a portion of the overall protein, which may have additional functionality 
unrelated to its proposed role as a tRNA modifying enzyme that deserves to be investigated.   
 Lastly, the mechanism by which the absence of MnmA ultimately results in organelle 
disruption has not been elucidated. In other systems MnmA has been shown to be 
important for tRNA-ribosome binding (26), wobble codon recognition (27, 28), reading 
frame maintenance (29), and the reduction of frameshifts and missense errors (30–32). The 
essential role that it may be playing within the apicoplast, and the mechanism by which its 





 Overall, we have been able to demonstrate that the majority of proteins within the 
SUF pathway in addition to MnmA are essential for blood-stage parasite survival. These 
proteins are also closely related to bacterial orthologs (33, 34), and deserve to be studied 
further to investigate their suitability as drug targets.  
 
Carbon Metabolism, Energy, Reducing Power, and NTP/dNTP Generation within 
the Apicoplast 
 To fuel anabolic pathways within the apicoplast, carbon backbones, energy, and 
reducing power is required. However, there are many gaps in our understanding of how the 
apicoplast meets these needs.  
 Several enzymes in the apicoplast require reduced nicotinamide adenine 
dinucleotides (NADH or NADPH) for enzymatic activity.  Our results show that the 
ferredoxin/ferredoxin reductase system is essential, and it is known from biochemical assays 
that P. falciparum ferredoxin reductase requires NADPH for activity (35). The 
ferredoxin/ferredoxin reductase system is central to apicoplast metabolism and is predicted 
to deliver reducing equivalents to LipA, NifU, MiaB, IspG and IspH (1, 36–38). However, 
the source of reducing power within the apicoplast is unclear. One potential source is the 
triose phosphate isomerase (TPI) / glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
cycle, in which imported DHAP is converted by TPI to form GA3P, which in turn is 
converted into 1,3-diphosphoglycerate (1,3-DPGA) by GAPDH, reducing NADP+ to 
NADPH in the process (39, 40). The 1,3-DPGA can then presumably be exchanged for 
DHAP by the triose phosphate transporters, creating an electron shuttle (39). However, we 
have been able to demonstrate that TPI is dispensable in blood-stage parasites. In the 





the organelle, but GAPDH has been shown to be localized to the cytosol and is not 
predicted to be localized to the apicoplast (41). This cycle would provide the only predicted 
source of NADPH within the apicoplast, but it does not appear to be present or active 
within the apicoplast (1). Thus, it is predicted that the apicoplast may rely wholly on NADH 
for reducing power (1). In the apicoplast the only known source of NADH, and thus 
potentially all reducing power in the organelle is generated by the decarboxylation of 
pyruvate into acetyl-CoA by the pyruvate dehydrogenase (PDH) complex (42). However, we 
were successful in deleting the PDH E2 subunit, and previous studies have been successful 
in deleting the PDH e1α subunit (43). Thus, the source of reducing power within the 
apicoplast remains unclear, and is deserving of further inquiry. It may be interesting to create 
a dual deletion of the PDH E2 subunit along with TPI to eliminate all predicted sources of 
reducing power within the apicoplast in the PfMev line under mevalonate supplementation 
to determine if together these genes are essential for parasite survival and apicoplast 
maintenance.  
 Another outstanding question is the source of energy in the form of ATP in the 
apicoplast, in addition to the source of all NTPs and dNTPs within the organelle. PyrKII is 
the only predicted source of ATP within the apicoplast, and no NTP transporters that are 
predicted to localize to the apicoplast have been identified (1). PyrKII is predicted to be 
involved in the conversion of PEP and ADP into ATP and pyruvate, with that pyruvate 
being fed into the FasII and MEP isoprenoid precursor pathways (1, 44). We were successful 
in deleting PyrKII in our PfMev line under mevalonate supplementation and were able to 
show that it is essential for the maintenance and replication of the apicoplast. Following up 
on this, we made deletions in the pathways reliant on pyruvate, but these deletions did not 





utilization of pyruvate is not required for organelle maintenance, but that the generation of 
ATP likely is. Since there is no other known source of NTPs within the organelle, we 
hypothesized that PyrKII may be capable of generating all NTPs/dNTPs within the 
apicoplast. This would not be unprecedented as pyruvate kinase enzymes have been 
previously demonstrated to be active against multiple different NDPs often with very low 
substrate specificity (45–48). Additionally, in other systems pyruvate kinase enzymes are 
believed to play an import role in the generation of nucleoside triphosphates, and may 
function as a competent substitute for nucleoside diphosphate kinase (46). Thus, we tested 
the enzyme activity of the P. falciparum PyrKII and showed that it did not have any strong 
substrate preferences, indicating that it may be capable of generating all NTPs/dNTPs 
within the apicoplast. Additionally, were also able to mislocalize PyrKII away from the 
apicoplast and measure mRNA levels within the organelle as a proxy for NTP levels, and 
observed a sharp drop in transcript levels, helping to bolster this hypothesis.  
 While the above results suggest that PyrKII is essential within the apicoplast due to 
its function in generating NTPs, and may be potentially be responsible for the generation of 
all NTPs/dNTPs within the cell, the results are not entirely conclusive. We have not tracked 
the incorporation of NTP products generated by PyrKII into parasite mRNA. Additional 
experiments could be conducted in order to follow up and confirm the ultimate mechanism 
by which deletion of PyrKII results in loss of the apicoplast organelle. For example, one 
could attempt to complement PyrKII with a different pyruvate kinase enzyme that shows a 
high substrate specificity for a single NDP, helping to demonstrate that the low substrate 
specificity of the endogenous PyrKII is an essential feature of the enzyme. Additionally, 
there is the chance that PyrKII is essential for apicoplast maintenance due to some function 





the parasite with a catalytically dead PyrKII to determine if the apicoplast loss phenotype is 
replicated.  
 Based on our results, PyrKII appears to be essential for parasite survival in addition 
to apicoplast maintenance and replication. Additionally, pyruvate kinase II enzymes are 
evolutionary distinct, and appear to occur only within Apicomplexans, and thus may 
represent attractive and viable drug targets (49). To this end, enzymatic assays have already 
been developed to screen small molecule inhibitors against pyruvate kinase enzymes, with 
over 100,000 small molecules screened in a single publication (50). Research in other systems 
have already identified drugs that are active against other pyruvate kinase enzymes that work 
to clear pathogenic infections (51, 52). These same assays could be applied to the P. 
falciparum PyrKII as well. Additionally, to further drug discovery efforts, the crystal structure 
of PyrKII could be useful, which is an endeavor that our lab has been pursuing.  
 
The Role of the Apicoplast in CoA Generation and Utilization  
 CoA was expected to be essential for parasite survival since it was discovered that 
parasites are reliant on exogenous pantothenate decades ago (53, 54). This hypothesis was 
supported by studies demonstrating that pantothenate analogs inhibit this pathway and result 
in parasite death (55–57). Additionally, studies demonstrate that certain enzymes within this 
pathway are refractory to deletion (58–60). We were able to add to this body of knowledge 
by more fully demonstrating that the last step of this pathway, mediated by the enzyme 
dephospho-CoA kinase (DPCK), is essential for parasite survival. We showed that DPCK 
could only be deleted when the parasites were functionally complemented with the E. coli 
DPCK, and that the subsequent knockdown of DPCK activity resulted in parasites failing to 





 Other than its essentiality, DPCK has remained an interesting enzyme due to its 
proposed localization to the apicoplast organelle (1). Previous work demonstrated that the 
apicoplast is dispensable in blood-stage parasites if IPP is supplemented in sufficient 
quantities (61). The resulting interpretation has been that the essentiality all proteins and 
pathways within the apicoplast can be bypassed in blood-stage parasites when IPP is 
provided. However, this is puzzling due to the requirement of CoA for parasite survival, 
which cannot be bypassed by IPP. The disrupted apicoplast phenotype results in loss of the 
apicoplast genome and the presence of vesicles within the cell that presumably contain 
proteins destined for the once present apicoplast (10, 61, 62). Thus, we hypothesized that 
DPCK remains active in vesicles, and were able to provide evidence for this by 
demonstrating co-localization of DPCK and apicoplast markers in the vesicles of parasites 
containing a disrupted apicoplast.  
 While our results suggest that DPCK is functionally active in the vesicles of parasites 
containing a disrupted organelle, further research could be done in this area. It is possible 
that other apicoplast-specific proteins are still present and active in these vesicles and playing 
essential roles in parasite survival. This work may help to dispel previous assumptions that 
parasites containing a disrupted apicoplast are ‘apicoplast-negative’ and that all apicoplast-
specific proteins are functionally absent. Further research characterizing these vesicles would 
also be informative, such as the determination if transporters are present and active on the 
surface of these vesicles, potentially allowing for the import of substrates and the export of 
products.  
 Interestingly, we were also able to demonstrate that CoA is likely required within the 
apicoplast in blood-stage parasites, due to its predicted use by ACP-S to modify ACP with a 





PfMev parasites under mevalonate supplementation, which resulted in disruption of the 
organelle. This was a surprising finding since the only proposed role of ACP and ACP-S is 
their function within the FASII pathway, which is not essential for blood-stage parasite 
survival (63). Thus, it is likely that ACP and ACP-S have secondary functions that are 
essential and required for apicoplast maintenance. Thus, further investigation into the 
activity of these proteins is merited. Some secondary functionality has already been 
described, with ACP demonstrating the ability to function as a malonyl-transferase (64) in 
addition to showing the ability to self-acylate (65), and ACP-S appears to contain a metal-
dependent hydrolase domain (66). However, it is yet to be determined if these specific 
potential secondary functional activities are required for organelle maintenance. In other 
systems ACP, and specifically the 4’-phosphopantetheine prosthetic group, was shown to 
play an important role in the generation of sulfur by the cysteine desulfurase enzyme, in 
addition to the formation of iron-sulfur clusters (67). While we were able to demonstrate 
that the cysteine desulfurase activity of SufS is essential for apicoplast maintenance, we don’t 
know whether ACP and ACP-S are required for this activity in P. falciparum.  
 
Final Remarks 
 Through this work we have been able to determine the essentiality and role of 
numerous apicoplast-specific proteins, with these findings summarized in Figure 6-1 and 
Table 6-1. We hope that the research outlined in this thesis will help contribute to the 
overall understanding of apicoplast biology in P. falciparum parasites, and that these findings 
will be translated into helping further drug discovery efforts and reduce the burden of 
infections and deaths caused by Plasmodium parasites. Additionally, we hope that the 





this thesis can be translated to other Apicomplexan species and reduce the disease burden 





















































Figure 6-1 Apicoplast metabolic map showing which genes are essential for 
dispensable, essential, or required for apicoplast maintenance in blood-stage 
parasites 
The resulting phenotypes from the genetic deletions attempted in this work are shown above 
and color-coded. Genes not required for blood-stage parasite survival are shown in green. 
Genes that are essential for blood-stage parasite survival, but are not required for organelle 
maintenance are shown in orange. Genes that are essential for blood-stage survival and are 
required for apicoplast maintenance are shown in red.  Genes that could not be deleted are 









Table 6-2 Resulting apicoplast-specific gene deletion phenotypes 
 
Gene ID Gene Name  Phenotype 
PF3D7_1467300 DXPR Essential 
PF3D7_1344600 LipA Nonessential 
PF3D7_0622200 MiaB Nonessential 
PF3D7_1022800 IspG Essential 
PF3D7_0104400 IspH Essential 
PF3D7_1318100 Ferredoxin (Fd) Essential 
PF3D7_0623200 Ferredoxin reductase (FNR) Essential  
PF3D7_0522700 SufA Nonessential 
PF3D7_0921400 NifU Nonessential 
See above SufA + NifU Essential 
PF3D7_1103400 SufD Essential 
PF3D7_1413500 SufC Essential 
PF3D7_0206100 SufE Essential 
PF3D7_0716600 SufS Essential and Maintenance  
PF3D7_1019800 MnmA Essential and Maintenance  
PF3D7_1037100 PyrKII Essential and Maintenance 
PF3D7_0530200 iTPT Essential and Maintenance 
PF3D7_0508300 oTPT Unable to knockout  
PF3D7_1020800 PDH E2 Nonessential 
PF3D7_1337200 DXS Essential 
PF3D7_0318800 TPI Nonessential 
PF3D7_0208500 ACP Essential and Maintenance 
PF3D7_0420200 ACP-S Essential and Maintenance 
PF3D7_1312000 FabD Nonessential 
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When double strand breaks occur in P. falciparum parasites they are believed to rely 
almost exclusively on homology directed repair (HR) mechanisms to repair those breaks. 
While other eukaryotic organisms can typically use a combination of HR or non-
homologous end joining (NHEJ) mechanisms to repair double strand breaks, P. falciparum 
parasites apparently lack the NHEJ pathway. In this brief appendix we outline work 
conducted attempting to introduce an exogenous non-homologous end joining system into 
P. falciparum parasites. In this work, we generated a vector for the expression of the Ku and 
LigD proteins from Mycobacterium tuberculosis that have been previously validated and shown 
to function as a two-component NHEJ system that was capable of repairing double strand 
breaks in vitro, in addition to restoring double strand breaks in vivo in NHEJ deficient 
Saccharomyces cerevisiae, with indel formation seen in both cases. The motivation for the 
introduction of this system into P. falciparum parasites was to generate a new genetic tool. 
Presence of an NHEJ system could allow for an easier method to create genetic disruptions 
within genes that could be scaled up for larger genetic screens. Currently, methods used to 
create targeted disruption or deletions of specific genes rely on the creation of individual 
homology directed repair templates, making larger scale genetic investigations using this 




Double strand breaks of DNA can be highly detrimental to the cell in which it 
occurs, potentially resulting in chromosomal translocations, damage, or loss, and can induce 





repaired through one of two repair pathways, homology-directed repair (HR), or non-
homologous end joining (NHEJ) (2). In HR, double strand breaks are repaired by using a 
homologous sequence as a template for accurate repair of the broken region (3). NHEJ is 
typically more error prone, and does not require a template sequence, but instead joins the 
broken ends of DNA together, which can result in the insertion or deletion (indel) of 
nucleotides within the region being repaired (4).  
 In P. falciparum, the overall activity of the HR pathway has been validated, and 
multiple components of the pathway have been identified and functionally characterized, (5–
9). While homology directed repair relies on the presence of a homologous sequence for 
repair, typically such as a sister chromatid or homologous chromosome (10), P. falciparum 
parasites exist as haploid organisms within the blood-stage of the parasite lifecycle (11). 
Regardless of this fact, P. falciparum parasites have been demonstrated to rely almost 
exclusively on the HR pathway to repair DSBs within the parasite (12), with this pathway 
being critical for parasite survival (13). Intriguingly, the NHEJ pathway appears to be absent 
in P. falciparum parasites, with homologues of the proteins that would be typically involved in 
this process, such as Ku70/80, DNA ligase IV, DNA-PKc, and XRCC4 being seemingly 
absent from the parasite genome (14). Additionally, induction of DSBs does not result in 
repair products consistent with the presence of a NHEJ pathway, helping to provide 
additional evidence that this DNA repair pathway is likely absent in malaria parasites (15).  
 While the lack of an NHEJ pathway is surprising, it is not entirely unheard of, as 
other parasites such as Trichomonas vaginalis and Giardia lamblia appear to be lacking NHEJ 
machinery as well (16, 17). Surprisingly, the closely related apicomplexan parasite, T. gondii, 





suggesting that the loss of this pathway in malaria parasites happened relatively recently on 
an evolutionary timescale.   
 It should be noted, however, that additional repair pathways appear to be functional 
and present within the parasite, with studies showing the presence of microhomology-
mediated end joining (MMEJ), although occurring at extremely low frequencies (12, 19). 
Additionally, P. falciparum parasites have been shown to be capable of telomere healing, in 
which DSBs that occur within the distal subtelomeric regions are ‘healed’ by transforming 
the broken end of the chromosome into a functional telomere, but losing the broken 
subtelomeric region in the process (20, 21). While this process can repair DSBs within 
subtelomeric regions, which typically contain genes used for human infectivity but are largely 
dispensable for in vitro culture, this process is unlikely to be able to repair the conserved and 
essential genes that reside closer to the center of the chromosome.  
 While the lack of an NHEJ pathway in P. falciparum parasites is interesting, it is also 
makes certain approaches to genetic experimentation impossible within the parasite. For 
example, there was a recent study in the Apicomplexan parasite T. gondii, in which CRISPR-
Cas9 along with a guide RNA (gRNA) library was used to create DSBs throughout the 
genome with reliance on indel formation to remove or insert bases, resulting in frameshifts 
and gene disruption used to determine which genes are essential (22). This approach has also 
been used in other systems as well (23, 24), but these approaches rely on the presence of a 
functional NHEJ system to work.  
 One possibility that may make experiments such as this possible would be to 
introduce a NHEJ system into P. falciparum parasites through the expression of proteins 
involved in this pathway. However, the typical eukaryotic NHEJ pathway consists of 





Ku70/80, DNA ligase IV, DNA-PKc, and XRCC4 (14). However, a reduced end joining 
pathway is present within prokaryotic organisms. In Mycobacterium tuberculosis DNA ligase D 
(LigD) and Ku alone have been shown to join non-homologous DNA ends in vitro, and has 
been shown to be capable of reconstituting NHEJ in Saccharomyces cerevisiae (25). Thus, due to 
only two proteins being seemingly required for full reconstitution of NHEJ functionality, we 
attempted to express both of these proteins in P. falciparum parasites in order to introduce 




Design of the Pf-NHEJ Expression Plasmid and Sequence 
 The Ku and LigD genes from M. tuberculosis were synthesized and harmonized for 
expression in P. falciparum parasites to avoid any issues with translation due to the presence 
of rare codons (26). Minimal alternations were made to the genes themselves, with both the 
Ku and LigD genes containing an N-terminal nuclear localization signal in addition to a myc-
tag, replicating what had been done in the original work, complementing NHEJ deficient S. 
cerevisiae. The expression of these genes was driven by a bidirectional calmodulin promoter 
which promoted the expression of LigD, followed by a 2A skip peptide, followed by the Ku 
protein. The other end of the promoter drove the expression of the blasticidin deaminase 
drug resistance cassette (27), followed a 2A skip peptide, followed by super folder green 
(SFG), a green fluorescent protein engineered for rapid folding kinetics and stability (28, 29). 
Utilization of the 2A skip peptides was critical for the generation of this construct, as it 
allowed for the expression of multiple proteins within a single expression cassette (Figure 






Expression of the Pf-NHEJ Construct in P. falciparum Parasites 
 The above-mentioned plasmid was integrated into the genome of the NF54-attB P. 
falciparum parasite line using attP/attB integration (31, 32). Integration and expression of the 
construct was validated through live epifluorescent microscopy to check if the SFG protein 
was present in the cytosol of the transfected parasites (Figure ApI-2). While we were 
successful in detecting a number of parasites expressing SFG, this was by far not the 
majority of the parasite population. The estimated percentage of parasites clearly expressing 
SFG and emitting a fluorescent signal appeared to be between ~1-5% of the total parasite 
population.  
 
Attempted Generation of Double Strand Breaks and Indel Formation using gRNAs 
Targeting SFG 
 The NHEJ line was continuously cultured in the presence of 2.5µg/mL of 
blasticidin. Once this parasite line was generated, additional transfections were conducted in 
order to express the Cas9 enzyme along with a gRNA specific for the SFG protein. We 
attempted transfections with two separate gRNAs, that we are calling SFGg1 and SFGchrm. 
We were able to generate four and three lines respectively, in which we selected for the 
plasmids designed to express these gRNAs. We targeted SFG due to it potentially giving a 
phenotypic readout, with parasites being fluorescent or non-fluorescent, in addition to the 
gene being not essential for parasite survival, and thus indel formation and gene disruption 
should be tolerated. Once parasites were transfected with the plasmid containing the Cas9 





retention of the plasmid, and thus, hopefully resulting in constitutive expression of Cas9 and 
the gRNA to ensure cutting.  
 Upon the introduction of DSM1, the parasitemia quickly became undetectable by 
blood film and Giemsa stain, with parasite growth being observed ~20-25 days post 
transfection. Parasites were grown under continuous treatment with 2.5µg/mL of blasticidin 
and 1.5µM DSM1. Once the parasites reached a higher parasitemia (>5%), they were 
allowed to complete multiple growth cycles before samples were taken for analysis. For 
analysis, primers were used to amplify the region that should have been subject to cutting by 
the gRNA, containing a potential repair product and indel formation. Sequences were 
analyzed from the multiple parasite lines that were generated for both of the gRNAs specific 
to SFG, and while all lines were resistant to DSM1 and blasticidin, none showed any repair 
products, with all returning wild-type sequences (Figure ApI-3).  
 
Attempted Generation of Double Strand Breaks and Indel Formation using gRNAs 
Targeting FabD 
 Due to transfection of all constructs expressing the previous gRNAs all returning 
wild-type sequences, we attempted to create a double strand break in a separate region of the 
parasite genome, this time targeting the endogenous and dispensable gene FabD of the 
FASII pathway. We demonstrated previously that FabD is dispensable in chapter 5 of this 
thesis, and used the same gRNA expressing plasmid for use in this system. To accomplish 
this, we attempted 4 separate transfections, and saw a different result from what was 
observed when targeting SFG. While we conducted four transfections, we were only able to 





result in parasite survival and outgrowth. However, the one line that did survive selection 
returned a wild-type sequence (Figure ApI-4). 
 
CONCLUSIONS AND DISCUSSION 
 
As detailed in this work, we attempted to introduce an exogenous NHEJ pathway 
into P. falciparum. We did this with the hope that this line could be used as a genetic tool that 
could accelerate genetic investigations into P. falciparum parasites. NHEJ parasites could be 
used for high throughput screening of guide RNA libraries that could cause gene disruption 
through indel formation, instead of having to rely on current methods that require a 
homologous repair construct for each gene to be targeted (22–24). 
 We were able to design and construct a plasmid that allows for expression of the 
LigD and Ku proteins that comprise the two component NHEJ system in M. tuberculosis 
within P. falciparum parasites. We also transfected parasites with this plasmid, and validated 
that we were able to generate parasites that expressed protein components from this vector. 
However, when we attempted to induce double stranded breaks in the parasite genome and 
generate repair products that contained indels due to the error-prone action of the 
introduced NHEJ system, we were unsuccessful in doing so.  
 The logic behind our strategy for generating double strand breaks involved 
introducing a plasmid into the parasite expressing the CRISPR-Cas9 enzyme along with a 
gRNA specific for the gene of interest, either SFG or FabD. We then selected for parasites 
that had acquired that plasmid by treating them continuously with 1.5µM DSM1. We 
hypothesized that parasites that grew out under continuous drug selection must have 





gene of interest. Since double strand breaks typically result in cell death if not repaired (1), 
we reasoned that the parasites must have repaired the double strand break, potentially 
utilizing the introduced NHEJ system, which would result in likely indel formation at the cut 
site. We reasoned that the cut region should not be able to be repaired back to the original 
sequence due to the constant selection for the plasmid containing the Cas9 and gRNA. If the 
sequence was wild-type, or was repaired to the wild-type sequence, the Cas9 and gRNA 
would continuously cut the region until it was repaired in such a way that the sequence 
became unrecognizable to the gRNA, favoring this repair product over time.  
 However, this was not the result that we obtained. While we were able to obtain 
multiple parasites lines that survived and grew out after drug selection with DSM1, all of the 
regions in which double strand breaks and indel formation should have occurred, returned 
wild-type sequences. The reason as to why this occurred is unclear, but it is possible that the 
introduced NHEJ system simply did not work. However, if the double strand break was 
actually generated by the gRNA loaded Cas9, and a double strand break was created the 
sequence would need to be repaired, and if the gRNA loaded Cas9 was constitutively 
expressed, the sequence would continuously be cut if it remained wild-type and would 
presumably favor a repair product that resulted in the alteration of the wild-type sequence to 
avoid targeting and cutting by the gRNA-loaded Cas9.  
 An alternate hypothesis as to why the parasites survived selection, but returned wild-
type sequences is that the expression of the gRNA and Cas9 were somehow repressed or 
silenced (33). However, the expression of the Cas9 is driven by the same Cam/HOP 
bidirectional promoter that drives the expression of the yDHOD drug cassette (34). Thus, it 
is unclear through what mechanism the parasite would be able to silence a single gene on 





may occur though, is if the parasite is able to develop resistance to DSM1 and is able to turn 
off the entire expression cassette, which may be the case since parasites are capable of 
developing rapid and high-level resistance to DSM1 (35).  
 However, when expressing the gRNA specific for FabD, we saw a different result. 
While we did obtain parasites that survived DSM1 selection, with parasites that returned 
wild-type sequence results, the other three transfections did not yield parasites. The reasons 
for this are not clear, and may be due to low transfection efficiency, but this failure could 
also potentially be attributed to a multitude of other potential reasons. However, it is 
interesting that all transfections expressing the SFG specific gRNA yielded parasites, while 3 
out of four expressing the FabD gRNA did not. One can only speculate as to why this is, but 
it may be potentially due to more efficient cutting of the FabD gRNA target sequence and 
failure of the introduced NHEJ system to repair the break. Since there is no homologous 
template available, the parasite would likely be forced to rely on other repair pathways. If the 
NHEJ system did not work, the parasites would have to rely on alternative repair pathways 
that have been demonstrated to operate at a low efficiency. Thus, generation of a double 
strand break in this scenario may have resulted in parasite death with no significant ability to 
repair the break.  
 Future efforts may have better success using an alternative drug resistance cassette in 
which parasites are unable to develop rapid and high-level resistance (35). While it is purely a 
hypothesis that repair products were not found due to silencing of the genes involved in 
generating the double strand break, this may be the case, with formation of resistance being 
favored over the breakage and repair of the chromosome, which may result in a severe 
fitness defect, or death if the parasite is unable to repair the break. Thus, in order to truly test 





stranded break is needed. This could potentially be done by using a different drug resistance 




P. falciparum culture and maintenance 
 Unless otherwise noted, blood-stage P. falciparum parasites were cultured in human 
erythrocytes at 1% hematocrit in a 10mL total volume of CMA (complete medium with 
albumax) medium containing RPMI 1640 media with L-glutamine (USBiological Life 
Sciences), supplemented with 25mM HEPES, 0.3% sodium bicarbonate, 12.5µg/ml 
hypoxanthine, 5g/L Albumax II (Life Technologies) and 25µg/mL gentamicin. Cultures 
were maintained in gassed flasks (94% N2, 3% O2, 3% CO2) and incubated in sealed 75cm2 
flasks at 37°C. 
 
Generation of the NHEJ construct 
 The M. tuberculosis LigD and Ku proteins containing the N-terminal nuclear 
localization signal and Myc-tag, separated by a 2A skip peptide were synthesized, and codon 
harmonized for expression in P. falciparum parasites. This cassette was inserted in a plasmid 
under control of the bidirectional Cam/HOP promoter, with the other side of the plasmid 
containing the blasticidin deaminase drug resistance cassette, separated by a 2A skip peptide, 
followed by the green fluorescent protein SFG. The plasmid that these cassettes were 







P. falciparum transfections to generate the Pf-NHEJ line 
 Transfections were conducted as previously described (31, 36). Briefly, 400µL of red 
blood cells were washed with 5mL of CytoMix and resuspended in 340µL of CytoMix. The 
red blood cells were then electroporated with 75µg each of the NHEJ plasmid, along with 
75µg of the pINT plasmid expressing the Bxb1 integrase  (37). The electroporated RBCS 
were then mixed with ~2.5mL of the 10mL NF54 attb parasite line synchronized as 
schizonts at 1% hematocrit and ~10% parasitemia, and given 10mL media. After 48 hours 
transfectants were selected for with 2.5µg/mL of blasticidin for 7 days, after which, drug 
selection was removed. Infected RBCs were first observed, ~20-25 days after initiating drug 
selection. 
 
Generation of P. falciparum gRNA expressing constructs 
 Guide RNA sequences were synthesized as complementary oligos (Table ApI-1), 
annealed, and inserted into the pCasG plasmid via In-Fusion cloning. The pCasG plasmid 
contains the Cas9 enzyme, in addition to a guide RNA (gRNA) expression cassette. For 
insertion of the gRNA sequence, the pCasG plasmid was digested with BsaI and also treated 
with rSAP and then ethanol precipitated before insertion of the gRNA oligo. 
 
P. falciparum transfections to induce double strand breaks 
  Transfections were conducted as mentioned above, with red blood cells 
electroporated with 75µg of the gene specific pCasG plasmid (37). The electroporated RBCs 
were then mixed with ~2.5mL of the 10mL Pf-NHEJ parasite culture synchronized as 
schizonts at 1% hematocrit and ~10% parasitemia and given 10mL media. After 48 hours 





they were cultured. Infected RBCs were typically first observed, ~25-30 days after beginning 
drug selection.  
 
Amplification of potential indel sites 
 In order to screen for potential indel formation we used primers specific for the 
genetic region in which the gRNA was designed to cut (Table ApI-2). Samples for PCR 
were collected when the parasitemia reached been 5-10%, as determined via Giemsa stain. 
Approximately 100µL was taken from a resuspended parasite culture and placed in a heat 
block at 90°C for 2 minutes and stored at -20°C. For the PCR reaction 1µL of the parasite 
sample was added to reactions with a 50µL total volume. Reactions were conducted using a 
Veriti 96 well thermal cycler (Applied Biosystems) and Phusion High-Fidelity DNA 
polymerase (Thermo Fisher Scientific). PCR products were separated on a 1.5% agarose gel 
stained with ethidium bromide for visualization. The PCR product was then purified via 
ethanol precipitation and sequenced using the same primers used to amplify the genetic 
region from the genome of the parasite.  
 
The PCR reaction mix was as follows:  
 
Water 34.5µL 
5x Phusion HF buffer 10µL 
Forward primer (10 µM)1.5µL 
Reverse primer (10 µM) 1.5µL 
dNTPs (10mM)  1µL 
Phusion polymerase 0.5µL 
parasite lysate 1µL 
Total volume 50µL 
 
The PCR program was as follows: 
 
95°C 3.5 minutes 
95°C 30 seconds 





62°C 4 minutes 
4°C ∞ 
 
(steps 2 and 3 were repeated 35 times) 
 
Live cell epifluorescent microscopy 
  For sample preparation, 100µL of parasite culture with a hematocrit of 1% and a 
parasitemia between 8-10% was obtained. Parasites were stained with 30nM MitoTracker 
CMX-Ros (Invitrogen) and 1µg/mL 4′, 6-diamidino-2-phenylindole (DAPI), and incubated 
for 30 minutes at 37°C. Cells were then pelleted via mini-centrifuge (Fischer Scientific) for 
10 seconds, and the media was aspirated and the cells were resuspended in 100µL of CMA 
media and incubated for 5 minutes at 37°C. This was done three times to wash the cells, 
with the cells being resuspended in 20µL of CMA and then pipetted onto slides and sealed 
with wax (2 parts paraffin, 1 part Vaseline) for observation on a Zeiss AxioImager M2 
microscope. A series of images spanning 5µm were acquired with 0.2µm spacing and images 
were deconvolved with VOLOCITY software (PerkinElmer) to report a single combined z -

































Figure ApI-1 Schematic representation of the Pf-NHEJ construct 
The synthesized M. tuberculosis Ku and LigD genes harmonized for expression in P. falciparum 
were inserted downstream of the Cam/HOP bidirectional promoter, with both containing a 
N-terminal nuclear localization signal and Myc-tag.  The Ku and LigD proteins should be 
produced as two polypeptides since they are separated by a viral 2A skip peptide. The other 
end of the promoter helped to drive the expression of the blasticidin deaminase drug 























Figure ApI-2 Fluorescence microscopy of the NHEJ lines 
Live epifluorescent images of the Pf-NHEJ line expressing SFG (green), also stained with 
mitoTracker (red) and DAPI (blue). 

































Recombinant parasite sequence, with the with gRNA target sequence highlighted 
 
Transfection attempt 1 (3Y17): 
GATGTGAATGGCCATAAATTTTCTGTACGTGGTGAAGGCGAAGGAGATGCAACAAATGGAAAATTA 
 
Transfection attempt 2 (16Y17): 
GATGTGAATGGCCATAAATTTTCTGTACGTGGTGAAGGCGAAGGAGATGCAACAAATGGAAAATTA 
 
Transfection attempt 3 (24y17): 
GATGTGAATGGCCATAAATTTTCTGTACGTGGTGAAGGCGAAGGAGATGCAACAAATGGAAAATTA 
 








Recombinant parasite sequence, with the with gRNA target sequence highlighted 
 
Transfection attempt 1 (16y17): 
TACCGGTTCCATGGCCAACACTTGTAACGACCTTAACTTACGGAGTACAATGTTTTAGTCGAT 
 
Transfection attempt 2 (24Y17): 
TACCGGTTCCATGGCCAACACTTGTAACGACCTTAACTTACGGAGTACAATGTTTTAGTCGAT 
 




Figure ApI-3 Comparison of the wild-type and potential repair products for SFG 
Wild-type sequence of the SFG region targeted by the guide RNA, and the genetic sequence 















Recombinant parasite sequence, with the with gRNA target sequence highlighted 
 






Figure ApI-4 Comparison of the wild-type and potential repair products for FabD 
Wild-type sequence of the FabD region targeted by the guide RNA sequence, and the 

































Table ApI-1 Oligonucleotides designed for In-Fusion insertion of gRNA sequences 
  
Name Oligonucleotide Sequence 
SFGg gRNA F TAAGTATATAATATTTCTGTACGTGGTGAAGGCGAGTTTTAGAGCTAGAA 







FabD gRNA F TAAGTATATAATATTGATAGAAAATTTGGTTTATGGTTTTAGAGCTAGAA  



































Table ApI-2 Primer sequences used for amplifying potential indel regions 
  
Primer Name Primer Sequence 
SFG F GGAAATTTAACTTGTATAGTAGCAATAGGTAACGAAAATC 
SFG R CCTCTACATTATGTCTTATTTTAAAATTAGCTTTAATTCC 
FabD F ACAAAATGAATGATGATATTTTTATTGTTAGTTATATGAC 
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- Mosquito work for this project was conducted by collaborators at Walter Reed 






As outlined in this brief appendix, we attempted to replace the P. falciparum CSP 
protein with the P. vivax CSP. We did this with the goal of creating a parasite line that could 
be used for human trials to measure potential antibody responses to the P. vivax CSP 
protein, with the greater goal of furthering the development of potential vaccine strategies 
against P. vivax infection. While we were successful in creating this allelic exchange parasite 
line, modified parasites were not able to complete mosquito-stage development and form 
sporozoites. A small number of sporozoites expressing the P. vivax CSP were found, but 
they appeared to be phenotypically unhealthy. Based on our findings, it appears that the 
allelic exchange of P. falciparum and P. vivax CSP results in a fitness defect in the mosquito-
stage of the parasite. Additional optimization and troubleshooting would be required in 




Plasmodium vivax represents a significant public health concern, with over 2.5 billion 
people at risk for infection (1). In order to better develop methods to prevent or treat these 
parasitic infections, an in vitro culture system would help in the screening of potential 
therapeutic interventions. While continuous in vitro culturing of P. falciparum was established 
in the 1970s (2, 3), the development of a similar system for P. vivax has remained a challenge, 
even though some progress has been made in this area (4–7). This is largely due to P. vivax 
parasites having a tropism for reticulocytes which constitute a small percentage of the total 





vitro culture system makes any sort of experimentation on P. vivax extremely difficult, slowing 
any progress that could be made on drug discovery or vaccine development efforts.   
 Efforts to create an effective vaccine against P. falciparum parasites span many 
decades, with the most effective methods targeting the sporozoite stage of the parasite. 
These strategies typically administer attenuated parasites, or administer sporozoites with 
concomitant chemoprophylaxis (9, 10), and can result in sterilizing immunity (11). The 
primary target of the protective antibodies that are generated upon administration of 
sporozoites has been determined to be the circumsporozoite protein (CSP) (12, 13), which is 
the dominant protein present on the surface of the sporozoite stage parasite (14, 15) 
involved in adhesion to target cells (16). Targeting P. falciparum CSP is the basis of the RTS,S 
vaccine, which is the only malaria vaccine to have reached phase III clinical trials (17–19).  
 In order to test how efficacious a vaccine candidate is in protecting against infection 
from Plasmodium parasites, clinical trials using controlled human malaria infection (CHMI) 
are typically employed (20). While many of these studies have been conducted to test 
immunization and challenge against infection with P. falciparum (20, 21), much less has been 
done to investigate vaccination against P. vivax (22). This is largely due to the technical 
difficulty in conducting such trials with P. vivax since it cannot be cultured in vitro, and must 
rely on having the infected individual and lab strain mosquitos in the same physical 
proximity. Consequently, the few trials that have occurred have typically taken place in 
countries like Colombia where P. vivax is endemic (23–26). In countries where P. vivax is not 
endemic, such as the United States, this becomes more of a challenge, since infected 
mosquitos have to be shipped from an endemic country and maintained until challenge (22). 
The inability to culture P. vivax also results in parasite heterogeneity between and even 





parasites (27). Additionally, the infectivity of P. vivax parasites is also different, in that they 
are capable of becoming dormant, forming what is termed a hypnozoite phase of the 
parasite, which can result in relapse of the infection years after the primary infection (28). 
Thus, primaquine drug administration is typically required post-study to ensure the full 
clearance of the infection, which can still fail as a result of the genetic background of the 
individual (29–31), with relapse being seen in the few CHMI studies that have been 
conducted (22).  
 Due to these challenges, the progress in developing a vaccine against P. vivax has 
been hindered. Basic understanding of the immunogenicity and efficacy of CSP-based 
vaccines for P. vivax have lagged far behind what is known for P. falciparum. Research in this 
area is likely to be critical, due to the CSP proteins of P. falciparum and P. vivax being 
significantly different. For example, while P. falciparum has a single allele for CSP, P. vivax has 
two major alleles, termed VK210 and VK247 that differ in the repeat region of the protein 
when compared to P. falciparum and to each other (32), with both alleles occurring 
throughout the world (33). This is significant because the central repeat region of CSP plays 
an important role in protective immunity in P. falciparum (16).  
 In order to determine if a P. vivax CSP based vaccine can be effective, a greater 
understanding of the protective efficacy and basic mechanisms of immunity against it is 
required. Due to the difficulty associated with CHMI trials, and the absence of an easily 
tractable animal model (34–36), alternative approaches must be taken to speed progress in 
this area. To achieve this, numerous groups have worked to express the P. vivax CSP 
proteins on the surface of P. berghei parasites, which has essentially generated a tractable 
animal model. These studies resulted in numerous findings that have gone a long way 





well as their protective efficacy. Experiments demonstrate that prior vaccination with the P. 
vivax CSP is capable of eliciting a high level of cross protection in mice challenged with P. 
berghei parasites expressing P. vivax CSP (37–41).  
 Similar efforts could potentially utilize P. falciparum parasites as a vehicle to express 
the P. vivax CSP on the surface in order to analyze immune responses to this protein within 
human subjects, and may assist in furthering the development of new vaccine strategies 
against this parasite. This approach may address many of the issues seen with the CHMI 
studies using P. vivax. Namely, this would allow for the in vitro culture of clonal parasites 
which would remove the previous logistical issues that were faced, in addition to eliminating 
the risk of hypnozoite formation and parasite recrudescence. Additionally, the 
methodologies that have been previously established for P. falciparum, could be easily applied 
to this line. Thus, in order to generate such a system, we attempted to express the P. vivax 
(Belem) CSP protein on the surface of P. falciparum parasites. We attempted to achieve this 
through a markerless allelic exchange method, removing the entire P. falciparum CSP 
sequence and replacing it with the entire P. vivax CSP sequence utilizing CRISPR-Cas9. We 
were successful in generating this line, but found that this modification prevented the 
formation of large numbers of viable sporozoites, hindering further progress that could be 




Construction of the P. vivax CSP Allelic Exchange Plasmid 
 In order to generate P. falciparum parasites expressing the P. vivax CSP in lieu of the 





endogenous CSP fully with the introduced P. vivax CSP using allelic exchange in 
combination with CRISPR-Cas9 genome editing (42). In order to do this, we designed the 
plasmid to contain ~260bp from the 5’ UTR of the P. falciparum CSP gene immediately up to 
the start codon of the gene, representing the 5’ homology arm that would be needed for 
homology directed repair (HR) and allelic exchange. This sequence was immediately 
followed by the complete P. vivax CSP Belem sequence, beginning with the start codon and 
ending with the stop codon. This region was then followed by ~380bp from the 3’ UTR of 
the P. falciparum CSP beginning immediately after what would have been the endogenous 
CSP stop codon, with this region representing the 3’ homology arm used for HR and allelic 
exchange (Figure ApII-1). The construct was designed as such to prevent perturbation of 
the gene, keeping the 5’ and 3’ UTR regions unaltered, while fully replacing the CSP gene. 
 
Allelic Exchange of P. falciparum CSP with P. vivax CSP 
 Having generated the repair construct, we made an additional plasmid for the 
expression of a guide RNA targeting the endogenous CSP, which was co-transfected and 
selected for along with the repair construct. Selection for both plasmids was maintained for 
14 days. Parasites were then observed ~25-30 days post selection and then screened via PCR 
to look for integration of the P. vivax CSP, in addition to screening for the presence of the P. 
falciparum CSP, and thus the presence of any contaminating wild-type parasites. Using this 
method we were successful in exchanging the P. falciparum CSP for the P. vivax CSP, and thus 
generated the desired parasite line (Figure ApII-2).  
 






 Having successfully generated the P. falciparum line expressing the P. vivax CSP, we 
attempted to passage this line through mosquitos in order to determine if the parasites were 
competent in completing the mosquito-stage of the parasite lifecycle and were able to 
generate sporozoites. The parasites did appear to make sporozoites expressing the P. vivax 
CSP, as evidenced by their reactivity against P. vivax CSP specific antibodies, but only a very 
small number were generated and they did not appear to be phenotypically healthy (Figure 
ApII-3). Additionally, when passage through mosquitos was attempted at a later date, the 
sporozoites that were produced were predominantly those expressing the P. falciparum CSP, 
indicating the presence of a subpopulation of wild-type parasites that were likely selected for 
over time. This indicated that the line was not clonal, and also suggests that expression of 
the P. vivax CSP in lieu of the P. falciparum CSP likely imparts a fitness defect.  
 
CONCLUSIONS AND DISCUSSION 
 
Through this work we were able to demonstrate successful allelic exchange between 
the P. falciparum and P. vivax CSP genes. We were also successful in demonstrating that these 
parasites can successfully complete the mosquito-stage, and express the P. vivax CSP protein 
on the surface of the parasite. Expression of the P. vivax CSP on sporozoites was 
demonstrated by their reactivity against P. vivax CSP specific antibodies. However, it appears 
that the allelic exchange resulted in a fitness defect within the mosquito-stage of the parasite 
lifecycle, resulting in very few sporozoites being produced, with the few that were identified 
looking phenotypically unhealthy. The mechanism by which expression of the P. vivax CSP 
results in this fitness defect is unclear. It may be due to difficulty in generating the protein, as 





this issue, the P. vivax gene could be recoded and optimized for expression in P. falciparum 
parasites. However, the failure to produce large levels of healthy recombinant parasites could 
be due to other factors as well, such as the P. vivax protein being biologically incompatible, 
and not being able to complement the function of the endogenous P. falciparum CSP. 
However, overall we believe that this is a viable method for testing the immunogenicity of P. 





P. falciparum culture and maintenance 
 Blood-stage P. falciparum parasites were cultured in human erythrocytes at 1% 
hematocrit in a 10mL total volume of media containing RPMI 1640 media with L-glutamine 
(USBiological Life Sciences), supplemented with 25mM HEPES, 0.2% sodium bicarbonate, 
12.5µg/mL hypoxanthine and 10% human serum. Cultures were maintained in gassed flasks 
(94% N2, 3% O2, 3% CO2) and incubated in sealed 75cm2 flasks at 37°C. 
 
Generation of the allelic exchange and gRNA expression plasmids 
 The homology arms corresponding to the 5’ and 3’ UTR regions of the P. falciparum 
CSP sequence were synthesized and inserted into the repair template plasmid. Additionally, 
the full-length P. vivax CSP was amplified from the P. vivax Belem line, and inserted into the 
plasmid containing the P. falciparum 5’ and 3’ UTR regions, functioning as homology arms.  
 For guide RNA (gRNA) expression, the gRNA sequences were synthesized as oligos 
(Table ApII-1), and inserted into the pCasG plasmid containing a guide RNA (gRNA) 





via In-Fusion cloning after being digested with BsaI and also treated with rSAP, and then 
ethanol precipitated. 
 
P. falciparum transfections for allelic exchange 
  Transfections were conducted as previously described (44, 45), but briefly 400µL of 
red blood cells were washed with 5mL of CytoMix and resuspended in 340µL of CytoMix. 
The red blood cells were then electroporated with 75µg each of the pCasG and allelic 
exchange repair template plasmids (42). The electroporated RBCS were then mixed with 
~2.5mL of 10mL P. falciparum parasites synchronized as schizonts at 1% hematocrit and 
~10% parasitemia and given 10mL media. After 48 hours transfectants were selected for 
with 0.75µM DSM1 and 2.5nM WR99210 for 14 days. After 14 days, drug pressure was 
removed. Infected red blood cells (iRBC) were first observed ~25 and 30 days after 
beginning drug selection.  
 
Confirmation of allelic exchange 
 In order to screen for integration and successful allelic exchange, in addition to the 
potential presence of any contaminating residual wild-type parasites four sets of primers 
were used, including  
PfCSP 5’F, PfCSP 3’R, PfCSP wt 5’R, PfCSP wt 3’F, PvCSP 5’R, and PvCSP 3’F (Table 
ApII-2). These primers were designed to screen for integration at the 5’ and 3’ ends (Δ5’ and 
Δ3’) in addition to 5’ and 3’ regions of the WT gene (5’ and 3’). The same reactions were also 
performed on the parental parasite line concurrently as a control. Samples for PCR were 
collected when the parasitemia reached been 5-10%, as determined via Giemsa stain. 





block at 90°C for 2 minutes and stored at -20°C. For the PCR reaction 1µL of the parasite 
sample was added to reactions with a 50µL total volume. Reactions were conducted using a 
Veriti 96 well thermal cycler (Applied Biosystems) and Phusion High-Fidelity DNA 
polymerase (Thermo Fisher Scientific). PCR products were separated on a 1.5% agarose gel 
stained with ethidium bromide for visualization.  
 
The PCR reaction mix was as follows:  
 
Water 34.5µL 
5x Phusion HF buffer 10µL 
Forward primer (10 µM)1.5µL 
Reverse primer (10 µM) 1.5µL 
dNTPs (10mM)  1µL 
Phusion polymerase 0.5µL 
parasite lysate 1µL 
Total volume 50µL 
 
The PCR program was as follows: 
 
95°C 3.5 minutes 
95°C 30 seconds 
62°C 1 minute 
62°C 4 minutes 
4°C ∞ 
 























































Figure ApII-1 P. falciparum/P.vivax allelic exchange construct 
Construct used to generate the Pf/Pv-CSP-allelic exchange line, showing the 5’UTR and 


















Lane Primer Combination Parasite Line 
1.  Δ5’ PfCSP 5’F, PvCSP 5’R  
Pf/Pv CSP Exchange Line 2.  Δ3’ PvCSP 3’F, PfCSP 3’R 
3.  5’ WT PfCSP 5’F, PfCSP wt 5’R 
4.  3’ WT PfCSP wt 3’F, PfCSP 3’R 
5.  Δ5’ PfCSP 5’F, PvCSP 5’R  
Parental Line 6.  Δ3’ PvCSP 3’F, PfCSP 3’R 
7.  5’ WT PfCSP 5’F, PfCSP wt 5’R 




Figure ApII-2 Pf/Pv-CSP-allelic exchange PCR confirmation 
PCR confirming the allelic exchange of the P. vivax CSP gene, replacing the P. falciparum CSP 
gene, also showing no amplification indicating any residual wild-type population. The line 
was compared to wild-type parasites, showing amplification of only the recombinant locus. 



















Figure ApII-3 Pf/Pv-CSP allelic exchange mosquito passage and sporozoite 
formation  
Fluorescent microscopy of the Pf/Pv-CSP-allelic exchange line showing reactivity to a P. 
vivax CSP antibody. However, only a very small population of parasites expressing the P. 

















Table ApII-1 Oligonucleotides designed for In-Fusion insertion of gRNA sequences 
  
Oligo Name Oligo Sequence 
PfCSP gRNA F TAAGTATATAATATTTATCTAATTAAGGAACAAGAGTTTTAGAGCTAGAA 












































Table ApII-2 Primer sequences used for allelic exchange confirmation 
  
Primer Name Primer Sequence 
PfCSP 5’F GTAACTTTCTATCATACTTGTCATAAATTCTGAATTATC 
PfCSP 3’R CGTATACGTCTTATGCACAAATATAGTACATTTG 
PfCSP wt 5’R CAACAAATAAAAAGGAAGAAACAGATAAAATAGC 
PfCSP wt 3’F GTTCAATAGGATTAATAATGGTATTATCCTTCTTG 
PvCSP 5’R AGAAACAGCCAAGAGAATGAAGTTCTTC 
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The tricarboxylic acid (TCA) cycle is an oxidative pathway in aerobic organisms, 
producing energy from carbohydrates, fats, and amino acids. The mitochondria of the 
malarial parasite Plasmodium falciparum contain all of the TCA cycle enzymes as the parasite 
undergoes the intraerythrocytic developmental cycle (IDC). Recent experiments demonstrate 
that only two sequential TCA enzymes—fumarate hydratase and malate:quinone 
dehydrogenase—are essential for parasite growth during this period. Herein, we developed a 
metabolic network method that accounts for parasite transcriptomics and coupled host-
pathogen metabolomics to quantify the impact of fumarate, an obligatory side-product 
recycled through the TCA cycle, on metabolism during different stages of the IDC. At 8hr 
time intervals during the IDC, we collected metabolomic data from uninfected and parasite-
infected erythrocytes as well as transcriptomic data from P. falciparum. To predict the 
metabolic flux profiles of uninfected and parasite-infected erythrocytes, we first developed a 
method that utilizes metabolomic data, and identified key metabolites that the parasite 
consumes and secretes during the IDC. Next, we integrated the transcriptomic data with 
these metabolites to predict the metabolic flux profile of the parasite during the IDC. We 
then validated this profile by matching independent experimental measurements of DNA 
synthesis, RNA synthesis, and phospholipid synthesis, and used the validated model to gauge 
how fumarate levels impact metabolism during the IDC. Overall, we found that an increase 
in fumarate hydratase flux causes a comparable increase in aspartate aminotransferase 
activity, consistent with previous studies. Unexpectedly, we also found an equivalent increase 





phosphate levels). These findings suggest that fumarate, which is an essential side product of 
the obligatory purine salvage pathway, provides a feedback signal to maintain redox balance 




Malaria is an ancient disease caused by Plasmodium species characterized by a complex 
life cycle involving both mosquito and mammalian hosts. Recent studies suggest that, in the 
human-blood stage of the most lethal malarial parasite, Plasmodium falciparum, an enzyme in 
the tricarboxylic acid cycle—fumarate hydratase (fh)—is required for parasite survival. 
Although both host and parasite have fh, the parasite version is structurally distinct from the 
human version, and could be an attractive drug target. However, the physiological role of fh 
in the parasite remains unclear because of the entangled host-pathogen metabolism in 
infected host cells. Here, we resolve this question computationally by using a coupled host-
parasite metabolic network model with multiple -omics datasets to separate the metabolism 
of the parasite from that of the host. Our findings reveal that the fumarate generated by the 
parasite’s obligatory purine salvage pathway is associated with redox balance, suggesting that 
inhibiting fh could reduce the parasite’s ability to maintain redox balance and proliferate 
during the blood stage. Importantly, our use of linked transcriptome and metabolomic data 
with a genome-scale description of the coupled host-pathogen metabolism highlights how a 
computational biology analysis can reveal detailed mechanistic insights into complex 








Malaria causes about 212 million infections and 429,000 deaths worldwide yearly, of 
which almost 99% in Africa are caused by Plasmodium falciparum (1). The World Health 
Organization (WHO) recommends using artemisinin and its derivatives to treat 
uncomplicated P. falciparum malaria (2). However, increasing evidence suggests that the 
efficacy of artemisinin therapy has substantially declined (3). The recent incidents of 
artemisinin resistance, which are a growing concern in the scientific community given the 
prior experience with resistance to chloroquine (4), call for the identification of new 
treatment strategies. One such strategy uses atovaquone (5) to target the mitochondrion of 
P. falciparum, which is highly divergent from that of its host (6) and thus an excellent 
antimalarial target (7). During the intraerythrocytic developmental cycle (IDC) in which the 
parasite undergoes proliferation in host blood cells, the mitochondria contain all enzymes of 
the tricarboxylic acid (TCA) cycle (8)—a terminal oxidative pathway that uses carbohydrates, 
fatty acids, and amino acids to generate chemical energy in all aerobic organisms.  
Recent in vitro studies suggest that the TCA cycle of P. falciparum plays a limited role 
during the IDC. For example, although the parasite voraciously consumes glucose, only a 
very small fraction of it is oxidized to carbon dioxide (9). In fact, each of the TCA cycle 
enzymes can be individually deleted in IDC except for two enzymes fumarate hydratase (fh) 
and malate:quinone oxidoreductase (mqo) (10). These enzymes are apparently required for 
some function other than the TCA cycle. A study that specifically investigated the fate of 
fumarate showed that L-aspartate, formed from fumarate through fh, is incorporated into 
uridine monophosphate (UMP), a pyrimidine base, but not into purine nucleotides (11). 
These results suggest an additional role for fumarate during the IDC, given that UMP is 





reason why attempts to knock out fh have been unsuccessful (10, 12), because 1) the parasite 
can synthesize pyrimidine bases de novo (13) and 2) L-aspartate is found in hemoglobin (14), 
which is amply available to the parasite (15). 
To gain a quantitative understanding of the metabolic changes in response to rising 
fumarate levels during the IDC, we first sought to computationally disentangle erythrocyte 
metabolism from parasite metabolism—a problem that is difficult to address experimentally 
when the same host and parasite enzymes are separately involved in the metabolic processes 
of each organism (i.e., fh is active and present in the erythrocytic cytosol (16, 17) as well as in 
the mitochondria of P. falciparum (10, 17)). Therefore, we developed a computational 
framework that could 1) isolate the effect of parasite infection on erythrocyte metabolism 
and 2) quantify the effect of fumarate on P. falciparum metabolism during the three stages of 
the IDC (i.e., ring, trophozoite, and schizont). To this end, we first collected host 
metabolomic data from uninfected and parasite-infected erythrocytes and transcriptomic 
data from parasite-infected erythrocytes during the IDC, and then developed a method that 
requires only metabolomic data for predicting host metabolic flux profiles of uninfected and 
parasite-infected erythrocytes. Using this approach, we identified significantly altered host 
metabolic reactions in parasite-infected erythrocytes, and then used these metabolic fluxes 
and transcriptomic data in conjunction with a whole-genome metabolic network model of P. 
falciparum to predict its metabolic flux profiles during the IDC. After validating our model 
results, we computationally perturbed fumarate uptake and quantified the impact of this 
treatment on P. falciparum metabolic fluxes. Our model analysis revealed that increases in 
fumarate uptake levels leads to an increased flux through oxidative pentose phosphate 





(NADP+) – a critical component for thioredoxin reductase (18) and glutathione reductase 





During the IDC, P. falciparum metabolism is intertwined with erythrocyte metabolism. 
Current techniques for predicting parasite metabolism (11, 20, 21) rely on transcriptomic 
data, which come exclusively from the parasite but do not provide an exact representation of 
its metabolism at any given time during the IDC (see (22)). By contrast, metabolomic data 
provide an exact representation of host-parasite metabolism at a specific moment during the 
IDC, but include contributions from both the parasite and the host cells. To untangle the 
metabolism of the parasite from that of the host, we aimed to construct a computational 
framework that uses both metabolomic and transcriptomic data (Figure ApIII-1). We first 
searched the literature for metabolomic data describing extracellular changes in metabolites, 
to set the uptake and secretion of nutrients by uninfected and parasite-infected erythrocytes 
(Figure ApIII-1, Step 1) (23). We untangled erythrocyte metabolism from parasite 
metabolism, using erythrocyte-specific metabolomic data to drive metabolic alterations in 
uninfected and parasite-infected erythrocytes during the IDC (Figure ApIII-1, Step 2). 
Lastly, we used model-predicted interface reactions (Figure ApIII-1, Step 3a) and parasite-
specific transcriptomic data (Figure ApIII-1, Step 3b) to predict the P. falciparum metabolic 
flux profile during the IDC.  
 





We found 103 metabolic reactions in erythrocytes, in which the flux changed 
significantly upon parasite infection, as assessed by a paired t-test (p < 0.05). We also found 
145 such reactions in which the time course was altered. We chose the threshold of the 
correlation coefficient (r) to identify reactions for which the time courses in the infected and 
uninfected erythrocytes were poorly correlated (r < 0.25). In all, parasite invasion altered 33 
metabolic reactions in terms of both flux level and time course. Table ApIII-1 lists some 
reactions belonging to glycerophospholipid metabolism, glycolysis/gluconeogenesis and ion 
transport. We have provided a complete list of all metabolic reactions whose flux level and 
time course were altered in erythrocytes in the Supporting Information (S1 Table, Sheet 3). 
In the column denoted ‘fit effect’ (S1 Table), we have also provided additional information 
on whether these changes may be due to fitting nutrient secretion or uptake data. In 
addition, we have listed all metabolic reactions that significantly changed (Sheet 1) or were 
poorly correlated (Sheet 2). 
 
Alteration in interface reactions 
As an intracellular parasite, P. falciparum acquires nutrients from the culture medium 
indirectly via the erythrocyte. Therefore, we focused on metabolic reactions of the 
erythrocyte which are known to take part in parasite metabolism during the IDC 
(henceforth, referred to as the interface reactions). We found 86 such reactions. Of these, we 
incorporated the effects of only those interface reactions that were altered in flux level (p < 
0.05) or in their time course (r < 0.25). Consequently, we integrated 11 reactions with the P. 
falciparum metabolic network. We provide a table containing the estimated values of these 
interface reactions in the Supporting Information (S2 Table). Palmitic and oleic acid 





acids, together with lipid-free albumin, are sufficient to support parasite growth during the 
IDC (27).  
 
Validating predicted values of P. falciparum metabolism  
We integrated the interface reactions and transcriptomic data to predict the P. 
falciparum metabolic flux profile (Figure ApIII-1). As in a previous study (20), we compared 
the metabolic flux predictions with data from an independent dataset describing DNA (28), 
RNA (28), and lipid (29) synthesis during the IDC to validate these predictions (see Figure 
ApIII-2). Our model predictions (Figure ApIII-2, open circles) of DNA, RNA, and lipid 
synthesis rates during the IDC showed trends that were generally consistent with the 
experimental data (Figure ApIII-2, solid black bars). We provide a comparison of the 
current approach and a previous method that only included transcriptomic data (20) in the 
Supporting Information (Section A of S1 Text). Notably, our current approach generally 
captured the temporal peaks of DNA, RNA, and lipid synthesis, even though the 
experimental data were independent of those used to obtain the predictions.  
 
Quantifying the effect of fumarate on metabolism in P. falciparum 
Our perturbation analysis of parasitic fumarate helps us to quantify the enzymatic 
changes expected to occur within the parasite when fumarate levels increase. As expected, an 
increase in cytosolic fumarate led to an increase in the activities of fh, mqo, and aspartate 
aminotransferase (aspta) during the IDC. Specifically, we observed an average increase of 9% 
during IDC in the activities of fh, mqo, and aspta, respectively. Table ApIII-2 lists stage-





in fumarate production through the obligatory purine salvage pathway. We provide a 
complete list of estimated enzymatic changes in the Supporting Information (S1 File).  
Our model analysis revealed that an increase in cytosolic fumarate causes a concomitant 
increase in oxidative PPP enzyme fluxes, i.e., in glucose 6-phosphate dehydrogenase, 
phosphogluconate dehydrogenase, and 6-phosphogluconate dehydrogenase (6pgd). The 
extent of this increase was equivalent for all three enzymes. (See inset in Figure ApIII-3 for 
the observed increase in the flux of 6pgd in response to 5%–20% increase in cytosolic 
fumarate production.) Our analysis also suggests that arginine production increases in 
response to increased production of cytosolic fumarate. Our model captures this through 
increased argininosuccinate synthase and argininosuccinase enzyme fluxes, which ultimately 
produce arginine and fumarate. Note that arginine metabolism is important for parasite 
growth during liver stage (31) and IDC (32).  
 
 
CONCLUSIONS AND DISCUSSION 
 
 
Parasite-induced alteration in erythrocyte metabolism 
When P. falciparum merozoites invade an erythrocyte, they alter its morphology and 
physiology (24, 33, 34) to facilitate parasite growth. Here, we used erythrocyte-specific 
metabolomic data to predict alterations in erythrocyte metabolism in response to parasite 
invasion. Consistent with previous studies, we found that the parasite alters erythrocyte 
metabolism by 1) altering Na+, K+, Cl- and HCO3- homeostasis within the infected 
erythrocyte (22, 35); 2) increasing activity of glycolysis enzymes, such as hexokinase, enolase, 





precursor of 2,3-diphosphoglycerate, which declines in infected erythrocytes (36); and 4) 
increasing uptake of phospholipids (35).  
We found that parasite invasion altered 33 erythrocyte metabolic reactions 
significantly in terms of both flux level and time course. Most enzyme alterations (26 out of 
33) were consistent with the literature (see above paragraph). The five out of the remaining 
seven reactions do not have direct evidence supporting a decrease or increase in their flux 
upon parasite invasion. These five reactions are involved in maintenance of pyridine 
nucleotide pool and hence oxidative stress which is increased in parasite infected 
erythrocytes (26, 37, 38). Specifically, we predict an increase in flux through glucose-6-
phosphate dehydrogenase (g6pd) of the infected erythrocyte. Available literature evidence 
suggests that g6pd activity is mandatory for malaria infection (39, 40) but we do not know 
whether g6pd flux increases in the infected erythrocyte. Our model predictions suggest an 
increase in galactokinase flux but we did not find any literature evidence either supporting or 
opposing it.  
 
Impact of fumarate on central carbon metabolism 
We found that a 10% increase in cytosolic fumarate production results in a 
comparable increase in flux through fh (Table ApIII-2). Figure ApIII-3 also shows that 
this increase propagates to malate dehydrogenase (mdh) through mqo and the oxaloacetate 
transporter (oaat). However, the impact of increasing fumarate on phosphoenolpyruvate 
carboxykinase (ppck) is different at the ring, trophozoite, and schizont stages. Specifically, the 
ppck flux marginally decreases during the ring stage and increases during the trophozoite and 
schizont stage. This decrease and then increase in ppck flux is a result of the interplay 





fluxes. We believe that the flux through ppck decreases during the ring stage because it is an 
energy-consuming reaction and, hence, it is unimportant during this stage. However, the 
increase in this flux during the trophozoite and schizont stage suggests improved coupling 
between fumarate and ppck. In contrast, other cytosolic enzymes associated with consuming 
oxaloacetate show an increase with fumarate (e.g., mdh and aspta) suggesting better coupling 
at all stages.  
 
Identifying the link between PPP and fumarate 
Our perturbation analysis revealed an increase in oxidative PPP enzyme fluxes with 
an increase in fumarate production. We investigated the possible mechanism underlying this 
phenomenon to better understand the relationship between PPP and fumarate. We sought 
to identify the minimal number of reactions that are sufficient to cause an increase in 
fumarate production and an increase in oxidative PPP enzyme fluxes (e.g., 6pgd). We 
obtained these minimal reactions by iteratively solving the optimization problem shown in 
Step 3 in Figure ApIII-1. Specifically, we sequentially fixed the flux of each individual P. 
falciparum enzyme to its value attained in response to fumarate perturbation (i.e., in vpert; see 
the Materials and Methods Section for details) and then computed a new solution. After 
comparing all solutions, we found that OAA transport out of the mitochondria alone was 
sufficient to cause equivalent increases in fumarate production and oxidative PPP enzyme 
fluxes. Notably, OAA is a substrate for cytosolic malate dehydrogenase (mdh) and plays a 
role in regulating redox balance in the cytosol of the parasite. Therefore, as a next step, we 
searched for a possible solution in reactions involving nicotinamide adenine dinucleotide 
(NAD). Our investigation revealed that an increase in glyceraldehyde-3-phosphate 





increase in mdh fluxes (Figure ApIII-4) were sufficient to increase fumarate production and 
oxidative PPP enzyme fluxes (6pgd flux in Figure ApIII-3). Our results suggest that 
fumarate generated via the purine salvage pathway can regulate the oxidative arm of PPP and 
consequently maintain redox balance in the parasite cytosol. Any alteration in the fumarate-
PPP link will lead to a disconnection between purine salvage (which is essential for parasite 
growth) and redox balance (which is essential to impede oxidative stress).  
To verify that the increase in oxidative PPP enzyme fluxes with fumarate did not 
depend on the strain of parasite or experiment, we also performed similar perturbation 
analyses by replacing the transcriptomic data for the NF54 strain with those for the HB3 
strain (41), and found a similar increase in oxidative PPP enzyme fluxes with increase in 
fumarate production. We also performed simulations with different increases in fumarate 
production rates (5%, 10%, 15%, and 20%) and added Gaussian noise (5%, 10%, and 15%) 
to the transcriptomic data (S1 and S2 File). In each case, an increase in cytosolic fumarate 
production concomitantly increased oxidative PPP enzyme fluxes (S1 File). Furthermore, we 
found that the mechanism identified for the NF54 strain (Figure ApIII-4) applied to the 
HB3 strain as well (Section B of S1 Text). A review of the existing literature revealed one 
study (42) where the authors observed an increase in PPP metabolites by adding fumarate to 
the culture medium. Although their observations (42) do not validate our findings per se, they 
suggest that an increase in fumarate can lead to an increase in PPP metabolites.  
 
Fumarate: a friend or a foe of P. falciparum? 
In this article, we aimed to understand the biological consequences of fumarate 
changes for P. falciparum metabolism, using a metabolic network model. Specifically, we 





a culture medium (23), metabolomic data from an erythrocyte (this work), and 
transcriptomic data from a parasite (this work). After validating our model-predicted 
metabolic flux profile, we elevated the amount of fumarate in the parasite’s cytosol by 
increasing and fixing the cytosolic fumarate production to a value slightly higher (10%) than 
that of the control condition in the model. This allowed us to increase the amount of 
fumarate available inside the parasite’s cytosol without perturbing any other enzyme reaction.  
In the P. falciparum metabolic network model, cytosolic fumarate is produced from 
the obligatory purine salvage pathway and is recycled by fh in the mitochondria, in agreement 
with the literature (10). A recent systematic study of the role of TCA cycle enzymes in P. 
falciparum (10) found that only two of the eight enzymes (i.e., fh and mqo) are essential for the 
parasite during the IDC. The fh is considered essential because it generates aspartate, which 
is a precursor of purine and pyrimidine metabolism (Figure ApIII-3). Previously, Bulusu et 
al. showed in 14C-labeled fumarate experiments (11) that fumarate is only incorporated into 
UMP (a pyrimidine base) via aspartate. This is probably not the only reason why fh is 
essential for the parasite during the IDC, because sufficient aspartate from hemoglobin 
degradation should always be available for the parasite (43).  
We propose that fumarate accumulation is potentially toxic for the parasite in the 
absence of fh because: 1) fh is the primary mechanism by which the parasite recycles fumarate 
generated through the obligatory purine salvage pathway (11); 2) fumarate inhibits 
adenylosuccinate lyase (an enzyme which cleaves succinyl-adenosine monophosphate to 
form adenosine monophosphate and fumarate), which is an essential enzyme for 
synthesizing purines from hypoxanthine (44); 3) fumarate can modify the function of 





demonstrated that fh depletion causes succination of proteins and metabolites, and is toxic 
for Mycobacterium tuberculosis (49). 
In summary, we 1) generated time-dependent gene transcription and metabolite data 
of synchronized NF54 P. falciparum parasites during asexual reproduction in the blood stage, 
2) developed and validated an integrated computational metabolic network model based on 
these data to disentangling host erythrocyte and parasite metabolism, and 3) proposed a new 
role for fh, an essential enzyme in the TCA cycle of the parasite, in redox-balance 
maintenance. 
 
Limitations of the study 
In this study, we quantified the effect of fumarate on the metabolic reactions of P. 
falciparum during the ring, trophozoite, and schizont phases. Our model estimates depend on 
the experimental conditions under which omics data are collected. Specifically, in these 
experiments the erythrocytes were kept in Roswell Park Memorial Institute (RPMI) 1640 
culture medium, which contains nutrients essential for parasite growth in ample quantities. 
However, these nutrients will be present in variable quantities in vivo; for example, the 
average glucose level in non-diabetic human plasma is about 5.5mmol/L (50), whereas it is 
about 11mmol/L in RPMI medium. Moreover, because these nutrients vary between 
individuals in vivo, the quantitative effects of fumarate on P. falciparum enzymes will vary 
under in vivo conditions. 
A recent study by Carey et al. (51) demonstrated that the essentiality of some redox-
related genes depends on their location within the parasite (for example, cytosol vs. 
apicoplast). These results suggest that the link between fumarate and oxidative PPP 





within the model. However, fumarate hydratase (10, 52), the key enzyme responsible for 
fumarate recycling, and glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase 
(52), the initial bi-functional enzyme of the oxidative PPP, are correctly localized within our 
model. This suggests that the link between fumarate and oxidative PPP is not due to 




Parasite culture, purification of erythrocytes, and sample collection 
P. falciparum NF54 parasites (generously provided by David Fidock, Columbia 
University) were routinely propagated in human erythrocytes at 2% hematocrit in gassed 
flasks (94% N2, 3% O2, and 3% CO2) at 37°C. Infected erythrocytes were maintained in 
RPMI-1640 medium (Gibco, Gaithersburg, MD) supplemented with 25mM HEPES, 
12.5µg/mL hypoxanthine, 0.3% sodium bicarbonate, 25µg/mL gentamicin, 0.5µM R-lipoic 
acid, and 0.5% AlbuMAX II (Life Technologies Inc., Carlsbad, CA).  
For white blood cell (WBC) depletion, crudely enriched erythrocytes were overlayed 
on a 60% Percoll solution and centrifuged at 1,500g for 30 min. After removal of WBCs 
from the interface, pelleted erythrocytes were carefully collected and washed several times in 
RPMI-1640 before adjusting the hematocrit to 50%.  
To generate synchronized parasites, cultures were magnetically purified by passage 
through CS MACS columns (Miltenyi Biotec, Auburn, CA). This was done every 44–48hrs 
for four days prior to the initiation of the experiment. Parasitemia and synchronicity were 
monitored using Giemsa-stained blood smears and light microscopy. Additionally, 





confirmed by PCR, using primers specific for the gene encoding 16S ribosomal RNA (5′-
GGAGCAAACAGGATTAGATACCC, and 5′-CACCATCTGTCACTCTGTTAACC). 
Prior to sample collection, 300mL of synchronized parasite culture was passed 
through a CS column in four 75mL volumes, each of which was eluted with 20mL of culture 
medium. Eluates were pooled and adjusted to a total culture volume of 300mL at 2% 
hematocrit and 3% parasitemia levels using Percoll-purified blood, after which the culture 
was divided into four 75mL replicate flasks. Quadruplicate flasks containing 50mL of media 
with uninfected Percoll-purified erythrocytes at 2% hematocrit served as the control group 
for metabolomic analysis. MACS purification resulted in elution of late-stage trophozoites. 
Cultures were regularly observed by blood smear until 0–2hrs after merozoite invasion of 
erythrocytes, at which point the culture media from all flasks were replaced with fresh media 
(time 0 for this experiment). Samples were collected at the following times: 0, 8, 16, 24, 36, 
40, and 48hrs.  
The amounts of re-suspended parasite culture collected in 15mL conical tubes from 
test and control flasks were 10.5mL and 7.2mL, respectively. Tubes were centrifuged at 
1,500 g for 5 min to pellet the cells. Following aspiration of media, 100µL of test or control 
cell pellets and 50µL of test pellets were transferred to 1.5mL tubes for metabolomic and 
transcriptomic analyses, respectively. Tubes were flash-frozen in an ethanol/dry-ice bath and 
stored at –80°C. Quadruplicate samples were sent to the Johns Hopkins Genomic Analysis 
and Sequencing Core Facility for microarray analysis using Agilent microarray chip 







Sample preparation. Following receipt of samples by Metabolon, samples were 
inventoried and immediately stored at –80°C. To remove protein, dissociate small molecules 
bound to protein or trapped in the precipitated protein matrix, and recover chemically 
diverse metabolites, proteins were precipitated with methanol under vigorous shaking for 2 
min using a GenoGrinder 2000 (Glen Mills Inc., Clifton, NJ), and then centrifuged. The 
resulting extract was divided into five fractions: two for analysis by two separate reverse 
phase (RP) ultrahigh-performance liquid chromatography (UPLC) tandem mass 
spectrometry (MS/MS) methods with positive ion mode electrospray ionization (ESI), one 
for analysis by RP/UPLC-MS/MS with negative ion mode ESI, one for analysis by 
hydrophilic-interaction chromatography (HILIC) UPLC-MS/MS with negative ion mode 
ESI, and one for use as a backup sample. All methods utilized a Waters ACQUITY UPLC 
system (Waters Corp., Milford, MA) and a Q-Exactive high resolution/accurate mass 
spectrometer (Thermo Fisher Scientific, Hampton, NH) interfaced with a heated 
electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 
mass resolution. 
 
Data extraction and compound identification. 
Raw data were extracted, peaks were identified, and quality check (QC) was 
performed using Metabolon’s hardware and software. Compounds were identified by 
comparison to Metabolon’s library entries of purified standards or recurrent unknown 
entities. Biochemical identification was based on three criteria: a retention index (RI) within a 
narrow RI window of the proposed identification, accurate mass match to the library +/– 10 
ppm, and the MS/MS forward and reverse scores between the experimental data and 





the experimental spectrum to those present in the library spectrum. Although a molecule 
may resemble another based on one of these factors, the use of all three factors can 
distinguish and differentiate biochemicals. 
 
Extracellular metabolomic data from the literature 
The metabolomic data described thus far originate from the erythrocytes and the 
parasites. To capture the metabolism of nutrients transported across uninfected and infected 
erythrocytes accurately, we used extracellular metabolomic data from uninfected and infected 
erythrocytes provided by Olszewski et al. (23). The experimental conditions they employed 
closely resemble the culture conditions of our study. The only major difference was the 
method used to synchronize the parasite culture during the IDC: whereas Olszewski et al. 
used sorbitol, we used a magnet. We performed student’s t-test to compare their intracellular 
metabolomic data with the corresponding data from our experiments to verify whether the 
difference in synchronization method greatly altered the metabolomic data. We found that 
only 10 out of 68 common metabolites were significantly (p < 0.01) altered during the IDC, 
which suggests that the synchronization method has little effect on metabolomic data. We 
have also provided a direct comparison of the transcriptomic data from Olszewski et al. (23) 
with those from our experiments (S1 Text, Section C).  
 
Microarray methods 
RNA quality: For each data point, RNA was extracted from 50 µL of packed 
erythrocyte culture with Trizol Reagent and the PureLink Mini Kit (Invitrogen/Thermo 
Fisher Scientific, Carlsbad, CA). Trizol (1mL) was added to each sample, followed by high-





FastPrep 120 Instrument at speed 6 for 20 seconds. Homogenates were subsequently 
processed according to the PureLink Mini Kit manufacturer’s (Invitrogen/Thermo Fisher 
Scientific) protocol, including on-column DNase treatment. Following elution of purified 
RNA from the PureLink columns with nuclease-free water, quantitation was performed 
using a NanoDrop spectrophotometer (Thermo Fisher Scientific) and quality assessment 
determined by RNA ScreenTape analysis on an Agilent TapeStation 2200 (Agilent 
Technologies, Santa Clara, CA). 
Microarray: From 100ng of total RNA, Cyanine 3-labeled cRNA was prepared 
using the Low Input Quick Amp Labeling Kit One-Color (Agilent Technologies). A mixed 
stage RNA pool control and the seven time course samples were hybridized (along with the 
manufacturer’s control RNA spike-in samples) according to a standard protocol to the eight 
sectors of an Agilent 8x15K platform microarray (AMADID 037237) (53, 54), with separate 
microarray slides used for each biological replicate (in quadruplicate for each condition). 
Post-hybridization washes were performed, followed by scanning with a G2600D SureScan 
microarray scanner (Agilent Technologies), using the scan protocol AgilentHD_GX_1color. 
Scan control software automatically performed autofocus, autogain, and gal file download. 
Agilent’s Feature Extraction Software was used to assign grids, provide raw image files per 
array, and generate QC metric reports from the microarray scan data. The QC metric reports 
were used for quality assessment of all hybridizations and scans. Txt files from Agilent’s 
Feature Extraction Software were transferred to Partek Genomics Suite software (v6.6) 
(Partek Inc., St Louis, MO). Within Partek Genomics Suite, the gene expression workflow 
was followed for Agilent Feature Extraction files, starting with gProcessingSignal, Quantile 






Metabolic network model: We used metabolomic data to further identify 
metabolites known to exist in parasites but which were not included in our model of P. 
falciparum (55). Specifically, we identified five enzyme reactions not included in the model: 1) 
betaine-homocysteine S-methyltransferase; 2) argininosuccinase; 3) argininosuccinate 
synthetase; 4) aspartate carbamoyltransferase; and 5) UDP-glucose-6-dehydrogenase. 
Incorporation of these enzyme reactions resulted in the addition of five new metabolites: 1) 
glycine betaine; 2) dimethylglycine; 3) L-argininosuccinate; 4) L-citrulline; and 5) UDP-
glucuronate. We provide details of these metabolic reactions in Table ApIII-3, along with 
the SBML code in the Supporting Information (S4 File). The resulting metabolic network 
model of P. falciparum had 1,025 reactions and 923 metabolites. Our erythrocyte metabolic 
network model was based on the model of Wallqvist et al. (21), which includes different 
metabolic pathways related to carbohydrates, nucleotides, amino acids, cofactors, and 
phospholipids. We modified this model to include interface reactions that lie at the interface 
of erythrocyte metabolism and P. falciparum metabolism. We also added L-citrulline and L-
argininosuccinate to the erythrocyte model, which have been detected in the metabolomic 
data and which participate in the urea cycle of the erythrocyte (56). The updated erythrocyte 
model had 407 metabolites and 590 reactions. We have provided a complete list of the 
reactions added to the erythrocyte model (S6 Table). The SBML code is provided in the 
Supporting Information (S5 File). We did not add any other reactions to the erythrocyte 
model because erythrocytes have a relatively simple metabolism (9) given their primary role 
as oxygen transporters (57).  
 





P. falciparum, like other parasites of the phylum Apicomplexa, needs a host cell as a 
source of nutrients and to provide protection from host defense mechanisms. During the 
IDC, P. falciparum takes up metabolites from, and secretes them to, the culture medium via 
the erythrocyte cytosol. Once the parasite invades an erythrocyte, it alters the metabolism of 
the erythrocyte to make the environment conducive to IDC progression (66, 67). However, 
owing to experimental difficulties, it is impossible to accurately quantify the changes in 
erythrocyte metabolism introduced by the parasite. To computationally quantify such 
changes, we first used metabolomic data that delineate changes in the culture medium during 
the IDC to constrain the uptake and secretion of metabolites by an erythrocyte (23). Then, 
we used erythrocyte-specific metabolomic data obtained under uninfected and parasite-
infected conditions to predict the metabolic flux profile of the erythrocyte during the IDC. 
Computationally, we performed the mathematical procedures described in the next three 
sections. 
Estimating uptake and secretion rates of metabolites in the culture medium (Fig 1, 
Step 1).  
Olszewski et al. (23) measured 59 culture medium metabolites at seven time points 
during the IDC but we were able to calculate uptake/secretion rates for only 22 metabolites 
whose initial concentrations were known. We calculated uptake/secretion rates at a given 
hour via linear regression, by plotting relative levels of culture medium metabolites (weighted 
by their standard deviation) as a function of time for (t, t+2) points, where t is the time point 
for which the rate is being calculated. Using the initial concentration of the metabolite and 
the dry weight (gDW) of an erythrocyte, we converted the estimated slopes of the regression 
lines (uptake/secretion rates) to units of mmol h–1 per gDW of erythrocyte. We used these 





and infected erythrocytes during the IDC. Similarly, we estimated the average nutrient 
uptake/secretion rate during the IDC ( nutv ) by performing linear regression on relative 
levels of culture medium metabolites during the IDC. We used these estimated average rates, 
shown in Table ApIII-4, to estimate the average metabolic state of the erythrocyte during 
the IDC (see equation 3). S4 Table presents the average and time-dependent rates of 
nutrient uptake/secretion by uninfected and infected erythrocytes during the IDC. 
 
Using metabolomic data to estimate reaction fluxes (Fig ApIII-1, Step 2).  
Currently, few methods integrate metabolomic data with large-scale metabolic 
networks to predict reaction fluxes (68). Here, we used a simple concept to integrate 
metabolomic data from uninfected and infected erythrocytes with a metabolic network 
model. We assumed that 1) flux through an enzyme is proportional to the amount of 
substrate and 2) a substrate with the lowest concentration becomes rate-limiting for 
reactions with multiple substrates. These assumptions hold true for substrates as well as 
products if a reaction is unidirectional. Specifically, we used the relative metabolite levels of 
substrates and products to scale nominal unidirectional fluxes of the erythrocyte and to 
predict the time course of erythrocyte metabolism during the IDC. We performed the 
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Here, RBCS is the stoichiometric matrix and 
ta  is a column vector with each element 
containing the minimum value of a substrate and product metabolite relative to its median 
during the IDC at a given time t. We focused on only those metabolites that are part of 
erythrocyte metabolism and not part of P. falciparum metabolism. We provide a list of these 
metabolites and associated reactions in the Supporting Information (S5 Table). ‘R’ is a set of 
unidirectional reactions, ‘N’ is the set of reactions associated with nutrient uptake/secretion, 
and ‘M’ is the set of all metabolic reactions in the erythrocyte. lbv and ubv are vectors 
representing the lower and upper bounds, respectively, of the metabolic reactions of the 
erythrocyte. We determined the directionality of the reactions by identifying their 
thermodynamic feasibility, which is equivalent to analyzing flux variability without any closed 
loop in the metabolic network (69, 70). The relative value of a given metabolite is equal to 
the area under the curve (AUC) of the metabolite normalized by the Bradford protein 
concentration (71) of each sample and the median value of the AUC over the IDC. To 
simulate infected erythrocytes, we normalized the AUC of the metabolites by the median 
value of the AUC of the metabolites over the IDC from the uninfected sample. 





uninfected or infected erythrocytes over the IDC. These uptake and secretion rates were 
multiplied by a factor of 2 to account for differences in hematocrit level in the culture media 
of Olszewski et al. (23) and our experiments. { }Mv Î= i:RBCnomi,RBCnomv  is the nominal flux vector 
of the erythrocyte obtained by solving the following optimization problem: 
NaKmaxv                                                                        (3) 
subject to 0RBC =vS   
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Here, nutv  is a vector representing the average rate of metabolites secreted or 
consumed by an erythrocyte from the RPMI-1640 medium. These values are the slopes of 
the regression lines obtained by performing a linear regression of the extracellular 
metabolites measured by Olszewski et al. (23) over the entire IDC from uninfected or 
infected erythrocytes. When simulating uninfected erythrocytes, we set µ  to be 35% of the 
maximum attainable sodium pump (NaK) flux in the erythrocyte model because NaK 
controls the membrane potential, which is greatly reduced in an uninfected erythrocyte (24). 
On the other hand, when simulating parasite-infected erythrocytes, we maximized NaK 
activity while keeping the metabolite consumption/secretion at its average value, because the 
membrane potential of an infected erythrocyte is much larger than that of an uninfected 





Identifying interface reactions and integration with P. falciparum metabolism (Fig 
ApIII-1, Step 3).  
We identified reactions that form the interface of erythrocyte metabolism and P. 
falciparum metabolism (i.e., interface reactions), based on 1) statistical significance and 2) changes 
in directionality and time course. We employed paired t-tests to identify statistically 
significant (p < 0.05) differences in metabolic fluxes of uninfected and infected erythrocytes. 
We performed correlation tests to identify reactions with altered directionality by a negative 
correlation (r < 0) and those with altered time course by a low correlation (| r | < 0.25). 
Note that although these interface reactions are in units of mmol h–1 per gDW of 
erythrocyte, metabolic reactions within the parasite model are in units of mmol h–1 per gDW 
of parasite. As the parasite mass changes throughout the IDC, conversion of gDW of 
erythrocyte into gDW of parasite is not straightforward. However, the parasite mass within 
the erythrocyte at the beginning of the IDC is minimal and increases during the IDC. 
Therefore, when obtaining nominal fluxes of the parasite (as described in the next section), 
we used the median flux of each interface reaction as the minimum of that reaction. On the 
other hand, when estimating parasite metabolism during the IDC, we normalized each 
interface reaction by its median value during the IDC to obtain unitless temporal profiles of 
interface reactions. Before solving the optimization problem, the temporal profile of each 
normalized interface reaction was multiplied by its nominal value to realize the units of 
mmol h–1 per gDW of parasite. 
We first solved the following optimization problem, using interface reactions to 









imin                                                                   (4) 
subject to g=growthv   
jint vv £ " j Î I  
0Pf =vS  and ublb vvv ££  
Here, B is the set of reactions that contribute to the parasite’s growth in silico. 
Following the original work of Fang et al. (20), we set the nominal growth rate (g) to be 0.48 
g h–1 per gDW of the original merozoite, as this is indicative of the average growth rate of 
the parasite during the IDC. intv is the median value of the estimated interface reaction flux 
during the IDC, I is the set of all interface reactions, and PfS is the stoichiometric matrix. We 
integrated these nominal fluxes and transcriptomic data with the P. falciparum metabolic 
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where G is a set containing all unidirectional intracellular fluxes of P. falciparum. Here, 
( )tjtj gr j= , where tjg  is the temporal gene-expression profile of a reaction ‘j’, and inttv is the 
normalized temporal profile of each interface reaction ‘j’ times the nominal value of this 
reaction obtained by solving equation (4). Following the original work of Fang et al. (20), we 
obtain tJ , shown in equation (6), by solving the following: 








jmin                                                        
(7) 
subject to 0vS =tPf  
jint
t vv £ " j Î interface reactions 
ub
t
lb vvv ££  
Note that, while simulating the NF54 strain, we computationally suppressed the 
expression of four genes involved in DNA synthesis (PlasmoDB ID: PF3D7_1015800, 
PF3D7_1405600, PF3D7_1437200, PF3D7_0923800) and four genes involved in lipid 
synthesis (PlasmoDB ID: PF3D7_0922900, PF3D7_0211400, PF3D7_0615100, 
PF3D7_1232200) to achieve minimal DNA and lipid synthesis during the first 15 h of the 
IDC. Specifically, we achieved this by modifying the transcriptional delays of these genes, 
which were previously set to 11hrs —the median gene-protein delay (20, 22). In Table 
ApIII-5, we have provided the transcriptional delays estimated for the DNA and lipid 
synthesis genes mentioned above.  
Validation of model simulations.  
We validated our model simulations of parasite-infected erythrocyte metabolism and 





data from parasite-infected erythrocytes and parasites during the IDC. Specifically, we 
validated parasite-infected erythrocyte simulations by comparing their outputs with observed 
alterations in glycolytic enzymes (25), ion homeostasis (22, 35), uptake of phospholipids (35), 
synthesis of 2,3-diphosphoglycerate (36), and uptake of arginine (56) (Table ApIII-1). 
Following Fang et al. (10), we validated model simulations of parasite metabolism by 
comparing their outputs with experimental data on DNA (28), RNA (28), and lipid synthesis 
(29) during the IDC (Fig 2).  
Quantifying the impact of fumarate on parasite metabolism.  
We used our validated P. falciparum metabolic fluxes as baseline data and perturbed 
cytosolic fumarate production to identify the most fumarate-sensitive reactions. Specifically, 
we computed the following metric: ρstage= median ∆v
t  where, t Î ring, trophozoite, or 
schizont stage and ∆v = vpert/vctrl, where both ctrlv and pert
v  belong to the space{ }f®ÂnS : . 
Here, S is the stoichiometry matrix of the parasite model, 
nÂ is an n-dimensional real 
coordinate space, and f is the kernel of the linear transformation S. ctrlv  and pertv are obtained 
by solving equations (4) and (5); however, while solving for pertv , the fumarate boundary flux 
is increased by a small quantity ‘𝛿’ to simulate an increase in fumarate inside the parasite’s 
cytosol. Specifically, we increased the fumarate exchange flux by 5%, 10%, 15%, or 20% of 











Figure ApIII-1 Schematic of our computational approach for predicting P. 
falciparum metabolic fluxes during the intraerythrocytic developmental cycle (IDC)  
There are three major steps: 1) compute the rates at which nutrients are transported across 
the membrane of an uninfected or parasite-infected erythrocyte during the IDC (light blue 
dotted lines); 2) integrate host metabolomic data obtained from uninfected or parasite-
infected erythrocytes with the erythrocyte metabolic network model to predict the metabolic 
flux profile of the corresponding erythrocyte during the IDC (orange dotted lines); and 3) 
integrate the a) nutrient consumption or secretion rate of the parasite during the IDC 





sample as that used to acquire the metabolomic data, with the P. falciparum metabolic 
















































Table ApIII-1 Erythrocyte metabolic reactions altered by parasite invasion 
 




Chloride + Bicarbonate 







Hexokinase  ATP + D-glucose ⇌ ADP + 
glucose-6-phosphate + H 






Chloride (medium) + 
Potassium (medium) ⇌ 






Malic enzyme L-malate + nadp ⇌ CO2 + 








D-glucose + H + nadph ⇌ 


















‡A forward reaction is read from left to right.  
*A metabolic reaction flux is said to increase (or decrease) upon parasite invasion if its 
median value (taken over the IDC) is greater (or smaller) than its median value under 
uninfected conditions.  
¶ The parasite-infected erythrocyte is exposed to increased oxidative stress, which requires 









Figure ApIII-2 Model predictions of DNA, RNA, and lipid synthesis during the 
intraerythrocytic developmental cycle (IDC)  
Flux predictions (open circles with error bars) and the experimental data (solid black bars) 
for DNA, RNA, and phospholipid synthesis are normalized by their respective maximum 
values during the IDC. The error bars show mean ± standard error computed from 20 
random simulations performed after adding 5% Gaussian noise to the transcriptomic data. 
The predictions capture the temporal peaks of DNA and RNA synthesis reasonably well. 
Furthermore, they reproduce the increase in phospholipid synthesis satisfactorily. Overall, 
the predictions made with the current approach are at the least equally well as compared to 






Table ApIII-2 Average estimated deviation in P. falciparum enzymatic fluxes 
expressed relative to a 10% increase in fumarate‡ 
 
Reaction name PlasmoDB ID Estimated increase/decrease 
(% of fumarate perturbation) 
Pathway 
Ring Trophozoite Schizont 
Oxaloacetate 
transporter 























PF3D7_1426700 +1.4±0.7 –15.1±8.8 +0.3±0.3 Pyruvate 
metabolism  
Fumarate hydratase PF3D7_0927300 +9.8±0.1 +8.6±0.4 +9.0±0.2 TCA cycle 
Malate:quinone 
oxidoreductase 
PF3D7_0204500 +9.6±0.1 +8.7±0.4 +9.3±0.1 TCA cycle 
Citrate synthase PF3D7_1022500 +4.6±0.1 +4.3±0.1 +4.5±0.0 TCA cycle 
Oxoglutarate 
dehydrogenase 




PF3D7_1034400 +0.1±0.1 –50.0±15.8 –3.6±2.6 TCA cycle 
†Transport is shown to occur in vitro, but the gene specific to this transporter has not been 
identified (18, 30).  
‡ Values represent mean ± one standard error of 20 random simulations after adding 5% 








Figure ApIII-3 Fate of fumarate based on perturbation analysis  
Arrows and metabolites highlighted in red indicate the flow of fumarate (FUM) entering the 
tricarboxylic acid cycle. Recycling of FUM in the mitochondrion starts with its conversion 
into malate (MAL), which is then converted into oxaloacetate (OAA) by malate:quinone 
oxidoreductase (mqo). In this process, mqo reduces ubiquinone (q8) to ubiquinol (q8h2), 
which feeds into the electron transport chain (ETC). Cytosolic OAA reacts with 
phosphoenolpyruvate carboxykinase (ppck) to yield phosphoenolpyruvate (PEP). It also 
reacts with aspartate aminotransferase (aspta) to yield aspartate (ASP), which is a precursor of 
pyrimidine. ASP is also a precursor of cytosolic FUM in purine metabolism, which 
completes the FUM recycling process. Our analysis reveals that oxidative pentose phosphate 
pathway enzyme fluxes, which reduce nicotinamide adenine dinucleotide phosphate 





comparison between the estimated increases in 6-phosphogluconate dehydrogenase (6pgd) 
and fumarate hydratase (fh) fluxes during the ring stage in response to a 5%–20% increase in 
cytosolic FUM production. Values are means ± standard errors computed over 20 
simulations after adding 5% Gaussian noise to the transcriptomic data. Note that the error 
bars in the inset are eclipsed by the markers. Abbreviations: AKG, alpha-ketoglutatare; aspta, 
aspartate transaminase; G6P, glucose-6-phosphate; mdh, malate dehydrogenase; oaat, 

















Figure ApIII-4 Proposed mechanism responsible for an increase in oxidative pentose 
phosphate pathway (PPP) enzyme fluxes in response to an increase in cytosolic 
fumarate (FUM)  
An increase in cytosolic FUM production increases oxaloacetate (OAA) via fumarate 
hydratase (fh) and malate:quinone oxidoreductase (mqo). An increase in OAA increases 
malate dehydrogenase (mdh) flux, and hence, creates a demand for reduced nicotinamide 
adenine dinucleotide (NADH). This demand is met by an increase in glyceraldehyde-3-
phosphate dehydrogenase (gapd). An increase in mdh also decreases pyridine nucleotide 
transhydrogenase (pnt) flux, possibly because of overflow of nicotinamide adenine 
dinucleotide (NAD) from mdh. Abbreviations: 13DPG, D-glycerate 1,3-bisphosphate; 6pgd, 
6-phosphogluconate dehydrogenase; G3P, glyceraldehyde-3-phosphate dehydrogenase; 







Table ApIII-3 Metabolites and reactions added to the models based on intracellular 
metabolomic data 
 





P. falciparum metabolism model‡  
dimethylglycine L-homocysteine + glycine 
betaine ⇌ L-methionine + 
dimethylglycine 
2.1.1.5 C01026 (58, 59) 
glycine betaine L-homocysteine + glycine 
betaine ⇌ L-methionine + 
dimethylglycine 




arginine + fumarate 
4.3.2.1 C03406 (56, 60) 
L-citrulline L-aspartate + L-citrulline + 
ATP ⇌ L-argininosuccinate + 
AMP + diphosphate + H 
6.3.4.5 C00327 (23, 56, 58, 
60) 
UDP-glucuronate UDP-glucose + 2NAD + H20 ⇌ 
UDP-glucuronate + 2NADH + 
3H 
1.1.1.22 C00167  (60, 61) 
Erythrocyte metabolism model¶  
L-
argininosuccinate 
ATP + L-citrulline + L-
aspartate ⇌ AMP + PPi + L-
argininosuccinate 




arginine + fumarate 
4.3.2.1 C03406 (56) 
L-citrulline L-ornithine + carbamoyl 
phosphate ⇌ L-citrulline + Pi + 
H 
2.1.3.3 C00327 (56, 62) 
‡All metabolic reactions are as provided at biocyc.org (63) for P. falciparum  
¶All metabolic reactions are as provided at ExPASy (64) and KEGG (65).  














Table ApIII-4 Average rates of uptake/secretion of 10 nutrient by uninfected and 
infected erythrocytes during the IDC† 
 
Nutrient Estimated rate (mmol h–1 per gDW of erythrocyte) 
Uninfected erythrocytes Infected erythrocytes 
D-glucose –1.94 × 10–2 +1.09 × 100 
Hypoxanthine –7.44 × 10–4 +3.42 × 10–3 
Inositol –9.06 × 10–4 –4.19 × 10–5 
L-aspartate –5.10 × 10–4 +1.38 × 10–3 
L-glutamate –1.43 × 10–2 –3.68 × 10–2 
L-valine –4.73 × 10–2 –1.09 × 10–1 
Nicotinamide –5.48 × 10–4 +9.52 × 10–4 
Pyridoxine +2.27 × 10–4 +1.67 × 10–4 
Riboflavin –5.17 × 10–5 –3.10 × 10–5 
Thiamine –2.33 × 10–4 –5.75 × 10–4 



































Table ApIII-5 Gene transcription delays for DNA and lipid synthesis genes 
 





PF3D7_1015800 4 +3 Nucleotide, Redox 
PF3D7_1405600 4 +3 Nucleotide, Redox 
PF3D7_1437200 4 +3 Nucleotide, Redox 
PF3D7_0923800 2 +3 Nucleotide, Redox 
PF3D7_0922900 20 +5 Lipid 
PF3D7_0211400 21 +5 Lipid 
PF3D7_0615100 12 +25 Lipid 
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